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Alzheimer’s disease (AD) is consider as a disorder of progressives, unremitting, 
neurodegenerative which cause loss of memory and severely causing cognitive ability. 
Until now, reduce the level of the formation of neurotoxic Aβ species in brain is 
consider as priority pathology of AD treatment. Recent studies show Pyroglutamate-
Abeta (pE-Aβ) which express highly abundant in the brains of AD is rapid 
aggregation and more toxicity than Aβ. pE-Aβ is product of a substrate amino-
terminally truncated Aβ beginning at glutamate 3 or 11 which catalyzed by 
Glutaminyl Cyclase (QC). 
Recent clinical studies show that QC could be an alternative therapeutic target to treat 
AD. Our research group focus on investigation and development a series of QC 
inhibitors with an extended pharmacophoric scaffold, modification in B and C region. 
In this work, firstly we researched on the structure activity relationship (SAR) of 
analogues mimic Arg region. Most compounds in this series exhibited potent activity 
in vitro. The selected compound with IC50 < 10 nM was subjected to in vivo test. The 
result show that addition of aminoethyl group to 2-aminopyridine ring slightly 
improved the in vitro activity up to 2.5-fold. And the molecular docking studies 
present compound 202 as a potential candidate since it forms an additional 
hydrophobic interaction in the hQC active site.  
From the aforementioned result, in part 2, we continued to develop novel QC 
inhibitors that contain 3-aminoaklyloxy-4-methoxyphenyl and 4-
aminoalkyloxyphenyl group to replace the above designed pharmacophore. Some 
novel inhibitors were identified based on the IC50 value. They were further studied 
for in vitro toxicity and in vivo activity. The result showed that inhibitors 51 & 53 
displayed the most potent AβN3pE-40-lowering effect in vivo acute model with 
reasonable BBB penetration, without showing cytotoxicity and hERG inhibition. 
Among two compound, we chosen compound 53 as subject of modeling analysis. The 
salt bridge interaction and hydrogen bonding in the active site explain its high potency. 
This compound having favorable BBB penetration could be serve as potential 
candidate for anti-Alzheimer’s agents.  
Last but not least, we find out that the dimethoxy group in C region is not stable and 
cause toxicity to liver metabolism and the modification in B region increase the in 
vitro activity. Hence, we continued to introduce novel heterocyclic in C region and 
the linker between B & C region together. However, compare with the parent 
 
ii 
compound, heterocyclic in C region reduced remarkable the affect biological activity, 
especially the ring of indole, benzofuran, benzooxazole, benzothiazole from 2.0 to 
6.0 fold. The addition of some ring to B region interestingly slightly increase the in 
vitro affect. This result suggests us valuable information for our effort in lead 
optimization to identify QC inhibitors with better penetration and in vivo activity. 
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1. Introduction 
1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressives, unremitting, neurodegenerative 
disorder that affects wide areas of the cerebral cortex and hippocampus(1). It was 
firstly reported by Dr. Alzherimer in German in 1907 in 51-year-old woman with 
strong feeling of jealousy toward her 
husband and other person(2). up to now, 
It is estimated that there were 46.8 
million people worldwide living with 
dementia in 2015 and will be reach 3 
times greater in 2050 (3). It is worsen 
over time.  
 
AD is officially listed as the 6th leading cause of death in US (4). It is also estimated 
that the number of people age 65 and older with AD will nearly triple from 5.3 million 
to nearly 13.8 million by 2050 all over the world (5). For example, Indonesia, the 
world’s 4th most populated country, estimated in 2015 over 550,000 people with AD 
and will rise quarter to nearly 2.3 million in 2030. The Republic of Korea, a high 
income country, between 2000 and 2015, was the 4th fastest rate of ageing in the world, 
and have nearly 480,000 people with AD in 2015 and will be increase about triple in 
2030(3). 
 
1.1. Stage of AD  
In its early stages, memory 
loss is mild, but with late-
stage Alzheimer's, 
individuals lose the ability to 
carry on a conversation and 
respond to their environment.  
 
  
Figure 1: Estimated number of AD in 2050(3) 
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1.2. The risk factors of AD  
There are two kind of risk factors:  
- The 1st is the non-genetic risk factor such as: age, sex, alcohol consumption, 
depression, etc. Most AD patient are 65 and older-third of people age 85 and 
older have AD (7,8).  
- The second factor related to the genetic one, i.e. APP, PS-1, PS-2, APOE, 
CTNNA3, GAB2,PVRL2,TOMM40, APOC1 which are considered as reason of 
AD(9)  
AD treatment in present 
Until now, it has no current cure, but treatments for symptoms are available, or delay 
its onset, and prevent it from developing. Hence, AD is the most expensive disease, 
take America as example, in 2017, the direct costs to American society of caring for 
AD patients and other dementias are nearly $259 billion. Estimating that Medicare 
spending on AD patients will increase about quarter in 2050, nearly $570 billion. It 
means one in every $3 of total Medicare spending.  
In the base opinion, the 
global costs of dementia 
increase 35.4% from $ 604 
billion to $ 818 billion in 
2015, nearly 1.01% of global 
GDP. But the most 
proportion of costs incurred 
in high income contries 
(nearly 80%) and other low 
and middle income countries 
is too small. The main reason 
for expensive spending is 
that there is currently no cure 
for AD, thus AD should be suggest to use medical support and medication in order to 
reduce and slow down the progression of the AD developing.  
Unfortunately, up to day, in order to face with AD, it is used drug and non-drug 
treatment to improve cognitive and behavioral symptoms.  
- For treating cognitive - FDA has approved two type of medications: 
Cholinesterase inhibitors (Donepezil (Aricept),  
Figure 3: Alzheimer’s prevalence and cost to 
medicare and mediaid in USA 2017 (10) 
INTRODUCTION 
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Rivastigmine (Exelon), Galatamine (RazadyneMenantine (Namenda)(11)  
- For treating behaviors and sleep changes: mostly base on non-drug approaches 
before introducing medication since up to now no drug are specially approved by 
FDA to treat behavioral dementia symptoms.  
In recent research, there is supposed that AD is thought to be related with two-
prolonged attach on the brain, adding to degeneration of nature neurons, disruption 
of the neurogenic niches in the brain.(12)  
Most of studies agreed that the 
accumulation of insoluble forms 
of amyloid-β (Aβ) in plaques in 
extracellular spaces, walls of 
bloods vessels13, 14 and 
aggregation of the microtubule 
protein tau in neurofibrillary 
tangles in neurons are main 
factors of AD.15,16 Microtubule-
associated protein tau is a major 
antigenic component of paired 
helical filaments in Alzheimer 
disease17 
2. Genetic factors in AD 
2.1. Aβ in AD 
Step 1: Amyloid‑ β (Aβ) is cleaved from amyloid precursor protein (APP; step 1) 
and is released into the extracellular milieu — by a process that is unclear — as 
diffusible oligomers (Aβo).  
Step 2: Aβo can be cleared by mechanisms that involve APOE or can be taken up by 
astrocytes via low‑ density lipoprotein receptor‑ related protein 1 (LRP1; step 2).  
Step 3: Aβo can also aggregate in the intercellular space to form fibrillary constructs, 
which in turn assemble into plaques (step 3).  
Step 4: Aβ plaques can be cleared from the brain via degradation by endocytic or 
phagocytic clearance (in macrophages and microglia), or by endoproteases from 
astrocytes (such as insulin‑ degrading enzyme (IDE), neprolysin (NEP) and matrix 
metalloproteinase (MMP); step 4). 




Ngo Thi Hong Van _ 2013.31349 
 
Figure 5: Pathways leading to plaques and tangles form the basis of the amyloid-β 
theory of Alzheimer’s disease18. 
  
Step 5: However, some conformational oligomers that dissociate from Aβ fibrils and 
plaques may not be cleared and are toxic to adjacent synapses (step 5), it disrupt the 
signal transmit from one synapse to the other as well as immune the surrounding 
neuron and around blood vessels in the brain cause blood loss call CAA  
Step 6: Tau damage occurs in neurons and is mediated by the development of 
tau‑ positive neurofibrillary tangles (which extend into the dendrites; step 6). 
Step 7: Fibrillar tau can be released and taken up by healthy neurons, triggering tau 
damage in the uptaking cell (step 7). In addition, Aβ oligomers might drive 
α‑ synuclein aggregation in the plaques. Besides Aβ oligomers, mitochondrial 
damage or dysfunction might also be involved in the neurodegenerative process. 
Hence, it is important to monitor and reduce the level of Ab in brain to cure AD.  
INTRODUCTION 
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2.2. APP in AD 
APP gene is located on 
chromosome 21 in humans 
with 3 major isoforms19. It is 
suggested that protein and 
mRNA levels of KPI (Kunitz 
Protease Inhibitor)- 
containing APP isoforms 
are elevated in AD brain 
and associated with increase Aβ deposition20. APP belongs to a protein family that 
includes APP-like protein 1 ( APLP1) and 2 (APLP2) in mammals21, 22.   
APP, type I transmembrane protein, is synthesized in the endoplasmic reticulum (ER), 
transported through Golgi apparatus to the TGN (trans-Golgi-networkn)24, 25.   
α-secretase & sAPPα 
APP in the cell surface is cleavage by α-secretase at cleavage site (at the Lys16-Leu17 
bond) to generate sAPPα – a large soluble ectodomain or αCTF26.  or reinternalized 
via and endosomal lysosomal degradation27,28. Most of APP’s normal function is 
mediated by sAPPα. sAPPα have role in neuronal plasticity and for the early CNS 
development, protective against excitotoxicity, regulate neural stem cell proliferation, 
inhibit stress-induced CDK5 activation, join in neuroprotective reagent-mediated 
excitoprotection29, 30.   
Β-secretase & sAPPβ 
APP is cleavage at β-site location, Asp1 and Glu 11, by β-secretase, BACE1 to release 
sAPPβ and βCTF31.  sAPPβ differs from sAPPα by lacking Aβ1-16 region at its 
carboxyl-terminus, have function as death receptor 6 ligand, mediate axonal pruning, 
neuronal cell death, rescue gene expression of thrasthyretin and Klotho32, 33.   
γ-secretase & its  fragments  
In APP process, APP αCTF and βCTF are further cleaved by γ-secretase complex at 
one of several sites varying from +40 to +44 to generate Aβ peptides (1-40 & 1-42: 
most common) 
γ-secretase & γ-processing 
APP αCTF and βCTF are then cleaved by γ-secretase to obtain p83 and Aβ.  
p83 is believed have no important role since degraded rapidly.  
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Meanwhile, overproduction of Aβ is suggest as result in neurodegenerative cascade, 
synaptic dysfunction, neuron loss in affected area of brain will be discussed later34. 
Meanwhile, γ-secretase activity to reside in a high molecular weight complex 
consisting of at least four compnents: Presenilin (PS, PS1, PS2), Niscastrin, anterior 
pharynx-defective1 (APH-1), Presenilin enhancer-2 (PEN-2)35, 36.   
PS1:  
+ located on chromosome 14 (14q24.3); 
+ mutation in PS1 count for greater percentage of EOAD case about 18-50%37  
+ can be substantial variation in age of on set ( mean 45.5 years old) 
+ severity of disease (after diagnosis: live about 8.4 year more) 
+ mutation in PS1 could cause the secretase activity of γ-secretase and increase the 
ratio of Aβ42 to Aβ40. 
PSEN 2: 
+ located on chromosome 1(1q31-q42) 
+ PSEN2-related AD is rare compared PSEN1  
+ higher age of onset (about 53.7 year old), live longer after diagnosis (10.6 years)  
 
2.3. TAU IN AD 
Tau is a cytosolic protein encoded by a gene on chromosome 17 (17q21),have > 
100kb and 16 exons 
Normally, Tau proteins interact with tubulin, make microtubules stable and promote 
the assembly of tubulin into microtubules. They are the product of alternative splicing 
from a single gene call “MAPT” (microtubule-associated protein tau). When tau 
proteins are defective, they no longer stabilize microtubules properly. They are 
capable of aggregating and fibrillating to form NFTs, another pathological hallmark 
of AD 
 
Figure 7: Structure of TAU39 
INTRODUCTION 
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Moreover, amyloid fibril 
formation alters the 
phosphorylation state of 
tau,  induced the concomitant 
activation of MAP kinase and 
GSK3 beta, resulting in the 
loss of microtubule binding 
capacity and somatodendritic 
accumulation, properties also 
exhibited by tau in the AD 
brain. Hence, it may therefore 
be an abnormal 
phosphorylation of tau and 
neuritic degeneration in AD41, 42.  
      
 
3. QC in AD 
3.1. Pyrutamate in AD 
 
 
Pyroglutamate-Abeta (pE-Aβ), hightly abundant in the brains of AD are type of N-
truncated Aβ forms containing an N-terminal pyroglutamate at position 3 or 11 in Aβ. 
Due to their increase hydrophobicity, pE-Aβ product are prone to rapid  aggregation  
Figure 8: TAU in AD40 
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and are much more resistant to proteolytic degradation and causing exacerbated 
neurotoxicity. Moreover, pE-Aβ is considered more neurotoxic than Aβ1-40 and Aβ1-
42 and promote the formation of amyloid and tau plaques.  The formation of the 
pyroglutamate from the N-terminal glutamate of Aβ is catalyzed by glutaminyl 
cyclase (QC)  
  
N-truncated pyroglutamate Aβ3–42 are more toxic as compared to full-length 
Aβ1–42 due to reduced neutralization via plaque formation (figure 10)44. Figure 10A 
Monomers and low- and high-molecular weight aggregates of Aβ1–42 (blue) are in 
equilibrium and are toxic as long as they stay soluble  Once high-molecular weight 
aggregates are formed, they rapidly react into highly ordered and insoluble, non-toxic 
fibrils Aβfound in plaques. Therefore, although soluble low- and high molecular 
weight oligomers are toxic, it can be non-toxicity by forming monomers and/or fibrils. 
As Aβ1–42 is a physiological peptide, which is continuously generated also in healthy 
individuals, plaque formation may be one way to neutralize full-length Aβ during the 
prodromal stage of the disease. Meanwhile, figure 10B displayed soluble monomers, 
low- and high-molecular weight aggregates of N-truncated pyroglutamate Aβ3–42 
are in disequilibrium and are toxic. High-molecular weight aggregates also can be 
neutralized by plaque formation to be nontoxic. However, the process is significant 
A 
B 
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slower tendency as compared to full-length Aβ, because the fibrillation process is 
unordered forming only amorphous fibrils. As a result, the level of soluble low- and 
high-molecular weight aggregates of N-truncated Aβ variants increase over time. 
Hence, the novel pE-Aβ has altered biochemical properties with severe pathological 
consequences. Such as increase hydrophobicity; neurological deficits as show in 
figure 11; thereby pE-Aβ playing a major role in AD. Therefore, if GC was inhibited, 
the pE-Ab formation will be decreased 
 
Figure 11: Severe pathological consequence of Aβ 
  
3.2. Glutaminyl Cyclase (QC)  
QC (QCs, EC 2.3.2.5) have been identified in both animal and plant such as45-47. GC 
is widely distributed in mammalian brain with expression in hippocampus and 
cortex48-49.    
Two types of QCs have been defined thus far. Type I QCs were found in plants and 
in several pathogenic bacteria and human parasites, while type II QCs were mainly 
identified in the neuroendocrine tissues of mammals50-52.  
Papaya QC (pQC) is the best-known type I QC. This enzyme was first discovered in 
the latex of the tropical plant Carica papaya53.  
Structure of human QC 
Overall Structure. The mature domain (residues 33–361) of human QC was shown 
to possess glutaminyl and glutamyl cyclase in physiological substrate of hQC. 
Structure of hQC. (A) A ribbon diagram of the overall structure of human QC. The 

















Ngo Thi Hong Van _ 2013.31349 
edge are colored cyan, magenta, and yellow, respectively. The zinc ion is shown as a 
yellow sphere. The zinc-coordinated residues, Arg-54 (genetic mutation to Trp 
residue occurred frequently in adult women with osteoporosis), and a sulfate ion are 
depicted with a ball-and-stick model. The coils and loops adjacent to the catalytic 
center are painted green, whereas those distant from the active site are colored gray. 
Gray dots represent the disordered region of residues 183–188. (B) A topology 
diagram of the human QC structure. The color codes for secondary structural 
elements are identical to those in A. (C) A stereo-view of the human QC catalytic 
region. The active-site residues in conformation-A are shown and labeled. Possible 
hydrogen and coordination bonds are represented with dotted lines colored cyan and 
yellow, respectively. The green dotted lines depict the possibly unusual hydrogen 
bonds between D305 and E201 (3.06 Å) and between D305 and D248 (2.53 Å).54   
In the past, there are two possible mechanism of hQC catalysis.  
First, the catalysis of the formation of a covalent intermediate could happen. At the 
beginning, a nucleophilic residue attacks the γ-amide group of N-terminal glutaminyl 
form acyl-enzyme intermediate and release ammonia. Then α-amino group of 
glutamine attack nucleophile the γ-carbonyl. 
The second proposal ones is based on non-covalent reaction catalyzied by hQC.  
Catalytic cycle of hQC catalyzing N-terminal glutaminyl substrates. First step is 
the formation of the Michaelis-Menten complex via binding of the substrate. Thereby 
it showes the coordinated water molecule and occupies the fourth coordination site 
of the catalytic zinc. The catalytic Zn ion acts as a Lewis acid, pulls out electrons 
from the γ-carbonyl moiety of the N-terminal glutamine, hence activating the γ-
carbonyl carbon electrophile. Moreover, Glu201 activates via acid-base catalysis the 
α-amino group, which in turn gets more nucleophilic. Afterwards, the α-amino group 
performs a nucleophilic attack on the γ-carbonyl carbon, forming to a short-lived 
tetrahedral intermediate. Then, an intrinsic proton transfer to the potential leaving 
group via a conserved hydrogen bond network is performed to subsequently release 
ammonia and the product. 
More detail, Huang et al. also propose detail substrate specificity of hQC and its 
structural relationship.  
INTRODUCTION 
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The Zn-binding 
environment of the free-
form human QC. The 
2Fo-Fc electron density 
maps (contoured at 1.0) 
(gray) corresponding to 
the water molecules 
inside the active-site 
pocket are shown. 
Representations of the 
models, hydrogen 
bonds, and coordination 
bonds are identical to 
those in Fig. 1C. (B–D) 
Structures of hQC 
bound to 1-
vinylimidazole (1.68-Å resolution), 1-benzylimidazole (1.64-Å resolution), and N--
acetylhistamine (1.56-Å resolution), respectively. The 2Fo-Fc maps (contoured at 1.0) 
(magenta) for the inhibitors are overlaid with the final refined models. Distances for 
enzyme–inhibitor interaction are indicated in Å. 
The conserved Glu-
201 plays as the 
general base and 
acid to transfer a 
proton from the -
amino group of the 
substrate (blue) to 
the leaving amino 
group on the scissile 
-amide. The zinc 
ion polarizes the -
amide carbonyl 
group of the 
substrate and 
simultaneously 
Figure 12: Structures of human QC bound to 
imidazole-derived inhibitors. 
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stabilizes the oxyanion formed by the nucleophilic attack of the -nitrogen. Asp-248 
probably stabilizes the leaving -amide amino group during the catalysis process. In 
the mechanism of glutamyl cyclase activity, this leaving amino group is replaced by 
a hydroxyl group, and the reaction is good at pH 6.0 (Figure 13). 
QC have important role in the production of AβpE3, i.e: injection of Aβ3-40 cause to 
significant level of AβpE3-4050. Beside, in order to study the effect of ectopic hQC 
overexpression, 5XFAD mice was crossed with the transgenic mice expressing hQC 
5XFAD/hQC bigenic mice showed remarkable increased levels of TBS-, SDS- and 
formic acid soluble AβpE3-42. Effect of endogenous QC was verified by generating 
5XFAD/QC-KO mice. 5XFAD/QC-KO mice showed a worthy reduction in AβpE3-42 
levels55, 56. 
Involvement of hQC activity in the formation of pyroglutamyl peptides. By the 
inhibition of QC in neuronal cellsof the central nervous system of AD patients would 
suppress the formation of N-terminal of N-terminal glutamyl cyclization. Thus, QC 
is a key factor in monitor AβpE3-x level in vivo.  
 
3.3.  Some QC inhibitors – promising treatment strategy 
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As mentioned, in present QC is becoming promising strategy in treatment of AD. 
Take PQ-912 as example, the product is developed by Probiodrug, has well tolerated 
and metabolically stability for patients57. Base on the good result, it is now in phase 
II of clinical58. Also our previous researched compound HVH 34159 has potent in vitro 
activity. The two different transgenic model mice of AD, APP/PS1, and 5xFAD 
showed that it not only reduced the brain concentration of pE-Aβ and total Aβ in 
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1. Design and Pharmacophore 
Previously reported QC inhibitors have three pharmacophores designated the A-, B- 
and C-regions, as shown in Figure 1.1.60, 61 The A-region contains a zinc-binding 
motif (ZBM), the B-region contains a hydrogen bond donor, and the C-region 
contains an aromatic ring that mimics the Phe side chain at the penultimate position 
to the N-terminus of the substrate Aβ3E-42. Inspired by these findings, our group 
previously investigated a series of QC inhibitors with an extended scaffold based on 
the N-terminal tripeptide (Glu-Phe-Arg) of Aβ3E-42, and identified an additional 
pharmacophore, the D-region, which mimics the binding interaction of the guanidine 
moiety of Arg.59 The newly developed QC inhibitors display improved potency, 5 to 
40-fold increases, compared to the previously reported inhibitor 1. According to our 
molecular modeling studies, the Arg mimetic D-region forms strong interactions with 
the carboxylate group of Glu327, supporting our hypothesis that the additional 
pharmacophore provides an extra binding interaction. 
 
Figure 1.1: Representative structures of QC inhibitors 
Although compound 2 was the most potent inhibitor in our previous study (IC50 = 0.7 
nM for hQC), it displayed moderate efficacy in an in vivo model, likely due to the 
low blood-brain barrier (BBB) penetration, whereas compound 3 showed a better in 
vivo efficacy, reducing the brain concentrations of Aβ and restoring cognitive 
functions in AD mice. Based on these findings, we aim to develop a library of D-
region-modified analogues with improved potency and BBB penetration. All 
compounds in this series have the same scaffolds in the A-, B-, and C-regions, but 
they contain various moieties, including substituted piperazines, 2-aminopyridines, 
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anilines, and phenyl group derivatives, in the D-region. We also synthesized a group 
of compounds that contain a phenyl and a benzyl linker group between the C- and D-
regions to study the conformational effect of modifications at this specific position. 
We evaluated the QC inhibitory activity in vitro and the in vivo activity of several 
selected compounds; we also analyzed the specific binding interactions between the 
selected inhibitor and the QC active site by performing molecular docking studies. 
 
2. Result and discussion 
2.1. Chemistry 
A library of 46 compounds with modifications in the D-region was 
synthesized. We first synthesized the C/D-region, 4-alkyl(or aryl)oxy-3-
methoxyaniline fragment, and then coupled them to 3-(5-methyl-1H-imidazol-1-
yl)propan-1-amine, which represents the A-region, to obtain the final compounds. 
 
 
Scheme 1.1. Synthesis of piperidine derivatives. Reagents and conditions: (a) PhTf2, 
LDA, THF, -78 °C, overnight; (b) phenylboronic acids, Pd(PPh3)4, MeCN, Na2CO3, 
reflux, overnight; (c) 2-bromo-5-nitroanisole, Cs2CO3, TMEDA, CuI, DMF, 90 °C, 
24 h; (d) H2, Pd/C, MeOH, rt, 2 h; (e) 4-nitroguaiacol, DEAD, PPh3, DCM, r.t., 3 h. 
For the synthesis of the 4-phenylpiperidine D-region fragments (Scheme 1.1), 
the protected piperdin-4-one (5) was converted to the corresponding triflate 6,62 
which underwent the Suzuki coupling reaction with phenylboronic acid derivatives 
to afford compounds 7 and 8, respectively.63 The phenol 7 was reacted with 2-bromo-
5-nitroanisole through the Ullmann reaction to generate the 4-
phenyltetrahydropyridine 9.64 The double bond of compound 8 was carefully reduced 
to piperidine 10 and then coupled with 4-nitroguaiacol in the Mitsunobu reaction to 
afford 4-phenylpiperidine 11.  
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Scheme 1.2. Synthesis of piperazine derivatives. Reagents and conditions: (a) Boc2O, 
DCM, r.t., overnight; (b) HCHO, HCOOH, reflux, overnight; (c) 2-bromo-5-
nitroanisole, Cs2CO3, TMEDA, CuI, DMF, 90 °C, 24 h; (d) t-butyl piperazine-1-
carboxylate, BINAP, PhCH3, Pd(OAc)2, NaOtBu, 100 °C, 15 min; (e) LiAlH4, THF, 
0 °C, 1 h; (f) 4-nitroguaiacol, DEAD, PPh3, DCM, r.t., 3 h. 
For the synthesis of 4-phenylpiperazine fragments (Scheme 1.2), 4-
(piperazin-1-yl)phenol 12 was protected by a Boc group or reductively methylated to 
yield compound 13 or 14, respectively, which underwent the Ullmann coupling 
reaction with 2-bromo-5-nitroanisole to afford compounds 15 and 16. Methyl 3-
bromobenzoate 17 was reacted with N-Boc piperazine under Buchwald-Hartwig 
conditions65 to yield compound 18, whose ester underwent reduction followed by the 
Mitsunobu reaction with 4-nitroguaiacol to produce compound 20.  
For the synthesis of 4-alkylpiperidine, 4-alkylpiperazine and 4-amidoalkyl 
D-region fragments (Schemes 1.3), 4-nitroguaiacol 21 was condensed with 1-Boc-4-
(2-hydroxyethylpiperidine) using the Mitsunobu reaction to yield 4-ethylpiperazine 
derivative 28. The Williamson reaction of compound 21 with dibromoalkanes 
followed by N-alkylation with the corresponding piperazine derivatives produced 4-
alkylpiperazine derivatives 29-38, respectively. For 4-oxopiperidine and piperazine 
derivatives, the acids (39 and 41) were obtained by the hydrolysis of corresponding 
esters (25 and 26), which were prepared by the O-alkylation of compound 21. 
Meanwhile, acid 40 was synthesized from the corresponding alcohol 27 through the 
unwanted β-elimination of 3-bromopropanoate during the O-alkylation with 
compound 21. The acids (39-41) were converted to acyclic and cyclic amides (42-51) 
by coupling with the corresponding amines, respectively. The N-Boc piperidine and 
piperazine derivatives (28-31, 46, and 49) were deprotected to provide the 
corresponding amines (52-57), which underwent N-alkylation or N-acetylation to 
afford compounds 58-72, respectively.  
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Scheme 1.3. Synthesis of 4-alkylpiperidine, 4-alkylpiperazine and 4-amidoalkyl D-
region fragments Reagents and conditions: (a) Br(CH2)nBr or Br(CH2)3OH or 
Br(CH2)nCOOCH3, Cs2CO3, DMF, 100 °C, 30 min; (b) piperazine derivatives, 
Cs2CO3, DMF, 70 °C, 30 min; (c) 1-Boc-4-(2-hydroxyethyl)piperazine, DEAD, PPh3, 
DCM, r.t., overnight; (d) NaOH, MeOH, reflux, 1 h; (e) K2Cr2O7, H2SO4, acetone, 
H2O, r.t., overnight; (f) EDC∙HCl, HOBt, DCM, NH3 (or NH(CH3)2∙HCl, 1-Boc-4-
piperidinamine, 1-Boc piperazine), MC, r.t., overnight; (g) TFA, DCM, r.t., overnight; 
(h) RBr, Cs2CO3, DMF, 100 °C, 30 min; (i) acetyl chloride, TEA, DCM, r.t., 1 h (for 
compound 62). 
The 4-carboxamidopiperidine fragment 75 was synthesized from compound 
21 in 3 steps (Scheme 1.4). For the syntheses of 4-alkyl-2-aminopyridine fragments 
(Scheme 4), 2-amino-4-picoline 76 was protected and then alkylated with O-TBS 3-
bromopropanol to generate compound 78. After deprotection of compound 78, the 
Mitsunobu reaction was performed with 4-nitroguaiacol followed by N-alkylation 
with the corresponding alkyl iodides to generate compounds 80-82, respectively. 
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Scheme 1.4. Synthesis of 4-carboxamidopiperidine fragment and 2-aminopyridyl 
moiety. Reagents and conditions: (a) 2-(2-bromoethyl)isoindoline-1,3-dione, K2CO3, 
DMF, 100 °C, 30 min; (b) N2H4∙H2O, EtOH, r.t., overnight; (c) 1-Boc piperidine-4-
carboxylic acid, EDC∙HCl, HOBt, DCM, r.t., overnight; (d) Boc2O, t-BuOH, r.t., 
overnight; (e) Br(CH2)3OTBS, n-BuLi, THF, -78 °C; (f) TBAF, THF, r.t., 2 h, then 
4-nitroguaiacol, DEAD, PPh3, DCM; (g) RI, Cs2CO3 (or NaH), DMF, heat. 
 
The synthesis of the final compounds is described in Scheme 1.5. The 4-
nitroguaiacol fragments prepared above were reduced by either reacting them with 
zinc powder in acidic medium or hydrogenation to yield the corresponding anilines 
83-125, respectively. All synthesized anilines were coupled in situ with 3-(5-methyl-
1H-imidazol-1-yl)propan-1-amine66 via isothiocyanate to provide the final thioureas 
162, 171-175, 179-182, and 196, as well as the precursors that were converted to the 
final compounds 160-161, 166-168, 170, 177, 184-186, 188-191, 193-195, 199-203, 
and 205 by Boc deprotection, 164-165, 176, 187, 192, and 204 by TBS deprotection 
and 163 and 169 by benzoyl deprotection, respectively. The amide final compounds 
178 and 181 were synthesized from ester 157 by condensation with the corresponding 
amines. The 1-alkyl-4-phenylpiperazines containing the final compounds 197-198 
were prepared from compound 195 by N-alkylation followed by deprotection. 
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Scheme 1.5. Synthesis of final compounds. Reagents and conditions: (a) Zn, MeOH, 
AcOH, r.t., 2 h; (b) Pd/C, H2, MeOH, r.t., 3 h; (c) 3-(5-methyl-1H-imidazol-1-
yl)propan-1-amine, TCDI, TEA, DCM, r.t., overnight; (d) TFA, DCM, r.t., overnight; 
(e) RBr, NaH, DMF, 0 °C to 100 °C, 30 min; (f) HCl, MeOH, r.t., overnight or 
TFA:H2O (9:1), DCM, r.t., overnight; (g) NaOH, MeOH, H2O, reflux, 30 min; (h) 
NH3 or NH(CH3)2, MeOH, rt, overnight. 
 
2.2.  In vitro assay 
 We performed QC activity assays using a fluorogenic substrate, Gln-AMC 
(L-glutamine 7-amido-4-methylcoumarin), and pyroglutamyl peptidase (pGAP) as an 
auxiliary enzyme67 to evaluate the ability of the D-region-modified library to inhibit 
QC. We first investigated a group of compounds containing the modified piperazine 
ring in the D-region and summarized their structures and in vitro inhibition as Group 
I in Table 1. The incorporation of a methyl group at the 2- or 3-position of the 
piperazine (160 and 161) led to a slight reduction in activity, probably due to steric 
hindrance. Among the 4-N substituted piperazine analogues (162-175), compounds 
with a relatively small sized substituent displayed slightly better activity than 
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compounds with aromatic and heteroaromatic rings. Specifically, compounds with an 
alkylamine substituent (167 and 170) appeared to be the most potent of the Group I 
compounds, with IC50 values of 3.8 and 3.6 nM, respectively, suggesting that their 
terminal amino groups may be involved in an additional ionic interaction. When we 
varied the length of the spacer between the piperazine substituent and the C-ring 
oxygen (compounds 163-168, n = 1 to 3), we did not observe any particular trend in 
the inhibitory effect, suggesting that specific interactions, such as the ionic interaction 
inside the binding pocket, may be more important than steric effects. The 4-phenyl 
(171), benzyl (172) and pyrimidine (173-175) derivatives showed moderate 
inhibition (IC50 = 12 to 21.6 nM), and the introduction of a halogen at the 5-position 
of the pyrimidine further reduced the activity. The two piperidine surrogates (176 and 
177) were slightly less active than the corresponding piperazine derivatives (163 and 
166). 
Table 1.1. IC50 values for the inhibition of hQC by Group I (piperazine and piperidine) 
compounds 
 
Compound R n IC50 (nM)a 




2 0.7c  
160 
 
2 5.8 (±1.0) 
161 
 
2 9.9 (±0.7) 
162 
 
2 30.8 (±4.2) 
163 
 
2 7.4 (±1.2) 
164 3 23.5 (±9.8) 
165 4 4.8 (±1.0) 
166 
 
2 7.5 (±6.8) 
167 3 3.8 (±1.9) 
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168 4 8.6 (±0.6) 
169 
 
2 17.3 (±3.1) 
170 
 
2 3.6 (±1.6) 
171 
 
2 21.6 (±5.0) 
172 
 
2 12.7 (±2.9) 
173 
 
2 12 (±3.2) 
174 
 
2 40.3 (±24) 
175 
 
2 66.8 (±45.4) 
176 
 
2 9.0 (±3.7) 
177 
 
2 10.6 (±2.2) 
a Values indicate the means of at least three experiments; b   
 
 Next, we examined the amidoalkyl derivatives in the D-region since the 
aminoalkyl derivatives showed potent inhibitory activity in our previous study.59 As 
described in Table 1.2, compounds with a primary amide (178-180), tertiary amide 
(181-183) and piperazinyl amide (184-186) appeared to be less potent than the 
previously reported aminoalkyl derivatives, probably due to the decreased basicity of 
the amide nitrogen that is thought to be involved in the salt bridge interaction with 
the enzyme. The amide surrogate of 4-aminoethylpiperazinyl derivative (188) 
exhibited a comparable activity to the compound without the amide group (166) 
because both compounds contain the terminal amine. Among the N-(piperidin-4-
yl)amido derivatives (189-194), the N-(aminoethyl)piperidinyl derivative (193) was 
the most potent in the series, with an IC50 of 4.5 nM. In addition, (piperidin-4-
yl)carbamoyl derivative 190 exhibited comparable activity, even without the 4-
aminoethyl group (IC50 = 5.5 nM), whereas its reverse amide (194) showed reduced 
inhibition (IC50 = 15.7 nM). Interestingly, the length of the spacer between the C-
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region oxygen and the D-region (n = 1 to 3) appears to affect the inhibitory activity 
of compounds within this series; compounds with the ethylene spacer (n = 2) 
generally displayed better potency, likely due to the location of the amide nitrogen.  
 
Table 1.2. IC50 values for the inhibition of hQC by Group II (amido compounds) 
 
Compound  n IC50 (nM)a 
178 
 
1 89.7 (±17) 
179 2 19.0 (±11.0) 
180 3 53.8 (±5.7) 
181 
 
1 117 (±19.4) 
182 2 35.4 (±4.0) 
183 3 51.0 (±4.0) 
184 
 
1 15.0 (±2.5) 
185 2 7.7 (±1.8) 
186 3 7.0 (±1.1) 
187 
 
1 48.7 (±3.5) 
188 
 
1 7.8 (±4.1) 
189 
 
1 10.3 (±1.5) 
190 2 5.5 (±0.2) 
191 3 16.7 (±1.1) 
192 
 
1 17.7 (±6.0) 
193 
 
1 4.5 (±4.8) 
PART 1- POTENTIALS ANTI ALZHEIMER’S AGENTS: SAR OF ARG-MIMETIC 
REGION  
23 
Ngo Thi Hong Van _ 2013.31349 
194 
 
2 15.7 (±2.0) 
a Values indicate the means of at least three experiments. 
  
 Next, we modified the linker that connects the C- and the D-regions to 
confer a rigid conformation and evaluated the inhibitory activity of these derivatives 
(Table 1.3). In general, compounds in this series displayed slightly decreased activity 
compared to the compounds with a flexible linker. The piperidine analogue 195 and 
the piperazine analogues 199, 200, and 202 displayed similar inhibitory activities. 
Compounds with a benzyl linker (201 and 202) showed a comparable activity to the 
compounds with a phenyl linker. Overall, the conformational rigidity between the 
two regions did not appear to have a significant impact on QC inhibition. 
 
Table 3. IC50 values for the inhibition of hQC by Group III compounds 
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a Values indicate the means of at least three experiments. 
 
 Finally, we evaluated the inhibitory activity of analogues containing the 2-
aminopyridine group containing and summarized these results in Table 1.4. The 2-
aminoethylamino substituent in compound 205 improved the inhibitory activity (IC50 
= 1.8 nM) compared to its parent compound 3 (IC50 = 4.2 nM), which was also 
observed with the piperidine derivatives. In contrast, the 2-methylamino pyridine 
derivative (203) and the 2-hydroxyethylamino pyridine derivative (204) exhibited 
slightly decreased activity compared to compound 3. 
 
Table 1.4. IC50 values for the inhibition of hQC by Group IV compounds 
 













a Values indicate the means of at least three experiments; b Ref.[31]  
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2.3. In vivo activity 
 Based on the in vitro QC inhibition data, we selected 20 compounds with 
IC50 values less than 10 nM for further in vivo studies. We first screened these 
compounds at one fixed concentration (10 µM) in an immortalized hippocampal 
neuronal cell line (HT-22) to evaluate cytotoxicity, and found that none of the 
compounds, with the exception of compound 170, were cytotoxic. We successively 
injected human Aβ3-40 (5 µg) and each compound (25 mg/kg) into deep 
cortical/hippocampal tissues of ICR mice (male, six weeks old) by 
intracerebroventricular (icv) administration to assess the in vivo activity of the 
selected compounds. We measured the levels of human AβN3pE-40 in the brain extracts 
of these mice on the next day to determine the QC inhibitory activity. As described 
in Table 1.5, compounds 185, 190, 199 and 202 appeared to suppress the formation 
of AβN3pE-40 by 13.5% to 30% compared to the vehicle control. In particular, 
compound 202, which showed the potent inhibition in vitro with an IC50 value of 6.2 
nM, exhibited the most potent AβN3pE-40-42 lowering effects (30%). Because 
compound 202 contains a benzylic linker with a piperidine moiety, this potent in vivo 
activity may be attributed to its high BBB penetration. 
We performed a parallel artificial membrane permeability assay (PAMPA)68 
that can be translated to the ability of the compounds to penetrate the blood-brain 
barrier (BBB). The four most active compounds in vivo 185, 190, 199, and 202, 
showed reasonable permeability, with a range of 4.9-5.8 for –logPe, supporting the 
hypothesis that the in vivo activity of these compounds resulted from good BBB 
penetration and QC inhibition. In contrast, the compounds that showed potent in vitro 
activity but were ineffective in vivo, such as 167, 168, 188, 204 and 205, exhibited 
very low permeability (–logPe = 10). 
We performed an hERG channel assay for all compounds to assess potential 
drug toxicity. Although compounds 185 and 190 slightly inhibited the hERG channel 
by less than 5%, compounds 199 and 202 moderately inhibited the hERG channel by 
52.8% and 40.1%, respectively, at 10 µM. Although compound 202 moderately 
inhibited the hERG channel, overall, this compound exhibited potent in vitro and in 
vivo activities and good brain penetration; therefore, we decided to perform a 
molecular docking study with compound 202. 
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at 10 µM 
 (% of control) 
% inhibition of  





at 10 µM 
(% inhibition)  
160 5.8 ~100 3.01 5.8 33.4 
161 9.9 ~100 NEb 5.3 2.5 
163 7.4 ~100 NE 6.0 9.7 
165 4.8 ~100 NTc 8.7 NT 
166 7.5 ~100 5.43 5.7 2.5 
167 3.8 ~100 NE 10.0 28.9 
168 9.7 ~100 NE 10.0 21.1 
170 3.6 51.1 NT NT NT 
176 9.0 ~100 0.19 6.7 8.2 
185 7.7 ~100 18.7 5.7 1.7 
186 7.0 ~100 8.07 5.7 1.9 
188 7.8 ~100 NE 10.0 14.0 
190 5.5 ~100 13.5 5.6 5.0 
193 4.5 ~100 NE 6.4 17.8 
195 8.5 ~100 NE 5.6 39.7 
199 9.4 ~100 16.1 4.9 52.8 
200 9.9 ~100 NE 5.6 72.8 
202 6.2 ~100 30.0 5.8 40.1 
204 8.7 ~100 NE 10.0 44.4 
205 1.8 ~100 NE 10.0 31.5 
a Five microliters of human Aβ3−40 in PBS (1 µg/µL) were injected into the deep 
cortical/hippocampal tissues of 5-week-old ICR mice (25 g, n = 4, males) using a 
stereotaxic frame to induce acute Aβ toxicity. Test compounds were administered via 
an icv. A sandwich ELISA was performed to quantify the brain AβN3pE-40 level; bNE 
= not effective; cNT = not tested. 
 
2.4. Molecular modeling 
We performed sequential molecular modeling studies using the X-ray crystal 
structure of hQC (PDB id: 3PBB)69 to investigate the interactions between hQC and 
compound 202. The initial docking study was conducted using the piperidine 
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protonated form of compound 202 at pH 7.4, utilizing Glide SP (Standard Precision). 
The presence of the 5-methyl imidazole in the A-region chelated zinc and formed an 
H-bond with the indole NH of Trp329, as well as several hydrophobic interactions 
with Leu249, Trp207, and Ile321. The thiourea group in the B-region contributed to 
the appropriate positioning of the C-region phenyl ring for the hydrophobic 
interaction with Tyr299. Interestingly, the phenyl ring located between the C- and D-
regions participated in a hydrophobic interaction with Pro324. The piperidine ring of 
the D-region participated in a hydrophobic interaction with Pro326 (Figure 1.2A).  
 
Figure 1.2. Binding modes of compound 202 in hQC after (A) Glide SP docking, (B) 
QPLD, (C) local optimization, and (D) Monte Carlo minimization. Binding modes of 
the protonated form of compound 202 are shown in each step. Interactions with 
Glu327 are highlighted in red-dotted boxes, and the distances between Glu327 and 
the terminal N from the D-region of the ligands are marked with black dashed lines. 
Subsequently, we performed Glide QM-Polarized Ligand Docking (QPLD) 
in Maestro. The piperidine ring in the D-region moved toward Glu327 of the hQC 
active site (Figure 1.2B). The local optimization refinement further shifted the 
Glu327 side chain toward the piperidine ring of compound 202 (Figure 1.2C). We 
conducted Monte Carlo minimization to identify the global minimum (Figure 1.2D). 
This type of sequential optimization of the protein-ligand complexes induced a 
remarkable change in the orientation of the Glu327 side chain, leading to the 
formation of a salt bridge interaction, along with the H-bond with the D-region of 
compound 202. Overall, the A-region maintained its binding position and interactions 
throughout the optimization procedure, whereas the phenyl ring in the C-region 
formed an additional H-bond with Tyr299. Moreover, the phenyl ring located 
between the C- and D-regions showed additional π- π interactions with Phe325 
(Figure 1.3). 
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Figure 1.3. Refined structure of compound 202 docked with hQC. (A) Binding 
interactions of compound 202 at the active site of the hQC. Compound 202 is 
displayed as sticks with magenta carbon atoms, and Zn2+ is depicted as a purple ball. 
The interacting residues are depicted as light blue sticks. Hydrogen bonds are 
depicted as black dashed lines. (B) A 2D representation of the interactions of 
compound 202 with the active site residues of hQC. Hydrophobic interactions are 
marked in light brown. Hydrogen bonds are shown as red-dotted arrows with the 
indicated directionality. The π-π stacking interaction is marked as a blue disc and 
arrow, and the salt bridge interaction is displayed as blue wedged line. 
 
3. Conclusion 
 In the present study, we synthesized and evaluated the biological activity of the 
D-region-modified analogues based on the previously developed lead compounds 2 
and 3. In general, the modification of the piperazinyl group maintained or slightly 
reduced QC inhibition in vitro compared to its parent compound 2, and the 
rigidification of the linker between the C- and D-regions did not appear to affect 
biological activity. Compared to the lead compound 3, the addition of an aminoethyl 
group to the 2-aminopyridine ring of the D-region slightly improved the in vitro 
activity up to 2.5-fold. When we tested compounds with low IC50 values (<10 nM) in 
mice, four compounds with high membrane penetration (-logPe = 4.9 to 5.8) 
displayed good in vivo activity. In particular, compound 202 reduced AβN3pE-40 
formation in the brain by 30% compared to the vehicle-treated control. According to 
the molecular docking study of compound 202, the benzyl linker between the C- and 
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D-regions participated in an additional hydrophobic interaction with Phe325 in the 
active site. We believe that our SAR studies added valuable information regarding 
the D-region pharmacophore, and we will continue our efforts in lead optimization to 
identify QC inhibitors with better penetration and in vivo activity without any 
potential toxicity.  
 
4. Experimental  
4.1. Chemistry 
4.1.1. General 
All chemical reagents were commercially available. Silica gel column 
chromatography was performed on silica gel 60, 230-400 mesh, Merck. 1H NMR 
spectra were recorded on a a JEOL JNM-LA 300 at 300 MHz, Bruker Analytik, 
DE/AVANCE Digital 400 at 400 MHz, a Bruker Analytik, DE/AVANCE Digital 500 
at 500 MHz, and a JEOL JNM-ECA-600 at 600 MHz. Mass spectra were recorded 
on a VG Trio-2 GC−MS instrument and a 6460 Triple Quad LC−MS instrument. 
Melting points were determined on a melting point Buchi B-540 apparatus and are 
uncorrected. All final compounds were assessed for purity by high performance liquid 
chromatography (HPLC) on Agilent 1120 Compact LC (G4288A) system via the 
following conditions. Column: Agilent TC-C18 column (4.6 mm × 250 mm, 5 μm). 
Mobile phase A: MeOH, Mobile phase B: 0.1% TFA in water (v/v) in 30 min. 
Wavelength: 254 nM. Flow: 0.7 mL/min. According to the HPLC analyses, all final 
compounds showed a purity of ≥95%. 
4.1.2. General procedure 
4.1.2.1. Suzuki coupling (Procedure 1) 
A solution containing the triflate compound (1.0 equiv) and boronic compound (1.0 
equiv) in acetonitrile and sodium carbonate (1.5 equiv) was added to a dried two-neck 
flask. Then, the mixture was degassed and back-filled with dry nitrogen before a 
suspension of tetrakis(triphenylphosphine)palladium(0) (5% mol) in acetonitrile was 
added. The reaction was refluxed overnight, then cooled to room temperature, 
quenched with water, extracted with EtOAc (2x 50 mL), dried over MgSO4, and 
concentrated. The concentrate was purified by silica gel chromatography with EA:n-
hexane to obtain the product.  
 
4.1.2.2. Ullmann reaction (Procedure 2)  
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A dried two-neck flask was charged with aryl halide (1 equiv), phenol compound (1 
equiv), cesium carbonate (2 equiv) and N,N′-dimethylethylenediamine (0.2 equiv) in 
anhydrous DMF. The reaction was degassed and back-filled with dry nitrogen before 
CuI (0.1 equiv) in DMF was added. The reaction was stirred at 90-100 °C for 24 h, 
cooled to room temperature, quenched with NaHCO3 and extracted with EtOAc (2x 
50 mL). The organic layer was washed with water 3 times, dried over MgSO4, and 
concentrated. The concentrate was purified by silica gel chromatography with 
EtOAc:n-hexane to obtain the desired product.  
 
4.1.2.3. Mitsunobu reaction (Procedure 3)  
Triphenylphosphine (1.3 equiv) was added to a solution of 4-nitroguanicol (1.0 equiv) 
in DCM under a nitrogen atmosphere, followed by the addition of a primary alcohol 
(1.2 equiv) and a solution of diethyl azodicarboxylate (1.3 equiv) in DCM. After the 
solution was stirred for 30 minutes at room temperature, the reaction was poured onto 
a column of silica and was eluted with EtOAc:n-hexane to yield the desired product. 
 
4.1.2.4. Reduction (Procedure 4) 
Procedure 4.1: AcOH (5 equiv) and Zn dust (5 equiv) were added to a solution of a 
nitro compound in MeOH (10 mL) at room temperature. The reaction mixture was 
stirred at room temperature for 30 minutes and then filtered through a celite filter. 
The filtrate was portioned between H2O (10 mL) and DCM (30 mL). The organic 
layer was separated, dried over MgSO4, concentrated, and purified by column 
chromatography to provide the product.  
Procedure 4.2: The nitro compound or alkene derivative was dissolved in MeOH (or 
mixture of MeOH and THF) and then 10% Pd/C was added. The mixture was stirred 
at room temperature under hydrogen gas until all starting material was consumed 
(confirmed by TCL). The crude mixture was filtered through celite filter, washed with 
MeOH (3 x 50 mL) and then concentrated. The product was subjected to the next step 
without further purification. 
 
4.1.2.5. Williamson reaction (Procedure 5)  
Alkyl halide (4.0 equiv) was added to a suspension of 4-nitroguanicol (1.0 equiv) and 
cesium carbonate (2.0 equiv) in anhydrous DMF. The reaction mixture was heated to 
100 °C for 1 hour and then cooled to room temperature before being quenched with 
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water. The mixture was extracted with EtOAc (2 x 50 mL). The organic layer was 
washed with water 3 times, dried with MgSO4 and concentrated. The concentrate was 
purified by column chromatography to obtain the product. 
 
4.1.2.6. Boc protection and deprotection 
Procedure 6.1: Triethylamine (1.2 equiv) and di-tert-butyl dicarbonate (2.5 equiv) in 
DCM were added to a suspension of the starting amine material (1.0 equiv) in DCM 
in an ice bath. The mixture was stirred at room temperature until starting material was 
consumed (confirmed by TLC). Water was added to the mixture and subsequently 
extracted with DCM. The organic layer was washed with a 10% aqueous NaHCO3 
solution, water and brine, dried over MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography to obtain the desired product. 
 
Procedure 6.2: Trifluoroacetic acid (10 equiv) was added to the solution of the boc-
protected compound (1.0 equiv) in DCM (DCM:TFA = 1:1 (v/v)). Then, the mixture 
was stirred at room temperature until the starting material was consumed and 
evaporated. The residue was dissolved in MeOH and purified on an ion-exchange 
column to obtain the desired product or subjected to the next step without further 
purification. 
 
4.1.2.7. TBDMS deprotection (Procedure 7)  
A solution of conc. HCl (0.1 mL) was added to the solution of t-butyl dimethyl silyl 
ether dissolved in MeOH (10 mL). The mixture was stirred at room temperature 
overnight and then concentrated. The concentrate was dissolved in MC and washed 
with water. The organic layer was concentrated to obtain the desired product or 
purified by flash chromatography.  
 
4.1.2.8. Thiourea coupling (Procedure 8)  
A solution of the amine (1.0 equiv) in anhydrous DCM was added to a solution of 
1,1’-thiocarbonyldiimidazole (1.02 equiv) in anhydrous DCM in a dropwise manner 
under nitrogen gas at room temperature. The reaction mixture was stirred at room 
temperature until the starting material was consumed. Then, the solution of 3-(5-
methyl-1H-imidazol-1-yl)propan-1-amine (1.1 equiv) in anhydrous DCM was added 
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dropwise, followed by the addition of triethylamine (3.0 equiv), and stirred at room 
temperature until the reaction was complete (monitored with TLC). The mixture was 
washed with water 2 times, the combined organic layer was dried over MgSO4, 
concentrated, and purified by column chromatography. 
 
4.1.2.9. EDC coupling (Procedure 9)  
EDC.HCl (1.1 equiv) and N,N-diisopropylethylamine (2.2 equiv) were added to a 
solution of the amine compound (1.0 equiv), acid compound (1.0 equiv) and HOBt 
(1.1 equiv) in DCM. The mixture was stirred for 24 hours at room temperature under 
nitrogen. The solvent was removed in vacuo and the residue purified by column 
chromatography on silica gel eluted with DCM:MeOH to produce the desired 
compound. 
 
4.1.2.10. N-Alkylation (Procedure 10) 
A mixture of the alkyl halide, nitrogen-containing compound and excess base (NaH 
for compounds 80 and 81, Cs2CO3 for other compounds) in DMF was stirred at 60 
°C for 30 min. The reaction was quenched with water and extracted with EA. The 
organic layer was washed with water and brine, concentrated and purified by column 
chromatography.              
 
4.1.3. Intermediate compound 
4.1.3.1. tert-Butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-
carboxylate (6). tert-Butyl 4-oxopiperidine-1-carboxylate (1 eq) was added slowly to 
solution of LDA (1.1 eq) in THF at -78 oC. The resulting solution was warmed to 
room temperature and stirred for 30 min. The solution was cooled to -78 oC again and 
a solution N-phenyltrifluromethanesulfonimide (1.05 eq) in THF was added slowly. 
The solution was warmed to room temperature and allowed to stir for 2 more hours. 
The reaction was quenched with water (50 mL). Aqueous extraction was performed 
with EA (2 x 50 mL), dried over MgSO4 and dried under vacuum rotation to get crude 
oil (51%). 1H NMR (300 MHz, CDCl3) δ 5.80-5.72 (m, 1H), 4.06-4.02 (m, 2H), 3.63 
(t, J = 5.60 Hz, 2H), 2.48-2.40 (m, 2H), 1.47 (s, 9H).  
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4.1.3.2. tert-Butyl 4-(4-hydroxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate (7). 
Prepare from compound 6 following the general procedure 1 to get product (86%). 
1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.61 Hz, 2H), 6.83 (d, J = 8.61 Hz, 2H), 
5.89 (s, 1H), 4.06 (d, J = 2.73 Hz, 2H), 3.63 (t, J = 5.67 Hz, 2H), 2.47 (t, J = 5.67 Hz, 
2H), 1.48 (s, 9H).  
 
4.1.3.3. tert-Butyl 4-(3-(hydroxymethyl)phenyl)-5,6-dihydropyridine-1(2H)-
carboxylate (8). From compound 6, procedure 1; white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.37-7.27 (m, 4H), 6.03 (s, 1H), 4.69 (d, J = 5.55 Hz, 2H), 4.08 (br, 2H), 
3.61 (t, J = 5.40 Hz, 2H), 2.51 (br, 2H), 1.69 (t, J = 5.85 Hz, 1H), 1.47 (s, 9H). 
 
4.1.3.4. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)phenyl)-3,6-dihydropyridine-
1(2H)-carboxylate (9). Prepare from compound 7 following the general procedure 2 
to get product (75%).  
 
4.1.3.5. tert-Butyl 4-(3-(hydroxymethyl)phenyl)piperidine-1-carboxylate (10). From 
compound 8, procedure 4.2; yield 99%, white solid.  1H NMR (300 MHz, CDCl3) δ 
7.22-7.12 (m, 4H), 4.69 (s, 2H), 4.23 (br, 2H), 2.80 (t, J = 11.73 Hz, 2H), 2.66 (tt, J 
= 12.09, 3.87 Hz, 1H), 1.83-1.80 (m, 2H), 1.70-1.56 (m, 2H), 1.48 (s, 9H). 
 
4.1.3.6. tert-Butyl 4-(3-((2-methoxy-4-nitrophenoxy)methyl)phenyl)piperidine-1-
carboxylate (11). From compound 10, procedure 3; yield 64%, light yellow solid. 1H 
NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 8.79, 2.55 Hz, 1H), 7.77 (d, J = 2.55 Hz, 
1H), 7.36-7.26 (m, 2H), 7.18 (d, J = 8.52 Hz, 2H), 6.92 (d, J = 8.97 Hz, 1H), 5.22 (s, 
2H), 4.23 (br, 2H), 3.97 (s, 3H), 2.80 (t, J = 12.09 Hz, 2H), 2.66 (t, J = 12.27 Hz, 1H), 
1.84-1.79 (m, 2H), 1.68-1.57 (m, 2H), 1.48 (s, 9H). 
 
4.1.3.7. tert-Butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate (13). Prepare from 
commercially available 4-(1-piperazinyl)phenol 12 following the general procedure 
6.1 to collect desired product (98%). 1H NMR (300 MHz, CDCl3) δ 6.86-6.82 (m, 
2H), 6.79-6.75 (m, 2H), 3.58 (t, J = 4.95 Hz, 4H), 3.00 (t, J = 4.95 Hz, 4H), 1.48 (s, 
9H). 
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4.1.3.8. 4-(4-Methylpiperazin-1-yl)phenol (14). A solution of 4-(1-
piperazinyl)phenol 12 in formic acid and formaldehyde (1:1, v/v) was refluxed 
overnight. Then mixture was basified by dilute bicarbonate solution. DCM work-up 
to get crude white solid (49%). 1H NMR (300 MHz, CDCl3) δ 6.86-6.83 (m, 2H), 
6.77-6.74 (m, 2H), 3.11 (t, J = 4.95 Hz, 4H), 2.60 (t, J = 4.95 Hz, 4H), 2.35 (s, 3H). 
 
4.1.3.9. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)phenyl)piperazine-1-carboxylate 
(15). Prepared from compound 13 following the general procedure 2 to afford yellow 
solid (63%). 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 2.55 Hz, 1H), 7.79 (dd, J = 
2.76, 8.97 Hz, 1H), 7.02-6.93 (m, 4H), 6.76 (d, J = 8.79 Hz, 1H), 4.01 (s, 3H), 3.61 
(t, J = 4.92 Hz, 4H), 3.14 (t, J = 4.95 Hz, 4H), 1.49 (s, 9H).  
 
4.1.3.10. 1-(4-(2-Methoxy-4-nitrophenoxy)phenyl)-4-methylpiperazine (16). Prepare 
from compound 14 following the general procedure 2 to get titled product 125 mg 
(43%). 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 2.55 Hz, 1H), 7.78 (dd, J = 2.67, 
8.79 Hz, 1H), 6.99-6.96 (m, 4H), 6.75 (d, J = 8.97 Hz, 1H), 4.01 (s, 3H), 3.20 (t, J = 
4.95 Hz, 4H), 2.60 (t, J = 4.95 Hz, 4H), 2.37 (s, 3H). 
 
4.1.3.11. tert-Butyl 4-(3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (18). A 
mixture of tert-butyl piperazine-1-carboxylate (1.0 eq), 17 (1.0 eq.), BINAP (5% mol) 
and sodium tert-butoxide (3.0 eq) were placed in two neck round bottom flask. Then 
anhydrous toluene was added to the mixture. The mixture was degassed and back-
filled with dry nitrogen gas before suspension of palladium (II) acetate (5% mol) in 
dry toluene was added. The mixture reaction was stirred at 100 oC for 15 min, cooled 
to room temperature, quenched by water. Normal extraction and purification was 
applied to get white solid, yield 30%. 1H NMR (300 MHz, CDCl3) δ 7.59 (s, 1H), 
7.54 (d, J = 7.68 Hz, 1H), 7.33 (t, J = 8.04 Hz, 1H), 7.10 (d, J = 8.25 Hz, 1H), 3.91 
(s, 3H), 3.59 (t, J = 4.95 Hz, 4H), 3.18 (t, J = 5.31 Hz, 4H), 1.49 (s, 9H). 
 
4.1.3.12. tert-Butyl 4-(3-(hydroxymethyl)phenyl)piperazine-1-carboxylate (19). The 
solution of 18 (1.0 eq.) in THF was cooled in ice bath. Then LAH (2.0 eq) was added 
slowly in the solution. After stirring 30 min the mixture reaction was applied Fisher 
work-up, concentrated to get white solid, yield 88%.  1H NMR (300 MHz, CDCl3) δ 
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7.25 (t, J = 7.89 Hz, 1H), 6.96 (s. 1H), 6.89-6.85 (m, 2H), 4.66 (s, 2H), 3.58 (t, J = 
4.77 Hz, 4H), 3.15 (t, J = 5.13 Hz, 4H), 1.48 (s, 9H). 
 
4.1.3.13. tert-Butyl 4-(3-((2-methoxy-4-nitrophenoxy)methyl)phenyl)piperazine-1-
carboxylate (20). From compound 19, procedure 3, yield 66%, light yellow. 1H NMR 
(300 MHz, CDCl3) δ 7.84 (dd, J = 8.79, 2.58 Hz, 1H), 7.76 (d, J = 2.37 Hz, 1H), 7.29 
(t, J = 7.71 Hz, 1H), 6.98-6.88 (m, 4H), 5.21 (s, 2H), 3.97 (s, 3H), 3.58 (t, J = 4.41 
Hz, 4H), 3.15 (t, J = 4.20 Hz, 4H), 1.48 (s, 9H). 
 
4.1.3.14. 1-(2-Bromoethoxy)-2-methoxy-4-nitrobenzene (22). From 1,2-
dibromoethane and 21, procedure 5, yield 73%. 1H NMR (300 MHz, CDCl3) δ 7.92 
(dd, J = 8.97, 2.58 Hz, 1H), 7.78 (d, J = 2.73 Hz, 1H), 6.94 (d, J = 8.97 Hz, 1H), 4.44 
(t, J = 6.39 Hz, 2H), 3.96 (s, 3H), 3.73 (t, J = 6.39 Hz, 2H). 
 
4.1.3.15. 1-(3-Bromopropoxy)-2-methoxy-4-nitrobenzene (23). Prepare from 
commercially available 21 following the general procedure 5 to get product as pale 
solid (67%). 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 2.55, 8.61 Hz, 1H), 7.75 (d, 
J = 2.37 Hz, 1H), 6.96 (d, J = 8.97 Hz, 1H), 4.28 (t, J = 5.85 Hz, 2H), 3.94 (s, 3H), 
3.66 (2H, 6.21 Hz, 2H), 2.44 (quintet, J = 7.14 Hz, 2H).  
 
4.1.3.16. 1-(4-Bromobutoxy)-2-methoxy-4-nitrobenzene (24). Prepare from 
commercially available 21 and dibromobutane following the general procedure 5 to 
get product (85%). 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 2.76, 8.97 Hz, 1H), 
7.52 (d, J = 2.55 Hz, 1H), 6.91 (d, J = 8.97 Hz, 1H), 4.17 (t, J = 5.88 Hz, 2H), 3.94 
(s, 3H), 3.53 (t, J = 6.39 Hz, 2H), 2.08-2.03 (m, 4H)  
 
4.1.3.17. Methyl 2-(2-methoxy-4-nitrophenoxy)acetate (25). Prepare from 
commercial compound 4-nitro guaiacol 21 following the general procedure 5 to get 
product as a pale yellow solid (90%). 1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 
2.55, 8.79 Hz, 1H), 7.79 (d, J = 2.58 Hz, 1H), 6.83 (d, J  = 8.79 Hz, 1H), 4.81 (s, 2H), 
3.98 (s, 3H), 3.82 (s, 3H). 
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4.1.3.18. Methyl 4-(2-methoxy-4-nitrophenoxy)butanoate (26).  Prepare from 4-
nitroguaiacol 21 following the general procedure 5 to afford product as a pale yellow 
solid (99%). 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.58, 8.97 Hz, 1H), 7.74 (d, 
J = 2.58 Hz, 1H), 6.93 (d, J = 8.97 Hz, 1H), 4.19 (t, J = 6.21 Hz, 2H), 3.94 (s, 3H), 
3.70 (s, 3H), 2.59 (t, J = 7.14 Hz, 2H), 2.25 (quintet, J = 6.57 Hz, 2H). 
 
4.1.3.19. 3-(2-Methoxy-4-nitrophenoxy)propan-1-ol (27). From compound 21, 
procedure 5; yield 74%, light yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J 
= 8.97, 2.55 Hz, 1H), 7.75 (d, J = 2.58 Hz, 1H), 6.93 (d, J = 8.79 Hz, 1H), 4.29 (t, J 
= 6.06 Hz, 2H), 3.95 (s, 3H), 3.90 (q, J = 7.14 Hz, 2H), 2.14 (quintet, J = 5.67 Hz, 
2H). 
 
4.1.3.20. t-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperidine-1-carboxylate 
(28). Prepare from 4-nitroguaiacol 21 following the general procedure 3 to get a 
yellow oil (90%). 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.58, 8.79 Hz, 1H), 
7.75 (d, J = 2.55 Hz, 1H), 6.90 (d, J = 8.97 Hz, 1H), 4.18-4.08 (m, 4H), 3.94 (s, 3H), 
2.72 (t, J = 12.45 Hz, 2H), 1.87 (q, J = 6.42 Hz, 2H), 1.75-1.66 (m, 3H), 1.45 (s, 9H), 
1.23-1.14 (m, 2H).  
 
4.1.3.21. tert-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazine-1-carboxylate 
(29). From tert-butyl piperazine-1-carboxylate and compound 22, procedure 10, yield 
92%, orange solid. 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 8.97, 2.55 Hz, 1H), 
7.75 (d, J = 2.58 Hz, 1H), 6.93 (d, J  = 8.97 Hz, 1H), 4.26 (t, J = 6.03 Hz, 2H), 3.94 
(s, 3H), 3.46 (t, J = 4.77 Hz, 4H), 2.91 (t, J = 5.85 Hz, 2H), 2.56 (t, J = 4.95 Hz, 4H), 
1.46 (s, 9H). 
 
4.1.3.22. tert-Butyl 4-(3-(2-methoxy-4-nitrophenoxy)propyl)piperazine-1-
carboxylate (30). Prepare from 23 following the general procedure 10 to afford white 
solid (70%). 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.55, 8.97 Hz, 1H), 7.74 (d, 
J = 2.55 Hz, 1H), 6.95 (d, J = 8.97 Hz, 1H), 4.21 (t, J = 6.60 Hz, 2H), 3.94 (s, 3H), 
3.45 (t, J = 4.77 Hz, 4H), 2.56 (t, J = 7.14 Hz, 2H), 2.42 (t, J = 4.59 Hz, 4H), 2.09 
(quintet, J = 6.60 Hz, 2H), 1.46 (s, 9H).  
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4.1.3.23. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)butyl)piperazine-1-carboxylate 
(31). Prepare from 24 following the general procedure 5 to get product (76%). 1H 
NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.58, 8.79 Hz, 1H), 7.74 (d, J = 3.18 Hz, 
1H), 6.91 (d, J = 8.79 Hz, 1H), 4.15 (t, J = 6.42 Hz, 2H), 3.94 (s, 3H), 3.44 (t, J = 
4.95 Hz, 4H), 2.42-2.37 (m, 6H), 1.95 (quintet, J = 6.57 Hz, 2H), 1.71 (quintet, J = 
6.96 Hz, 2H), 1.45 (s, 9H).  
 
4.1.3.24. tert-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)ethyl)-3-methylpiperazine-1-
carboxylate (32). From tert-butyl-3-methylpiperazine-1-carboxylate and compound 
22, procedure 10, yield 63%, light yellow oil. 
 
4.1.3.25. tert-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)ethyl)-2,6-dimethylpiperazine-
1-carboxylate (33). From compound 22, procedure 10, white solid. 1H NMR (300 
MHz, CDCl3) δ 7.90 (dd, J = 8.97, 2.55 Hz, 1H), 7.75 (d, J = 2.55 Hz, 1H), 6.96 (d, 
J = 8.79 Hz, 1H), 4.25 (t, J = 5.85 Hz, 2H), 4.13-4.05 (m, 2H), 3.94 (s, 3H), 2.85 (t, 
J = 6.03 Hz, 2H), 2.71 (d, J = 11.16 Hz, 2H), 2.32 (dd, J = 11.34, 4.38 Hz, 2H), 1.46 
(s, 9H), 1.26 (d, J = 6.96 Hz, 6H). 
 
4.1.3.26. 1-(2-(2-Methoxy-4-nitrophenoxy)ethyl)-4-phenylpiperazine (34). From 1-
phenylpiperazine and compound 22, procedure 10, yield 99%, light yellow solid. 1H 
NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 8.97, 2.76 Hz, 1H), 7.75 (d, J = 2.55 Hz, 
1H), 7.30-7.25 (m, 2H), 6.96-6.93 (m, 3H), 6.87 (t, J = 7.32 Hz, 1H), 4.29 (t, J = 6.06 
Hz, 2H), 3.95 (s, 3H), 3.23 (t, J = 4.95 Hz, 4H), 2.96 (t, J = 6.24 Hz, 2H), 2.78 (t, J = 
4.95 Hz, 4H). 
 
4.1.3.27. 1-Benzyl-4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazine (35). Prepare 
from 22 following the general procedure 5 to give product as yellow solid (70%). 1H 
NMR (300 MHz, CD3OD) δ 7.91 (dd, J = 2.58, 8.97 Hz, 1H), 7.73 (d, J = 2.73 Hz, 
1H), 7.32-7.23 (m, 5H), 6.92 (d, J = 8.97 Hz, 1H), 4.25 (t, J = 6.24 Hz, 2H), 3.92 (s, 
3H), 3.51 (s, 2H), 2.91 (t, J = 6.21 Hz, 2H), 2.63 (br, 4H), 2.50 (br, 4H). 
 
4.1.3.28. 2-(4-(2-(2-Methoxy-4-nitrophenoxy)ethyl)piperazin-1-yl)pyrimidine (36). 
From 2-(piperazin-1-yl)pyrimidine and compound 22, procedure 10, yield 70%. 1H 
NMR (300 MHz, CDCl3) δ 8.31 (d, J = 4.8 Hz, 2H), 7.90 (dd, J = 8.8, 2.6 Hz, 1H), 
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7.75 (d, J = 2.6 Hz, 1H), 6.94 (d, J = 9.0 Hz, 1H), 6.50 (d, J = 4.8 Hz, 1H), 4.29 (t, J 
= 6.0 Hz, 2H), 3.95 (s, 3H), 3.86 (t, J = 5.0 Hz, 4H), 2.94 (t, J = 6.0 Hz, 2H), 2.67 (t, 
J = 5.0 Hz, 4H). 
 
4.1.3.29. 5-Fluoro-2-(4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazin-1-
yl)pyrimidine (37). From compound 22, procedure 10 
 
4.1.3.30. 5-Chloro-2-(4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazin-1-
yl)pyrimidine (38). From 5-chloro-2-(piperazin-1-yl)pyrimidine and compound 22, 
procedure 10, yield 57%. 1H NMR (400 MHz, CDCl3) δ 8.22 (s, 2H), 7.90 (dd, J = 
8.80, 2.6 Hz, 1H), 7.75 (d, J = 2.60 Hz, 1H), 6.94 (d, J = 8.80 Hz, 1H), 4.29 (t, J = 
6.00 Hz, 2H), 3.95 (s, 3H), 3.80 (t, J = 5.00 Hz, 4H), 2.94 (t, J = 6.00 Hz, 2H), 2.67 
(t, J = 5.00 Hz, 4H). 
 
4.1.3.31. 2-(2-Methoxy-4-nitrophenoxy)acetic acid (39). Prepare from 25 following 
hydrolysis reaction in solution of NaOH to get  a yellow oil as product (88%). 1H 
NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 2.76, 8.97 Hz, 1H), 7.80 (d, J = 2.58 Hz, 
1H), 6.89 (d, J = 9.00 Hz, 1H), 4.82 (s, 2H), 3.49 (s, 3H).  
 
4.1.3.32. 3-(2-Methoxy-4-nitrophenoxy)propanoic acid (40). The cooled solution of 
27 in acetone was added slow excess of solution K2Cr2O7 in sulfuric acid. The mixture 
reaction was stirred room temperature overnight, extraced by EA. The organic layer 
was collected, washed by dilute bicarbonate solution, concentrated and purified by 
silica gel to get light yellow solid, yield 68%. 1H NMR (300 MHz, CDCl3) δ 7.90 (dd, 
J = 8.97, 2.73 Hz, 1H), 7.75 (d, J = 2.55 Hz, 1H), 6.94 (d, J = 8.79 Hz, 1H), 4.39 (t, 
J = 6.39 Hz, 2H), 3.94 (s, 3H), 2.98 (t, J = 6.21 Hz, 2H). 
 
4.1.3.33. 4-(2-Methoxy-4-nitrophenoxy)butanoic acid (41). Prepare from compound 
26 following the hydrolysis reactin to give product as light yellow solid (58%). 1H 
NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.55, 8.97 Hz, 1H), 7.74 (d, J = 2.55 Hz, 
1H), 6.92 (d, J  = 8.79 Hz, 1H), 4.20 (t, J  = 6.24 Hz, 2H), 3.93 (s, 3H), 2.65 (t, J  = 
7.14 Hz, 2H), 2.32 (quintet, J  = 6.78 Hz, 2H). 
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4.1.3.34. 3-(2-Methoxy-4-nitrophenoxy)propanamide (42). From compound 40 and 
solution of NH3 in THF, procedure 9, yield 42%, light yellow solid. 1H NMR (300 
MHz, CDCl3) δ 7.91 (dd, J = 8.79, 2.58 Hz, 1H), 7.56 (d, J = 2.55 Hz, 1H), 6.97 (8.97 
Hz, 1H), 4.40 (t, J = 6.03 Hz, 2H), 3.94 (s, 3H), 2.81 (t, J = 6.03 Hz, 2H). 
 
4.1.3.35. 4-(2-Methoxy-4-nitrophenoxy)butanamide (43). Prepare from compound 41 
following the general procedure 9 to afford the desired product (70%). 1H NMR (300 
MHz, CDCl3) δ 7.91 (dd, J = 2.73, 8.97 Hz, 1H), 7.75 (d, J = 2.73 Hz, 1H), 6.95 (d, 
J = 8.97 Hz, 1H), 5.62-5.38 (br, 2H), 4.21 (t, J = 6.06 Hz, 2H), 3.94 (s, 3H), 2.51 (t, 
J = 7.32 Hz, 2H), 2.26 (quintet, J  = 6.24 Hz, 2H). 
 
4.1.3.36. 3-(2-Methoxy-4-nitrophenoxy)-N,N-dimethylpropanamide (44). From 
compound 40 and dimethylamine, procedure 9, yield 45%, light yellow solid. 1H 
NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 8.97, 2.76 Hz, 1H), 7.74 (d, J = 2.58 Hz, 
1H), 7.00 (d, J = 8.97 Hz, 1H), 4.46 (t, J = 7.14 Hz, 2H), 3.94 (s, 3H), 3.07 (s, 3H), 
2.98 (s, 3H), 2.95 (t, J = 7.14 Hz, 2H). 
 
4.1.3.37. 4-(2-Methoxy-4-nitrophenoxy)-N,N-dimethylbutanamide (45). Prepare from 
compound 41 following the general procedure 9 to give desired product (38% yield). 
1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.73, 8.97 Hz, 1H), 7.75 (d, J = 2.73 Hz, 
1H), 6.95 (d, J = 8.97 Hz, 1H), 4.21 (t, J = 6.24 Hz, 2H), 3.94 (s, 3H), 3.02 (s, 3H), 
2.95 (s, 3H), 2.56 (t, J = 7.32 Hz, 2H), 2.25 (quintet, J = 6.27 Hz, 2H).  
 
4.1.3.38. tert-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)acetyl)piperazine-1-carboxylate 
(46). Prepare from 39 following the general procedure 9 to furnish the product as 
white foam (87%). 1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 2.55, 8.79 Hz, 1H), 
7.77 (d, J = 2.58 Hz, 1H), 7.00 (d, J = 8.97 Hz, 1H), 4.87 (s, 2H), 3.96 (s, 3H), 3.58-
3.36 (m, 4H), 3.44-3.40 (m, 4H), 1.46 (s, 9H). 
 
4.1.3.39. tert-Butyl 4-(3-(2-methoxy-4-nitrophenoxy)propanoyl)piperazine-1-
carboxylate (47). From compound 40 and N-Bocpiperazine, procedure 9; yield 76%, 
light yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 8.79, 2.55 Hz, 1H), 
7.74 (d, J = 2.55 Hz, 1H), 6.98 (d, J = 8.97 Hz, 1H), 4.46 (t, J = 6.75 Hz, 2H), 3.93 
(s, 3H), 3.52 (br, 4H), 3.45-3.41 (m, 4H), 2.93 (t, J = 6.78 Hz, 2H), 1.48 (s, 9H). 
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4.1.3.40. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)butanoyl)piperazine-1-
carboxylate (48). Prepare from compound 41 following the general procedure 9 to 
give desired product (32% yield) as a light yellow solid. 1H NMR (300 MHz, CDCl3) 
δ 7.91 (dd, J = 2.55, 8.79 Hz, 1H), 7.74 (d, J = 2.58 Hz, 1H), 6.97 (d, J = 8.97 Hz, 
1H), 4.22 (t, J = 6.21 Hz, 2H), 3.94 (s, 3H), 3.60 (t, J = 7.32 Hz, 2H), 3.45 (m, 6H), 
2.59 (t, J = 6.96 Hz, 2H), 2.25 (quintet, J = 6.60 Hz, 2H), 1.47 (s, 9H).  
 
4.1.3.41. tert-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)acetamido)piperidine-1-
carboxylate (49). Prepare from 39 following the general procedure 9 to get the 
product as a white foam (84%). 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 2.55, 
8.76 Hz, 1H), 7.20 (d, J = 2.55 Hz, 1H), 6.94 (d, J = 8.97 Hz, 1H), 6.70 (br, 1H), 4.58 
(s, 2H), 4.03-4.00 (m, 3H), 3.98 (s, 3H), 2.92 (t, J = 11.34 Hz, 2H), 1.95-1.92 (m, 
2H), 1.46 (s, 9H), 1.41-1.37 (m, 2H).  
 
4.1.3.42. tert-Butyl 4-(3-(2-methoxy-4-nitrophenoxy)propanamido)piperidine-1-
carboxylate (50). Prepare from 40 following the general procedure 9 to give desired 
product (76%) as a light yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 
2.55, 8.79 Hz, 1H), 7.76 (d, J = 2.55 Hz, 1H), 6.96 (d, J = 8.79 Hz, 1H), 6.00 (br, 
1H), 4.39 (t, J = 5.85 Hz, 2H), 3.93-3.92 (m, 3H), 3.93 (s, 3H), 2.89 (t, J = 7.32 Hz, 
2H), 2.75 (t, J = 5.67 Hz, 2H), 1.89-1.87 (m, 2H), 1.45 (s, 9H), 1.33-1.32 (m, 2H). 
 
4.1.3.43. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)butanamido)piperidine-1-
carboxylate (51). From compound 41 and 1-Bocpiperidin-4-amine, procedure 9, 
yield 94%, light yellow solid.  
 
4.1.3.44. 1-(2-(2-Methoxy-4-nitrophenoxy)ethyl)piperazine (52). From compound 
29, procedure 6.2, yield 85%. 
 
4.1.3.45. 1-(3-(2-Methoxy-4-nitrophenoxy)propyl)piperazine.trifluoroacetic 
acid    (53). Prepare from 30 following the general procedure 6.2 to give a pale yellow 
oil (93%). 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 2.58, 8.79 Hz, 1H), 7.82 (d, J 
= 2.58 Hz, 1H), 7.14 (d, J = 8.97 Hz, 1H), 4.31 (t, J = 5.49 Hz, 2H), 3.94 (s, 3H), 
3.64-3.49 (m, 8H), 3.53 (t, J = 7.32 Hz, 2H), 2.37 (quintet, J = 6.60 Hz, 2H). 
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4.1.3.46. 1-(4-(2-Methoxy-4-nitrophenoxy)butyl)piperazine (54). Prepare from 31 
following the general procedure 6.2 to give a pale yellow oil (95%). 1H NMR (300 
MHz, CDCl3) δ 7.91 (dd, J = 2.22, 8.79 Hz, 1H), 7.74 (d, J = 2.19 Hz, 1H), 6.90 (d, 
J = 8.97 Hz, 1H), 4.14 (t, J = 6.06 Hz, 2H), 3.93 (s, 3H), 3.25-3.22 (m, 4H), 2.84-
2.81 (m, 4H), 2.64 (t, J = 6.96 Hz, 2H), 1.95-1.90 (quintet, J = 4.95 Hz, 2H), 1.75 
(quintet, J = 6.96 Hz, 2H). 
 
4.1.3.47. 4-(2-(2-Methoxy-4-nitrophenoxy) ethyl) piperidine (55). Prepare from 28 
following the general procedure 6.2 to give a pale yellow oil (90%). 1H NMR (300 
MHz, CDCl3) δ 7.90 (dd, J = 2.76, 8.97 Hz, 1H), 7.74 (d, J = 2.76 Hz, 1H), 6.90 (d, 
J = 8.97 Hz, 1H), 4.15 (t, J = 6.75 Hz, 2H), 3.94 (s, 3H), 3.17 (d, J = 12.27 Hz, 2H), 
2.72-2.62 (m, 2H), 1.87 (q, J = 6.57 Hz, 2H), 1.81-1.73 (m, 3H), 1.45 (s, 9H), 1.23-
1.14 (m, 2H).  
 
4.1.3.48. 2-(2-Methoxy-4-nitrophenoxy)-1-(piperazin-1-yl)ethan-1-one (56). Prepare 
from 46 following the general procedure 6.2 to get desired product as a pale yellow 
semi liquid (98%). 1H NMR (300 MHz, DMSO) δ 8.98 (br, 1H), 7.87 (dd, J = 2.73, 
8.97 Hz, 1H), 7.76 (d, J = 2.55 Hz, 1H), 7.10 (d, J = 8.97 Hz, 1H), 5.11 (s, 2H), 3.90 
(s, 3H), 3.66-3.64 (m, 4H), 3.20-3.16 (m, 4H)  
 
4.1.3.49. 2-(2-Methoxy-4-nitrophenoxy)-N-(piperidin-4-yl)acetamide (57). Prepare 
from 49 following the general procedure 6.2 to get desired product as a pale yellow 
semi liquid  (95%). 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 2.55, 8.97 Hz, 1H), 
7.80 (d, J = 2.55 Hz, 1H), 6.94 (d, J = 8.79 Hz, 1H), 6.70 (br, 1H), 4.58 (s, 2H), 3.98 
(s, 3H), 3.95-3.93 (m, 1H), 3.09-3.05 (m, 2H), 2.75 (t, J = 11.52 Hz, 2H), 1.96-1.92 
(m, 2H), 1.44-1.35 (m, 2H). 
 
4.1.3.50. 2-(4-(2-(2-Methoxy-4-nitrophenoxy)ethyl)piperazin-1-yl)ethyl 4-
methoxybenzoate (58). From 2-bromoethyl 4-methoxybenzoate and compound 52, 
procedure 10, light yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 8.97 Hz, 
2H), 7.89 (dd, J = 8.79, 2.58 Hz, 1H), 7.74 (d, J = 2.55 Hz, 1H), 6.94-6.90 (m, 3H), 
4.43 (t, J = 6.03 Hz, 2H), 4.24 (t, J = 6.03 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 2.89 (t, 
J = 6.06 Hz, 2H), 2.79 (t, J = 6.06 Hz, 2H), 2.64 (br, 8H). 
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4.1.3.51. tert-Butyl 2-(4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazin-1-
yl)ethylcarbamate (59). From 2-(boc-amino)ethyl bromide and compound 52, 
procedure 10, yield 33%, white solid. 
 
4.1.3.52. 2-(2-(4-(2-(2-Methoxy-4-nitrophenoxy)ethyl)piperazin-1-yl)ethoxy)ethyl 4-
methoxybenzoate (60). From 2-(2-bromoethoxy)ethyl 4-methoxybenzoate and 
compound 52, procedure 10, light yellow oil. 1H NMR (300 MHz, CDCl3) δ 8.00 (d, 
J = 8.79 Hz, 2H), 7.89 (dd, J = 9.00, 2.58 Hz, 1H), 7.74 (d, J = 2.55 Hz, 1H), 6.93-
6.89 (m, 3H), 4.44 (t, J = 4.92 Hz, 2H), 4.21 (t, J = 6.03 Hz, 2H), 3.93 (s, 3H), 3.85 
(s, 3H), 3.78 (t, J = 4.95 Hz, 2H), 3.67 (t, J = 5.67 Hz, 2H), 2.87 (t, J = 6.21 Hz, 2H), 
2.62 (br, 10H). 
 
4.1.3.53. tert-Butyl 2-(2-(4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperazin-1-
yl)ethoxy)ethylcarbamate (61). From tert-butyl N-(2-(2-
bromoethoxy)ethyl)carbamate and compound 52, procedure 10, light yellow oil. 1H 
NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 8.79, 2.58 Hz, 1H), 7.74 (d, J = 2.76 Hz, 
1H), 6.91 (d, J = 8.79 Hz, 1H), 5.19 (br, 1H), 4.24 (t, J = 6.21 Hz, 2H), 3.91 (s, 3H), 
3.58 (t, J = 5.67 Hz, 2H), 3.51 (t, J = 4.95 Hz, 2H), 3.30 (q, J = 4.92 Hz, 2H), 2.90 (t, 
J = 6.03 Hz, 2H), 2.66 (br, 4H), 2.59 (t, J = 5.70 Hz, 6H), 1.45 (s, 9H). 
 
4.1.3.54. 1-(4-(2-(2-Methoxy-4-nitrophenoxy)ethyl)piperazin-1-yl)ethanone (62). 
The solution of 52 in DCM was added excess acetyl chloride and TEA at 0-5 oC. The 
mixture reaction was stirred at room temperature for 1 h, then diluted with DCM and 
quenched by water. The organic layer was washed with water, concentrated and 
purified by silica gel to get light yellow solid, yield 93%.  
 
4.1.3.55. 1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-4-(3-(2-methoxy-4-
nitrophenoxy)propyl)piperazine (63). Prepare from 53 following the general 
procedure 10 to afford red solid (65%). 1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 
2.60, 8.96 Hz, 1H), 7.72 (d, J = 2.56 Hz, 1H), 6.92 (d, J = 8.96 Hz, 1H), 4.17 (t, J = 
6.56 Hz, 2H), 3.91 (s, 3H), 3.75 (t, J = 6.36 Hz, 2H), 2.53-2.49 (m, 12H), 2.06 
(quintet, J = 6.80 Hz, 2H), 0.86 (s, 9H), 0.03 (s, 6H). 
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4.1.3.56. tert-Butyl (2-(4-(3-(2-methoxy-4-nitrophenoxy)propyl)piperazin-1-
yl)ethyl)carbamate (64). Prepare from 53 following the general procedure 10 to 
afford red solid (47%). 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 2.58, 8.79 Hz, 
1H), 7.74 (d, J = 2.58 Hz, 1H), 6.95 (d, J = 8.97 Hz, 1H), 4.97 (br, 1H), 4.20 (t, J = 
6.39 Hz, 2H), 3.94 (s, 3H), 3.24 (q, J = 6.96 Hz, 2H), 2.58-2.51 (m, 12H), 2.10 
(quintet, 2H), 1.45 (s, 9H). 
 
4.1.3.57. tert-Butyl (2-(4-(4-(2-methoxy-4-nitrophenoxy)butyl)piperazin-1-
yl)ethyl)carbamate (65). Prepare from 54 following the general procedure 10 to 
afford yellow semi solid (38%).  
 
4.1.3.58. 1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-4-(4-(2-methoxy-4-
nitrophenoxy)butyl)piperazine (66). Prepare from 54 following the general procedure 
10 to afford yellow semi solid (40%). 1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 
2.52, 8.96 Hz, 1H), 7.71 (d, J = 2.52 Hz, 1H), 6.88 (d, J = 8.92 Hz, 1H), 4.12 (t, J = 
6.64 Hz, 2H), 3.91 (s, 3H), 3.74 (t, J = 6.40 Hz, 2H), 2.52-2.49 (m, 10H), 2.40 (t, J = 
7.16 Hz, 2H), 1.92 (quintet, J = 4.95 Hz, 2H), 1.69 (quintet, J = 6.36 Hz, 2H), 0.86 
(s, 9H), 0.03 (s, 6H). 
 
4.1.3.59. 1-(2-(tert-Butyldimethylsilyloxy) ethyl)-4-(2-(2-methoxy-4-nitrophenoxy) 
ethyl) piperidine (67). Prepare from 55 following the general procedure 10 to afford 
a yellow semi solid (42%). 1H NMR (300 MHz, CDCl3) δ 7.84 (dd, J = 2.73, 8.97 Hz, 
1H), 7.68 (d, J = 2.55 Hz, 1H), 6.83 (d, J = 8.97 Hz, 1H), 4.11-4.06 (m, 4H), 3.88 (s, 
3H), 3.74 (t, J = 4.77 Hz, 2H) 2.72-2.62 (m, 2H), 1.87 (q, J = 6.6 Hz, 2H), 1.71-1.67 
(m, 3H), 1.21-1.13 (m, 4H), 0.82 (s, 9H), 0.03 (s, 6H) 
 
4.1.3.60. tert-Butyl 2-(4-(2-(2-methoxy-4-nitrophenoxy)ethyl)piperidin-1-
yl)ethylcarbamate (68). Prepare from 55 following the general procedure 10 to afford 
yellow semi solid (43%). 1H NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 2.55, 8.79 Hz, 
1H), 7.75 (d, J = 2.55 Hz, 1H), 6.93 (d, J = 8.97 Hz, 1H), 5.04 (s, NH), 4.16 (t, J = 
6.24 Hz, 2H), 3.94 (s, 3H), 3.24 (br, 2H), 2.47 (t, J = 6.06 Hz, 2H), 2.03-1.99 (m, 2H), 
1.87 (quintet, J = 6.42 Hz, 4H), 1.77-1.73 (m, 3H), 1.45 (s, 9H), 1.40-1.35 (m, 2H).  
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4.1.3.61. 1-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)-2-(2-methoxy-4-
nitrophenoxy)ethan-1-one (69). Prepare from 56 following the general procedure 10 
to get 353 mg (78%) of white solid. 1H NMR (300 MHz, CDCl3) δ 7.83 (dd, J = 2.55, 
9.00 Hz, 1H), 7.71 (d, J = 2.76 Hz, 1H), 6.92 (d, J = 8.79 Hz, 1H), 4.81 (s, 2H), 3.90 
(s, 3H), 3.71 (t, J = 5.88 Hz, 2H,), 3.57-3.49 (m, 2H), 3.53-3.50 (m, 2H), 2.50-2.42 
(m, 6H), 0.80 (s, 9H), 0.02 (s, 6H).    
 
4.1.3.62. tert-Butyl (2-(4-(2-(2-methoxy-4-nitrophenoxy)acetyl)piperazin-1-
yl)ethyl)carbamate (70). Prepare from 56 following the general procedure 10 to give 
a white solid (31%). 1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 2.58, 8.97 Hz, 1H), 
7.77 (d, J = 2.55 Hz, 1H), 6.98 (d, J = 8.97 Hz, 1H), 4.86 (s, 2H), 3.96 (s, 3H), 3.61-
3.58 (m, 4H), 3.24-3.20 (m, 2H), 2.46-2.43 (m, 6H), 1.45 (s, 9H)  
 
4.1.3.63. N-(1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperidin-4-yl)-2-(2-methoxy-4-
nitrophenoxy)acetamide (71). Prepare from 57 following the general procedure 10 to 
give an opaque semi liquid (45%). 1H NMR (300 MHz, CDCl3) δ 7.86 (dd, J = 2.40, 
8.79 Hz, 1H), 7.74 (d, J = 2.37 Hz, 1H), 6.87 (d, J = 8.79 Hz, 1H), 6.65 (br, 1H), 4.51 
(s, 2H), 3.92 (s, 3H), 3.88-3.84 (m, 1H), 3.71 (t, J = 6.21 Hz, 2H), 2.82-2.78 (m, 2H), 




yl)ethyl)carbamate (72). Prepare from 57 following the general procedure 5 to get 
pale semi solid (51%). 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 2.37, 8.97 Hz, 
1H), 7.80 (d, J = 2.40 Hz, 1H), 6.93 (d, J = 8.79 Hz, 1H), 6.68 (br, 1H), 4.93 (br, 1H), 
4.57 (s, 2H), 3.99 (s, 3H), 3.94-3.91 (m, 1H), 3.21 (q, J = 6.96 Hz, 2H), 2.83-2.79 (m, 
2H), 2.47 (t, J = 6.06 Hz, 2H), 2.19 (t, J = 10.80 Hz, 2H), 1.96-1.92 (m, 2H), 1.52-
1.46 (m, 2H), 1.45 (s, 9H).  
 
4.1.3.65. 2-(2-(2-methoxy-4-nitrophenoxy)ethyl)isoindoline-1,3-dione (73). Prepare 
from 4-nitroguaiacol 21 following the general procedure 5 to afford product as a 
white solid (87%). 1H NMR (600 MHz, CDCl3) δ 7.85-7.83 (m, 3H), 7.73-7.71 (m, 
2H), 7.68 (d, J = 2.76 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 4.36 (t, J = 6.0 Hz, 2H), 4.15 
(d, J = 6.42 Hz, 2H), 3.84 (s, 3H). 
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4.1.3.66. 2-(2-methoxy-4-nitrophenoxy)ethanamine (74). Prepare from 73 (530 mg, 
1.55 mmol) was dissolved in 5 mL mixture of ethanol and dichloromethane (4/1 = 
v/v), N2H4.H2O (0.3 mL, 6.2 mmol) was added dropwise. The mixture was stirred at 
room temperature for 2 hours. A white precipitate formed. The precipitation was 
removed by vacuum filtration through a filter. The solid was wash with EtOH (20 mL 
x 3). The filtrate was collected and concentrated by rotary evaporation and purified 
by column chromatography (MeOH/CH2Cl2 = 1/9) to give desired product as yellow 
solid (78%). 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 2.80, 8.72 Hz, 1H), 7.80 (d, 
J = 2.60 Hz, 1H), 7.11 (d, J = 8.92 Hz, 1H),  4.14 (t, J = 5.32 Hz, 2H), 3.93 (s, 3H), 
3.06 (t, J = 5.32 Hz, 2H). 
 
4.1.3.67. t-Butyl 4-(2-(2-methoxy-4-nitrophenoxy)ethylcarbamoyl)piperidine-1-
carboxylate (75). Prepare from 74 following the general procedure 9 to afforded the 
desired amide (84%). 1H NMR (400 MHz, CDCl3) δ 7.89 (dd, J = 2.56, 8.92 Hz, 1H), 
7.74 (d, J = 2.56 Hz, 1H), 6.91 (d, J = 8.96 Hz, 1H), 6.04 (br, NH) 4.19 (t, J = 5.08 
Hz, 2H), 4.16 (br, 2H), 3.93 (s, 3H), 3.73 (q, J = 5.36 Hz, 2H), 2.75 (t, J = 11.72 Hz, 
2H), 2.27-2.20 (m, 1H), 1.82-1.79 (m, 2H), 1.65-1.56 (m, 2H), 1.42 (s, 9H).  
 
4.1.3.68. tert-Butyl 4-methylpyridin-2-ylcarbamate (77). From 2-amino-4-picoline 
76, procedure 6.1, yield 77%, white solid. 1H NMR (300 MHz, CDCl3) δ 8.46 (s, 1H), 
8.14 (d, J = 5.13 Hz, 1H), 7.82 (s, 1H), 6.78 (d, J = 5.13 Hz, 1H), 2.35 (s, 3H), 1.54 
(s, 9H). 
 
4.1.3.69. tert-Butyl 4-(4-(tert-butyldimethylsilyloxy)butyl)pyridin-2-ylcarbamate 
(78). From compound 77, yield 94%, white solid. 1H NMR (300 MHz, CDCl3) δ 8.08 
(d, J = 5.13 Hz, 1H), 7.75 (s, 1H), 7.70 (br, 1H), 6.75 (dd, J = 5.31, 1.47 Hz, 1H), 
3.58 (t, J = 6.42 Hz, 2H), 2.57 (t, J = 7.32 Hz, 2H), 1.73-1.62 (m, 2H), 1.59-1.46 (m, 
2H), 1.49 (s, 9 H), 0.85 (s, 9H), 0.06 (s, 6H). 
 
4.1.3.70. tert-Butyl 4-(4-(2-methoxy-4-nitrophenoxy)butyl)pyridin-2-ylcarbamate 
(79). Compound 78 was first de protected group by tetra-n-butylammonium fluoride 
in THF then following the general procedure 3 to get light yellow solid product, yield 
74%. 1H NMR (300 MHz, CDCl3) δ 8.13 (d, J = 5.13 Hz, 1H), 7.89 (dd, J = 8.79, 
2.58 Hz, 1H), 7.82 (s, 1H), 7.74 (d, J = 2.55 Hz, 1H), 7.72 (br, 1H), 6.87 (d, J = 8.97 
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Hz, 1H), 6.81 (dd, J = 5.13, 1.47 Hz, 1H), 4.12 (t, J = 6.03 Hz, 2H), 3.94 (s, 3H), 2.70 
(t, J = 7.32 Hz, 2H), 1.95-1.84 (m, 4H), 1.53 (s, 9H). 
 
4.1.3.71. tert-Butyl (4-(4-(2-methoxy-4-nitrophenoxy)butyl)pyridin-2-
yl)(methyl)carbamate (80). Prepare from 79 following the general procedure 10 to 
afford pale yellow solid (64%). 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 5.13 Hz, 
1H), 7.91 (dd, J = 2.76, 9.15 Hz, 1H), 7.74 (d, J = 2.85 Hz, 1H), 7.55 (s, 1H), 6.89-
6.86 (m, 3H), 4.11 (t, J = 6.42 Hz, 2H), 3.94 (s, 3H), 3.41 (s, 3H), 2.72 (t, J = 7.71 
Hz, 2H), 1.93-1.84 (m, 4H), 1.52 (s, 9H). 
 
4.1.3.72. tert-Butyl (4-(4-(2-methoxy-4-nitrophenoxy)butyl)pyridin-2-
yl)(methyl)carbamate (81). Prepare from 79 following the general procedure 10 to 
afford pale yellow solid (53%). 
 
4.1.3.73. tert-Butyl (2-((tert-butoxycarbonyl)amino)ethyl)(4-(4-(2-methoxy-4-
nitrophenoxy)butyl)pyridin-2-yl)carbamate (82). Prepare from 79 following the 
general procedure 10 to afford red solid product (52%). 1H NMR (300 MHz, CDCl3) 
δ 8.25 (d, J = 4.95 Hz, 1H), 7.41 (s, 1H), 6.87 (dd, J = 1.47, 5.13 Hz, 1H), 6.72 (d, J 
= 8.40 Hz, 1H), 6.31 (d, J = 2.58 Hz, 1H), 6.23 (dd, J = 2.55, 8.43 Hz, 1H), 4.08 (t, J 
= 6.60 Hz, 2H), 3.95 (t, J = 6.03 Hz, 2H), 3.93 (s, 3H), 3.79 (t, J = 6.42 Hz, 2H), 2.68 
(t, J = 7.14 Hz, 2H), 1.83-1.79 (m, 4H), 1.51 (s, 9H), 1.41 (s, 9H).  
 
4.1.3.74. tert-Butyl 4-(4-(4-amino-2-methoxyphenoxy)phenyl)-3,6-dihydropyridine-
1(2H)-carboxylate (83). Prepare from compound 9 following the general procedure 
4.1 to get product as opaque solid (65%). 1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 
8.61 Hz, 2H), 6.85 (d, J = 8.61 Hz, 2H), 6.36 (d, J = 2.55 Hz, 1H), 6.28 (dd, J = 2.55, 
8.43 Hz, 1H), 6.25 (s, 1H), 5.93-5.90 (m, 1H),  4.05-4.02 (m, 2H), 3.75 (s, 3H), 3.64 
(t, J = 6.69 Hz, 2H), 2.48-2.45 (m, 2H), 1.48 (s, 9H). 
 
4.1.3.75. tert-Butyl 4-(3-((4-amino-2-methoxyphenoxy)methyl)phenyl)piperidine-1-
carboxylate (84). From compound 11, procedure 4.1; yield 93%, red solid. 1H NMR 
(300 MHz, CDCl3) δ 7.29-7.26 (m, 2H), 7.13-7.11 (m, 2H), 6.70 (d, J = 8.43 Hz, 1H), 
6.32 (d, J = 2.55 Hz, 1H), 6.16 (dd, J = 8.40, 2.55 Hz, 1H), 5.01 (s, 2H), 4.22 (br, 
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2H), 3.84 (s, 3H), 2.75 (t, J = 13.17 Hz, 2H), 2.65 (tt, J = 12.06, 1H), 1.83-1.79 (m, 
2H), 1.69-1.53 (m, 2H), 1.42 (s, 9H). 
 
4.1.3.76. tert-Butyl 4-(3-((4-amino-2-methoxyphenoxy)methyl)phenyl)piperazine-1-
carboxylate (85). From compound 20, procedure 4.1, yield 78%, red solid.  
 
4.1.3.77. tert-Butyl 4-(4-(4-amino-2-methoxyphenoxy)phenyl)piperidine-1-
carboxylate (86). Prepare from compound 9 following the general procedure 4.2 to 
get product as red semi solid (81%). 1H NMR (300 MHz, CDCl3) δ 7.08-7.05 (m, 
3H), 6.85 (d, J = 8.64 Hz, 2H), 6.36 (d, J = 2.58 Hz, 1H), 6.27 (dd, J = 2.76, 8.43 Hz, 
1H), 4.20 (t, J = 10.08 Hz, 2H), 3.76 (s, 3H), 2.77 (t, J = 11.52 Hz, 2H), 2.58-2.53 
(m, 1H), 1.81 (m, 2H), 1.54 (m, 2H), 1.45 (s, 9H).  
 
4.1.3.78. tert-Butyl 4-(4-(4-amino-2-methoxyphenoxy)phenyl)piperazine-1-
carboxylate (87). Prepared from compound 15 following the general producer 4.2 to 
afford a red solid (99%). 1H NMR (300 MHz, CDCl3) δ 6.84-6.80 (m, 4H), 6.79 (d, J 
= 8.43 Hz, 1H), 6.36 (d, J = 2.40 Hz, 1H), 6.25 (dd, J = 2.55, 8.40 Hz, 1H), 3.77 (s, 
3H), 3.58 (t, J = 4.95 Hz, 4H), 3.03 (t, J = 4.56 Hz, 4H), 1.47 (s, 9H).  
 
4.1.3.79. 3- Methoxy-4-(4-(4-methylpiperazin-1-yl)phenoxy)aniline (88). Prepare 
from compound 16 following the general procedure 4.2 to get titled product as red 
solid (96%). 
 
4.1.3.80. Methyl 2-(4-amino-2-methoxyphenoxy)acetate (89). Prepare from 
compound 25 following the general procedure 4.2 to to afford desired product as 
yellow solid (99%). 1H NMR (300 MHz, CDCl3) δ 6.77 (d, J = 8.40 Hz, 1H), 6.29 (s, 
1H), 6.20 (d, J = 8.43 Hz, 1H), 4.59 (s, 2H), 3.82 (s, 3H), 3.78 (s, 3H).  
 
4.1.3.81. tert-Butyl 4-(2-(4-amino-2-methoxyphenoxy)ethyl)-3-methylpiperazine-1-
carboxylate (90). From compound 32, procedure 4.2, yield 99%, pink oil. 
 
4.1.3.82. tert-Butyl 4-(2-(4-amino-2-methoxyphenoxy)ethyl)-2,6-dimethylpiperazine-
1-carboxylate (91). From compound 33, procedure 4.2; yield 99%, pink solid. 
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4.1.3.83. 3-Methoxy-4-(2-(4-phenylpiperazin-1-yl)ethoxy)aniline (92). From 
compound 34, procedure 4.2, yield 92%, red solid. 1H NMR (300 MHz, CDCl3) δ 
7.26 (t, J = 7.97 Hz, 2H), 6.94 (d, J = 7.86 Hz, 2H), 6.86 (t, J = 7.32 Hz, 1H), 6.77 
(d, J = 8.25 Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.21 (dd, J = 8.25, 2.37 Hz, 1H), 4.11 
(t, J = 6.03 Hz, 2H), 3.82 (s, 3H), 3.24 (t, J = 4.95 Hz, 4H), 2.86 (t, J = 6.21 Hz, 2H), 
2.75 (t, J = 4.95 Hz, 4H). 
 
4.1.3.84. 4-(2-(4-Benzylpiperazin-1-yl)ethoxy)-3-methoxyaniline (93). Prepare from 
35 following the general procedure 4.2 to afford desired product (94%). 1H NMR 
(300 MHz, CDCl3) δ 7.32-7.30 (m, 5H), 6.74 (d, J = 8.25 Hz, 1H), 6.28 (s, 1H), 6.21 
(d, J = 8.25 Hz, 1H), 4.07 (t, J = 5.85 Hz, 2H), 3.79 (s, 3H), 3.51 (s, 2H), 2.81 (t, J = 
6.21 Hz, 2H), 2.60 (br, 4H), 2.51 (br, 4H). 
 
4.1.3.85. 3-Methoxy-4-(2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethoxy)aniline (94). 
From compound 36, procedure 4.2, yield 77%. 1H NMR (400 MHz, CDCl3) δ 8.31 
(d, J = 4.80 Hz, 2H), 6.77 (d, J = 8.40 Hz, 1H), 6.48 (t, J = 4.80 Hz, 1H), 6.30 (d, J = 
4.60 Hz, 1H), 6.21 (dd, J = 8.40, 2.60 Hz, 1H), 4.11 (t, J = 6.00 Hz, 2H), 3.86 (t, J = 
5.00 Hz, 4H), 3.81 (s, 3H), 2.84 (t, J = 6.00 Hz, 2H), 2.64 (t, J = 5.00 Hz, 4H). 
 
4.1.3.86. 4-(2-(4-(5-Fluoropyrimidin-2-yl)piperazin-1-yl)ethoxy)-3-methoxyaniline 
(95). From compound 37, procedure 4.2, yield 67%. 1H NMR (400 MHz, CDCl3) δ 
8.19 (s, 2H), 6.77 (d, J = 8.40 Hz, 1H), 6.30 (d, J = 2.64 Hz, 1H), 6.21 (dd, J = 8.20, 
2.60 Hz, 1H), 4.10 (t, J = 6.00 Hz, 2H), 3.81-3.77 (m, 7H), 2.83 (t, J = 6.00 Hz, 2H), 
2.64 (t, J = 5.04 Hz, 4H). 
 
4.1.3.87. 4-(2-(4-(5-Chloropyrimidin-2-yl)piperazin-1-yl)ethoxy)-3-methoxyaniline 
(96). From compound 38, procedure 4.2, yield 36%. 1H NMR (400 MHz, CDCl3) δ 
8.21 (s, 2H), 6.76 (d, J = 8.40 Hz, 1H), 6.30 (d, J = 2.64 Hz, 1H), 6.21 (dd, J = 8.24, 
2.60 Hz, 1H), 4.10 (t, J = 6.00 Hz, 2H), 3.81-3.77 (m, 7H), 2.83 (t, J = 6.00 Hz, 2H), 
2.64 (t, J = 5.00 Hz, 4H). 
 
4.1.3.88. 3-(4-Amino-2-methoxyphenoxy)propanamide (97). From compound 42, 
procedure 4.2, yield 66%, red solid. 1H NMR (300 MHz, CDCl3) δ 6.79 (d, J = 8.43 
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Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.22 (dd, J = 8.25, 2.58 Hz, 1H), 5.43 (br, 2H), 
4.15 (t, J = 5.49 Hz, 2H), 3.81 (s, 3H), 2.68 (t, J = 5.49 Hz, 2H). 
 
4.1.3.89. 4-(4-Amino-2-methoxyphenoxy)butanamide (98). Prepare from compound 
43 and solution of NH3 in THF following the general procedure 4.2, (96%). 1H NMR 
(300 MHz, CDCl3) δ 6.75 (d, J = 8.40 Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.23 (dd, J 
= 2.73, 8.40 Hz, 1H), 5.96 (br, NH), 5.27 (br, NH), 4.00 (t, J  = 6.03 Hz, 2H), 3.80 
(s, 3H), 2.49 (t, J  = 6.93 Hz, 2H), 2.14 (quintet, J  = 5.85 Hz, 2H). 
 
4.1.3.90. 3-(4-Amino-2-methoxyphenoxy)-N,N-dimethylpropanamide (99). From 
compound 44, procedure 4.2, yield 88%, red solid. 1H NMR (300 MHz, CDCl3) δ 
6.79 (d, J = 8.43 Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.22 (dd, J = 8.25, 2.55 Hz, 1H), 
4.27 (t, J = 7.32 Hz, 2H), 3.81 (s, 3H), 3.04 (s, 3H), 3.96 (s, 3H), 2.85 (t, J = 7.35 Hz, 
2H). 
 
4.1.3.91. 4-(4-Amino-2-methoxyphenoxy)-N,N-dimethylbutanamide (100).  Prepare 
from compound 45 following the general procedure 4.2 to afford product (97%). 1H 
NMR (300 MHz, CDCl3) δ 6.75 (d, J = 8.22 Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.22 
(dd, J = 2.73, 8.40 Hz, 1H), 4.01 (t, J = 6.21 Hz, 2H), 3.80 (s, 3H), 3.01 (s, 3H), 2.94 
(s, 3H), 2.56 (t, J = 7.50 Hz, 2H), 2.12 (quintet, J = 7.68 Hz, 2H). 
 
4.1.3.92. tert-Butyl 4-(2-(4-amino-2-methoxyphenoxy)acetyl)piperazine-1-
carboxylate (101). From compound 46, procedure 4.2, yield 95% as red solid.   
 
4.1.3.93. tert-Butyl 4-(3-(4-amino-2-methoxyphenoxy)propanoyl)piperazine-1-
carboxylate (102). From compound 47, procedure 4.2, yield 88%, red solid.   
 
4.1.3.94. tert-Butyl 4-(4-(4-amino-2-methoxyphenoxy)butanoyl)piperazine-1-
carboxylate (103). Prepare from compound 48 following the general procedure 4.2 
to afford product (99%). 1H NMR (300 MHz, CDCl3) δ 6.74 (d, J = 8.43 Hz, 1H), 
6.30 (d, J = 2.58 Hz, 1H), 6.22 (dd, J = 2.58 Hz, 1H), 4.01 (t, J = 5.85 Hz, 2H), 3.80 
(s, 3H), 3.59-3.51 (m, 4H), 3.45-3.41 (m, 4H), 2.58 (t, J = 7.14 Hz, 2H), 2.12 (quintet, 
J = 7.32 Hz, 2H), 1.47 (s, 9H). 
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4.1.3.95. tert-Butyl 4-(2-(4-amino-2-methoxyphenoxy)acetamido)piperidine-1-
carboxylate (104). Prepare from 49 following the general procedure 4.2 to afford a 
red solid (86%). 1H NMR (300 MHz, CDCl3) δ 7.16 (br, 1H), 6.76 (d, J = 8.43 Hz, 
1H), 6.29 (d, J = 2.55 Hz, 1H), 6.23 (dd, J = 2.37, 8.25 Hz, 1H), 4.43 (s, 2H), 3.98-
3.88 (m, 3H), 3.84 (s, 3H), 2.93 (t, J = 12.63 Hz, 2H), 1.92-1.88 (m, 2H), 1.46 (s, 
9H), 1.36-1.33 (m, 2H) 
 
4.1.3.96. tert-Butyl 4-(3-(4-amino-2-methoxyphenoxy)propanamido)piperidine-1-
carboxylate (105).  Prepare from 50 following the general procedure 4.2 to afford 
product, yield (89%). 1H NMR (300 MHz, CDCl3) δ 6.76 (d, J = 8.40 Hz, 1H), 6.30 
(d, J = 2.58 Hz, 1H), 6.23 (dd, J = 2.37, 8.22 Hz, 1H), 4.15 (t, J = 5.67 Hz, 2H), 4.01-
3.98 (m, 3H), 3.80 (s, 3H), 2.93 (t, J = 11.55 Hz, 2H), 2.65 (t, J = 5.67 Hz, 2H), 1.92-
1.87 (m, 2H), 1.45 (s, 9H), 1.35-1.31 (m, 2H). 
 
4.1.3.97. tert-Butyl 4-(4-(4-amino-2-methoxyphenoxy)butanamido)piperidine-1-
carboxylate (106). From compound 51, procedure 4.2, yield 90%, red solid.  1H NMR 
(400 MHz, CDCl3) δ 6.70 (d, J = 8.32 Hz, 1H), 6.28 (d, J = 2.48 Hz, 1H), 6.19 (dd, J 
= 8.40, 2.52 Hz, 1H), 5.82 (d, J = 7.68 Hz, 1H), 3.95-3.87 (m, 5H), 3.79 (s, 3H), 2.80 
(t, J = 11.92 Hz, 2H), 2.37 (t, J = 7.08 Hz, 2H), 2.06 (quintet, J = 6.40 Hz, 2H), 1.81 
(br, 2H), 1.43 (s, 9H), 1.23-1.17 (m, 2H). 
 
4.1.3.98. 2-(4-(2-(4-Amino-2-methoxyphenoxy)ethyl)piperazin-1-yl)ethyl 4-
methoxybenzoate (107). From compound 52, procedure 4.2, yield 62%, pink oil. 
 
4.1.3.99. tert-Butyl 2-(4-(2-(4-amino-2-methoxyphenoxy)ethyl)piperazin-1-
yl)ethylcarbamate (108). From compound 59, procedure 4.2, yield 99%, pink solid. 
1H NMR (300 MHz, CDCl3) δ 6.74 (d, J = 8.43 Hz, 1H), 6.30 (d, J = 2.58 Hz, 1H), 
6.20 (dd, J = 8.43, 2.58 Hz, 1H), 4.99 (s, 1H), 4.06 (t, J = 6.03 Hz, 2H), 3.81 (s, 3H), 
3.22 (br, 2H), 2.80 (t, J = 6.03 Hz, 2H), 2.61 (br, 4H), 2.47 (br, 6H), 1.45 (s, 9H). 
 
4.1.3.100. 2-(2-(4-(2-(4-Amino-2-methoxyphenoxy)ethyl)piperazin-1-yl)ethoxy)ethyl 
4-methoxybenzoate (109). From compound 60, procedure 4.2, pink oil. 
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4.1.3.101. tert-Butyl 2-(2-(4-(2-(4-amino-2-methoxyphenoxy)ethyl)piperazin-1-




(111). From compound 62, procedure 4.2, yield 99%, red solid. 1H NMR (300 MHz, 
CDCl3) δ 6.74 (d, J = 8.43 Hz, 1H), 6.30 (d, J = 2.37 Hz, 1H), 6.21 (dd, J = 8.34, 2.37 
Hz, 1H), 4.06 (t, J = 5.67 Hz, 2H), 3.80 (s, 3H), 3.65 (t, J = 4.56 Hz, 4H), 3.49 (t, J = 
4.95 Hz, 4H), 2.80 (t, J = 5.85 Hz, 2H), 2.61-2.53 (m, 4H), 2.09 (s, 3H). 
 
4.1.3.103. 4-(3-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)propoxy)-3-
methoxyaniline (112). Prepare from 63 following the general procedure 4.2 to afford 
red solid (80%). 1H NMR (300 MHz, CDCl3) δ 6.69 (d, J = 8.22 Hz, 1H), 6.24 (d, J 
= 2.58 Hz, 1H), 6.17 (dd, J = 2.04, 7.99 Hz, 1H), 3.93 (t, J = 5.57 Hz, 2H), 3.75 (s, 
3H), 3.72 (t, J = 6.57 Hz, 2H), 2.49-2.45 (m, 12H), 1.95 (q, J = 7.86 Hz, 2H), 0.83 (s, 
9H), 0.02 (s, 6H).  
 
4.1.3.104. tert-Butyl (2-(4-(3-(4-amino-2-methoxyphenoxy)propyl)piperazin-1-
yl)ethyl)carbamate (113). Prepare from 64 following the general procedure 4.2 to 
afford red solid (92%). 1H NMR (300 MHz, CDCl3) δ 6.75 (d, J = 6.57 Hz, 1H), 6.29 
(d, J = 2.55 Hz, 1H), 6.22 (dd, J = 2.61, 8.85 Hz, 1H), 4.96 (br, 1H), 3.97 (t, J = 6.39 
Hz, 2H), 3.82 (s, 3H), 3.21-3.18 (m, 2H), 2.46-2.40 (m, 12H), 1.96 (quintet, J = 7.14 
Hz, 2H), 1.45 (s, 9H). 
 
4.1.3.105. tert-Butyl (2-(4-(4-(4-amino-2-methoxyphenoxy)butyl)piperazin-1-
yl)ethyl)carbamate (114). Prepare from 65 following the general procedure 4.2 to 
afford red solid (91%). 1H NMR (300 MHz, CDCl3) δ 6.71 (d, J = 8.43 Hz, 1H), 6.28 
(d, J = 2.37 Hz, 1H), 6.20 (dd, J = 2.55, 8.43 Hz, 1H), 4.94 (br, NH), 3.93 (t, J = 6.60 
Hz, 2H), 3.78 (s, 3H), 3.18 (q, J = 6.66 Hz, 2H), 2.44-2.34 (m, 12H), 1.76 (quintet, J 
= 7.14 Hz, 2H), 1.67 (quintet, J = 6.96 Hz, 2H), 1.43 (s, 9H). 
 
4.1.3.106. 4-(4-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)butoxy)-3-
methoxyaniline (115). Prepare from 66 following the general procedure 4.2 to afford 
red solid (91%). 
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4.1.3.107. 4-(2-(1-(2-(tert-Butyldimethylsilyloxy)ethyl)piperidin-4-yl)ethoxy)-3-
methoxyaniline (116). Prepare from 67 following the general procedure 4.2 to afford 
a red solid (73%). 1H NMR (300 MHz, CDCl3) δ 6.72 (d, J = 8.40 Hz, 1H), 6.30 (d, 
J = 2.55 Hz, 1H), 6.22 (dd, J = 2.55, 8.40 Hz, 1H), 3.97 (t, J = 6.78 Hz, 2H), 3.80 (s, 
3H), 3.78 (t, J = 7.14 Hz, 2H), 2.51 (br, 2H), 2.07 (br, 2H), 1.73-1.63 (m, 6H), 1.20-
1.13 (m, 3H), 0.88 (s, 9H), 0.05 (s, 6H)  
 
4.1.3.108. tert-Butyl 2-(4-(2-(4-amino-2-methoxyphenoxy)ethyl)piperidin-1-
yl)ethylcarbamate (117). Prepare from 68 following the general procedure 4.2 to 
afford a  red solid (75%). 1H NMR (300 MHz, CDCl3) δ 6.73 (d, J = 8.97 Hz, 1H), 
6.29 (d, J = 2.55 Hz, 1H),  6.22 (dd, J = 2.40, 8.40 Hz, 1H), 3.95  (t, J = 7.14 Hz, 2H), 
3.80 (s, 3H), 3.25 (br, 2H), 2.90 (br, 2H), 2.46 (br, 2H), 2.05 (br, 2H), 1.73-1.63 (m, 
5H), 1.45 (s, 9H), 1.25-1.14 (m, 2H) 
 
4.1.3.109. 2-(4-Amino-2-methoxyphenoxy)-1-(4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)ethan-1-one (118). Prepare from 69 
following the general procedure 4.2 to afford as red solid (91%). 1H NMR (300 MHz, 
CDCl3) δ 6.75 (d, J = 8.43 Hz, 1H), 6.23 (d, J = 2.55 Hz, 1H), 6.15 (dd, J = 2.58, 8.43 
Hz, 1H), 4.56 (s, 2H), 3.75 (s, 3H), 3.71 (t, J = 6.06 Hz, 2H), 3.57-3.54 (m, 4H), 2.48-
2.41 (m, 6H), 0.83 (s, 9H), 0.02 (s, 6H).  
 
4.1.3.110. tert-Butyl (2-(4-(2-(4-amino-2-methoxyphenoxy)acetyl)piperazin-1-
yl)ethyl)carbamate (119). Prepare from 70 following the general procedure 4.2 to 
afford as an red solid (61%). 1H NMR (400 MHz, CDCl3) δ 6.78 (d, J = 8.40 Hz, 1H), 
6.27 (d, J = 2.48 Hz, 1H), 6.18 (dd, J = 2.64, 8.48 Hz, 1H), 4.89 (br, 1H), 4.59 (s, 




butyldimethylsilyl)oxy)ethyl)piperidin-4-yl)acetamide (120). Prepare from 71 
following the general procedure 4.2 to afford red solid (86%). 1H NMR (400 MHz, 
CDCl3) δ 6.78 (d, J = 8.48 Hz, 1H), 6.26 (d, J = 2.52 Hz, 1H), 6.17 (dd, J = 2.52, 8.48 
Hz, 1H), 4.59 (s, 2H), 3.81-3.79 (m, 1H), 3.78 (s, 3H), 3.70 (t, J =  5.32 Hz, 2H), 
2.74-2.67 (m, 4H), 1.88-1.85 (m, 4H), 1.32-1.25 (m, 2H), 0.86 (s, 9H), 0.03 (s, 6H).  
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4.1.3.112. tert-Butyl (2-(4-(2-(4-amino-2-methoxyphenoxy)acetamido)piperidin-1-
yl)ethyl)carbamate (121). Prepare from 72 following the general procedure 4.2 to 
afford red solid (96%). 1H NMR (300 MHz, CDCl3) δ 7.10 (br, 1H), 6.76 (d, J = 8.40 
Hz, 1H), 6.30 (d, J = 2.55 Hz, 1H), 6.23 (dd, J = 2.58, 8.43 Hz, 1H), 4.96 (br, 1H), 
4.43 (s, 2H), 3.84 (s, 3H), 3.82-3.80 (m, 1H), 3.20 (q, J = 6.66 Hz, 2H), 2.82-2.79 (m, 
2H), 2.46 (t, J = 5.88 Hz, 2H), 2.17(t, J = 10.80 Hz, 2H), 1.94-1.90 (m, 2H), 1.49-
1.46 (m,  2H), 1.45 (s, 9H).  
 
4.1.3.113. tert-Butyl 4-(2-(4-amino-2-methoxyphenoxy)ethylcarbamoyl)piperidine-
1-carboxylate (122). Prepare from 75 following the general procedure 4.2 to give 
product (99%). 1H NMR (500 MHz, CD3OD) δ 6.74 (d, J = 8.40 Hz, 1H), 6.44 (d, J 
= 2.45 Hz, 1H),  6.26 (dd, J = 2.55, 8.52 Hz, 1H), 4.09 (d, J = 13.25 Hz, 2H), 3.93 (t, 
J = 5.4 Hz, 2H), 3.78 (s, 3H), 3.48 (t, J = 5.4 Hz, 2H), 2.78 (br, 2H), 2.41-2.35 (m, 
1H), 1.74 (d, J = 12 Hz, 2H), 1.59-1.51 (m, 2H), 1.44 (s, 9H). 
 
4.1.3.114. tert-Butyl (4-(4-(4-amino-2-methoxyphenoxy)butyl)pyridin-2-
yl)(methyl)carbamate (123). Prepare from 80 following the general procedure 4.2 to 
afford a  red solid (93%). 1H NMR (300 MHz, CDCl3) δ 8.26 (d, J = 5.13 Hz, 1H), 
7.49 (s, 1H), 6.87 (d, J = 5.13 Hz, 1H), 6.71 (d, J = 8.25 Hz, 1H), 6.30 (d, J = 2.58 
Hz, 1H), 6.22 (dd, J = 2.76, 8.43 Hz, 1H), 3.93 (t, J = 6.45 Hz, 2H), 3.80 (s, 3H), 3.38 
(s, 3H), 2.66 (t, J = 7.53 Hz, 2H), 1.82-1.80 (m, 4H), 1.51  (s, 9H). 
 
4.1.3.115. tert-Butyl (4-(4-(4-amino-2-methoxyphenoxy)butyl)pyridin-2-yl)(2-((tert-
butyldimethylsilyl)oxy)ethyl)carbamate (124). Prepare from 81 following the general 
procedure 4.2 to afford a red solid (91%). 1H NMR (300 MHz, CDCl3) δ 8.25 (d, 1H, 
J = 5.10 Hz), 7.41 (s, 1H), 6.87 (d, J = 5.13 Hz, 1H), 6.72 (d, J = 8.43 Hz, 1H), 6.31 
(d, J = 2.55 Hz, 1H), 6.23 (dd, J = 2.55, 8.40 Hz, 1H), 4.08 (t, J = 6.39 Hz, 2H), 3.94 
(t, J = 5.67 Hz, 2H), 3.81 (s, 3H), 3.79 (t, J = 6.42 Hz, 2H), 2.68-2.65 (m, 2H), 1.83-
1.79 (m, 4H), 1.50 (s, 9H), 0.82 (s, 9H), 0.01 (s, 6H).  
 
4.1.3.116. tert-Butyl (4-(4-(4-amino-2-methoxyphenoxy)butyl)pyridin-2-yl)(2-((tert-
butoxycarbonyl)amino)ethyl)carbamate (125). Prepare from 82 following the general 
procedure 4.2 to afford 60 mg as red solid (90%).   
 
PART 1- POTENTIALS ANTI ALZHEIMER’S AGENTS: SAR OF ARG-MIMETIC 
REGION  
54 
Ngo Thi Hong Van _ 2013.31349 
4.1.3.117. tert-Butyl 4-(2-(4-(3-(3-(1H-imidazol-1-yl)propyl)thioureido)-2-
methoxyphenoxy)ethyl)-3-methylpiperazine-1-carboxylate (126). From compound 




From compound 91, procedure 8, yield 50%, white solid. 
 
4.1.3.119. tert-Butyl 2-(4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)ethyl)piperazin-1-yl)ethylcarbamate (128). From 
compound 108, procedure 8, yield 68%, white solid. 1H NMR (300 MHz, CDCl3) δ 
7.55 (s, 1H), 7.37 (d, J = 0.93 Hz, 1H), 6.89 (d, J = 8.25 Hz, 1H), 6.75-6.69 (m, 3H), 
5.90 (s, 1H), 4.97 (s, 1H), 4.15 (t, J = 6.03 Hz, 2H), 3.89 (t, J = 7.14 Hz, 2H), 3.84 (s, 
3H), 3.66 (q, J = 6.39 Hz, 2H), 3.22 (br, 2H), 2.86 (t, J = 6.03 Hz, 2H), 2.62 (br, 4H), 
2.46 (br, 6H), 2.18 (d, J = 1.11 Hz, 3H), 2.05 (quintet, J = 7.32 Hz, 2H), 1.45 (s, 9H). 
 
4.1.3.120. tert-Butyl (2-(4-(3-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)propyl)piperazin-1-yl)ethyl)carbamate (129). Prepare 
from 113 following the general procedure 8 to afford the desired product as off white 
solid (63%). 1H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H), 7.45 (s, 1H), 6.83 (d, J = 
2.55 Hz, 1H), 6.67-6.63 (m, 3H), 6.09 (br, 1H), 4.92 (br, 1H), 4.04 (t, J = 6.57 Hz, 
2H), 3.87 (t, J = 7.14 Hz,  2H), 3.76 (s, 3H), 3.62-3.60 (m, 2H), 3.17-3.13 (m, 2H), 
2.53-2.49 (m, 12H), 2.12 (s, 3H), 1.99-1.97 (m, 4H), 1.38 (s, 9H). 
 
4.1.3.121. tert-Butyl (2-(4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)butyl)piperazin-1-yl)ethyl)carbamate (130). Prepare 
from 114 following the general procedure 8 to afford the desired product as off white 
solid (40%). 1H NMR (300 MHz, CDCl3) δ 7.47 (s, 1H), 7.35 (s, 1H), 6.86 (d, J = 
8.43 Hz, 1H), 6.71-6.66 (m, 3H), 4.94 (br, NH), 4.04 (t, J = 6.42 Hz, 2H), 3.89 (t, J 
= 6.96 Hz, 2H), 3.81 (s, 3H), 3.65 (q, J = 7.53 Hz, 2H), 3.18 (q, J = 7.14 Hz, 2H), 
2.45-2.37 (m, 12H), 2.15 (s, 3H), 2.04 (quintet, J = 7.32 Hz, 2H), 1.83 (quintet, J = 
6.96 Hz, 2H), 1.67-1.62 (quintet, J = 7.14 Hz, 2H), 1.42 (s, 9H). 
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4.1.3.122. tert-Butyl 2-(2-(4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)ethyl)piperazin-1-yl)ethoxy)ethylcarbamate (131). 
From compound 110, procedure 8, yield 50%, white solid. 1H NMR (300 MHz, 
CDCl3) δ 7.50 (s, 1H), 7.35 (s, 1H), 6.87 (d, J = 8.1 Hz, 1H), 6.71-6.66 (m, 3H), 5.87 
(s, 1H), 5.16 (br, 1H), 4.12 (t, J = 6.0 Hz, 2H), 3.67 (t, J = 6.9 Hz, 2H), 3.8 (s, 3H), 
3.63 (q, J = 6.3 Hz, 2H), 3.54 (t, J = 6.0 Hz, 2H), 3.49 (t, J = 4.8 Hz, 2H), 3.27 (q, J 
= 5.7 Hz, 2H), 2.85 (t, J = 6.3 Hz, 2H), 2.62 (br, 4H), 2.56 (t, J = 5.7 Hz, 6H), 2.15 
(d, J = 0.9 Hz, 3H), 2.02 (quintet, J = 6.9 Hz, 2H), 1.42 (s, 9H).  
 
4.1.3.123. tert-Butyl 2-(4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)ethyl)piperidin-1-yl)ethylcarbamate (132). Prepare 
from 117 following the general procedure 8 to afford the desired product as an off 
white solid (62%). 1H NMR (300 MHz, CDCl3) δ 7.58 (s, NH), 7.42 (s, 1H), 6.88 (d, 
J = 8.22 Hz, 1H), 6.73-6.71 (m, 3H), 5.58 (br, NH), 5.18 (br, NH), 4.05 (t, J = 6.60 
Hz, 2H), 3.90 (t, J = 7.14 Hz, 2H), 3.83 (s, 3H), 3.64 (q, J = 6.42 Hz, 2H), 3.28 (br, 
2H), 3.03 (br, 2H), 2.95 (br, 2H), 2.52 (br, 2H), 2.17 (d, J = 0.93 Hz, 3H), 2.09-2.02 
(m, 4H), 1.81-1.70 (m, 3H), 1.69-1.63 (m, 2H), 1.44 (s, 9H). 
 
4.1.3.124. tert-Butyl 4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)acetyl)piperazine-1-carboxylate (133). From 
compound 101, procedure 8; yield 74%, white solid.  
 
4.1.3.125. tert-Butyl 4-(3-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)propanoyl)piperazine-1-carboxylate (134). From 
compound 102, procedure 8, yield 71%, white solid.  
 
4.1.3.126. tert-Butyl 4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)butanoyl)piperazine-1-carboxylate (135).  Prepare 
from compound 103 following the general procedure 8 to afford product (54%). 1H 
NMR (300 MHz, CDCl3) δ 7.48 (s, 1H), 7.36 (s, 1H), 6.94 (d, J = 8.22 Hz, 1H), 6.74-
6.68 (m, 3H), 5.87 (s, 1H), 4.13 (t, J = 6.03 Hz, 2H), 3.91 (t, J = 7.32 Hz, 2H), 3.83 
(s, 3H), 3.69 (q, J = 6.39 Hz, 2H), 3.63-3.59 (m, 2H), 3.46-3.41 (m, 6H), 2.58 (t, J = 
6.96 Hz, 2H), 2.20 (t, J = 7.50 Hz, 2H), 2.17 (d, J = 0.90 Hz, 3H), 2.07 (quintet, J = 
6.96 Hz, 2H), 1.47 (s, 9H). 
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4.1.3.127. tert-Butyl (2-(4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)acetyl)piperazin-1-yl)ethyl)carbamate (136). Prepare 
from 119 following the general procedure 8 to afford the desired product as an off 
white solid (44%). 1H NMR (300 MHz, CDCl3) δ 7.63 (s, 1H), 7.43 (s, 1H), 6.93 (d, 
J = 8.40 Hz, 1H), 6.74-6.70 (m, 3H), 6.08 (br, 1H), 4.90 (br, 1H), 4.77 (s, 2H), 3.92 
(t, J = 7.14 Hz, 2H), 3.84 (s, 3H), 3.67-3.49 (m, 6H), 3.22 (q, J = 6.36 Hz, 2H), 2.49-
2.45 (m, 6H), 2.18 (d, J = 0.90 Hz, 3H), 2.07 (quintet, J = 7.14 Hz, 2H), 1.45 (s, 9H). 
 
4.1.3.128. tert-Butyl 4-(2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)acetamido)piperidine-1-carboxylate (137). Prepare 
from 104 following the general procedure 8 to afford afford the desired product as 




(138).  Prepare from 105 following the general procedure 8 to afforded product 
(76%). 1H NMR (300 MHz, CDCl3) δ 8.04 (s, 1H), 7.65 (s, 1H), 6.88-6.85 (m, 2H), 
6.77-6.74 (m, 2H), 6.64 (d, J = 7.68 Hz, 1H), 6.47 (br, 1H), 4.29 (t, J = 5.70 Hz, 2H), 
3.94-3.93 (m, 5H), 3.80 (s, 3H), 3.65 (q, J = 5.85 Hz, 2H), 2.92 (t, J = 12.81 Hz, 2H), 
2.69 (t, J = 5.88 Hz, 2H), 2.20 (s, 3H), 2.12 (quintet, J = 6.75 Hz, 2H), 1.92 (t, J = 
12.63 Hz, 2H),  1.45 (s, 9H), 1.30-1.25 (m, 2H).  
 
4.1.3.130. tert-Butyl 4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)butanamido)piperidine-1-carboxylate (139). From 
compound 106, procedure 8, yield 30%, white solid. 1H NMR (300 MHz, CDCl3) δ 
7.59 (s, 1H), 7.35 (s, 1H), 6.90 (d, J = 8.07 Hz, 1H), 6.74-6.70 (m, 3H), 5.93 (t, J = 
6.42 Hz, 1H), 5.78 (d, J = 7.89 Hz, 1H), 4.09 (t, J = 5.87 Hz, 2H), 4.07-3.98 (m, 3H), 
3.90 (t, J = 7.14 Hz, 2H), 3.84 (s, 3H), 3.66 (q, J = 6.42 Hz, 2H), 2.83 (t, J = 11.92 
Hz, 2H), 2.39 (t, J = 7.14 Hz, 2H), 2.17-2.13 (m, 5H), 2.06 (quintet, J = 6.96 Hz, 2H), 




Prepare from 121 following the general procedure 8 to afford the desired product as 
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an off white solid (28%). 1H NMR (300 MHz, CDCl3) δ 7.62 (s, 1H), 7.35 (s, 1H), 
6.89 (d, J = 8.97 Hz, 1H), 6.76 (s, 1H), 6.72-6.70 (m, 3H), 5.93 (br, 1H), 4.93 (br, 
1H), 4.50 (s, 2H), 3.94 (t, J = 7.14 Hz, 2H), 3.90 (s, 3H), 3.87-3.85 (m, 1H), 3.65 (q, 
J = 6.66 Hz, 2H), 3.20-3.17 (m, 2H), 2.78-2.75 (m, 2H), 2.44 (t, J = 5.97 Hz, 2H), 




Prepare from 122 following the general procedure 8 to afford the desired product as 
an off white solid (48%). 1H NMR (300 MHz, CD3OD) δ 7.59 (d, J = 0.90 Hz, 1H), 
6.97 (d, J = 6.00 Hz, 1H), 6.94 (s, 1H),  6.77 (dd, J = 2.10, 8.10 Hz, 1H),  6.66 (s, 
1H), 4.12-4.02 (m, 2H), 4.00 (t, J = 7.50 Hz, 2H), 3.82 (s, 3H), 3.61 (t, J = 6.90 Hz, 
2H), 3.56 (t, J = 5.43 Hz, 2H), 2.78 (br, 2H), 2.42-2.33 (m, 3H), 2.22 (d, J = 0.93 Hz, 
3H), 2.08 (quintet, J = 7.50 Hz, 2H), 1.75-1.71 (m, 2H), 1.65-1.48 (m, 2H), 1.44 (s, 
9H).  
 
4.1.3.133. tert-Butyl 4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-yl) propyl) 
thioureido) phenoxy)phenyl)piperazine-1-carboxylate (142). Prepared from 
compound 87 following the general producer 8 to afford an off white solid (72%). 1H 
NMR (300 MHz, CDCl3) δ 7.64 (s, 1H), 7.37 (s, 1H), 6.97-6.89 (m, 4H), 6.82-6.79 
(m, 2H), 6.73 (s, 1H), 6.69 (dd, J = 2.19, 8.19 Hz, 1H), 6.02 (br, 1H), 3.92 (t, J = 6.96 
Hz, 2H), 3.87 (s, 3H), 3.70 (q, J = 7.68 Hz, 2H), 3.60 (t, J = 4.95 Hz, 4H), 3.09 (t, J 




carboxylate (143). Prepare from compound 83 following the general procedure 8 to 
get desired product as off white solid (42%). 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 
1H), 7.39 (s, 1H), 7.35 (d, J = 8.64 Hz, 2H), 6.95-6.87 (m, 4H), 6.73 (d, J = 8.61 Hz, 
2H), 6.16 (br, 1H), 5.99 (s, 1H), 4.07-4.05 (m, 2H), 3.94 (t, J = 6.96 Hz, 2H), 3.83 (s, 
3H), 3.69 (t, J = 7.14 Hz, 2H), 3.63 (t, J = 6.96 Hz, 2H), 2.50-2.47 (m, 2H), 2.19 (s, 
3H), 2.10-2.05 (quintet, J = 7.50 Hz, 2H), 1.49 (s, 9H)    
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4.1.3.135. tert-Butyl 4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)phenyl)piperidine-1-carboxylate (144). Prepare from 
compound 86 following the general procedure 8 to get desired product as an off white 
solid (44%). 1H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H), 7.39 (s, 1H), 7.17 (d, J = 
8.61 Hz, 2H), 6.93-6.89 (m, 3H), 6.84 (d, J = 2.22 Hz, 1H), 6.73 (d, J = 8.58 Hz, 2H), 
6.07 (br, 1H), 4.25-4.21 (m, 2H), 3.93 (t, J = 7.14 Hz, 2H), 3.84 (s, 3H), 3.71-3.65 
(m, 2H), 2.79-2.74 (m, 2H), 2.62-2.58 (m, 1H), 2.18 (s, 3H), 2.10-2.05 (m, 2H), 1.83-
1.79 (m, 2H), 1.57-1.51 (m, 2H), 1.48 (s, 9H). 
 
4.1.3.136. tert-Butyl 4-(3-((2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)methyl)phenyl)piperazine-1-carboxylate (145). From 
compound 85, procedure 8, yield 56%, white solid.  
 
4.1.3.137. tert-Butyl 4-(3-((2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)methyl)phenyl)piperidine-1-carboxylate (146). From 
compound 84, procedure 8; yield 72%, white solid. 1H NMR (300 MHz, CDCl3) δ 
7.57 (s, 1H), 7.37 (s, 1H), 7.32-7.26 (m, 3H), 7.16 (t, J = 7.14 Hz, 1H), 6.90 (d, J = 
8.25 Hz, 1H), 6.73-6.67 (m, 3H), 5.93 (brt, 1H), 5.12 (s, 2H), 4.22 (br, 2H), 3.89 (t, J 
= 7.14 Hz, 2H), 3.86 (s, 3H), 3.66 (q, J = 7.68 Hz, 2H), 2.80 (t, J = 11.52 Hz, 2H), 
2.66 (tt, J = 12.09, 3.48, 1H), 2.16 (d, 0.93 Hz, 3H), 2.04 (quintet, J = 7.14 Hz, 2H), 
1.83-1.79 (m, 2H), 1.66-1.55 (m, 2H), 1.48 (s, 9H). 
 
4.1.3.138. tert-Butyl (4-(4-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)butyl)pyridin-2-yl)(methyl)carbamate (147). Prepare 
from 123 following the general procedure 8 to afford the desired product as off white 
solid (58%). 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 5.13 Hz, 1H), 7.60 (s, 1H), 
7.53 (s, 1H), 7.37 (s, 1H), 6.86-6.82 (m, 2H), 6.72-6.70 (m, 3H), 5.97 (br, 1H), 4.04 
(t, J = 5.61 Hz, 2H), 3.91 (t, J =7.14 Hz, 2H), 3.83 (s, 3H), 3.69 (q, J = 6.60 Hz, 2H), 
3.38 (s, 3H), 2.71 (t, J = 7.32 Hz, 2H), 2.17 (s, 3H), 2.09 (quintet, J = 7.32 Hz, 2H), 




yl)carbamate (148). Prepare from 125 following the general procedure 8 to afford the 
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desired product as off white solid (56%). 1H NMR (300 MHz, CDCl3) δ 8.24 (d, 1H, 
J = 5.13 Hz), 7.61 (s, 1H), 7.46 (s, 1H), 7.32 (s, 1H), 6.90 (m, 2H), 6.72 (m, 3H), 6.21 
(br, 1H), 5.95 (br, 1H), 4.06 (t, 2H, J = 6.21 Hz), 4.00 (t, 2H, J = 4.23 Hz), 3.91 (t, 
2H, J = 7.14 Hz), 3.83 (s, 3H), 3.69 (q, 2H, J = 6.42 Hz), 3.40 (q, 2H, J = 5.31 Hz), 
2.71 (t, 2H, J = 7.32 Hz), 2.17 (s, 3H), 2.07 (quintet, 2H, J = 7.32 Hz), 1.87-1.83 (m, 
4H), 1.52 (s, 9H), 1.42 (s, 9H). 
 
4.1.3.140. 1-(4-(3-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)propoxy)-
3-methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (149). Prepare 
from 112 following the general procedure 8 to afford the desired product as off white 
solid (37%).1H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 7.45 (s, 1H), 6.90 (d, J = 8.79 
Hz, 1H), 6.74 (m, 3H), 6.06 (br, 1H), 4.11 (t, J = 6.24 Hz, 2H), 3.93 (t, J = 7.14 Hz, 
2H), 3.83 (s, 3H), 3.80 (t, J = 6.03 Hz, 2H), 3.69 (q, J = 6.03 Hz, 2H), 2.61-2.55 (m, 
8H), 2.08-2.01 (m, 8H), 0.88 (s, 9H), 0.01 (s, 6H). 
 
4.1.3.141. 1-(4-(4-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)butoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (150). Prepare 
from 115 following the general procedure 8 to afford the desired product as off white 
solid (50%). 1H NMR (300 MHz, CDCl3) δ 7.53 (s, 1H), 7.34 (s, 1H), 6.82 (d, J = 
8.22 Hz, 1H), 6.68-6.65 (m, 3H), 5.91 (br, 1H), 4.00 (t, J = 6.42 Hz, 2H), 3.86 (t, J = 
7.14 Hz, 2H), 3.77 (s, 3H), 3.72 (t, J = 6.39 Hz. 2H), 3.64-3.57 (m, 2H), 2.51-2.35 
(m, 12H), 2.12 (s, 3H), 2.04 (quintet, J = 4.95 Hz, 2H), 1.83 (quintet, J = 6.36 Hz, 
2H), 1.65-1.62 (m, 2H), 0.83 (s, 9H), 0.01 (s, 6H) 
 
4.1.3.142. 1-(4-(2-(1-(2-(tert-Butyldimethylsilyloxy)ethyl)piperidin-4-yl)ethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (151). Prepare 
from 116 following the general procedure 8 to afford the desired product as off white 
solid (41%). 1H NMR (300 MHz, CDCl3) δ 7.54 (br, NH), 7.39 (s, 1H), 6.87 (d, J = 
8.25 Hz, 1H) 6.73-6.70 (m, 3H), 5.93 (br, NH), 4.05 (t, J = 6.60 Hz, 2H), 3.91 (t, J = 
7.14 Hz, 2H), 3.83 (s, 3H), 3.85-3.78 (m, 4H), 3.67 (q, J = 7.68 Hz, 2H), 3.03 (br, 
2H), 2.60 (br, 2H), 2.17 (s, 3H), 2.09-2.02 (m, 3H), 1.81-1.70 (m, 6H), 0.88 (s, 9H), 
0.05 (s, 6H). 
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4.1.3.143. 1-(4-(2-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)-2-
oxoethoxy)-3-methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea 
(152). Prepare from 118 following the general procedure 8 to afford the desired 
product as an off white solid (70%). 1H NMR (300 MHz, CDCl3) δ 7.67 (s, 1H), 7.28 
(s, 1H), 6.86 (d, J = 8.43 Hz, 1H), 6.71-6.63 (m, 3H), 6.13 (br, 1H), 4.71 (s, 2H), 3.86 
(t, J = 7.14 Hz, 2H), 3.78 (s, 3H), 3.69 (t, J = 5.85 Hz, 2H), 3.59-3.49 (m, 6H), 2.50-




Prepare from 120 following the general procedure 8 to afford the desired product as 




yl)carbamate (154). Prepare from 124 following the general procedure 8 to afford the 
desired product as an off white solid (56%). 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J 
= 5.13 Hz, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 6.86-6.85 (m, 2H), 6.73-6.69 
(m, 3H), 5.90 (br, 1H), 4.08 (t, J = 6.57 Hz, 2H), 4.04 (t, J = 6.03 Hz, 2H), 3.91 (t, J 
= 7.14 Hz, 2H), 3.83 (s, 3H), 3.81 (t, J = 6.21 Hz, 2H), 3.70 (q, J = 6.87 Hz, 2H), 2.69 
(t, J = 7.68 Hz, 2H), 2.17 (s, 3H), 2.07 (quintet, J = 7.14 Hz, 2H), 1.88-1.81 (m, 4H), 




From compound 107, procedure 8, yield 68%, white solid. 
 
4.1.3.147. 2-(2-(4-(2-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)ethyl) piperazin-1-yl)ethoxy)ethyl 4-methoxybenzoate 
(156). From compound 109, procedure 8, white solid. 
 
4.1.3.148. Methyl 2-(2-methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)-phenoxy)acetate (157). Prepare from compound 89 following 
the general procedure 8 afford the desired product as white solid (60%). 1H NMR 
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(300 MHz, CDCl3) δ 7.80 (s, 1H), 7.36 (s, 1H), 6.83-6.77 (m, 2H), 6.73-6.70 (m, 2H), 
6.15 (br, 1H), 4.71 (s, 2H), 3.92 (t, J = 6.96 Hz, 2H), 3.86 (s, 3H), 3.80 (s, 3H), 3.70 




Prepared from compound 195 following the general producer 10 to afford a white 
solid (45%). 1H NMR (300 MHz, CDCl3) δ 7.71 (s, 1H), 7.47 (s, 1H), 6.96-6.88 (m, 
5H), 6.83 (s, 1H), 6.80 (d, J = 8.43 Hz, 1H), 6.74 (s, 1H), 6.68 (dd, J = 2.55, 8.58 Hz, 
1H), 6.14 (br, 1H), 3.93 (t, J = 6.78 Hz, 2H), 3.86 (s, 3H), 3.70 (q, J = 6.78 Hz, 2H), 
3.26-3.24 (t, J = 5.97 Hz, 2H), 3.15 (t, J = 4.77 Hz, 4H), 2.63 (t, J = 4.77 Hz, 4H), 
2.54 (t, J = 5.85 Hz, 2H), 2.18 (s, 3H), 2.09 (quintet, J = 6.96 Hz, 2H), 1.45 (s, 9H) 
 
4.1.3.150. 1-(4-(4-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)phenoxy)-
3-methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (159). Prepared 
from compound 195 following the general producer 10 to afford a white solid (34%). 
1H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H), 7.46 (s, 1H), 6.92-6.88 (m, 4H), 6.82-
6.74 (m, 3H), 6.68 (dd, , J = 2.22, 8.07 Hz, 1H), 6.08 (br, 1H), 3.93 (t, J = 7.14 Hz, 
2H), 3.86 (s, 3H), 3.82 (t, J = 6.21 Hz, 2H), 3.68 (q, J = 6.96 Hz, 2H), 3.17 (t, J = 
4.56 Hz, 4H), 2.70 (t, J = 4.77 Hz, 4H), 2.60 (t, J = 6.39 Hz, 2H), 2.18 (s, 3H), 2.09 
(quintet, J = 7.32 Hz, 2H), 0.90 (s, 9H), 0.07 (s, 6H)  
 
4.1.4. Final compounds 
4.1.4.1. 1-(3-Methoxy-4-(2-(2-methylpiperazin-1-yl)ethoxy)phenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (160). Starting with compound 126 as following 
the general procedure 6.2, compound 160 was obtained as a white solid, 42% yield, 
mp = 77-78 oC. 1H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 7.37 (s, 1H), 6.89 (d, J = 
8.43 Hz, 1H), 6.75-6.73 (m, 3H), 5.92 (s, 1H), 4.13 (t, J = 6.42 Hz, 2H), 3.89 (t, J = 
6.96 Hz, 2H), 3.83 (s, 3H), 3.66 (q, J = 7.53 Hz, 2H), 3.22-3.13 (m, 1H), 2.93-2.78 
(m, 5H), 2.56-2.41 (m, 3H), 2.18 (d, J = 0.93 Hz, 3H), 2.05 (p, J = 7.32 Hz, 2H), 1.08 
(d, J = 5.88 Hz, 3H). MS (ESI) m/z 447 [M+H]+. HRMS (FAB) m/z calc. for 
C22H34N6O2S [M+H]+ 447.2542, found: 447.2535. Anal. HPLC 97.7% (Rt = 3.45 
min). 
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4.1.4.2. 1-(4-(2-(3,5-Dimethylpiperazin-1-yl)ethoxy)-3-methoxyphenyl)-3-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (161). Starting with compound 127 as 
following the general procedure 6.2, compound 161 was obtained as white solid, 78% 
yield, mp = 58-59 oC. 1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 6.95 (d, J = 8.61 
Hz, 1H), 6.94 (d, J = 2.37 Hz, 1H), 6.75 (dd, J = 8.43, 2.40 Hz, 1H), 6.67 (s, 1H), 
4.14 (t, J = 5.13 Hz, 2H), 3.98 (t, J = 6.96 Hz, 2H), 3.81 (s, 3H), 3.59 (t, J = 6.96 Hz, 
2H), 3.11 (br, 4H), 2.84 (t, J = 5.31 Hz, 2H), 2.22 (d, J = 0.90 Hz, 3H), 2.08-1.94 (m, 
4H), 1.16 (d, J = 6.21 Hz, 6H). MS (ESI) m/z 461 [M+H]+. HRMS (FAB) m/z calc. 




1H-imidazol-1-yl)propyl)thiourea (162). Starting with compound 111 as following 
the general procedure 8, compound 162 was obtained as white solid, 87% yield, mp 
= 55-56 oC. 1H NMR (300 MHz, CDCl3) δ 7.63 (s, 1H), 7.39 (s, 1H), 6.89 (d, J = 9.15 
Hz, 1H), 6.75-6.72 (m, 3H), 5.97 (s, 1H), 4.15 (t, J = 5.89 Hz, 2H), 3.90 (t, J = 7.14 
Hz, 2H), 3.81 (s, 3H), 3.69-3.62 (m, 4H), 3.49 (t, J = 4.95 Hz, 2H), 2.87 (t, J = 5.67 
Hz, 2H), 2.60 (t, J = 5.1 Hz, 2H), 2.56 (t, J = 5.10 Hz, 2H), 2.18 (s, 3H), 2.09 (s, 3H), 
2.05 (p, J = 7.14 Hz, 2H). MS (ESI) m/z 475 [M+H]+. HRMS (FAB) m/z calc. for 




(5-methyl-1H-imidazol-1-yl)propyl)thiourea (163). An excess solution of 10% NaOH 
was added in solution of 155 in MeOH (10 mL). The mixture was heated to reflux for 
30 minutes, diluted with DCM, washed with water. The organic layer was 
concentrated, purified by column chromatography to afford compound 163 as a white 
solid, 35% yield, mp = 64-65 oC. 1H NMR (300 MHz, CDCl3) δ 7.70 (s, 1H), 7.36 (s, 
1H), 6.89 (d, J = 8.79 Hz, 1H), 6.75-6.72 (m, 3H), 5.99 (s, 1H), 4.15 (t, J = 6.06 Hz, 
2H), 3.89 (t, J = 7.14 Hz, 2H), 3.83 (s, 3H), 3.69-3.60 (m, 4H), 2.87 (t, J = 5.85 Hz, 
2H), 2.63-2.54 (m, 10H), 2.18 (s, 3H), 2.05 (p, J = 7.32 Hz, 2H). MS (ESI) m/z 477 
[M+H]+. HRMS (FAB) m/z calc. for C23H36N6O3S [M+H]+ 477.2647, found: 
477.2633. Anal. HPLC 98.5% (Rt = 3.63 min). 
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4.1.4.5. 1-(4-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propoxy)-3-methoxyphenyl)-3-
(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (164). Starting with compound 149 
as following the general procedure 7, compound 164 was obtained as off white solid, 
47% yield, mp = 78-79 oC. 1H NMR (500 MHz, CD3OD) δ 7.58 (s, 1H), 6.95 (d, J = 
8.50 Hz, 1H), 6.90 (s, 1H), 6.75 (dd, J = 2.15, 8.50 Hz, 1H), 6.66 (s, 1H), 4.05 (t, J = 
6.05 Hz, 2H), 3.98 (t, J = 7.20 Hz, 2H), 3.80 (s, 3H), 3.68 (t, J = 6.00 Hz, 2H), 3.60 
(t, J = 6.35 Hz, 2H), 2.58-2.55 (m, 8H), 2.54 (t, J = 6.00 Hz, 4H), 2.21 (s, 3H), 2.06 
(p, J = 7.10 Hz, 2H), 1.97 (p, J = 6.95 Hz, 2H). MS (ESI) m/z 491 [M+H]+. HRMS 
(ESI) calc. for C24H38N6O3S [M+H]+ 491.2799, found 491.2795. Anal. HPLC 100% 
(Rt = 2.95 min). 
4.1.4.6. 1-(4-(4-(4-(2-Hydroxyethyl)piperazin-1-yl)butoxy)-3-methoxyphenyl)-3-(3-
(5-methyl-1H-imidazol-1-yl)propyl)thiourea (165). Starting with compound 150 as 
following the general procedure 7, compound 165 was obtained desired product as a 
white solid, 84% yield, mp = 58-59 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (s, 1H), 
6.95 (d, J = 8.43 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 2.22, 8.43 Hz, 1H), 
6.66 (s, 1H), 4.03 (t, J = 6.45 Hz, 2H), 3.97 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.68 (t, 
J = 6.03 Hz, 2H), 3.61 (t, J = 6.78 Hz, 2H), 2.54-2.41 (m, 12H), 2.22 (d, J = 0.90 Hz, 
3H), 2.05 (p, J = 4.95 Hz, 2H), 1.79-1.73 (m, 4H). MS (ESI) m/z 505 [M+H]+. HRMS 
(ESI) calc. for C25H40N6O3S [M+H]+ 505.2955, found 505.2957. Anal. HPLC 98.4% 
(Rt = 2.99 min). 
 
4.1.4.7. 1-(4-(2-(4-(2-Aminoethyl)piperazin-1-yl)ethoxy)-3-methoxyphenyl)-3-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (166). Starting with compound 128 as the 
general procedure 6.2, compound 166 was obtained as white solid, 85% yield, mp = 
81-82 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (d, J = 0.93 Hz, 1H), 6.96 (d, J = 8.43 
Hz, 1H), 6.92 (d, J = 2.40 Hz, 1H), 6.75 (dd, J = 8.40, 2.37 Hz, 1H), 6.66 (s, 1H), 
4.14 (t, J = 5.49 Hz, 2H), 3.97 (t, J = 6.96 Hz, 2H), 3.81 (s, 3H), 3.60 (t, J = 6.75 Hz, 
2H), 2.82 (t, J = 5.49 Hz, 2H), 2.79 (t, J = 6.60 Hz, 2H), 2.68 (br, 4H), 2.55 (br, 4H), 
2.47 (t, J = 6.42 Hz, 2H), 2.22 (d, J = 0.93 Hz, 3H), 2.03 (p, J = 6.96 Hz, 2H). MS 
(ESI) m/z 476 [M+H]+. HRMS (FAB) m/z calc. for C23H37N7O2S [M+H]+ 476.2808, 
found: 476.2823. Anal. HPLC 96.5% (Rt = 3.52 min). 
 
4.1.4.8. 1-(4-(3-(4-(2-Aminoethyl)piperazin-1-yl)propoxy)-3-methoxyphenyl)-3-(3-
(5-methyl-1H-imidazol-1-yl)propyl)thiourea (167). Starting with compound 129 as 
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following the general procedure 6.2, compound 167 was obtained as a red solid, 65% 
yield, mp = 107-108 oC. 1H NMR (500 MHz, CD3OD) δ 7.58 (s, 1H), 6.95 (d, J = 
8.55 Hz, 1H), 6.91 (d, J = 2.05 Hz, 1H), 6.75 (dd, J = 2.25, 8.35 Hz, 1H), 6.66 (s, 
1H), 4.03 (t, 2H, J = 6.20 Hz), 3.98 (t, J = 7.20 Hz, 2H), 3.80 (s, 3H), 3.60 (t, J = 6.60 
Hz, 2H), 2.74 (t, J = 6.70 Hz, 2H), 2.59-2.55 (m, 8H), 2.48-2.44 (m, 4H), 2.23 (s, 
3H), 2.09 (p, J = 7.10 Hz, 2H), 1.99 (p, J = 6.95 Hz, 2H). MS (ESI) m/z 490 [M+H]+. 
HRMS (ESI) calc. for C24H39N7O2S [M+H]+ 490.2959, found 490.2968. Anal. HPLC 
100% (Rt = 2.87 min). 
 
4.1.4.9. 1-(4-(4-(4-(2-Aminoethyl)piperazin-1-yl)butoxy)-3-methoxyphenyl)-3-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (168). Starting from compound 130 as 
following the general procedure 6.2, compound 168 was obtained as a white solid, 
71% yield, mp = 131-132 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (d, J = 0.90 Hz, 
1H), 6.95 (d, J = 8.31 Hz, 1H), 6.89 (d, J = 2.40 Hz, 1H), 6.76 (dd, J = 2.58, 6.03 Hz, 
1H), 6.66 (s, 1H), 4.03 (t, J = 5.88 Hz, 2H), 3.97 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 
3.59 (q, J = 6.42 Hz, 2H), 2.75 (t, J = 6.60 Hz, 2H), 2.53-2.47 (br, 12H), 2.22 (d, J = 
1.11 Hz, 3H), 2.03 (p, J = 7.50 Hz, 2H), 1.77-1.67 (m, 4H). MS (ESI) m/z 504 
[M+H]+. HRMS (ESI) calc. for C25H41N7O2S [M+H]+ 504.3115, found 504.3127. 
Anal. HPLC 99.5% (Rt = 2.99 min). 
 
4.1.4.10. 1-(4-(2-(4-(2-(2-Hydroxyethoxy)ethyl)piperazin-1-yl)ethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (169). Starting 
with compound 156 as following the experiment procedure used for compound 163 
to obtained compound 169 as a white solid, 50% yield, mp = 64-65 oC. 1H NMR (300 
MHz, CD3OD) δ 7.66 (s, 1H), 6.96 (d, J = 8.43 Hz, 1H), 6.93 (d, J = 2.19 Hz, 1H), 
6.75 (dd, J = 8.43, 2.4 Hz, 1H), 6.70 (s, 1H), 4.18 (t, J = 5.31 Hz, 2H), 3.99 (t, J = 
7.14 Hz, 2H), 3.81 (s, 3H), 3.66 (t, J = 4.92 Hz, 4H), 3.62-3.52 (m, 4H), 2.87 (t, J = 
5.31 Hz, 2H), 2.75 (br, 10 H), 2.23 (s, 3H), 2.04 (p, J = 7.14 Hz, 2H). MS (ESI) m/z 
521 [M+H]+. HRMS (FAB) m/z calc. for C25H40N6O4S [M + H]+ 521.2905, found: 
521.2896. Anal. HPLC 99.3% (Rt = 3.09 min). 
 
4.1.4.11. 1-(4-(2-(4-(2-(2-Aminoethoxy)ethyl)piperazin-1-yl)ethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (170). Starting 
with compound 131 as following the general procedure 6.2, compound 170 was 
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obtained as white solid, 73% yield, mp = 57-58 oC. 1H NMR (300 MHz, CD3OD) δ 
7.60 (s, 1H), 6.96 (d, J = 8.43 Hz, 1H), 6.92 (d, J = 2.73 Hz, 1H), 6.75 (dd, J = 8.43, 
2.37 Hz, 1H), 6.66 (s, 1H), 4.14 (t, J = 5.49 Hz, 2H), 3.97 (t, J = 7.14 Hz, 2H), 3.81 
(s, 3H), 3.63-3.57 (m, 4H), 3.50 (t, J = 5.13 Hz, 2H), 2.84-2.80 (m, 4H), 2.61 (br, 
10H), 2.22 (d, J = 0.93 Hz, 3H), 2.03 (p, J = 6.96 Hz, 2H). MS (ESI) m/z 520 [M+H]+. 
HRMS (FAB) m/z calc. for C25H41N7O3S [M + H]+ 520.3070, found: 520.3076. Anal. 
HPLC 96.1% (Rt = 3.35 min). 
 
4.1.4.12. 1-(3-Methoxy-4-(2-(4-phenylpiperazin-1-yl)ethoxy)phenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (171). Starting with compound 92 as following the 
general procedure 8, compound 171 was obtained as white solid, 50 % yield, mp = 
64-65oC. 1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 7.22 (t, J = 7.97 Hz, 2H), 7.00-
6.92 (m, 4H), 6.83 (t, J = 6.15 Hz, 1H), 6.76 (dd, J = 8.40, 2.73 Hz, 1H), 6.67 (s, 1H), 
4.19 (t, J = 5.31 Hz, 2H), 3.97 (t, J = 7.14 Hz, 2H), 3.82 (s, 3H), 3.59 (t, J = 6.57 Hz, 
2H), 3.20 (t, J = 4.95 Hz, 4H), 2.88 (t, J = 5.52 Hz, 2H), 2.80 (t, J = 4.95 Hz, 4H), 
2.22 (d, J = 0.93 Hz, 3H), 2.03 (p, J = 6.96 Hz, 2H). MS (ESI) m/z 509 [M+H]+. 
HRMS (FAB) m/z calc. for C27H37N6O2S [M + H]+ 509.2699, found: 509.2693. Anal. 
HPLC 96.9% (Rt = 3.81 min). 
 
4.1.4.13. 1-(4-(2-(4-Benzylpiperazin-1-yl)ethoxy)-3-methoxyphenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (172). Starting with compound 93 as following the 
general procedure 8, compound 172 was obtained as a white solid, 47% yield, mp = 
78-80 oC. 1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 7.32-7.26 (m, 5H), 6.96 (d, J 
= 8.58 Hz, 1H), 6.90 (d, J = 0.75 Hz, 1H), 6.76 (dd, J = 2.37, 8.40 Hz, 1H), 6.66 (s, 
1H), 4.14 (t, J = 5.49 Hz, 2H), 3.99 (t, J = 7.14 Hz, 2H), 3.79 (s, 3H), 3.59 (t, J = 5.49 
Hz, 2H), 3.53 (s, 2H), 2.83 (t, J = 5.49 Hz, 2H), 2.66-2.53 (m, 8H), 2.21 (s, 3H), 2.05 
(p, J = 7.14 Hz, 2H). MS (FAB) m/z 523 [M+H]+. HRMS (FAB) m/z calcd for 




(5-methyl-1H-imidazol-1-yl)propyl)thiourea (173). Starting with compound 94 as 
following the general procedure 8, compound 173 was obtained as white solid, 94% 
yield, mp = 71-72 oC. 1H NMR (300 MHz, CDCl3) δ 8.31 (d, J = 4.74 Hz, 2H), 7.77 
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(s, 1H), 7.42 (s, 1H), 6.91 (d, J = 8.97 Hz, 1H), 6.76-6.74 (m, 3H), 6.50 (t, J = 4.74 
Hz, 1H), 6.08 (br, 1H), 4.25-4.15 (m, 2H), 3.95-3.80 (m, 9H), 3.66 (dd, J = 13.74, 
6.60 Hz, 2H), 2.91 (t, J = 5.85 Hz, 2H), 2.75-2.60 (m, 4H), 2.18 (s, 3H), 2.13-1.97 
(m, 2H). MS (ESI) m/z 511 [M+H]+. HRMS (FAB) m/z calc. for C25H34N8O2S 
[M+H]+ 511.2604, found: 511.2609. Anal. HPLC 97.5% (Rt = 3.58 min). 
 
4.1.4.15. 1-(4-(2-(4-(5-Fluoropyrimidin-2-yl)piperazin-1-yl)ethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (174). Starting 
with compound 95 as following the general procedure 8, compound 174 was obtained 
as white solid, 78% yield, mp = 71-72 oC. 1H NMR (300 MHz, CDCl3) δ 8.20 (s, 2H), 
7.79 (s, 1H), 7.42 (s, 1H), 6.95-6.87 (m, 1H), 6.80-6.68 (m, 3H), 6.10 (br, 1H), 4.25-
4.13 (m, 2H), 3.95-3.86 (m, 2H), 3.83 (s, 3H), 3.82-3.75 (m, 4H), 3.72-3.60 (m, 2H), 
2.95-2.85 (m, 2H), 2.70-2.60 (m, 4H), 2.18 (s, 3H), 2.13-1.97 (m, 2H). MS (ESI) m/z 
529 [M+H]+. HRMS (FAB) m/z calc. for C25H33FN8O2S [M+H]+ 529.2509, found: 
529.2508. Anal. HPLC 97.3% (Rt = 3.56 min). 
 
4.1.4.16. 1-(4-(2-(4-(5-Chloropyrimidin-2-yl)piperazin-1-yl)ethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (175). Starting 
with compound 96 as following the general procedure 8, compound 175 was obtained 
as white solid, 35% yield, mp = 87-88 oC. 1H NMR (300 MHz, CDCl3) δ 8.22 (s, 2H), 
7.72 (s, 1H), 7.40 (s, 1H), 6.90 (d, J = 9.0 Hz, 1H), 6.76-6.72 (m, 3H), 6.04 (br, 1H), 
4.18 (t, J = 5.9 Hz, 2H), 3.89 (m, 2H), 3.83-3.80 (m, 7H), 3.65 (m, 2H), 2.89 (t, J = 
5.9 Hz, 2H), 2.65 (t, J = 5.1 Hz, 2H), 2.18 (s, 3H), 2.05 (m, 2H). MS (ESI) m/z 545 
[M+H]+. HRMS (FAB) m/z calc. for C25H33ClN8O2S [M + H]+ 545.2214, found: 
545.2220. Anal. HPLC 99.0% (Rt = 3.73 min). 
 
4.1.4.17. 1-(4-(2-(1-(2-Hydroxyethyl)piperidin-4-yl)ethoxy)-3-methoxyphenyl)-3-(3-
(5-methyl-1H-imidazol-1-yl)propyl)thiourea (176). Starting with compound 151 as 
following the general procedure 7, compound 176 was obtained as a pale red solid, 
62% yield, mp = 62-63 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (d, J = 1.11 Hz, 1H), 
6.95 (d, J = 8.61 Hz, 1H), 6.90 (d, J = 2.19 Hz, 1H), 6.75 (dd, J = 2.40, 8.43 Hz, 1H), 
6.66 (s, 1H), 4.05 (t, J = 6.21 Hz, 2H), 3.99 (t, J = 7.32 Hz, 2H), 3.81 (s, 3H), 3.67 
(t, J = 6.24 Hz, 2H), 3.59 (t, J = 6.78 Hz, 2H), 2.98-2.95 (m, 2H), 2.53 (t, J = 6.21 
Hz, 2H), 2.21 (d, J = 1.08 Hz, 3H), 2.14-1.98 (m, 5H), 1.79-1.68 (m, 4H), 1.37-1.28 
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(m, 2H). MS (ESI) m/z 476 [M+H]+. HRMS (ESI) m/z calcd for C24H37N5O3S [M+H]+ 
476.2690, found: 476.2677. Anal. HPLC 100.0% (Rt = 2.96 min). 
 
4.1.4.18. 1-(4-(2-(1-(2-Aminoethyl)piperidin-4-yl)ethoxy)-3-methoxyphenyl)-3-(3-
(5-methyl-1H-imidazol-1-yl)propyl)thiourea (177). Starting with compound 132 as 
following the general procedure 6.2, compound 177 was obtained as an off white 
solid, 76% yield, mp = 76-77 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (d, J = 1.08 
Hz, 1H), 6.95 (d, J = 8.43 Hz, 1H), 6.90 (d, J = 2.19 Hz, 1H), 6.75 (dd, J = 2.40, 8.43 
Hz, 1H), 6.66 (t, J = 2.55 Hz, 1H), 4.05 (t, J = 6.42 Hz, 2H), 3.99 (t, J = 7.14 Hz, 
2H), 3.81 (s, 3H), 3.59 (t, J = 7.14 Hz, 2H), 2.94 (br, 2H), 2.78 (t, J = 6.42 Hz, 2H), 
2.45 (t, J = 7.32 Hz, 2H), 2.21 (d, J = 1.11 Hz, 3H), 2.04-1.98 (m, 5H), 1.79-1.68 (m, 
4H), 1.37-1.28 (m, 2H). MS (ESI) m/z 475 [M+H]+. HRMS (ESI) calc. 




phenoxy)acetamide (178). Starting with compound 157 as following the reaction with 
NH3 to obtained compound 178, 62% yield, mp = 147-149 oC. 1H NMR (300 MHz, 
CD3OD) δ 7.59 (s, 1H), 7.02 (d, J = 2.37 Hz, 1H), 7.00 (d, J = 8.43 Hz, 1H), 6.79 (dd, 
J = 2.40, 8.61 Hz, 1H), 6.66 (s, 1H), 4.48 (s, 2H), 4.00 (t, J = 7.32 Hz, 2H), 3.85 (s, 
3H), 3.61 (t, J = 6.78 Hz, 2H), 2.22 (d, J = 0.90 Hz, 3H), 2.08 (p, J = 7.14 Hz, 2H). 
MS (FAB) m/z 378 [M+H]+. HRMS (FAB) m/z calcd for C17H23N5O3S [M+H]+ 
378.1600 found: 378.1604. Anal. HPLC 97.0% (Rt = 3.99 min). 
 
4.1.4.20. 3-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)propanamide (179). Starting with compound 97 as 
following the general procedure 8, compound 179 was obtained as white solid, 78% 
yield, mp = 115-117 oC.  1H NMR (300 MHz, CD3OD) δ 7.64 (s, 1H), 6.98 (d, J = 
8.58 Hz, 1H), 6.92 (d, J = 2.37 Hz, 1H), 6.75 (dd, J = 8.43, 2.40 Hz, 1H), 6.69 (s, 
1H), 4.24 (t, J = 6.24 Hz, 2H), 3.98 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.59 (t, J = 7.14 
Hz, 2H), 2.67 (t, J = 6.24 Hz, 2H), 2.22 (d, J = 0.93 Hz, 3H), 2.03 (p, J = 7.14 Hz, 
2H). MS (ESI) m/z 392 [M+H]+. MS (HRMS) calc. for C18H26N5O2S [M + H]+ 
392.1751, found 392.1750. Anal. HPLC 99.2% (Rt = 3.22 min). 
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4.1.4.21. 4-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)butanamide (180). Starting with compound 98 as 
following the general procedure 8, compound 180 was obtained as white solid, 20% 
yield, mp = 158-160 oC. 1H NMR (300 MHz, CD3OD) δ 7.56 (s, 1H), 6.92 (d, J = 
8.61 Hz, 1H), 6.86 (s, 1H), 6.71 (d, J = 8.61 Hz, 1H), 6.63 (s, 1H), 4.00 (t, J = 6.24 
Hz, 2H), 3.96 (t, J = 7.14 Hz, 2H), 3.77 (s, 3H), 3.57 (t, J = 6.78 Hz, 2H), 2.39 (t, J = 
7.32 Hz, 2H), 2.17 (d, J = 0.9 Hz, 3H), 2.04 (p, J = 7.32 Hz, 4H). MS (FAB) m/z 406 
[M+H]+. HRMS (FAB) m/z calcd for C19H27N5O3S [M + H]+ 406.1913, found: 
406.1907. Anal. HPLC 99.6% (Rt = 3.32 min). 
 
4.1.4.22. 2-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)-N,N-dimethylacetamide (181). Starting with 
compound 157 as following the reaction with dimethylamine, compound 181 was 
obtained as a white solid, 78% yield, mp = 120-122 oC. 1H NMR (400 MHz, CD3OD) 
δ 7.91 (s, 1H), 6.95 (d, J = 2.16 Hz, 1H), 6.91 (dd, J = 8.56 Hz, 1H), 6.81 (s, 1H), 
6.73 (dd, J = 8.52, 2.40 Hz, 1H), 4.79 (s, 2H), 4.03 (t, J = 7.20 Hz, 2H), 3.84 (s, 3H), 
3.61 (t, J = 6.88 Hz, 2H), 3.09 (s, 3H), 2.96 (s, 3H), 2.25 (d, J = 0.76 Hz, 3H), 2.07 
(p, J = 7.00 Hz, 2H). MS (ESI) m/z 406 [M + H]+. HRMS (FAB) for C19H28N5O3S 
[M + H]+ 406.1907, found 406.1908. Anal. HPLC 95.0% (Rt = 4.06 min). 
 
4.1.4.23. 3-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)-N,N-dimethylpropanamide (182). Starting with 
compound 99 as following the general procedure 8, compound 182 was obtained as 
white solid, 63% yield, mp = 181-183 oC. 1H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H), 
7.36 (s, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.71 (dd, J = 7.8, 3.0 Hz, 1H), 6.70 (s, 1H), 
6.68 (d, J = 2.1 Hz, 1H), 5.97 (t, J = 7.5 Hz, 1H), 4.33 (t, J = 7.2 Hz, 2H), 3.87 (t, J 
= 7.5 Hz, 2H), 3.80 (s, 3H), 3.64 (q, J = 7.5 Hz, 2H), 3.04 (s, 3H), 2.95 (s, 3H), 2.88 
(t, J = 6.9 Hz, 2H), 2.15 (d, J = 0.6 Hz, 3H), 2.02 (p, J = 6.9 Hz, 2H). MS (ESI) m/z 
420 [M + H]+. HRMS (ESI) calc. for C20H30N5O3S [M+H]+ 420.2064, found 
420.2065. Anal. HPLC 97.4% (Rt = 4.56 min). 
 
4.1.4.24. 4-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)-N,N-dimethylbutanamide (183). Starting with 
compound 100 as following the general procedure 8, compound 183 was obtained as 
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white solid, 60% yield, mp = 70-72 oC. 1H NMR (300 MHz, CDCl3) δ 7.59 (s, 1H), 
7.38 (s, 1H), 6.96 (d, J = 8.25 Hz, 1H), 6.74-6.69 (m, 3H), 5.98 (s, 1H), 4.14 (t, J = 
6.24 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.82 (s, 3H), 3.69 (q, J = 6.21 Hz, 2H), 3.02 
(s, 3H), 2.95 (s, 3H), 2.55 (t, J = 6.96 Hz, 2H), 2.17 (d, J = 0.90 Hz, 3H), 2.14 (p, J = 
6.78 Hz, 2H), 2.09 (p, J = 7.32 Hz, 2H). MS (FAB) m/z 434 [M+H]+. HRMS (FAB) 
m/z calcd for C21H31N5O3S [M+H]+ 434.2226, found: 434.2228. Anal. HPLC 98.6% 
(Rt = 3.40 min). 
 
4.1.4.25. 1-(3-Methoxy-4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (184). Starting with compound 133 as following 
the general procedure 6.2, compound 184 was obtained as white solid, 34% yield, mp 
= 124-125 oC. 1H NMR (300 MHz, CDCl3) δ 7.76 (s, 1H), 7.40 (s, 1H), 6.91 (d, J = 
8.43 Hz, 1H), 6.77 (d, J = 2.22 Hz, 1H), 6.70 (s, 1H), 6.69 (dd, J = 8.07, 2.37 Hz, 
1H), 6.21 (t, J = 7.14 Hz, 1H), 4.77 (s, 2H), 3.90 (t, J = 7.35 Hz, 2H), 3.82 (s, 3H), 
3.65 (t, J = 7.14 Hz, 2H), 3.39-3.55 (m, 4H), 2.88-2.84 (m, 4H), 2.18 (d, J = 0.75 Hz, 
3H), 2.03 (p, J = 7.14 Hz, 2H). MS (ESI) m/z 447 [M + H]+. HRMS (FAB) calc. for 
C21H31N6O3S [M+H]+ 447.2173, found 447.2165. Anal. HPLC 95.7% (Rt = 4.34 min). 
 
4.1.4.26. 1-(3-Methoxy-4-(3-oxo-3-(piperazin-1-yl)propoxy)phenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (185). Starting with compound 134 as following 
the general procedure 6.2, compound 185 was obtained as white solid, 31% yield, mp 
= 155-157 oC. 1H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H), 6.97 (d, J = 8.61 Hz, 1H), 
6.93 (d, J = 3.00 Hz, 1H), 6.74 (dd, J = 8.40, 2.37 Hz, 1H), 6.68 (s, 1H), 4.27 (t, J = 
6.24 Hz, 2H), 3.98 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.71-3.57 (m, 6H), 2.97 (t, J = 
4.95 Hz, 2H), 2.88 (t, J = 5.85 Hz, 4H), 2.22 (d, 1.11 Hz, 3H), 2.04 (p, J = 7.14 Hz, 
2H). MS (ESI) m/z 461 [M + H]+. HRMS (FAB) calc. for C22H33N6O3S [M+H]+ 
461.2329, found 461.2323. Anal. HPLC 95.0% (Rt = 3.15 min). 
 
4.1.4.27. 1-(3-Methoxy-4-(4-oxo-4-(piperazin-1-yl)butoxy)phenyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (186). Starting with compound 135 as following 
the general procedure 6.2, compound 186 was obtained as a white solid, 39% yield, 
mp = 91-93 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (s, 1H), 6.96 (d, J = 8.61 Hz, 
1H), 6.92 (d, J = 2.37 Hz, 1H), 6.76 (dd, J = 2.37, 8.61 Hz, 1H), 6.66 (s, 1H), 4.06 (t, 
J = 6.21 Hz, 2H), 3.99 (t, J = 7.50 Hz, 2H), 3.81 (s, 3H), 3.61-3.55 (m, 6H), 2.80-
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2.77 (m, 4H), 2.61 (t, J = 7.32 Hz, 2H), 2.22 (d, J = 0.93 Hz, 3H), 2.08 (p, J = 6.78 
Hz, 4H). MS (FAB) m/z 475 [M+H]+. HRMS (FAB) m/z calcd for C23H34N6O3S 
[M+H]+ 475.2491, found: 475.2483. Anal. HPLC 95.5% (Rt = 3.43 min). 
 
4.1.4.28. 1-(4-(2-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-oxoethoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (187). Starting 
with compound 152 as following the general procedure 7, compound 187 was 
obtained as a white solid, 44% yield, mp = 90-91 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (s, 1H), 6.87-6.84 (m, 2H), 6.71 (dd, J = 2.52, 9.03 Hz, 1H), 6.68 (s, 1H), 4.41 
(s, 2H), 3.98 (t, J = 7.23 Hz, 2H), 3.82 (s, 3H), 3.68 (t, J = 6.03 Hz, 2H), 3.59-3.55 
(m, 2H), 2.87 (t, J = 5.13 Hz, 4H), 2.52-2.48 (m, 6H), 2.21 (d, J = 1.2 Hz, 3H), 2.02 
(p, J = 6.96 Hz, 2H), MS (ESI) m/z 491 [M+H]+. HRMS (ESI) calc. 




3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (188). Starting with compound 136 
as following the general procedure 6.2, compound 188 was obtained as a white solid, 
24% yield, mp = 79-81 oC .1H NMR (400 MHz, CD3OD) δ 7.58 (s, 1H), 6.97 (d, J = 
2.28 Hz, 1H), 6.94 (d, J = 8.52 Hz, 1H), 6.75 (dd, J = 2.28, 8.48 Hz, 1H), 6.66 (s, 
1H), 4.78 (s, 2H), 3.99 (t, J = 7.16 Hz, 2H), 3.82 (s, 3H), 3.61-3.59 (m, 6H), 2.76 (t, 
J = 6.44 Hz, 2H), 2.51 (t, J = 3.16 Hz, 2H), 2.47 (t, J = 4.68 Hz, 4H), 2.21 (d, J = 
0.96 Hz, 3H), 2.07 (p, J = 5.44 Hz, 2H). MS (ESI) m/z 490 [M+H]+. HRMS (ESI) 
calc. for C23H35N7O3S [M+H]+ 490.2595, found 490.2595. Anal. HPLC 98.8% (Rt = 
2.87 min). 
4.1.4.30. 2-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)-N-(piperidin-4-yl)acetamide (189). Starting with 
compound 177 as following the general procedure 6.2, compound 189 was obtained 
as a white solid, 41% yield, mp = 57-58 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (d, 
J = 1.11 Hz, 1H), 7.07 (d, J = 2.40 Hz, 1H), 7.01 (d, J = 8.61 Hz, 1H), 6.80 (dd, J = 
2.40, 8.43 Hz, 1H), 6.66 (s, 1H), 4.49 (s, 2H), 4.00 (t, J = 7.32 Hz, 2H), 3.87 (s, 3H), 
3.84-3.81 (m, 1H), 3.62 (t, J = 6.78 Hz, 2H), 3.05 (d, J = 12.81 Hz, 2H), 2.68 (t, J = 
11.91 Hz, 2H), 2.22 (d, J = 1.08 Hz), 2.06 (p, J = 6.96 Hz, 2H), 1.88-1.84 (m, 2H), 
1.50-1.42 (m, 2H). MS (ESI) m/z 461 [M+H]+. HRMS (ESI) calc. 
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yl)propyl)thioureido)phenoxy)-N-(piperidin-4-yl)propanamide (190). Starting with 
compound 138 as following the general procedure 6.2, compound 190 was obtained 
as a white solid, 24% yield, mp = 89-90 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (s, 
1H), 6.97 (d, J = 8.43 Hz, 1H), 6.92 (d, J = 2.19 Hz, 1H), 6.77 (dd, J = 2.37, 8.61 Hz, 
1H), 6.66 (s, 1H), 4.25 (t, J = 6.03 Hz, 2H), 4.06-4.04 (m, 1H), 3.99 (t, J = 7.32 Hz, 
2H), 3.81 (s, 3H), 3.61 (t, J = 7.14 Hz, 2H), 3.08-3.03 (m, 2H), 2.71-2.60 (m, 4H), 
2.21 (d, J = 0.93 Hz, 3H), 2.05 (p, J = 6.96 Hz, 2H), 1.88-1.85 (m, 2H), 1.46-1.41 (m, 
2H). MS (FAB) m/z 475 [M+H]+. HRMS (FAB) m/z calcd for C23H34N6O3S [M + H]+ 
475.2491, found: 475.2477. Anal. HPLC 97.8% (Rt = 3.91 min). 
 
4.1.4.32. 4-(2-Methoxy-4-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thioureido)phenoxy)-N-(piperidin-4-yl)butanamide (191). Starting with 
compound 139 as following the general procedure 6.2, compound 191 was obtained 
as white solid, 87% yield, mp = 97-98 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (d, J 
= 0.90 Hz, 1H), 6.93 (d, J = 8.61 Hz, 1H), 6.92 (s, 1H), 6.74 (dd, J = 8.43, 2.40 Hz, 
1H), 6.66 (s, 1H), 4.01 (t, J = 6.06 Hz, 2H), 3.97 (t, J = 7.32 Hz, 2H), 3.81 (s, 3H), 
3.79-3.74 (m, 1H), 3.59 (t, J = 6.96 Hz, 2H), 3.08 (dt, J = 9.90, 2.94 Hz, 2H), 2.72 
(td, J = 12.09, 2.04 Hz, 2H), 2.38 (t, J = 7.14 Hz, 2H), 2.21 (d, J = 0.9 Hz, 3H), 2.10-
1.99 (m, 4H), 1.88 (d, J = 10.08 Hz, 2H), 1.41 (qt, J = 11.70, 2.91 Hz, 2H). MS (ESI) 
m/z 489 [M + H]+. HRMS (FAB) calc. for C24H37N6O3S [M+H]+ 489.2642, found 
489.2659. Anal. HPLC 98.5% (Rt = 3.52 min). 
 
4.1.4.33. N-(1-(2-Hydroxyethyl)piperidin-4-yl)-2-(2-methoxy-4-(3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thioureido)phenoxy)acetamide (192). Starting with compound 
153 as following the general procedure 7, compound 192 was obtained as a white 
solid, 41% yield, mp = 104-106 oC. 1H NMR (300 MHz, CDCl3) δ 7.59 (s, 1H), 7.05 
(d, J = 2.19 Hz, 1H), 7.01 (d, J = 8.40 Hz, 1H), 6.80 (dd, J = 2.37, 8.43 Hz, 1H), 6.66 
(s, 1H), 4.49 (s, 2H), 4.00 (t, J = 7.32 Hz, 2H), 3.87 (s, 1H), 3.85-3.82 (m, 1H), 3.69 
(t, J = 6.06 Hz, 2H), 3.61 (t, J = 6.96 Hz, 2H), 2.95 (d, J = 12.09 Hz), 2.54 (t, J = 6.06 
Hz, 2H), 2.22 (d, J = 0.72 Hz, 3H), 2.16-2.13 (m, 2H), 2.08 (p, J = 7.32 Hz), 1.88-
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1.82 (m, 2H), 1.66-1.54 (m, 2H). MS (ESI) m/z 505 [M+H]+. HRMS (ESI) calc. 
for C24H36N6O4S [M+H]+ 505.2592, found 505.2583. Anal. HPLC 100.0% (Rt = 2.97 
min).    
 
4.1.4.34. N-(1-(2-Aminoethyl)piperidin-4-yl)-2-(2-methoxy-4-(3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thioureido)phenoxy)acetamide (193). Starting with compound 
140 as following the general procedure 6.2, compound 193 was obtained as a white 
solid, 77% yield, mp = 125-126 oC. 1H NMR (500 MHz, CD3OD) δ 7.59 (s, 1H), 7.06 
(d, J = 1.75 Hz, 1H), 7.00 (d, J = 8.55 Hz, 1H), 6.79 (dd, J = 2.15, 8.50 Hz, 1H), 6.66 
(s, 1H), 4.49 (s, 2H),  3.99 (t, J = 7.20 Hz, 2H), 3.87 (s, 3H), 3.79-3.76 (m, 1H), 3.59 
(t, J = 6.60 Hz, 2H), 2.90 (d, J = 11.35 Hz, 2H), 2.82 (t, J = 6.55 Hz, 2H), 2.49 (t, J 
= 6.60 Hz, 2H), 2.22 (s, 3H), 2.19-2.14 (m, 2H), 2.07 (p, J = 7.10 Hz, 2H), 1.89-1.87 
(m, 2H), 1.62 (q, J = 8.95 Hz, 2H). MS (ESI) m/z 504 [M+H]+. HRMS (ESI) calc. for 




yl)propyl)thioureido)phenoxy)-ethyl)piperidine-4-carboxamide (194). Starting with 
compound 141 as following the general procedure 6.2, compound 194 was obtained 
as a white solid, 54% yield. 1H NMR (300 MHz, CD3OD) δ 7.51 (d, J = 1.29 Hz, 1H), 
6.89 (d, J = 2.40 Hz, 1H), 6.87 (d, J = 8.61 Hz, 1H), 6.69 (dd, J = 2.40, 8.61 Hz, 1H), 
6.57 (s, 1H), 3.98 (t, J = 5.67 Hz, 2H), 3.91 (t, J = 7.32 Hz, 2H), 3.71 (s, 3H), 3.52-
3.41 (m, 4H), 3.28-3.24 (m, 2H), 2.89 (td, J = 12.27 Hz, 3.66, Hz, 2H), 2.41-2.38 (m, 
1H), 2.13 (d, J = 0.90 Hz, 3H), 1.99 (quint, J = 6.75 Hz, 2H), 1.83-1.78 (m, 2H), 1.76-
1.71 (m, 2H). MS (FAB) m/z 475 [M+H]+. HRMS (FAB) m/z calcd for C22H34N6O3S 
[M+H]+ 475.2491, found: 475.2491. Anal. HPLC 99.6% (Rt = 4.29 min). 
 
4.1.4.36. 1-(3-Methoxy-4-(4-(piperazin-1-yl)phenoxy)phenyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (195). Starting with compound 142 as following the 
general producer 6.2, compound 195 was obtained as a white solid, 69% yield, mp = 
88-90 oC. 1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 7.09 (d, J = 2.37 Hz, 1H), 
6.92-6.89 (m, 2H), 6.86-6.81 (m, 3H), 6.76 (dd, J = 2.55, 8.58 Hz, 1H) 6.66 (s, 1H), 
4.01 (t, J = 7.14 Hz, 2H), 3.78 (s, 3H), 3.63 (t, J = 6.54 Hz, 2H), 3.06-3.02 (m, 4H), 
2.97-2.85 (m, 4H), 2.22 (s, 3H), 2.07 (p, J = 6.96 Hz, 2H). 
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MS (ESI) m/z 481 [M+H]+. HRMS (ESI) calc. 




methyl-1H-imidazol-1-yl)propyl)thiourea (196). Starting with compound 88 as 
following the general producer 8, compound 196 was obtained as a white solid, 49% 
yield, mp = 104-106 oC. 1H NMR (300 MHz, CD3OD) δ 7.63 (s, 1H), 7.10 (d, J = 
2.37 Hz, 1H), 6.95-6.92 (m, 2H), 6.89 (s, 1H), 6.86 (s, 1H), 6.84-6.81 (m, 2H), 6.79 
(dd, J = 2.37, 8.43 Hz, 1H), 4.02 (t, J = 7.23 Hz, 2H), 3.78 (s, 3H), 3.63 (t, J = 6.93 
Hz, 2H), 3.14 (t, J = 4.95 Hz, 4H), 2.66 (t, J = 4.95 Hz, 4H), 2.36 (s, 3H), 2.23 (d, J 
= 0.90 Hz, 3H), 2.10 (p, J = 6.78 Hz, 2H). MS (ESI) m/z 495 [M+H]+. HRMS (ESI) 




(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (197). Starting with compound 159 
as following the general producer 7, compound 197 was obtained as a white solid, 
89% yield, mp = 66-67 oC. 1H NMR (300 MHz, CD3OD) δ 7.92 (s, 1H), 7.12 (d, J = 
2.19 Hz, 1H), 6.97-6.94 (m, 2H), 6.87-6.84 (m, 2H), 6.82-6.77 (m, 3H), 4.07 (t, J = 
7.14 Hz, 2H), 3.82 (t, J = 5.52 Hz, 2H), 3.75 (s, 3H), 3.24-3.22 (m, 6H), 3.04 (t, J = 
4.56 Hz, 4H), 2.91 (t, J = 5.67 Hz, 2H), 2.26 (d, J = 0.90 Hz, 3H), 2.11 (p, J = 7.32 
Hz, 2H). MS (ESI) m/z 525 [M+H]+. HRMS (ESI) calc. for C27H36N6O3S [M+H]+ 
525.2642, found 525.2633. Anal. HPLC 96.3% (Rt = 2.92 min). 
 
4.1.4.39. 1-(4-(4-(4-(2-Aminoethyl)piperazin-1-yl)phenoxy)-3-methoxyphenyl)-3-(3-
(5-methyl-1H-imidazol-1-yl)propyl)thiourea (198). Starting with compound 158 as 
following the general producer 6.2, compound 198 was obtained as a white solid, 
75% yield, m.p = 75-77 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (s, 1H), 7.09 (d, J = 
2.37 Hz, 1H), 6.96-6.93 (m, 2H), 6.84-6.81 (m, 3H), 6.79 (dd, J = 2.22, 8.43 Hz, 1H), 
6.66 (s, 1H), 4.01 (t, J = 7.50 Hz, 2H), 3.78 (s, 3H), 3.61 (t, J = 7.14 Hz, 2H), 3.13 (t, 
J = 5.10 Hz, 4H), 2.82 (t, J = 6.39 Hz, 2H), 2.66 (t, J = 5.13 Hz, 4H), 2.53 (t, J = 6.60 
Hz, 2H), 2.22 (d, J = 0.90 Hz, 3H), 2.07 (p, J = 7.14 Hz, 2H). 
MS (ESI) m/z 524 [M+H]+. HRMS (ESI) calc. for 
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(5-methyl-1H-imidazol-1-yl)propyl)thiourea (199). Starting with compound 143 as 
following the general procedure 6.2, compound 199 was obtained as a white solid, 
91% yield, mp = 95-97 oC. 1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 7.34 (d, J = 
8.79 Hz, 2H), 7.15 (d, J = 2.40 Hz, 1H), 6.99 (d, J = 8.61 Hz, 1H), 6.84-6.80 (m, 3H), 
6.67 (s, 1H), 6.08 (s, 1H), 4.02 (t, J = 7.14 Hz, 2H), 3.76 (s, 3H), 3.64 (t, J = 6.78 Hz, 
2H), 3.44 (q, J = 3.12 Hz, 2H), 3.04 (t, J = 5.88 Hz, 2H), 2.47-2.43 (m, 2H), 2.23 (d, 
J = 0.93 Hz, 3H), 2.08 (p, J = 7.14 Hz, 2H). MS (ESI) m/z 478 [M+H]+. HRMS (ESI) 




imidazol-1-yl)propyl)thiourea (200). Starting with compound 144 as following the 
general procedure 6.2, compound 200 was obtained as a white solid, 61% yield, mp 
= 87-89 oC. 1H NMR (400 MHz, CD3OD) δ 7.59 (s, 1H), 7.15-7.12 (m, 3H), 6.94 (d, 
J = 8.40 Hz, 1H), 6.82-6.80 (m, 3H), 6.66 (s, 1H), 4.01 (t, J = 7.28 Hz, 2H), 3.78 (s, 
3H) 3.63 (t, J = 6.96 Hz, 2H), 3.14-3.11 (m, 2H), 2.74-2.71 (m, 2H), 2.64-2.62 (m, 
1H), 2.23 (d, J = 0.64 Hz, 3H), 2.14-2.00 (m, 4H), 1.63-1.57 (m, 2H). MS (ESI) m/z 
480 [M+H]+. HRMS (ESI) calc. for C26H33N5O2S [M+H]+ 480.2428, found 480.2424. 
Anal. HPLC 97.7% (Rt = 2.90 min). 
 
4.1.4.42. 1-(3-Methoxy-4-(3-(piperazin-1-yl)benzyloxy)phenyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (201). Starting with compound 145 as following the 
general procedure 6.2, compound 201 was obtained as a white solid, 75% yield, mp 
= 106-108 oC. 1H NMR (300 MHz, CD3OD) δ 7.59 (s, 1H), 7.23 (t, J = 7.86 Hz, 1H), 
7.06 (s, 1H), 6.97 (d, J = 7.89 Hz, 1H), 6.93-6.90 (m, 3H), 6.71 (dd, J = 7.89, 1.83 
Hz, 1H), 6.66 (s, 1H), 5.07 (s, 2H), 3.96 (t, J = 7.14 Hz, 2H), 3.84 (s, 3H), 3.59 (t, J 
= 6.96 Hz, 2H), 3.13 (t, J = 4.38, 4H), 2.96 (t, J = 5.31 Hz, 4H), 2.21 (s, 3H), 2.02 (p, 
J = 7.14 Hz, 2H). MS (ESI) m/z 495 [M + H]+. HRMS (FAB) calc. for C26H35N6O2S 
[M+H]+ 495.2537 found 495.2542. Anal. HPLC 95.0% (Rt = 3.15 min). 
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4.1.4.43. 1-(3-Methoxy-4-(3-(piperidin-4-yl)benzyloxy)phenyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (202). Starting with compound 146 as following the 
general procedure 6.2, compound 202 was obtained as a white solid, 68% yield, mp 
= 166-167 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (d, J = 1.08 Hz, 1H), 7.33-7.26 
(m, 3H), 7.19 (tt, J = 6.24 Hz, 1H), 6.97 (d, J = 8.61 Hz, 1H), 6.94 (d, J = 2.37 Hz, 
1H), 6.72 (dd, J = 8.43, 2.37 Hz, 1H), 6.66 (s, 1H), 3.96 (t, J = 7.14 Hz, 2H), 3.83 (s, 
3H), 3.59 (t, J = 6.78 Hz, 2H), 3.25 (br, 1H), 3.21 (br, 1H), 2.84 (td, J = 12.45, 2.94 
Hz, 2H), 2.74 (tt, J = 11.91, 3.66 Hz, 1H), 2.21 (d, J = 0.90 Hz, 3H), 2.03 (p, J = 7.14 
Hz, 2H), 1.90-1.86 (br, 2H), 1.75 (p, J = 8.40, 3.84 Hz, 2H). MS (ESI) m/z 494 [M + 
H]+. HRMS (FAB) calc. for C27H36N5O2S [M+H]+ 494.2584, found 494.2595. Anal. 
HPLC 97.7% (Rt = 3.18 min). 
 
4.1.4.44. 1-(3-Methoxy-4-(4-(2-(methylamino)pyridin-4-yl)butoxy)phenyl)-3-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (203). Starting with compound 147 as 
following the general procedure 6.2, compound 203 was obtained as a white solid, 
83% yield, mp = 56-58 oC. 1H NMR (300 MHz, CD3OD) δ 7.79 (d, J = 4.95 Hz, 1H), 
7.59 (d, J = 0.90 Hz, 1H), 6.93 (d, J = 8.79 Hz, 1H), 6.89 (d, J = 2.55 Hz, 1H), 6.75 
(dd, J = 2.37, 8.01 Hz, 1H), 6.66 (s, 1H), 6.45 (dd, J = 1.29, 5.31 Hz, 1H), 6.35 (s, 
1H), 4.04 (t, J = 5.64 Hz, 2H), 3.94 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.61 (t, J = 6.57 
Hz, 2H), 2.82 (s, 3H), 2.57 (t, J = 7.29 Hz, 2H), 2.21 (d, J = 0.90 Hz, 3H), 2.07 (p, J 
= 7.32 Hz, 2H), 1.80-1.78 (m, 4H). MS (ESI) m/z 483 [M+H]+. HRMS (ESI) calc. for 
C25H34N6O2S [M+H]+ 483.2537, found 483.2534. Anal. HPLC 99.2% (Rt = 2.96 min). 
 
4.1.4.45. 1-(4-(4-(2-((2-Hydroxyethyl)amino)pyridin-4-yl)butoxy)-3-
methoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (204). Starting 
with compound 154 as following the general procedure 7, compound 204 was 
obtained as a white solid, 68% yield, mp = 103-104 oC. 1H NMR (300 MHz, CD3OD) 
δ 7.79 (d, J = 5.28 Hz, 1H), 7.59 (s, 1H), 6.93-6.90 (m, 2H), 6.75 (dd, J = 2.55, 9.12 
Hz, 1H), 6.66 (s, 1H), 6.46 (d, J = 5.31 Hz, 1H), 6.41 (s, 1H), 4.00 (t, J = 5.97 Hz, 
2H), 3.97 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.70 (t, J = 5.49 Hz, 2H), 3.59 (q, J = 
6.87 Hz, 2H), 3.37 (t, J = 5.49 Hz, 2H), 2.57 (m, 2H), 2.21 (d, J = 0.90 Hz, 3H), 2.02 
(p, J = 6.96 Hz, 2H), 1.79 (m, 4H). MS (ESI) m/z 513 [M+H]+. HRMS (ESI) calc. 
for C26H36N6O3S [M+H]+ 513.2642, found 513.2633. Anal. HPLC 98.1% (Rt = 2.95 
min). 
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4.1.4.46. 1-(4-(4-(2-((2-Aminoethyl)amino)pyridin-4-yl)butoxy)-3-methoxyphenyl)-
3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (205). Starting with compound as 
148 following the general procedure 6.2, compound 205 was obtained as a white 
solid, 46% yield, mp = 100-102 oC. 1H NMR (500 MHz, DMSO) δ 9.51 (br, 1H), 
7.82 (d, 1H, J = 5.05 Hz), 7.76 (br, 1H), 7.53 (s, 1H), 6.97 (s, 1H), 6.89 (d, 1H, J = 
9.05 Hz), 6.76 (d, 1H, J = 8.15 Hz), 6.60 (s, 1H), 6.33-6.27 (m, 3H), 3.93 (t, 2H, J = 
5.55 Hz), 3.89 (t, 2H, J = 7.05 Hz), 3.71 (s, 3H), 3.43 (q, J = 5.34 Hz, 2H), 3.19 (q, 
2H, J = 6.20 Hz), 2.66 (t, 2H, J = 6.25 Hz), 2.47-2.45 (m, 2H), 2.14 (s, 3H), 1.92 (p, 
2H, J = 7.00 Hz), 1.68-1.61 (m, 4H). MS (ESI) m/z 512 [M+H]+. HRMS (ESI) calc. 
for C26H37N7O2S [M+H]+ 512.2802, found 512.2800. Anal. HPLC 97.1% (Rt = 2.80 
min). 
 
4.2. Molecular Modeling  
The X-ray crystal structure of human glutaminyl cyclase (PDB ID: 3PBB) [39] was 
prepared using the Protein Preparation Wizard in Maestro v.10.2 (Schrödinger, LLC, 
New York, NY, USA). During the preparation process, bond orders were assigned, 
zero-order bonds to Zn2+ were created, and hydrogen atoms were added. All hydrogen 
atoms were energy minimized with the optimized potential for liquid simulation 
(OPLS) 2005 force field. The protonation states of the ligand molecules were 
predicted using the pKa prediction module in ACD/I-Lab web server (ACD/Labs, 
Toronto, ON, Canada). The 3D structure of compound 202 was generated by LigPrep 
v.3.4 in Maestro and the resulting structure was energy minimized in implicit solvent 
with OPLS 2005 force field in Maestro. The prepared ligand molecules were docked 
to hQC using Glide v.6.7 in Maestro. The grid for the active site was generated using 
the centroid of the co-crystallized ligand, PBD150, and the grid box size was set as 
default. The metal coordination constraint was set to the tetrahedral geometry for Zn2+. 
Glide SP docking was performed with the maximum number of 30 poses per ligand. 
The resulting top 5 poses of compound 202 were selected and used for the following 
QM-Polarized Ligand Docking (QPLD) process. The partial charges of the docked 
ligands were calculated using Jaguar with the option of accurate QM level. Then, the 
ligands with the updated charges were re-docked using Glide extra precision (XP). 
The protein-ligand complex obtained from QPLD was used for further optimization 
by the Refine Protein-Ligand Complex module in Prime v.4.0 in Maestro. Protein 
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residues within 5 Å of the docked ligand were minimized by local optimization 
refinement. The side chain conformations of the selected protein residues were 
predicted and minimized along with the docked ligand during this process. The 
resulting structures were further energy minimized using Monte Carlo sampling 
algorithm in Maestro in 2500 steps. All figures of the molecular structures were 
generated using PyMOL software (http://www.pymol.org). All computational studies 
were performed on an Intel Xeon Octa-Core 2.67 GHz workstation with Linux 
CentOS release 6.7. 
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1. Design and  Pharmacophore 
Previously reported QC inhibitors were developed by a pharmacophore design based 
on the N-terminal structure of its substrate Aβ3-42. The representative inhibitors 
developed by Probiodrug (1, 2),60, 61, 70,  Wu and colleagues (3)71 and our research 
group (4)59, 66, 72 are shown in Figure 2.1. Naturally occurring inhibitors73, 74 and other 
small molecule inhibitors developed by the fragment-based approach75 were also 
reported; however, these inhibitors demonstrated only modest activity. Currently, 
PQ912, developed by Probiodrug, is undergoing a clinical trial, and it has exhibited 
favorable safety and tolerability. More importantly, PQ912 demonstrated a slight 
improvement in synaptic and neurological functions in patients with AD in a recently 
completed phase IIa clinical trial 76, 77 supporting that QC is a potential therapeutic 
target for the treatment of AD. 
 
 
Figure 2.1. Representative QC inhibitors. 
 
 The Probiodrug compound 1 contains three key pharmacophores derived 
from the N-terminal Glu-Phe moiety of Aβ3E-42. 60, 61 The 5-methylimidazole ring (red) 
mimics the N-terminal carboxylic acid as a zinc-binding motif. The distal NH of 
thiourea (blue) serves as a hydrogen bond donor, mimicking the first peptide bond 
from the N-terminus. The phenyl ring (green) mimics the Phe side chain at the 
penultimate position to the N-terminus. Inspired by this approach, we had previously 
developed a series of QC inhibitors (template A), with an extended scaffold as 
described in Figure 2.2.59, 72 The scaffold contains an additional pharmacophore that 
mimics the binding interaction of the guanidine side chain of Arg at the 
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antepenultimate position to the N-terminus. The newly developed QC inhibitors 
displayed much improved potency with a range of 5 to 40-fold more potent inhibition 
than 1. Specifically, compound 4 not only exhibited potent inhibition without 
cytotoxicity but also significantly reduced the brain concentrations of pE-Aβ and total 
Aβ while restoring cognitive functions in an AD animal model. The molecular 
modeling analysis of 4 indicated that the 2-aminopyridine moiety showed strong 
interactions with the carboxylate group of Glu327 in the QC binding site. 
 
Figure 2.2. Design rationale for QC inhibitors with novel templates 
 
 In this study, we investigated a series of 3-aminoalkyloxy-4-methoxyphenyl 
(template B) and 4-aminoalkyloxyphenyl (template C) surrogates as variants of 
template A. We anticipate that these templates would provide useful information to 
optimize the position of Arg-mimetic region (from template B) and to identify the 
significance of the 3-methoxy group (from template C) for QC inhibition. We 
evaluated the human QC inhibitory activity of the synthesized compounds in vitro 
and selected several potent inhibitors (IC50 < 10 nM). We further tested these 
compounds for in vitro toxicity/permeability and in vivo activity in acute AD model 
mice. Finally, a molecular modeling study was performed to analyze the specific 
binding interactions in the QC active site. 
 
2. Results and discussion 
2.1. Chemistry 
In general, the final thiourea compounds were synthesized by the coupling 
reaction between 3-(5-methyl-1H-imidazol-1-yl)propan-1-amine and aniline 
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intermediates obtained by the reduction of nitro fragments prepared in Schemes 2.1 
and 2.2. 
The synthesis of the 3-aminoalkyloxy-4-methoxy-1-nitrobenzene fragments 
is described in Scheme 2.1. Starting from 5-nitroguaiacol (5), the Mitsunobu reaction 
or Williamson reaction incorporated N-protected aminoalkyl moieties into the 
phenolic position to provide 6-17. Among them, the N-Boc protected amino (6-12) 
and phthalimide protected amino (13, 14) intermediates were directly employed for 
the thiourea coupling. The bromides 15-17 were reacted with N-Boc piperazine to 
give 22-24. After deprotection, the free amines (18, 21) were converted to the N-
methylpiperidine (19) and dimethylamino (29) analogues by reductive amination, 
respectively. Meanwhile, the amines (20, 21) were protected with a Boc group and 
then N-methylated to afford the corresponding N-Boc methylamino (27, 28) 
analogues. 
 
Scheme 2.1. 3-aminoalkyloxy-4-methoxy-1-nitrobenzene fragments. Reagents and 
conditions: (a) N-Boc ethanolamine, N-Boc piperidine derivatives or tert-butyl (4-(2-
hydroxyethyl)pyridin-2-yl)carbamate, DEAD, PPh3, DCM, r.t., overnight; (b) alkyl 
halides, K2CO3, DMF, 100 °C, 1 h; (c) TFA, DCM; (d) ZnCl2, HCHO, NaBH3CN, 
MeOH, r.t., overnight; (e) N2H4.H2O, EtOH, r.t., overnight; (f) Boc2O, TEA, DCM; 
(g) CH3I, NaH, THF, 0 °C for 27, 28; (h) N-Boc piperazine, DMF, TEA, 60 °C, 2 h. 
 
The synthesis of 4-aminoalkyloxy-1-nitrobenzene fragment is shown in 
Scheme 2.2. The N-Boc aminoalkyloxy analogues (32, 33) were prepared from 4-
nitrophenol (30) by alkylation reactions. The N-Boc amido analogues (37, 38, 42, 43, 
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50) were synthesized from 4-nitrobenzoic acid (34), 2-(4-nitrophenoxy)acetic acid, 
(35) or 4-nitro cinnamic acid (36), by coupling with the corresponding amines. The 
N-aminoethyl piperazinyl (40) and piperidinyl (47-49) analogues were prepared from 
the corresponding piperazine (39) and piperazine (44-46) precursors by alkylation 
with tert-butyl (2-iodoethyl)carbamate. 
 
Scheme 2.2. 4-aminoalkyloxy-1-nitrobenzene fragment. Reagents and conditions: (a) 
alkyl halide, Cs2CO3, DMF, heat; (b) N-Boc piperazine, Cs2CO3, DMF, heat; (c) 
RNH2, EDC, HOBt, DCM; (d) TFA, DCM; (e) tert-Butyl (2-iodoethyl)carbamate, 
NaH, DMF, 0 °C to r.t., 2 h. 
 
Scheme 2.3. Synthesis of final compound of Phe-Arg mimetic region. Reagents and 
conditions: (a) Pd, H2, MeOH; (b) Zn, AcOH, MeOH; (c) 3-(5-methyl-1H-imidazol-
1-yl)propan-1-amine, TCDI, Et3N, DCM, r.t., overnight; (d) TFA, DCM, 0 °C to r.t., 
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overnight; (e) N2H4.H2O, EtOH, r.t., overnight; (f) 2-chloropyrimidine, TEA, EtOH, 
reflux, 2 days. 
The synthesis of the final thiourea compounds is illustrated in Scheme 2.3. 
The synthesized anilines were reduced either by hydrogenation or by zinc in acetic 
acid to provide the corresponding amines, which were then coupled with 3-(5-methyl-
1H-imidazol-1-yl)propan-1-amine by previous method59 to afford the corresponding 
thioureas. Finally, the deprotection of N-Boc and N-phthalimide provided the final 3-
aminoalkyloxy-4-methoxyphenyl (51-66) and 4-aminoalkyloxyphenyl (68-78) 
derivatives, respectively. The pyrimidine 67 was synthesized from amine 53 by 
reacting with 2-chloropyrimidine. 
 
2.2. In vitro QC Inhibition 
 As previously reported, to evaluate the human QC inhibition of the 
synthesized compounds we performed the QC activity assays employing a 
fluorogenic substrate, Gln-AMC (L-glutamine 7-amido-4-methylcoumarin), and 
pyroglutamyl peptidase (pGAP) as an auxiliary enzyme. 67 
 First, we investigated a series of 3-aminoalkyloxy-4-methoxyphenyl 
analogues represented as template B (Table 2.1). The primary amine derivatives (51-
53) exhibited similarly potent inhibition regardless of the length of linkers with a 
range of IC50 = 7.9-9.0 nM, which were 3.5-fold more potent than the parent 1. The 
secondary amine derivatives (54, 55) were found approximately 3-fold less active 
than the corresponding primary amines (52, 53). The tertiary amine derivative (56) 
showed poor inhibition compared to the corresponding secondary derivative (55). 
Next, we examined the cyclic amine derivatives. The piperazine derivatives (57-59) 
also displayed reasonable inhibitory effect regardless of the linker length. The 
piperidine derivatives (60-62) exhibited better activity than those of piperazine 
derivatives, and they showed similar IC50 values compared to the primary amine 
derivatives (51-53). However, the N-methylation of the piperidine (63) resulted in the 
loss of activity. Because the previously developed 2-aminopyridine derivatives 
(template A, Figure 2) showed promising activities both in in vitro (IC50 = 4.5 nM 
for 4) and in vivo, we also examined the 2-aminopyridine analogues (64-66). 
Unfortunately, these compounds were found to be less potent than their 3-
methoxyphenyl-4-aminoalkyloxy counter parts (template A). When the 
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aminopyridine group was replaced with a 2-aminopyrimidine (67), the compound 
showed similar inhibition as the aminopyridine analogue 66. 
 
Table 2.1. IC50 values for the inhibition of hQC by 3-aminoalkyloxy-4-methoxy-1-
nitrobenzene compounds 
 
Cpd# R n IC50 (nM)a 
1   29.2
b  
51  2 7.9 (±0.7) 
52  3 9.0 (±2.3) 
53  4 8.8 (±0.6) 
54 
 
3 26.8 (±4.7) 
55 
 
4 22.0 (±6.8) 
56 
 
4 46.8 (±10.8) 
57 
 
2 18.4 (±1.9) 
58 
 
3 15.8 (±2.8) 
59 
 
4 15.0 (±0.5) 
60 
 
2 7.3 (±6.3) 
61 
 
3 8.8 (±2.2) 
62 
 
4 7.9 (±2.1) 
63 
 
2 20.6 (±7.4) 
64 
 
2 26.4 (±8.8) 
65 
 
3 15.0 (±2.9) 
66 
 
4 15.9 (±7.4) 
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67 
 
4 15.2 (±2.0) 
a The values indicate the mean of at least three experiments. b Refs. 14 and 18 
 
 Next, we examined a series of 4-aminoalkyloxyphenyl analogues, in which 
the 3-methoxy group was removed and only contained the substituent at the 4-
position and was represented as template C (Table 2.2). We first tested compounds 
68 and 69, which were most potent when they contained the 3-methoxy group.59 
However, it was found that compounds 68 and 69 were much less active, by 27- and 
5.5-fold respectively, than their previously reported 3-methoxy counterparts, 
suggesting that the 3-methoxy group represents an important binding interaction for 
inhibitory effect. We also examined inhibition of compounds 70-72 with an amido 
linker to compare the structure-activity relationship of the previously developed 
derivatives containing a 3-methoxy group.71 These compounds appeared to maintain 
similar activity compared to the previously reported compounds,71 while the N-
aminoethyl piperidine derivative (72) was found to be more potent than that of 70, 
suggesting that the presence of an additional amide group may aid extra binding 
interactions and that the terminal amino group may serve as an Arg-mimetic. 
However, shortening or rigidifying the linker group mostly resulted in the loss of 
activity, as demonstrated in 73 and 74 (a 2-fold reduction than compounds 69 and 72, 
respectively). As a bioisostere of methyleneoxy group in the linker, we also tested the 
cinnamic linker surrogates (75-78). Although compounds containing the cinnamic 
linker appeared to be slightly less active than the corresponding alkyloxy derivatives, 
the addition of an N-aminoethyl group to compound 75 increased the activity 3-fold 
to give potent inhibitor 76 with an IC50 = 6.4 nM, again suggesting that the terminal 
amino group likely served as an Arg-mimetic group to interact with QC. 
 
Table 2.2. IC50 values for inhibition of hQC by 4-aminoalkyloxy-1-nitrobenzene 
compounds  
 
Cpd# R IC50 (nM)a 
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a The values indicate the mean of at least three experiments. 
 
2.3. In vivo activity 
 Based on the in vitro QC inhibition of the synthesized compounds, we selected 
eight of the most potent inhibitors with IC50 values less than 10 nM for further 
evaluation. We first examined cytotoxicity by incubating HT-22 cells, an 
immortalized hippocampal neuronal cell line, with 10 µM of each compound, and 
performed MTT assays. All tested compounds were not cytotoxic, demonstrating 
normal cell viability. We also evaluated the ability of hERG channel blocking for all 
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compounds to assess drug toxicity. All compounds showed moderate (35.1%, 62) to 
low inhibition (2.8%, 53) at 10 µM, indicating that they pose a marginal to low risk 
for cardiotoxicity. To evaluate the ability of the compounds to penetrate the blood-
brain barrier (BBB), we carried out a parallel artificial membrane permeability assay 
(PAMPA). Six compounds, 51-53 and 60-62, showed reasonable permeability, with 
a range of 5.0-5.9 for –logPe. Interestingly, all of the primary amine (51-53) and 
piperidine (60-62) derivatives showed reasonable values for BBB penetration 
regardless of the length of the carbon linker, whereas the N-aminoethyl derivatives, 
72 and 76, exhibited very low permeability (–logPe = 10 and 9.0). 
 







at 10 µM 
(% of control) 
hERG assay 




% inhibition of  
human AβN3pE-40  
formation (icv)a 
51 7.9 ~100 15.3 5.7 35.3 
52 9.0 ~100 8.8 5.6 12.8 
53 8.8 ~100 2.8 5.9 36.6 
60 7.3 ~100 14.9 5.3 1.8 
61 8.8 ~100 25.6 5.0 5.5 
62 7.9 ~100 35.1 5.7 14.4 
72 7.9 ~100 19.9 10.0 NE 
76 6.4 ~100 7.2 9.0 22.9 
a 5 µL of human Aβ3−40 in PBS (1 µg/µL) was injected into the deep 
cortical/hippocampus to 5 weeks old ICR mice (25 g, n = 4, male) using a stereotaxic 
frame to induce acute Aβ toxicity. Test compounds were administrated via icv  
injection. Sandwich ELISA was performed for the quantification of the brain AβN3pE-
40 
Finally, we tested each compound in acute AD model mice to evaluate QC 
inhibition in vivo. We first injected human Aβ3-40 (5 µg) and each compound (25 
mg/kg) successively into deep cortical/hippocampal tissues of ICR mice (male, six 
weeks old) by intracerebroventricular (icv) administration. On the next day, we 
measured the levels of human AβN3pE-40 in the brain extracts of each mouse to 
determine the QC inhibitory activity. As described in Table 2.3, compounds 51-53, 
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62 and 76 suppressed the formation of AβN3pE-40 by 12.8% to 36.6% compared to the 
vehicle control. In particular, compounds 51 and 53, with in vitro IC50 values of 7.9 
and 8.8 nM, exhibited the most potent AβN3pE-40-lowering effects by 35.3 and 36.6% 
reduction, respectively, indicating that the specific inhibition of QC resulted in the 
reduced brain levels of AβN3pE-40. Overall, these two compounds exhibited potent in 
vitro and in vivo QC inhibitory activities and good brain penetration without potential 
toxicity. 
 
2.4. Molecular modeling 
To evaluate the binding interactions between the hQC and the potent inhibitor 
53, we carried out the sequential docking studies using X-ray crystal structure of hQC 
(PDB id: 3PBB).69 For the initial docking study, the protonated amine form of 53 at 
pH 7.4 was used and placed into a Glide SP (Standard Precision).  
The result exhibited that the N-3 nitrogen of the 5-methyl imidazole chelated 
with zinc and formed a hydrogen bonding with Trp329. Additionally, the 5-methyl 
group occupied a hydrophobic pocket composed of Trp207, Leu249, Ile303, Ile321, 
and Phe325. The thiourea group caused the appropriate positioning of the phenyl ring 
for the hydrophobic interaction with Ile303, while the methoxy oxygen on the phenyl 
ring formed a hydrogen bond with Tyr299 (Figure 2.3). 
 
Figure 2.3. Sequential docking and refinement of 53 in hQC. 
(A) Glide SP docking, (B) QPLD, (C) Local optimization, and (D) Monte Carlo 
minimization. Binding modes of 53 in protonated form were shown in each step. The 
distances between Glu327 and the terminal N from D-region of the ligands were 
revealed in black dashed lines. 
 
Afterwards, Glide QM-Polarized Ligand Docking (QPLD) in Maestro was 
implemented, and the result showed the amino group in the side chain shifted toward 
Glu327 of the hQC active site (Figure 2.3B). The local optimization refinement was 
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conducted, and the result displayed the bended Glu327 side chain, and constituted a 
salt bridge with the amino group of 53 (Figure 2.3C). To search for the global 
minimum, we performed a Monte Carlo minimization (Figure 2.3D). This type of 
sequential optimization for the protein-ligand complexes formed hydrogen bonding 
as well as salt bridge interactions, along with the H-bonding with the phenyl ring of 
53 (Figure 2.3).  
Accordingly, the imidazole ring formed π-π interactions with Trp329, and the 
thiourea group showed a hydrogen bond with Gln304 while the dimethoxyphenyl 
group formed a H-bonding interaction and π-π interaction with Phe325. Moreover, 
the protonated amine group located in the side chain displayed a salt bridge 
interaction with Glu327 and H-bonding with Pro326 and Glu327. Overall, we believe 
that switching the substituents in the 3-and 4-positions did not alter the binding 
interactions significantly, partly due to the flexibility of the 4-aminoalkoxy chain, 
which is also supported by the SAR found in the analogues with rigid and short linkers. 
 
Figure 2.4. Docked and refined structure of 53 in hQC. 
(A) Binding interactions of 53 at the active site of the hQC. Ligand is displayed as 
sticks with cyan carbon atoms, and Zn2+ is in purple ball. The interacted residues are 
shown in light blue sticks. Hydrogen bonds are described as black dashed lines. (B) 
2D illustration of the binding interactions between 53 with hQC. Hydrophobic 
interactions are indicated in light brown. Hydrogen bonds are exposed as red- and 
green-dotted point with the directionality. The π-π stacking interaction is signified in 
purple disc and arrow, and the salt bridge interaction is displayed as purple wedge 
line. 
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3. Conclusion 
 In this study, we investigated a series of QC inhibitors containing 4-
aminoalkyloxy-3-methoxyphenyl and 3-aminoalkyloxyphenyl groups as Phe-Arg 
mimetics of Aβ3-42. The primary amines (51-53) and 4-piperidinyl (57-59) derivatives 
exhibited potent QC inhibition, demonstrating 3-4 fold more potent activity than the 
parent inhibitor 1 by Probiodrug. Further in vivo studies revealed that inhibitors 51 
and 53 displayed the most potent AβN3pE-40-lowering effects with 35.3 and 36.6% in 
vivo, respectively, with reasonable BBB penetration, which also corresponded to their 
in vitro potency. The molecular modeling analysis of 53 indicated that the salt bridge 
interaction and the hydrogen bonding of the protonated amine group with Glu327 and 
Pro326 provided a high potency compared to the parent inhibitor 1. Given the potent 
QC inhibitory effect, favorable BBB penetration, and the toxicity profile, we believe 
that compound 53 may serve as a potential candidate for anti-Alzheimer’s agents. 
 
4. Experimental  
4.1. Chemistry 
4.1.1. General 
All chemical reagents were commercially available. Melting points were determined 
on a melting point Buchi B-540 apparatus and are uncorrected. Silica gel column 
chromatography was performed on silica gel 60, 230-400 mesh, Merck. 1H NMR 
spectra were recorded on a a JEOL JNM-LA 300 at 300 MHz, Bruker Analytik, 
DE/AVANCE Digital 400 at 400 MHz, a Bruker Analytik, DE/AVANCE Digital 500 
at 500 MHz, and a JEOL JNM-ECA-600 at 600 MHz. Mass spectra were recorded 
on a VG Trio-2 GC−MS instrument and a 6460 Triple Quad LC−MS instrument. All 
final compounds were assessed for purity by high performance liquid 
chromatography (HPLC) on Agilent 1120 Compact LC (G4288A) system via the 
following conditions. Column: Agilent TC-C18 column (4.6 mm × 250 mm, 5 μm). 
Mobile phase A: MeOH, Mobile phase B: 0.1% TFA in water (v/v) in 30 min. 
Wavelength: 254 nM. Flow: 0.7 mL/min. According to the HPLC analyses, all final 
compounds showed a purity of  ≥95%. 
 
4.1.2. General procedure 
4.1.2.1. Mitsunobu reaction (Procedure 1) 
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Triphenylphosphine (1.3 eq) was added under nitrogen to a solution of 5-
nitroguaiacol (1.0 eq) in CH2Cl2, followed by adding alcohol (1.2 eq) and a solution 
of diethyl azodicarboxylate (1.3 eq) in CH2Cl2. After the solution was stirred for 30 
min at room temperature, the reaction was poured onto a column of silica and was 
eluted with EtOAc/n-hexane to give desired product. 
 
4.1.2.2. Williamson reaction (Procedure 2) 
Alkyl halide (4.0 eq) was added to a suspension of 5-nitroguaiacol or 4-nitrophenol 
(1.0 eq) and Cs2CO3 (2.0 eq) in anhydrous DMF. The reaction mixture was heated to 
100 °C for 1 h and then cooled to room temperature before quenched by H2O. The 
mixture was extracted with EtOAc (2 x 50 mL). The organic layer was washed by 
H2O three times, dried by MgSO4 and concentrated. This concentration was then 
purified by column chromatography to get product.  
 
4.1.2.3. Deprotection of phthalimide group (Procedure 3)  
Hydrazine monohydrate was added to a solution of phthalimide compound in ethanol 
and stirred at room temperature overnight. The precipitate was filtered and washed 
with EtOH. The filtrate was collected and concentrated in vacuo. The residue was 
then purified by PLC (MeOH/CH2Cl2) to give product. 
 
4.1.2.4. N-Alkylation (Procedure 4)  
A mixture of alkyl halide, amine, and excess base in DMF was stirred at 60 °C for 30 
min. The mixture reaction was quenched by H2O and extracted by EtOAc several 
times. The combined organic layer was washed with H2O and brine and concentrated 
in vacuo. The residue was purified by column chromatography.       
 
4.1.2.5. Boc protection (Procedure 5) 
To a suspension of starting material amine (1.0 eq) in CH2Cl2 was added 
triethylamine (1.2 eq) and di-tert-butyl dicarbonate (2.5 eq) in CH2Cl2 under ice bath. 
The mixture was stirred at room temperature until starting material was consumed, 
by checking with TLC. The mixture was diluted with H2O and extracted with CH2Cl2 
several times. The combined organic layers were washed with 10% aqueous NaHCO3 
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solution, H2O and brine, dried over MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography to get the desired product. 
 
4.1.2.6. Boc deprotection (Procedure 6)  
Trifluoroacetic acid (10 eq) was added to the solution of Boc-protected compound 
(1.0 eq) in CH2Cl2 (DCM:TFA = 1:1 (v/v)). Then, the mixture was stirred at room 
temperature until the starting material consumed and evaporated. The residue was 
dissolved in MeOH and purified by ion-exchange column to get desired product or 
carried to the next step without further purification. 
 
4.1.2.7. Reductive methylation of amine (Procedure 7) 
To a stirred solution of amine (1 eq) in MeOH (5 mL) containing 37% aqueous 
formaldehyde (3 eq) at room temperature was added a solution of sodium 
cyanoborohydride (1 eq) and zinc chloride (0.5 eq) in MeOH (5 mL). After the 
reaction mixture was stirred at room temperature for overnight, the solution was taken 
up in 0.1 N NaOH (10 mL), and most of the MeOH was evaporated under reduced 
pressure. After the aqueous solution was extracted with EtOAc (20 mL x 3), the 
combined extracts were washed with H2O and brine, dried over MgSO4 and 
evaporated until dry . The residue was distilled in vacuo to give the desired product. 
 
4.1.2.8. EDC coupling (Procedure 8)  
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide HCl (EDC-HCl, 1.1 eq) and N,N- 
diisopropylethylamine (2.2 eq) were added to a solution of amine (1.0 eq), acid (1.0 
eq) and 1-hydroxybenzotriazole (HOBt, 1.1 eq) in CH2Cl2. The mixture was stirred 
for 24 h at room temperature under nitrogen. The solvent was removed in vacuo and 
the residue purified by column chromatography on silica gel, eluting with 
CH2Cl2/MeOH to provide the desired compound. 
 
4.1.3. Intermediate compounds 
4.1.3.1. tert-Butyl (2-(2-methoxy-5-nitrophenoxy)ethyl)carbamate (6). The title 
compound was prepared from 5-nitroguaiacol (5) according to procedure 1 as a 
yellow solid in 99% yield. 1H NMR (300 MHz, CDCl3) δ 7.95 (dd, J = 8.97, 2.55 Hz, 
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1H), 7.76 (d, J = 2.58 Hz, 1H), 6.93 (d, J = 8.97 Hz, 1H), 5.07 (br, NH), 4.15 (t, J = 
5.31 Hz, 2H), 3.96 (s, 3H), 3.61 (q, J =  5.49 Hz, 2H), 1.45 (s, 9H). 
 
4.1.3.2. tert-Butyl 4-(2-(2-methoxy-5-nitrophenoxy)ethyl)piperidine-1-carboxylate 
(7). The title compound was prepared from compound 5 according to procedure 1 as 
a yellow oil in 63% yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.97, 2.58 Hz, 
1H), 7.73 (d, J = 2.55 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H),  4.35-4.17 (m, 3H), 3.96 (s, 
3H), 2.72 (t, J = 11.73 Hz, 2H), 1.85-1.80 (m, 2H), 1.75-1.72 (m, 2H), 1.46 (s, 9H), 
1.46-1.45 (m, 2H), 1.36-1.30 (m, 2H). 
 
4.1.3.3. tert-Butyl 4-(3-(2-methoxy-5-nitrophenoxy)propyl)piperidine-1-carboxylate 
(8). The title compound was prepared from compound 5 according to procedure 1 as 
a yellow oil in 76% yield. 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 8.97, 2.73 Hz, 
1H), 7.73 (d, J = 2.73 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H),  4.15-4.05 (m, 4H), 3.96 (s, 
3H), 3.48 (m, 1H), 2.72 (t, J = 12.06 Hz, 2H), 1.95 (p, J = 6.60 Hz, 2H), 1.72 (d, J = 
13.53 Hz, 2H), 1.45 (s, 9H), 1.45-1.39 (m, 2H), 1.17-1.11 (m, 2H). 
 
4.1.3.4. tert-Butyl 4-(4-(2-methoxy-5-nitrophenoxy)butyl)piperidine-1-carboxylate 
(9). The title compound was prepared from compound 5 according to procedure 1 as 
a brown oil in 63% yield. 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 8.79, 2.55 Hz, 
1H), 7.73 (d, J = 2.76 Hz, 1H), 6.91 (d, J = 8.79 Hz, 1H), 4.15-4.06 (m, 4H), 3.96 (s, 
3H), 2.71 (t,  J = 12.09 Hz, 2H), 1.91 (p, J = 6.96 Hz, 2H), 1.68-1.64 (m, 2H), 1.51-
1.47 (m, 3H), 1.45 (s, 9H), 1.35-1.28 (m, 2H), 1.15-1.02 (m, 2H). 
 
4.1.3.5. tert-Butyl (4-(2-(2-methoxy-5-nitrophenoxy)ethyl)pyridin-2-yl)carbamate 
(10). The title compound was prepared from compound 5 according to procedure 1 
as a yellow solid in 59% yield. 1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 5.13 Hz, 
1H), 7.94-7.90 (m, 2H), 7.73 (d, J = 2.55 Hz, 1H), 7.43 (br, NH), 6.94 (dd, J = 5.13, 
1.47 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H), 4.33 (t, J = 6.78 Hz, 2H), 3.96 (s, 3H), 3.19 
(t, J = 6.78 Hz, 2H), 1.53 (s, 9H). 
 
4.1.3.6. tert-Butyl (4-(3-(2-methoxy-5-nitrophenoxy)propyl)pyridin-2-yl)carbamate 
(11). The title compound was prepared from compound 5 according to procedure 2 
as a yellow solid in 65% yield. 1H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 5.10 Hz, 
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1H), 7.93 (dd, J = 8.79, 2.55 Hz, 1H), 7.84 (s, 1H), 7.70 (d, J = 2.58 Hz, 1H), 7.64 (s, 
1H), 6.92 (d, J = 8.79 Hz, 1H), 6.84 (dd, J = 5.13, 2.28 Hz, 1H), 4.11 (t, J = 6.24 Hz, 
2H), 3.97 (s, 3H), 2.86 (t, J = 7.14 Hz, 2H), 2.27 (p, J = 6.24 Hz, 2H), 1.52 (s, 9H). 
 
4.1.3.7. tert-Butyl (4-(4-(2-methoxy-5-nitrophenoxy)butyl)pyridin-2-yl)carbamate 
(12). The title compound was prepared from compound 5 according to procedure 2 
as a yellow solid in 65% yield. 1H NMR (300 MHz, CDCl3) δ 8.11 (d, J = 5.31 Hz, 
1H), 7.92 (dd, J = 8.97, 2.76 Hz, 1H), 7.80 (br, NH), 7.72 (d, J = 2.55 Hz, 1H), 7.21 
(br, NH), 6.91 (d, J = 8.79 Hz, 1H), 6.83 (dd, J = 4.95, 1.47 Hz, 1H), 4.11 (t, J = 6.06 
Hz, 2H), 3.96 (s, 3H), 2.72 (t, J = 7.68 Hz, 2H), 1.89-1.81 (m, 4H), 1.52 (s, 9H). 
 
4.1.3.8. 2-(3-(2-Methoxy-5-nitrophenoxy)propyl)isoindoline-1,3-dione (13). The title 
compound was prepared from compound 5 according to procedure 2 as a yellow solid 
in 61% yield. 1H NMR (300 MHz, CDCl3) δ 7.90-7.81 (m, 3H), 7.75-7.61 (m, 3H), 
6.84 (d, J = 8.97 Hz, 1H), 4.18 (t, J = 6.03 Hz, 2H), 3.96 (d, J = 6.60 Hz, 2H), 3.73 
(s, 3H), 2.31 (p, J  = 6.24 Hz, 2H). 
 
4.1.3.9. 2-(4-(2-Methoxy-5-nitrophenoxy)butyl)isoindoline-1,3-dione (14). The title 
compound was prepared from compound 5 according to procedure 2 as a yellow solid 
in 94% yield. 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 8.97, 2.55 Hz, 1H), 7.86-
7.81 (m, 2H), 7.75-7.69 (m, 3H), 6.90 (d, J = 8.97 Hz, 1H), 4.14-4.10 (m, 2H), 3.94 
(s, 3H), 3.81-3.77 (m, 2H), 1.94-1.91 (m, 4H). 
 
4.1.3.10. 2-(2-Bromoethoxy)-1-methoxy-4-nitrobenzene (15). The title compound 
was prepared from compound 5 according to procedure 2 as a yellow solid in 73% 
yield. 1H NMR (300 MHz, CDCl3) δ 7.97 (dd, J = 8.76, 2.55 Hz, 1H), 7.77 (d, J = 
2.58 Hz, 1H), 6.95 (d, J = 8.97 Hz, 1H), 4.42 (t, J = 6.42 Hz, 2H), 3.98 (s, 3H), 3.72 
(t, J = 6.21 Hz, 2H).  
 
4.1.3.11. 2-(3-Bromopropoxy)-1-methoxy-4-nitrobenzene (16). The title compound 
was prepared from compound 5 according to procedure 2 as a yellow solid in 71% 
yield. 1H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 8.97, 2.58 Hz, 1H), 7.78 (d, J = 
2.58 Hz, 1H), 6.93 (d, J = 8.76 Hz, 1H), 4.28 (t, J = 7.14 Hz, 2H), 3.96 (s, 3H), 3.80 
(t, J = 6.21 Hz, 2H), 2.37 (p, J = 6.06 Hz, 2H). 
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4.1.3.12. 2-(4-Bromobutoxy)-1-methoxy-4-nitrobenzene (17). The title compound 
was prepared from compound 5 according to procedure 2 as a yellow solid in 63% 
yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.97, 2.55 Hz, 1H), 7.74 (d, J = 
2.58 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H), 4.14 (t, J = 5.85 Hz, 2H), 3.96 (s, 3H) 3.53 
(t, J = 6.24 Hz, 2H), 2.10-2.05 (m, 4H). 
 
4.1.3.13. 4-(4-(2-Methoxy-5-nitrophenoxy)butyl)piperidine (18). The title compound 
was prepared from compound 7 according to procedure 6 as a red solid in 75% yield. 
1H NMR (300 MHz, CD3OD) δ 7.91 (dd, J = 8.97, 2.76 Hz, 1H), 7.76 (d, J = 2.58 
Hz, 1H), 7.09 (d, J = 8.97 Hz, 1H), 4.14 (t, J = 5.85 Hz, 2H), 3.93 (s, 3H), 3.06-3.02 
(m, 2H), 2.65-2.56 (m, 2H), 1.80-1.74 (m, 5H), 1.29-1.18 (m, 2H).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
 
4.1.3.14. 4-(2-(2-Methoxy-5-nitrophenoxy)ethyl)-1-methylpiperidine (19). The title 
compound was prepared from compound 18 according to procedure 7 as a white solid 
in 45% yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.40, 2.58 Hz, 1H), 7.73 
(d, J = 2.73 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H), 4.14 (t, J = 6.60 Hz, 2H), 3.96 (s, 3H), 
3.12 (d, J = 11.88 Hz, 2H), 2.45 (s, 3H), 2.26 (t, J = 9.90 Hz, 2H), 1.89-1.83 (m, 4H), 
1.56-1.47 (m, 3H) 
 
4.1.3.15. 3-(2-Methoxy-5-nitrophenoxy)propan-1-amine (20). The title compound 
was prepared from compound 13 according to procedure 3 as a light yellow solid in 
94% yield. 1H NMR (300 MHz, CDCl3) δ 7.87 (dd, J = 8.43, 2.43 Hz, 1H), 7.72 
(d, J = 2.43 Hz, 1H), 6.88 (d, J = 8.46 Hz, 1H), 4.13 (t, J = 5.82 Hz, 2H), 3.93 (s, 3H), 
2.62 (t, J = 6.12 Hz, 2H), 1.98-1.88 (m, 2H). 
 
4.1.3.16. 4-(2-Methoxy-5-nitrophenoxy)butan-1-amine (21). The title compound was 
prepared from compound 14 according to procedure 3 as a white solid in 85% yield. 
1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 8.40, 2.40 Hz, 1H), 7.71 (d, J = 2.40 Hz, 
1H), 6.88 (d, J = 8.88 Hz, 1H), 4.13 (t, J = 5.80 Hz, 2H), 3.93 (s, 3H), 2.79 (t, J = 
6.68 Hz, 2H), 2.00-1.83 (m, 4H) 
 
4.1.3.17. tert-Butyl 4-(2-(2-methoxy-5-nitrophenoxy)ethyl)piperazine-1-carboxylate 
(22). The title compound was prepared from compound 15 according to procedure 4 
as a white solid in 75% yield. 1H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 8.40, 2.58 
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Hz, 1H), 7.80 (d, J = 2.58 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H), 4.24 (t, J = 5.85 Hz, 
2H), 3.95 (s, 3H), 3.47 (t, J = 4.95 Hz, 4H), 2.90 (t, J = 5.85 Hz, 2H), 2.56 (t, J = 4.74 
Hz, 4H), 1.46 (s, 9H). 
 
4.1.3.18. tert-Butyl 4-(3-(2-methoxy-5-nitrophenoxy)propyl)piperazine-1-
carboxylate (23). The title compound was prepared from compound 16 according to 
procedure 4 as a white solid in 89% yield. 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J 
= 9.15, 2.55 Hz, 1H), 7.77 (d, J = 2.19 Hz, 1H), 6.91 (d, J = 9.15 Hz, 1H), 4.18 (t, J 
= 6.57 Hz, 2H), 3.95 (s, 3H), 3.44 (t, J = 4.95 Hz, 2H), 2.57 (t, J = 6.60 Hz, 4H), 2.41 
(t, J = 4.95 Hz, 4H), 2.08 (p, J = 6.78 Hz, 2H), 1.46 (s, 9H). 
 
4.1.3.19. tert-Butyl 4-(4-(2-methoxy-5-nitrophenoxy)butyl)piperazine-1-carboxylate 
(24).  The title compound was prepared from compound 17 according to procedure 4 
as a white solid in 75% yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.97, 2.55 
Hz, 1H), 7.73 (d, J = 2.55 Hz, 1H), 6.92 (d, J = 8.79 Hz, 1H), 4.15 (d, J = 6.96 Hz, 
2H), 3.95 (s, 3H), 3.44 (t, J = 5.13 Hz, 4H), 2.45-2.37 (m, 6H), 1.96 (p, J = 6.75 Hz, 
2H), 1.74 (p, J = 7.89 Hz, 2H), 1.46 (s, 9H). 
 
4.1.3.20. tert-Butyl (2-(2-methoxy-5-nitrophenoxy)ethyl)carbamate (25). The title 
compound was prepared from compound 20 according to procedure 5 as an opaque 
semi-solid in 72% yield, which was used for the next step without further purification. 
 
4.1.3.21. tert-Butyl (3-(2-methoxy-5-nitrophenoxy)propyl)carbamate (26). The title 
compound was prepared from compound 21 according to procedure 5 as a white solid 
in 62% yield, which was used for the next step without further purification. 
 
4.1.3.22. tert-Butyl (2-(2-methoxy-5-nitrophenoxy)ethyl)(methyl)carbamate (27). 
The title compound was prepared from compound 25 according to procedure 4 as a 
light yellow solid in 51% yield. 1H NMR (300 MHz, CDCl3) δ 7.87 (dd, J = 8.46, 
2.40 Hz, 1H), 7.72 (d, J = 2.43 Hz, 1H), 6.87 (d, J = 8.61 Hz, 1H), 4.14 (t, J = 6.03 
Hz, 2H), 3.93 (s, 3H), 2.92 (t, J = 6.12 Hz, 2H), 2.78 (s, 3H), 2.01-1.90 (m, 2H), 1.44 
(s, 9H). 
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4.1.3.23. tert-Butyl (3-(2-methoxy-5-nitrophenoxy)propyl)(methyl)carbamate (28). 
The title compound was prepared from compound 26 according to procedure 4 as a 
light yellow solid in 55% yield. 1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 8.79, 
2.73 Hz, 1H), 7.72 (d, J = 2.73 Hz, 1H), 6.89 (d, J = 8.97 Hz, 1H), 4.14 (t, J = 6.21 
Hz, 2H), 3.94 (s, 3H), 2.65 (t, J = 6.12 Hz, 2H), 2.80 (s, 3H), 2.01-1.87 (m, 4H), 1.44 
(s, 9H). 
 
4.1.3.24. 4-(2-Methoxy-5-nitrophenoxy)-N,N-dimethylbutan-1-amine (29). The title 
compound was prepared from compound 21 according to procedure 7 as a red semi-
solid in 21% yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.97, 2.73 Hz, 1H), 
7.74 (d, J = 2.58 Hz, 1H), 6.92 (d, J = 8.97 Hz, 1H), 4.14 (t, J = 6.24 Hz, 2H), 3.96 
(s, 3H), 2.62 (t, J = 8.61 Hz, 2H), 2.40 (s, 6H), 1.95 (p, J = 6.60 Hz, 2H), 1.82 (p, J = 
7.32 Hz, 2H).  
 
4.1.3.25. 1-(2-Bromoethoxy)-4-nitrobenzene (31). The title compound was prepared 
from compound 30 according to procedure 2 as a yellow solid in 64% yield. 1H NMR 
(300 MHz, CDCl3) δ 8.20 (m, 2H), 6.97 (m, 2H), 4.36 (d, J = 6.03 Hz, 2H), 3.68 (d, 
J = 6.24 Hz, 2H). 
 
4.1.3.26. tert-Butyl 4-(2-(4-nitrophenoxy)ethyl)piperazine-1-carboxylate (32). The 
title compound was prepared from compound 31 according to procedure 4 as a white 
solid in 61% yield. 1H NMR (300 MHz, CDCl3) δ 8.19 (2H, m), 6.97 (2H, m), 4.19 
(t, J = 5.67 Hz, 2H), 3.45 (m, 4H), 2.85 (t, J = 5.70 Hz, 2H), 2.52 (m, 4H), 1.45 (s, 
9H).  
 
4.1.3.27. tert-Butyl (4-(4-(4-nitrophenoxy)butyl)pyridin-2-yl)carbamate (33). The 
title compound was prepared from compound 30 according to procedure 2 as a white 
solid in 91% yield. 1H NMR (300 MHz, CDCl3) δ 8.19 (d, J = 9.15 Hz, 2H), 8.11-
8.09 (m, 2H), 7.86 (s, 1H), 6.94 (d, J = 9.15 Hz, 2H), 6.82 (dd, J = 5.73, 1.47 Hz, 1H), 
4.06 (t, J = 5.67 Hz, 2H), 2.68 (t, J = 6.06 Hz, 2H), 1.86-1.81 (m, 4H), 1.51 (s, 9H). 
4.1.3.28. tert-Butyl 4-(2-(4-nitrophenoxy)acetyl)piperazine-1-carboxylate (37). The 
title compound was prepared from compound 35 according to procedure 8 as a yellow 
solid in 81% yield. 1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 9.33 Hz, 2H), 6.99 (d, 
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J = 9.33 Hz, 2H), 4.75 (s, 2H), 3.53-3.49 (m, 2H), 3.46-3.43 (m, 2H), 3.40-3.34 (m, 
4H), 1.39 (s, 9H).  
 
4.1.3.29. tert-Butyl (E)-4-(3-(4-nitrophenyl)acryloyl)piperazine-1-carboxylate (38). 
The title compound was prepared from commercial available 36 according to 
procedure 8 as a white solid in 80% yield. 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 
8.79 Hz, 2H), 7.70 (d, J = 15.36 Hz, 1H), 7.65 (d, J = 8.61 Hz, 2H), 7.02 (d, J = 15.57 
Hz, 1H), 3.72-3.64 (m, 4H), 3.42-3.36 (m, 4H), 1.48 (s, 9H).  
 
4.1.3.30. (E)-3-(4-Nitrophenyl)-1-(piperazin-1-yl)prop-2-en-1-one (39). The title 
compound was prepared from compound 38 according to procedure 6 as a yellow oil 
in 94% yield. 1H NMR (300 MHz, CD3OD) δ 8.27 (d, J = 8.79 Hz, 2H), 7.89 (d, J = 
8.58 Hz, 2H), 7.71 (d, J = 15.57 Hz, 1H), 7.39 (d, J = 15.57 Hz, 1H), 4.00-3.95 (m, 
4H), 3.39-3.22 (m, 4H). 
 
4.1.3.31. tert-Butyl (E)-(2-(4-(3-(4-nitrophenyl)acryloyl)piperazin-1-
yl)ethyl)carbamate (40). The title compound was prepared from compound 39 
according to procedure 4 as a pale yellow solid in 54% yield. 1H NMR (300 MHz, 
CDCl3) δ 8.27 (d, J = 8.79 Hz, 2H), 7.72-7.65 (m, 3H), 7.03 (d, J = 15.57 Hz, 1H), 
3.76-3.66 (m, 4H), 3.27 (q, J = 5.31 Hz, 2H), 2.53-2.47 (m, 6H), 1.46 (s, 9H). 
 
4.1.3.32. tert-Butyl 4-(4-nitrobenzamido)piperidine-1-carboxylate (41). The title 
compound was prepared from compound 34 according to procedure 8 as a white solid 
in 80% yield. 1H NMR (300 MHz, CDCl3) δ 8.30 (d, J = 8.79 Hz, 2H), 7.95 (d, J = 
8.79 Hz, 2H), 6.18 (d, J = 7.50 Hz, NH), 4.15-4.10 (m, 3H), 2.94 (t, J = 12.24 Hz, 
2H),  2.06 (t, J = 4.59 Hz, 2H), 1.46 (s, 9H), 1.42-1.39 (m, 2H). 
 
4.1.3.33. tert-Butyl 4-(2-(4-nitrophenoxy)acetamido)piperidine-1-carboxylate (42). 
The title compound was prepared from compound 35 according to procedure 8 as a 
white solid in 82% yield. 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 9.15 Hz, 2H), 
7.02 (d, J = 9.33 Hz, 2H), 6.32 (br, NH), 4.54 (s, 2H), 4.13-4.09 (m, 3H), 2.88 (t, J = 
12.09 Hz, 2H), 1.93-1.90 (m, 2H), 1.43 (s, 9H), 1.38-1.33 (m, 2H). 
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4.1.3.34. tert-Butyl (E)-4-(3-(4-Nitrophenyl)acrylamido)piperidine-1-carboxylate 
(43). The title compound was prepared from compound 36 according to procedure 8 
as a white solid in 83% yield. 1H NMR (300 MHz, CDCl3) 8.25 (d, J = 8.79 Hz, 2H), 
7.70 (d, J = 15.36 Hz, 1H), 6.65 (d, J = 8.61 Hz, 2H), 6.54 (d, J = 15.57 Hz,  1H), 
5.76 (d, J = 7.89 Hz, NH), 4.13 (m, 3H), 2.93 (t, J = 11.73 Hz, 2H). 2.05-1.98 (m, 
2H), 1.46 (s, 9H), 1.36-1.32 (m, 2H).  
 
4.1.3.35. 4-Nitro-N-(piperidin-4-yl)benzamide (44). The title compound was 
prepared from compound 41 according to procedure 6 as a pale yellow oil in 89% 
yield. 1H NMR (300 MHz, CDCl3) δ 8.31 (d, J = 8.79 Hz, 2H), 7.94 (d, J = 8.79 Hz, 
2H), 6.05 (d, J = 7.89 Hz, NH), 4.14-4.04 (m, 1H), 3.16 (td, J = 12.45, 2.55 Hz, 2H), 
2.81 (dt, J = 12.27, 2.55 Hz, 2H), 2.08-2.08 (m, 2H), 1.51-1.38 (m, 2H). 
 
4.1.3.36. 2-(4-Nitrophenoxy)-N-(piperidin-4-yl)acetamide (45). The title compound 
was prepared from compound 42 according to procedure 6 as a a brown semi-solid in 
92% yield. 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 8.97 Hz, 2H), 7.02 (d, J = 9.03 
Hz, 2H), 6.32 (br, NH), 4.54 (s, 2H), 4.13-4.09 (m, 1H), 3.16-3.10 (m, 2H), 2.78 (t, J 
= 12.09 Hz, 2H), 2.00-1.95 (m, 2H), 1.48-1.39 (m, 2H). 
 
4.1.3.37. (E)-3-(4-Nitrophenyl)-N-(piperidin-4-yl)acrylamide (46). The title 
compound was prepared from compound 43 according to procedure 6 as a yellow 
solid in 94% yield. 1H NMR (300 MHz, CD3OD) δ 8.27 (d, J = 8.79 Hz, 2H), 7.80 
(d, J = 8.79 Hz, 2H), 7.65 (d, J =15.93 Hz, 1H), 6.77 (d, J = 15.90 Hz, 1H), 4.08-4.01 
(m, 1H), 3.53-3.43 (m, 2H), 3.19 (dt, J = 12.99, 3.12 Hz , 2H), 2.18-2.14 (m, 2H), 
1.79-1.65 (m, 2H).  
 
4.1.3.38. tert-Butyl (2-(4-(4-nitrobenzamido)piperidin-1-yl)ethyl)carbamate (47). 
The title compound was prepared from compound 44 according to procedure 4 as an 
opaque semi-solid in 51% yield. 1H NMR (300 MHz, CDCl3) δ 8.31 (d, J = 8.61 Hz, 
2H), 7.93 (d, J = 8.79 Hz, 2H), 6.07 (d, J = 8.07 Hz, NH), 4.98 (br, NH), 4.02-3.95 
(m, 1H), 3.24 (q, J = 6.69 Hz, 2H), 2.93-2.90 (m, 2H), 2.51 (t, J = 6.06 Hz, 2H), 2.26 
(t, J = 11.55 Hz, 2H), 2.08-2.04 (m, 2H), 1.63-1.59 (m, 2H), 1.45 (s, 9H).  
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4.1.3.39. tert-Butyl (2-(4-(2-(4-nitrophenoxy)acetamido)piperidin-1-
yl)ethyl)carbamate (48). The title compound was prepared from compound 45 
according to procedure 4 as a red semi-solid in 55% yield. 1H NMR (300 MHz, CDCl3) 
δ 8.24 (d, J = 9.15 Hz, 2H), 7.01 (d, J = 9.15 Hz, 2H), 6.38 (br, NH), 5.12 (br, NH), 
4.53 (s, 2H), 3.94-3.90 (m, 1H), 3.25-3.23 (m, 2H), 2.93-2.91 (m, 2H), 2.54-2.51 (m, 
2H), 2.24-2.20 (m, 2H), 1.96-1.94 (m, 2H), 1.62-1.58 (m, 2H), 1.42 (s, 9H). 
 
4.1.3.40. tert-Butyl (E)-(2-(4-(3-(4-nitrophenyl)acrylamido)piperidin-1-
yl)ethyl)carbamate (49). The title compound was prepared from compound 46 
according to procedure 4 as a pale yellow solid in 21% yield. 1H NMR (300 MHz, 
CD3OD) δ 8.27 (d, J = 8.97 Hz, 2H), 7.80 (d, J = 8.79 Hz, 2H), 7.60 (d, J =15.90 Hz, 
1H), 6.79 (d, J = 15.72 Hz, 1H), 4.08-4.01 (m, 1H), 3.53-3.43 (m, 2H), 2.93-2.87 (m, 
2H), 2.55-2.51 (m, 2H), 2.42-2.39 (m, 2H), 1.96-1.89 (m, 2H), 1.65-1.55 (m, 2H), 
1.42 (s, 9H). 
4.1.3.41. tert-Butyl (4-((2-(4-nitrophenoxy)acetamido)methyl)pyridin-2-
yl)carbamate (50). The title compound was prepared from compound 35 according 
to procedure 8 as a white solid in 65% yield. 1H NMR (300 MHz, CDCl3) δ 8.24 (d, 
J = 9.15 Hz, 2H), 8.19 (d, J = 5.31 Hz, 1H),  7.88 (s, 1H), 7.06 (d, J = 9.15 Hz, 2H), 
6.87 (dd, J = 5.31, 1.47 Hz, 1H), 4.64 (s, 2H), 4.53 (d, J = 6.03 Hz, 2H), 1.50 (s, 9H).  
 
4.1.4. Final compounds 
4.1.4.1. General procedure for final compound 
All nitro compounds were reduced by either hydrogenation using 10% Pd/C or zinc 
powder in acidic medium to obtain the corresponding amines, respectively. The 
amines were converted into the isothiocyanates by 1,1’-thiocarbonyldiimidazole 
(1.02 eq) in anhydrous CH2Cl2, and then coupled with 3-(5-methyl-1H-imidazol-1-
yl)propan-1-amine (1.1 eq) to afford the corresponding thiourea, respectively. The 
Boc deprotection by following the general procedure 6 provided the final compounds. 
 
4.1.4.2. N-(3-(2-Aminoethoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thiourea (51). mp = 58-59 oC. 1H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 
7.37 (s, 1H), 6.91 (d, J = 8.43 Hz, 1H), 6.78-6.72 (m, 3H), 5.93 (br, 1H), 4.02 (t, J = 
5.13 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.88 (s, 3H), 3.69 (q, J = 6.24 Hz, 2H), 3.14 
(t, J = 5.13 Hz, 2H), 2.17 (d, J = 0.93 Hz, 3H), 2.09 (p, J = 7.14 Hz, 2H). MS (FAB) 
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m/z 364 [M+H]+. HRMS (FAB) m/z calcd for C17H25N5O2S [M + H]+ 364.1807, found: 
364.1818. Anal. HPLC 99.33% (Rt = 3.723 min). 
 
4.1.4.3. N-(3-(3-Aminopropoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thiourea (52). mp = 154-155 oC. 1H NMR (300 MHz, CDCl3) δ 7.79 (br, 
1H), 7.38 (s, 1H), 6.88-6.85 (m, 1H), 6.76-6.72 (m, 3H), 6.10 (br, 1H),  4.09 (t, J = 
6.03 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.86 (s, 3H), 3.68 (q, J = 6.24 Hz, 2H), 2.93 
(t, J = 6.60 Hz, 2H), 2.17 (d, J = 0.90 Hz, 3H), 2.09-1.92 (m, 4H). MS (FAB) m/z 378 
[M+H]+. HRMS (FAB) m/z calcd for C18H27N5O2S [M + H]+ 378.1964, found: 
378.1972. Anal. HPLC 99.53% (Rt = 3.641 min) 
 
4.1.4.4. N-(3-(4-Aminobutoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thiourea (53). mp = 55-56 oC. 1H NMR (300 MHz, CDCl3) δ 7.60 (br, 1H), 
7.43 (s, 1H), 6.80 (d, J = 8.43 Hz, 1H), 6.76-6.70 (m, 3H), 6.00 (br, 1H), 4.00 (t, J = 
6.60 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.87 (s, 3H), 3.68 (q, J = 6.42 Hz, 2H), 2.79 
(t, J = 6.78 Hz, 2H), 2.17 (d, J = 0.90 Hz, 3H), 2.09 (p, J = 7.14 Hz, 2H), 1.92 (p, J 
= 6.78 Hz, 2H), 1.66-1.59 (m, 2H). MS (FAB) m/z 392 [M+H]+. HRMS (FAB) m/z 
calcd for C19H29N5O2S [M + H]+ 392.2120, found: 392.2127. Anal. HPLC 100.00% 
(Rt = 3.199 min). 
 
4.1.4.5. N-(4-Methoxy-3-(3-(methylamino)propoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (54). mp = 88-89 oC. 1H NMR (300 MHz, CDCl3) δ 
7.42 (s, 1H), 6.86 (d, J = 8.43 Hz, 1H), 6.78 (dd, J = 8.43, 2.37 Hz, 1H), 6.73 (d, J = 
2.19 Hz, 1H), 6.68 (s, 1H), 6.09 (br, 1H), 4.07 (t, J = 6.24 Hz, 2H), 3.89 (t, J = 6.96 
Hz, 2H), 3.87 (s, 3H), 3.66 (q, J = 6.60 Hz, 2H), 2.83 (t, J = 6.57 Hz, 2H), 2.47 (s, 
3H), 2.17 (s, 3H), 2.09-2.02 (m, 4H). MS (ESI) m/z 392 [M+H]+. HRMS (ESI) calcd 




imidazol-1-yl)propyl)thiourea (55). mp = 76-77 oC. 1H NMR (300 MHz, CD3OD) δ 
7.43 (d, J = 0.93 Hz, 1H), 6.85 (d, J = 8.43 Hz, 1 H), 6.84 (d, J = 2.40 Hz, 1H), 6.69 
(dd, J = 8.61, 2.37 Hz, 1H), 6.57 (s, 1H), 3.92-3.85 (m, 4H), 3.73 (s, 3H), 3.49 (t, J = 
6.96 Hz, 2H), 2.67 (t, J = 7.32 Hz, 2H), 2.37 (s, 3H), 2.12 (d, J = 0.90 Hz, 3H), 1.93 
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(p, J = 7.14 Hz, 2H), 1.75-1.58 (m, 4H). MS (ESI) m/z 406 [M+H]+. HRMS (ESI) 
calcd for C20H31N5O2S [M + H]+ 406.2271, found 406.2262. Anal. HPLC 97.6% (Rt 
= 3.012 min). 
 
4.1.4.7. N-(3-(4-(Dimethylamino)butoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (56). mp = 51-52 oC. 1H NMR (300 MHz, CD3OD) δ 
7.58 (s, 1H), 6.96 (d, J = 8.61 Hz, 1H), 6.91 (d, J = 2.40 Hz, 1H), 6.77 (dd, J = 8.58, 
2.55 Hz, 1H). 6.66 (s, 1H), 4.01 (t, J = 6.06 Hz, 2H), 3.97 (t, J = 7.32 Hz, 2H), 3.82 
(s, 3H), 3.61 (t, J = 6.96 Hz, 2H), 2.42 (t, J = 7.71 Hz, 2H), 2.25 (s, 6H), 2.21 (d, J = 
0.90 Hz, 3H), 2.05 (p, J = 7.14 Hz, 2H), 1.81-1.75 (m, 2H), 1.72-1.67 (m, 2H). MS 
(FAB) m/z 420 [M+H]+. HRMS (FAB) m/z calcd for C21H33N5O2S [M + H]+ 420.2428, 
found: 420.2438. Anal. HPLC 98.23% (Rt = 3.454 min). 
 
4.1.4.8. N-(4-Methoxy-3-(2-(piperazin-1-yl)ethoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (57). mp = 71-72 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (s, 1H), 6.79-6.94 (m, 2H), 6.80 (dd, J = 8.43, 2.37 Hz, 1H), 6.66 (s, 1H), 4.14 
(t, J = 5.49 Hz, 2H), 3.99 (t, J = 7.14 Hz, 2H), 3.81 (s, 3H), 3.59 (q, J = 7.14 Hz, 2H), 
2.88 (t, J = 4.92 Hz, 4H), 2.82 (t, J = 5.49 Hz, 2H), 2.61 (t, J = 4.95 Hz, 4H), 2.22 (d, 
J = 1.08 Hz, 3H), 2.05 (p, J = 6.78 Hz, 2H). MS (FAB) m/z 433 [M+H]+. HRMS 
(FAB) m/z calcd for C21H32N6O2S [M + H]+ 433.2380, found: 433.2370. Anal. HPLC 
99.30% (Rt = 4.101 min). 
 
4.1.4.9. N-(4-Methoxy-3-(3-(piperazin-1-yl)propoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (58). mp = 58-59 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (d, J = 0.90 Hz, 1H), 6.96 (d, J = 8.58 Hz, 1H), 6.91 (d, J = 2.37 Hz, 1H), 6.77 
(dd, J = 8.40, 2.37 Hz, 1H), 6.66 (s, 1H), 4.05 (t, J = 6.03 Hz, 2H), 3.99 (t, J = 6.96 
Hz, 2H), 3.81 (s, 3H), 3.61 (t, J = 6.75 Hz, 2H), 2.87 (t, J = 4.95 Hz, 4H), 2.57-2.49 
(m, 6H), 2.22 (d, J = 1.11 Hz, 3H), 2.07-1.96 (m, 4H). MS (ESI) m/z 447 [M+H]+. 
HRMS (ESI) m/z calcd for C22H34N6O2S [M + H]+ 447.2537, found: 447.2534. Anal. 
HPLC 99.32% (Rt = 3.799 min). 
 
4.1.4.10. N-(4-Methoxy-3-(4-(piperazin-1-yl)butoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (59). mp = 82-83 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (s, 1H), 6.95-6.92 (m, 2H), 6.77 (dd, J = 8.40, 2.37 Hz, 1H), 6.66 (s, 1H), 4.03 
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(t  ̧J = 6.03 Hz, 2H), 3.99 (t, J = 7.32 Hz, 2H), 3.82 (s, 3H), 3.61 (t, J = 7.14 Hz, 2H), 
2.92 (t, J = 4.92 Hz, 4H), 2.50-2.41 (m, 6H), 2.22 (d, J = 1.11 Hz, 2H), 2.08 (p, J = 
7.50 Hz, 2H), 1.80 (p, J = 6.21 Hz, 2H), 1.69-1.61 (m, 2H). MS (FAB) m/z 461 
[M+H]+. HRMS (FAB) m/z calcd for C23H36N6O2S [M + H]+ 461.2693, found: 
461.2705. Anal. HPLC 99.69% (Rt = 3.701 min). 
 
4.1.4.11. N-(4-Methoxy-3-(2-(piperidin-4-yl)ethoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (60). mp = 83-84 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (d, J = 1.11 Hz, 1H), 6.96 (d, J = 8.61 Hz, 1H), 6.91 (d, J = 2.19 Hz, 1H), 6.77 
(dd, J = 8.43, 2.40 Hz, 1H), 6.67 (s, 1H), 4.04 (t, J = 5.85 Hz, 2H), 3.99 (t, J = 7.14 
Hz, 2H), 3.82 (s, 3H), 3.58 (t, J = 6.96 Hz, 2H), 3.07-3.02 (m, 2H), 2.65 (td, J = 10.08, 
3.84 Hz, 2H), 2.22 (d, J = 0.93 Hz, 3H), 2.07 (p, J = 7.14 Hz, 2H), 1.80-1.74 (m, 4H), 
1.73-1.72 (m, 1H), 1.23-1.11 (m, 2H). MS (FAB) m/z 432 [M+H]+. HRMS (FAB) 
m/z calcd for C22H33N5O2S [M + H]+ 432.2433, found: 432.2426. Anal. HPLC 
95.47% (Rt = 4.070 min). 
 
4.1.4.12. N-(4-Methoxy-3-(3-(piperidin-4-yl)propoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (61). mp = 49-50 oC. 1H NMR (300 MHz, CD3OD) δ 
7.60 (d, J  = 1.11 Hz, 1H), 6.95 (d, J  = 8.58 Hz, 1H), 6.91 (d, J = 2.40 Hz, 1H), 6.76 
(dd, J = 8.43, 2.40 Hz, 1H), 6.66 (s, 1H), 3.98 (t, J = 6.39 Hz, 4H), 3.82 (s, 3H), 3.61 
(t, J = 6.96 Hz, 2H), 3.11-3.07 (m, 2H), 2.69 (td, J = 12.27, 2.58 Hz, 2H), 2.22 (d, J 
= 0.93 Hz, 3H), 2.07 (p, J = 7.14 Hz, 2H), 1.86-1.76 (m, 5H), 1.44-1.37 (m, 2H), 
1.25-1.12 (m, 2H). MS (FAB) m/z 446 [M+H]+. HRMS (FAB) m/z calcd for 




imidazol-1-yl)propyl)thiourea (62). mp = 64-65 oC. 1H NMR (300 MHz, CD3OD) δ 
7.50 (s, 1H), 6.87 (d, J  = 8.61 Hz, 1H), 6.81 (d, J = 2.19 Hz, 1H), 6.67 (dd, J = 8.40, 
2.37 Hz, 1H), 6.57 (s, 1H), 3.90 (t, J = 6.21 Hz, 4H), 3.73 (s, 3H), 3.52 (t, J = 6.96 
Hz, 2H), 2.99-2.95 (m, 2H), 2.57 (t, J = 12.45 Hz, 2H), 2.14 (d, J = 0.93 Hz, 3H), 
1.98 (p, J = 7.14 Hz, 2H), 1.67-1.63 (m, 5H), 1.40-1.35 (m, 2H), 1.25-1.18 (m, 2H), 
1.11-1.03 (m, 2H). MS (FAB) m/z 460 [M+H]+. HRMS (FAB) m/z calcd for 
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methyl-1H-imidazol-1-yl)propyl)thiourea (63). mp = 71-72 oC. 1H NMR (300 MHz, 
CDCl3) δ 7.58 (s, 1H), 6.95-6.91 (m, 2H), 6.77 (dd, J = 8.40, 2.55 Hz, 1H), 6.66 (s, 
1H), 4.04 (t, J = 6.06 Hz, 2H), 3.96 (t, J = 7.50 Hz, 2H), 3.81 (s, 3H), 3.58 (t, J = 7.14 
Hz, 2H), 2.88 (d, J = 10.26 Hz, 2H), 2.26 (s, 3H), 2.21 (d, J = 0.90 Hz, 3H), 2.08-
2.00 (m, 4H), 1.80-1.71 (m, 4H), 1.33-1.29 (m, 3H). MS (FAB) m/z 446 [M+H]+. 
HRMS (FAB) m/z calcd for C23H35N5O2S [M + H]+ 446.2584, found: 446.2581. Anal. 
HPLC 98.99% (Rt = 4.109 min). 
 
4.1.4.15. N-(3-(2-(2-Aminopyridin-4-yl)ethoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (64). mp = 66-67 oC. 1H NMR (300 MHz, CD3OD) 
δ 7.77 (d, J = 5.31 Hz, 1H), 7.51 (s, 1H), 6.96-6.91 (m, 2H), 6.78 (dd, J = 8.61, 2.37 
Hz, 1H), 6.65 (s, 1H), 6.60 (dd, J = 5.52, 1.47 Hz, 1H), 6.53 (s, 1H), 4.21 (t, J = 6.60 
Hz, 2H), 3.98 (t, J = 7.14 Hz, 2H), 3.80 (s, 3H), 3.60 (t, J = 6.21 Hz, 2H), 2.98 (t, J = 
6.39 Hz, 2H), 2.20 (d, J = 0.75 Hz, 3H), 2.06 (p, J = 6.93 Hz, 2H). MS (FAB) m/z 
441 [M+H]+. HRMS (FAB) m/ calcd for C22H28N6O2S z [M + H]+ 441.2067, found: 
441.2067. Anal. HPLC 99.52% (Rt = 3.967 min). 
 
4.1.4.16. N-(3-(3-(2-Aminopyridin-4-yl)propoxy)-4-methoxyphenyl)-N’-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (65). mp = 76-77 oC. 1H NMR (400 MHz, 
CD3OD) δ 7.75 (d, J = 5.24 Hz, 1H), 7.58 (s, 1H). 6.97 (d, J = 8.56 Hz, 1H), 6.88 (d, 
J = 2.16 Hz, 1H), 6.78 (dd, J = 8.52, 2.36 Hz, 1H), 6.65 (s, 1H), 6.50 (d, J = 4.28 Hz, 
1H), 6.45 (s, 1H), 3.99-3.94 (m, 4H), 3.84 (s, 3H), 3.60 (t, J = 6.88 Hz, 2H), 2.70 (t, 
J = 7.43 Hz, 2H), 2.20 (d, J = 0.72 Hz, 3H), 2.08-2.00 (m, 4H). MS (FAB) m/z 455 
[M+H]+. HRMS (FAB) m/z calcd for C23H30N6O2S [M + H]+ 455.2224, found: 
455.2223. Anal. HPLC 96.06% (Rt = 3.979 min). 
4.1.4.17. N-(3-(4-(2-Aminopyridin-4-yl)butoxy)-4-methoxyphenyl)-N’-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (66). mp = 63-64 oC. 1H NMR (300 MHz, CDCl3) 
δ 7.91 (d, J = 5.49 Hz, 1H), 7.60 (s, 1H), 7.39 (s, 1H), 6.89 (d, J = 8.43 Hz, 1H), 6.76-
6.73 (m, 2H), 6.66 (d, J = 2.19 Hz, 1H), 6.51 (d, J = 5.49 Hz, 1H), 6.36 (s, 1H), 5.94 
(br, NH), 3.98 (t, J = 6.06 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.87 (s, 3H), 3.69 (q, J 
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= 6.60 Hz, 2H), 2.60 (t, J = 7.32 Hz, 2H), 2.17 (d, J = 0.72 Hz, 3H), 2.09 (p, J = 7.32 
Hz, 2H), 1.85-1.80 (m, 4H). MS (FAB) m/z 469 [M+H]+. HRMS (FAB) m/z calcd for 




1H-imidazol-1-yl)propyl)thiourea (67). To a solution of 53 (1 eq) in EtOH was added 
2-chloropyrimidine (2 eq) and triethylamine (2.5 eq). The mixture was refluxed for 2 
days, then solvent was removed by evaporation. The residue was purified by column 
chromatography (MeOH : CH2Cl2) to give white solid, 35% yield. mp = 50-51 oC. 1H 
NMR (300 MHz, CDCl3) δ 8.26 (d, J = 4.74 Hz, 2H), 7.60 (s, 1H), 7.37 (s, 1H), 6.88 
(d, J = 8.61 Hz, 1H), 6.76-6.68 (m, 3H), 6.52 (t, J = 4.77 Hz, 1H), 5.94 (br, 1H), 5.35 
(br, 1H), 4.03 (t, J = 6.21 Hz, 2H), 3.91 (t, J = 7.14 Hz, 2H), 3.87 (s, 3H), 3.69 (q, J 
= 6.42 Hz, 2H), 3.52 (q, J = 6.60 Hz, 2H), 2.17 (d, J = 0.93 Hz, 3H), 2.09 (p, J = 7.32 
Hz, 2H), 1.99 (p, J = 7.86 Hz, 2H), 1.85 (p, J = 6.78 Hz, 2H). MS (FAB) m/z 470 
[M+H]+. HRMS (FAB) m/z calcd for C23H31N7O2S [M + H]+ 470.2338, found: 
470.2340. Anal. HPLC 96.60% (Rt = 4.414 min). 
 
4.1.4.19. N-(4-(2-(Piperazin-1-yl)ethoxy)phenyl)-N’-(3-(5-methyl-1H-imidazol-1-
yl)propyl)thiourea (68). mp = 85-86 oC. 1H NMR (300 MHz, CD3OD) δ 7.58 (s, 1H), 
7.17 (m, 2H), 6.97 (m, 2H), 6.66 (s, 1H), 4.15 (t, J = 5.31 Hz, 2H), 3.98 (t, J = 6.96 
Hz, 2H), 3.60 (t, J = 6.96 Hz, 2H), 2.87 (m, 4H), 2.81 (t, J = 5.70 Hz, 2H), 2.57 (m, 
4H), 2.21 (s, 3H), 2.04 (m, 2H). MS (FAB) m/z 403 [M+H]+. HRMS (FAB) m/z calcd 




imidazol-1-yl)propyl)thiourea (69). mp = 58-59 oC. 1H NMR (300 MHz, CD3OD) δ 
7.75 (d, J = 5.49 Hz, 1H), 7.59 (s, 1H), 7.14 (d, J = 8.79 Hz, 2H), 6.93 (d, J = 8.97 
Hz, 2H), 6.66 (s, 1H), 6.49 (dd, J = 5.31, 1.47 Hz, 1H), 6.44 (s, 1H), 3.99-3.97 (m, 
4H), 3.60 (t, J = 6.39 Hz, 2H), 2.56 (t, J = 6.96 Hz, 2H), 2.21 (s, 3H), 2.04 (p, J = 
6.96 Hz, 2H), 1.78-1.75 (m, 4H). MS (FAB) m/z 439 [M+H]+. HRMS (FAB) m/z 
calcd for C23H30N6OS [M + H]+ 439.2275, found: 439.2268. Anal. HPLC 99.67% (Rt 
= 2.957 min). 
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4.1.4.21. N-(4-(2-Oxo-2-(piperazin-1-yl)ethoxy)phenyl)-N’-(3-(5-methyl-1H-
imidazol-1-yl)propyl)thiourea (70). mp = 95-96 oC. 1H NMR (300 MHz, CD3OD) δ 
7.59 (s, 1H), 7.18 (d, J = 8.97 Hz, 2H), 6.69 (d, J = 8.97 Hz, 2H), 6.66 (s, 1H), 4.82 
(s, 2H), 3.99 (t, J = 7.32 Hz, 2H), 3.60-3.50 (m, 6H), 2.85-2.77 (m, 4H), 2.21 (s, 3H), 
2.07 (p, J = 6.96 Hz, 2H). MS (FAB) m/z 417 [M+H]+. HRMS (FAB) m/z calcd for 




imidazol-1-yl)propyl)thiourea (71). mp = 98-99 oC. 1H NMR (300 MHz, CDCl3) δ 
7.59 (s, 1H), 7.21 (d, J = 8.79 Hz, 2H), 7.01 (d, J = 8.97 Hz, 2H), 6.66 (s, 1H), 4.50 
(s, 2H), 3.99 (t, J = 7.32 Hz, 2H), 3.91-3.84 (m, 1H), 3.58 (t, J = 6.06 Hz, 2H), 3.08-
3.04 (m, 2H), 2.71 (t, J = 12.27 Hz, 2H), 2.22 (s, 3H), 2.07 (p, J = 6.96 Hz, 2H), 1.87-
1.83 (m, 2H), 1.50-1.45 (m, 2H). MS (FAB) m/z 431 [M+H]+. HRMS (FAB) m/z 
calcd for C21H30N6O2S [M + H]+ 431.2224, found: 431.2246. Anal. HPLC 100.00 % 
(Rt = 2.947 min). 
 
4.1.4.23. N-(4-(2-((1-(2-Aminoethyl)piperidin-4-yl)amino)-2-oxoethoxy)phenyl)-N’-
(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (72). mp = 73-74 oC. 1H NMR (300 
MHz, CD3OD) δ 7.59 (s, 1H), 7.21 (d, J = 8.76 Hz, 2H), 7.01 (d, J = 8.76 Hz, 2H), 
6.66 (s, 1H), 4.49 (s, 2H), 3.99 (t, J = 7.32 Hz, 2H), 3.79-3.74 (m, 1H), 3.58 (t, J = 
6.66 Hz, 2H), 2.88-2.85 (m, 2H), 2.75-2.71 (t, J = 6.78 Hz, 2H), 2.45 (t, J = 6.75 Hz, 
2H), 2.22 (s, 3H), 2.14-2.11 (m, 2H), 2.05-2.01 (p, J = 6.93 Hz, 2H), 1.86-1.82 (m, 
2H), 1.65 (m, 2H). MS (FAB) m/z 474 [M+H]+. HRMS (FAB) m/z calcd for 




(5-methyl-1H-imidazol-1-yl)propyl)thiourea (73). mp = 90-91 oC.1H NMR (300 MHz, 
CD3OD) δ 7.79 (d, J = 5.49 Hz, 1H), 7.58 (s, 1H), 7.20 (d, J = 8.98 Hz, 2H), 7.03 (d, 
J = 8.97 Hz, 2H), 6.66 (s, 1H), 6.50 (dd, J = 5.31, 1.53 Hz, 1H), 6.45 (s, 1H),  4.60 
(s, 2H), 4.34 (s, 2H), 4.00 (t, J = 6.96 Hz, 2H), 3.59 (t, J = 6.06 Hz, 2H), 2.22 (d, J = 
0.93 Hz, 3H), 2.05 (p, J = 6.66 Hz, 2H). MS (FAB) m/z 454 [M+H]+. HRMS (FAB) 
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m/z calcd for C22H27N7O2S [M + H]+ 454.2020, found: 454.2046. Anal. HPLC 98.24% 
(Rt = 4.023 min) 
  
4.1.4.25. N-(4-((1-(2-Aminoethyl)piperidin-4-yl)carbamoyl)phenyl)-N’-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (74). mp = 91-92 oC. 1H NMR (300 MHz, 
CD3OD) δ 7.81 (d, J = 8.61 Hz, 2H), 7.60 (s, 1H), 7.50 (d, J = 8.43 Hz, 2H), 6.67 (s, 
1H), 4.01 (t, J = 7.32 Hz, 2H), 3.87-3.84 (m, 1H), 3.62 (t, J = 7.14 Hz, 2H), 2.99-2.95 
(m, 2H), 2.75 (t, J = 6.96 Hz, 2H), 2.49 (t, J = 6.87 Hz, 2H), 2.23 (s, 3H), 2.16-2.14 
(m, 2H), 2.10 (t, J = 6.93 Hz, 2H), 1.95-1.88 (m, 2H), 1.72-1.65 (m, 2H). MS (FAB) 
m/z 444 [M+H]+. HRMS (FAB) m/z calcd for C22H33N7OS [M + H]+ 444.2540, found: 
444.2557. Anal. HPLC 99.61% (Rt = 3.661 min). 
 
4.1.4.26. N-((E)-4-(3-oxo-3-(piperazin-1-yl)prop-1-en-1-yl)phenyl)-N’-(3-(5-methyl-
1H-imidazol-1-yl)propyl)thiourea (75). mp = 112-113 oC. 1H NMR (300 MHz, 
CD3OD) δ 7.63-7.60 (m, 3H), 7.57 (d, J = 15.36 Hz, 1H), 7.41-7.35 (m, 2H), 7.11 (d, 
J = 15.39 Hz, 1H), 6.67 (s, 1H), 4.02 (t, J = 7.14 Hz, 2H), 3.68-3.59 (m, 6H), 2.84-
2.80 (m, 4H), 2.23 (d, J = 0.93 Hz, 3H), 2.09 (p, J = 6.75 Hz, 2H), MS (FAB) m/z 
413 [M+H]+. HRMS (FAB) m/z calcd for C21H28N6OS [M + H]+ 413.2118, found: 
413.2111. Anal. HPLC 96.61% (Rt = 2.938 min). 
 
4.1.4.27. N-((E)-4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-
yl)phenyl)-N’-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (76). mp =  66-67 oC. 
1H NMR (300 MHz, CD3OD) δ 7.63 (m, 3H), 7.57 (d, J = 15.36 Hz, 1H), 7.41 (d, J 
= 8.61 Hz, 2H), 7.11 (d, J = 15.39 Hz, 1H), 6.67 (s, 1H), 4.02 (t, J = 7.14 Hz, 2H), 
3.68-3.64 (m, 4H), 3.61 (t, J = 6.57 Hz, 2H), 2.84 -2.81 (m, 4H), 2.52-2.48 (m, 4H), 
2.23 (s, 3H), 2.09 (p, J = 6.96 Hz, 2H). MS (FAB) m/z 456 [M+H]+. HRMS (FAB) 
m/z calcd for C23H33N7OS [M + H]+ 456.2540, found: 456.2518. Anal. HPLC 98.74% 
(Rt = 2.943 min). 
 4.1.4.28. N-((E)-4-(3-oxo-3-(piperidin-4-ylamino)prop-1-en-1-yl)phenyl)-N’-(3-(5-
methyl-1H-imidazol-1-yl)propyl)thiourea (77). mp = 76-77 oC. 1H NMR (300 MHz, 
CD3OD) δ 7.59 (s, 1H), 7.55-7.46 (m, 3H), 7.40 (d, J = 8.43 Hz, 2H), 6.67 (s,1H), 
6.57 (d, J = 15.70 Hz, 1H), 4.02 (t, J = 7.50 Hz, 2H), 3.78-3.72 (m, 1H), 3.61 (t, J = 
6.69 Hz, 2H), 3.07-3.03 (m, 2H), 2.70-2.63 (m, 2H), 2.23 (d, J = 0.93 Hz, 3H), 2.09 
(p, J = 6.96 Hz, 2H), 1.93-1.90 (m, 2H), 1.59-1.55 (m, 2H). MS (FAB) m/z 427 
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[M+H]+. HRMS (FAB) m/z calcd for C22H30N5OS [M + H]+ 427.2275, found: 
427.2277. Anal. HPLC 98.19% (Rt = 2.602 min). 
 
4.1.4.29. N-(E)-(4-(3-(4-(2-Aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-
yl)phenyl)-N’-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea (78). mp = 80-81 oC. 
1H NMR (500 MHz, CD3OD) δ 7.62 (d, J = 8.45 Hz, 2H), 7.59 (s, 1H), 7.56 (d, J = 
15.40 Hz, 1H), 7.42 (d, J = 8.50 Hz, 2H), 7.11 (d, J = 15.40 Hz, 1H), 6.67 (s, 1H), 
4.02 (t, J = 7.15 Hz, 2H), 3.76-3.72 (m, 5H), 3.62-3.55 ( m, 2H), 2.83 (t, J = 6.25 Hz, 
2H), 2.52-2.40 (m, 6H), 2.23 (d, J = 1.00 Hz, 3H), 2.10 (p, J = 7.05 Hz, 2H). MS 
(FAB) m/z 456 [M+H]+. HRMS (FAB) m/z calcd for C23H33N7OS [M + H]+ 456.2540, 
found: 456.2518. Anal. HPLC 97.30% (Rt = 2.863 min). 
 
4.2. Molecular Modeling  
The X-ray crystal structure of the human glutaminyl cyclase (PDB ID: 3PBB)26 was 
prepared via the Protein Preparation Wizard in Maestro v.10.2 (Schrödinger, LLC, 
New York, NY, USA). During the preparation process, bond orders were assigned, 
zero-order bonds to Zn2+ were generated, and hydrogen atoms were added. The entire 
hydrogen atoms were energy minimized with the optimized potential for liquid 
simulation (OPLS) 2005 force field. The protonation states of the ligand molecules 
were forecasted by the pKa prediction module in ADMET Predictor™ (Simulations 
Plus, Lancaster, CA, USA). The 3D structure of 53 was created by LigPrep v.3.4 in 
Maestro and the resulting structure was energy minimized in implicit solvent with 
OPLS 2005 force field in Maestro. The prepared ligand molecules were docked to the 
hQC with Glide v.6.7 in Maestro. The grid for the active site was generated through 
the centroid of the co-crystallized ligand, PBD150, and the grid box size was selected 
as default. Metal coordination constraint was set as tetrahedral geometry for the Zn2+. 
Glide SP docking was completed with the maximum number of 30 poses per ligand. 
The resulting best pose of 53 were chosen and conducted for the subsequent QM-
Polarized Ligand Docking (QPLD) procedure. The partial charges of the docked 
ligands were analyzed by Jaguar with the option of accurate QM level. Then, the 
ligands accompanied with the updated charges were re-docked using Glide extra 
precision (XP). The protein-ligand complex obtained from the QPLD was taken for 
further optimization by Refine Protein-Ligand Complex module in Prime v.4.0 in 
Maestro. Protein residues within 5 Å of the docked ligand were minimized by local 
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optimization refinement. The side chain conformations of the selected protein 
residues were predicted and minimized along with the docked ligand during this 
process. The results were further energy minimized using Monte Carlo sampling 
algorithm in 2500 steps in Maestro.  
All the molecular graphic figures were generated by PyMOL software 
(http://www.pymol.org). All computational studies were undertaken on an Intel Xeon 
Octa-Core 2.67 GHz workstation with Linux CentOS release 6.7. 
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1. Design and  Pharmacophore 
 
 
Figure 3.1: Binding complex of compound 1 and hQC acitive site 
The parent compound 1 may have 4 conformations: cis-cis; trans-trans; trans-
cis and cis-trans in order to interact with hQC active site. Base of the binding complex 
of compound 1 with hQC active site (Figure 3.1), we know that it interacts with hQC 
by trans-cis conformation; Hence, to make easy to have trans-cis conformation, we 
introduced a substituent group at B region that produce the compound with potent in 
vitro activity from 3-22 fold better then parent compound 1. Unfortunately, their in 
vivo assays exhibited less potent due to low brain permeability.  
 
 
Figure 3.2: Urea and Thiurea QC inhibitors effects 
So we changed from thiourea type to Urea type in order to improve BBB 
penetration (Figure 3.2). The in vitro results prove that these compounds had 
Potent in vitro activity:  
3-22 fold 
Low BBB penetration!!! 
Comparable in vitro activity 
Good BBB penetration 
Not stable  
K
i 
= 24.6 ± 0.7 nM J Pharmacol Exp A-region: Benzimidazole & 
imidazole 
B-region: cyclic substituents 
C/D-region: Biosteroisomer 
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comparable activity as well as good BBB penetration. However, they are not stable 
in metabolism due to the dimethoxy group at C region78. In the fact, Oxygen in 
heterocyclic at C/D region have hydrogen bonding with hQC active site, having an 
important function in pharmacophore. So in this series we anticipate that bioisomer 
in C region would maintain the hydrogen bonding also keep compound stable in 
metabolism.  
Based on our previous study, compound 4 have IC50 = 162 nM, decrease 
nearly 5.5-fold less than the compound 1. However, when B region was substituted 
by different group R, it showed significantly increase the QC inhibition activity. Also, 
the docking study of PQ91279 which was developed by Probiodrug exhibited the Zinc 
binding motif between benzimidazole and Zinc of hQC active site. Hence, we 
continued to survey the modification of C/D region with heterocyclic ring with 
different substituted group at B region as well as the A region with normal 5-methyl 
imidazole and novel benzimidazole. We anticipated that these modifications could 
provide useful information for the investigation of Phe-Agr mimetic region. 
 
2. Result and discussion 
2.1. Chemistry 
 
Scheme 3.1.  Synthesis of 3-methyl-5-nitroindazole derivatives. Reagents and 
conditions : (a) HNO3, c.H2SO4,-15 oC, 20 mins; (b) N2H4.H2O, EtOH, reflux, o.n.; 
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(c) Boc2O, DMAP, DCM; (d) halide alkyl, Cs2CO3, DMF; (e) N-methylpiperazine, 
Cs2CO3, DMF (for 7); (f) Pd/C, H2, MeOH; (g) aldehyde or ketone derivatives, 
NaBH3CN, AcOH, MeOH, o.n; (h) 2-nitrobenzenesulfonyl chloride, TEA, DCM, 0 
oC-r.t., 4h; (i) cyclopentylmethanol, DEAD, Ph3P, DCM, r.t, o.n.; (k) thiophenol, 
K2CO3, ACN, r.t., o.n. 
First for synthesis the 3-methyl-5-nitroindazole fragments which was showed 
in scheme 3.1, 2'-fluoro-acetophenone was nitration via electrophile substitution in 
fuming nitric acid and conc. H2SO4 at -42 oC to obtain compound 280. Nitro 
compound was intramolecular cyclized in excess hydrazine to produce 5-indazole 
derivative 381. Compound 3 was protected by Boc-group then reduce to obtain 
intermediate 9. Meanwhile it also underwent Williamson reaction and N-alkylation 
to achieve intermediate 5-8. All of these intermediates were subjected for reduction 
to get the corresponding amine 10-13. The primary amine 9-13 underwent directly 
reductive amination with different aldehyde or ketone to obtain secondary amine82 
18, 20-21, 23-27, 29. In order to obtain intermediate 19, 22, 28 with 
cyclopentylmethyl substituent, their corresponding primary amine were firstly 
protected with 2-nitrobenzensulfonyl chloride81, then alkylation amine group by 
Mitsunobu reaction to obtaine 16-17.1. the nitrobenzensulfomide removed easily 
with soft nucleophiles via Meisenheimer complexes to give the corresponding 
secondary amines83.  
 
Scheme 3.2. Synthesis of 5-nitro indazole derivatives. Reagents and conditions: (a) 
halide alkyl, Cs2CO3, DMF; (b) Pd/C, H2, MeOH; (c) aldehyde or ketone derivatives, 
NaBH3CN, AcOH, MeOH, o.n. 
Meanwhile, 5-indazole without the 3-methyl group derivatives were 
synthesized as in scheme 3.2. N-alkylation of 5-nitro-indazole to achieve 
intermediate 31, 32 which were reduced to get corresponding amine 33, 34. The 
primary amines were reacted with 4-fluorobenzyaldehyde and cyclohexanone to 
produce 35-38.  
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Scheme 3.3. Synthesis of 3-methyl-6-nitroindazole derivatives. Reagents and 
conditions: (a) Boc2O, DMAP, DCM; (b) alkyl halide, Cs2CO3, DMF; (c) Pd/C, H2, 
MeOH; (d) aldehyde or ketone derivatives, NaBH3CN, AcOH, MeOH, o.n.; (e) 2-
nitrobenzenesulfonyl chloride, TEA, DCM, 0 oC-r.t., 4h; (f) cyclopentylmethanol, 
DEAD, Ph3P, DCM, r.t, o.n.; (g) thiophenol, K2CO3, ACN, r.t., o.n. 
Scheme 3.3 showed the synthesis of 3-methylindazole-6-yl derivative. 3-
methyl-6-nitroindazole 39 reacted with Boc2O or alkyl halide to achieve 40-44 which 
was reduced in hydrogenation to obtain primary amine of 45-49. The primary amine 
underwent the reduction amination with aldehyde or ketone to produce secondary 
amine of 54, 56-59, 61-64, 66-67. Meanwhile, primary amine 45-46 was reacted with 
2-nitrobenzensulfonyl chloride then Mitsunobu reaction with cyclopentylmethanol to 
produce 52-53. The protected group of nitrobenzensulfonyl was removed by thiol to 
obtain the corresponding secondary amine 54, 60.  
N-(4-fluorobenzyl)-indazol-6-amine-1-yl derivatives were synthesized as 
scheme 3.4. 6-nitroindazole reacted with Boc2O or N-alkylation of alkyl halide, then 
reduced in hydrogenation to obtain corresponding primary amine 72-74. The amine 
then underwent reductive amination with 4-fluorobenzaldehyde to get the secondary 
amine of 75-77 
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Scheme 3.4. Synthesis of 6-nitroindazole derivatives. Reagents and conditions: (a) 
Boc2O, DCM; (b) alkyl halide, Cs2CO3, DMF; (c) Pd/C, H2, MeOH; (d) 4-
fluorobenzaldehyde, NaBH3CN, AcOH, MeOH, o.n. 
 
Scheme 3.5. Synthesis of 5-nitroindole derivatives. Reagent and conditions: (a) allyl 
bromide, t-BuOK, DMF, 30 min, 0 °C-r.t, 18 h; (b) Boc2O, DMAP, DCM; (c) t-
Bu4NBr, TEA, Pd(OAc)2, xantphos, DMF, reflux, 48h; (d) TFA, MC; (e) alkyl halide, 
Cs2CO3, DMF; (f) Pd/C, H2, MeOH; (g) aldehyde or ketone derivatives, NaBH3CN, 
AcOH, MeOH, o.n.; (h) 2-nitrobenzenesulfonyl chloride, TEA, DCM, 0 oC-r.t., 4h; 
(i) cyclopentylmethanol, DEAD, Ph3P, DCM, r.t, o.n.; (k) thiophenol, K2CO3, ACN, 
r.t., o.n. 
5-indole derivatives were produced as in scheme 3.5. 2-chloro-4-nitroaniline 
78 firstly was alkylated and Boc protection to achieve intermediate 80. The 
compound was intramolecular cyclized via Buchward Hardwig reaction to get 5-
indole 81 84.  
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Scheme 3.6. Synthesis of benzofuran derivatives. Reagents and conditions: (a) BH3-
THF, 0 oC-rt; (b) MnO2, DCM; (c) N2CHCO2Et, HBF4.Et2O, DCM, 0 oC, 1h, c. H2SO4; 
(d) i. DIBAL, toluene; ii. I2, Ph3P, Imidazole, DCM, r.t., 1h; iii. NaBH4, diglyme, r.t., 
2h; (d) SnCl2, c.HCl, EtOH, reflux, 2h; (e) aldehyde or ketone derivatives, NaBH3CN, 
AcOH, MeOH, o.n. 
The Boc group of compound was removed by TFA in MC then followed by 
N-alkylate to achieve 83-84. Also, 85 was obtained from N-alkylation of 5-
nitroindole 82. These nitro intermediates were reduced in hydrogenation to get the 
primary amine of 86-88 which were not only protected with 2-nitrobenzensulfonyl 
before substituted with cyclopentylmethyl, but also underwent the reductive 
amination with aldehyde or ketone derivative to introduce intermediate 95-103.  
For synthesis of 5/6-benzofuran derivatives as in scheme 3.6, 4/5-nitrobenzoic acid 
was reduced in BH3 then oxidized by MnO2 to achieve intermediate 106-107. The 
benzaldehyde intermediates were intra molecular cyclized by diazo derivatives85, 
then underwent the reduction and Appel reaction to provide primary amine 110-111. 
These primary amines were subjected for reductive amination to achieve secondary 
amine of 112-114.  
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Scheme 3.7. Synthesis of benzooxazole and benzothiazole derivatives. Reagents and 
conditions: (a) triethyl orthoformate, 80 oC, 1h; (b) Pd/C, H2, MeOH; (c) SnCl2, 
c.HCl, EtOH, reflux, 2h; (d) aldehyde or ketone derivatives, NaBH3CN, AcOH, 
MeOH, o.n.; (e) 2-nitrobenzenesulfonyl chloride, TEA, DCM, 0 oC-r.t., 4h; (f) 
cyclopentylmethanol, DEAD, Ph3P, DCM, r.t, o.n.; (g) thiophenol, K2CO3, ACN, r.t., 
o.n. 
Benzothiazole and benzoxazole were synthesized as in scheme 3.7, 
nitrophenol derivatives 115-116 were cyclized intra molecular in triethyl 
orthoformate to achieve heterocyclic 117-120. These intermediates were reduced by 
hydrogenation or tinc chloride to obtain corresponding amine 121-124. The primary 
amine underwent reductive amination with aldehyde or ketone or via Mitsunobu 
reaction for cyclopentylmethyl to produce secondary amine of 133-144.  
For achieve the final compound as showed in scheme 3.8, secondary amines 
were coupled with Azide derivative via Aza Wittig coupling86 to have final 
compounds of 173-178; 180-186; 193-199; 202-205; 217-240 and other precursors 
of 145-168. All of the precursors were removed the protected group to have to obtain 
the remaining final compounds of 169-172; 179; 187-192; 200-201; 206-216.  
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Scheme 3.8. Synthesis of final compounds. Reagents and conditions: (a) azide 
derivatives, Ph3P, CO2, toluene, reflux, o.n.; (b) TFA, DCM, r.t., o.n. 
 
2.2. In vitro assay   
We performed QC activity assays using a fluorogenic substrate, Gln-AMC (L-
glutamine 7-amido-4-methylcoumarin), and pyroglutamyl peptidase (pGAP) as an 
auxiliary enzyme67 to evaluate the ability of the D-region-modified library to inhibit 
QC. We first investigated a group of compounds containing 5-amino-3-
methylindazole derivatives in D-region Table 3.1.  
Table 3.1. IC50 values for inhibition of hQC by N-substituted urea compounds of 5-




R1 R2 IC50 (nM)a 
Parent compound 162 
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H 29.0 (±0.6)  
179 
 
H 11.4 (±1.6) 
a The values indicate the mean of at least three experiments. 
This is result of in vitro of 3-methyl-5-indazole derivatives, It showed that 
biosteroisomer derivatives increase in vitro activity. When B region was substituted 
by different group to have a trans-cis conformation, the compound activity increases 
significantly about 9-70 fold. Especially, compound 170 with cyclohexyl at B region 
is the most potent in this series. It suggested that substituent groups at B region made 
compound easier to having binding complex with hQC active side and nitrogen on 
heterocyclic had H-bond also. When addition methyl group at position 1 of indazole, 
compound 173-179 also have comparable activity. Furthermore, when B region was 
substituent ground and D region was moiety of methyl-piperazylethyl and 2-amino-
pyridylbutyl, which moiety in our previous study displayed potent activity due to 
terminally amine position, compounds less activity compare with the above-
mentioned compound.  
However, in table 2, 5-indazole without methyl group at position 3, and 
position 1 was propyl or isobutyl and B region was substituted by cyclohexyl and 4-
fluorobenzyl. The compounds showed less comparable with compounds in previous 
table. May be the steric bulk at position 1 affect to H-bonding between Nitrogen and 
hQC active site. However, interestingly compound 181 with 4-fluorobenzyl at B-
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region and isopropyl at position 1 have better activity than compound 183 with 
isobutyl at position 1 about 3.8 fold. 
Table 3.2. IC50 values for inhibition of hQC by N-substituted urea compounds of 5-
aminoindazole derivatives 
 













a The values indicate the mean of at least three experiments. 
 
We also consider the effect of Nitrogen at position 2 by survey 2,3-
dimethylindazole-5-yl derivatives in table 3.3.  Unfortunately, these compound also 
exhibited less activity. Even when, 3-aminopyridylmethyl-substitued B region 
compound 186 displayed weak activity with IC50 = 210 nM. 
Next, we examined series of 6-amino-3-methylindazole as shown in table 
3.4. Firstly, the compounds in this series also showed good activity as compound of 
1-methyl-indazole-5-yl derivatives. When substituted B region with different cyclic 
group, their activity increase from 3-50 fold compared with compound 4. Also, 
addition methyl group at position 1, these compound 193-198 had comparable 
activity with IC50 of 2.3 to 9.8 nM, except compound 197 with B region substituted 
by 3-pyridymethyl displayed weak activity with IC50  of 65.9 nM. Moreover, when 
surveyed D-region with moieties of N-methylpiperazylethyl and 2-aminopyridyl-4yl-
butyl, the compound 199-200 showed less activity compare with compound of methyl 
substituents with IC50 of 71.2 and 20.4 nM, respectively.  
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Table 3.3. IC50 values for inhibition of hQC by N-substituted urea compounds of 5-
amino-2,3-dimethylindazole derivative 
 










a The values indicate the mean of at least three experiments. 
 
In previous series, compound 190 and 196 with 4-fluorobenzyl at B region 
showed comperable potent in indazole   series with IC50 of 11.1 and 2.3 nM, 
respectively. Hence, in table 3.5, we examined the compound with B region is 4-
fluorobenzyl and modified the C-linker of 1-substitued groups. Unfortunately, the 
activity of these compounds 201-203 showed moderate potent of IC50 from 29.0 to 
66.2 nM.  
 





R1 R2 IC50 (nM)a 
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H 71.2 (±0.6)  
200 
 
H 20.4 (±1.9) 
a The values indicate the mean of at least three experiments. 
 
Table 3.5. IC50 values for inhibition of hQC by N-substituted urea compounds of 6-
aminoindazole derivatives 
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a The values indicate the mean of at least three experiments. 
 
For survey the 2,3-dimethyl derivative with B region is 4-fluorobenzyl and 3-
pyridylmethyl, IC50 of these compound showed less active as corresponding 
compound of 5-indazole as showed in table 3.6. Interestingly, compound 204 with 4-
fluorobenzyl at B-region is more active 3-times than compound 205 with 3-
pyridylmethyl at B region.  
 
Table 3.6. IC50 values for inhibition of hQC by N-substituted urea compounds of 6-
amino-2,3-dimethylindazole derivatives 
 







a The values indicate the mean of at least three experiments. 
 
In order to optimize A region with benzimidazole, table 3.7 and table 3.8 displayed 
QC inhibitory activity of compounds of 5/6-indazole with different group at B region. 
The IC50 results display less activity compare with those of imidazole in A region, 
regardless of the steric hindrance with IC50 of 24.6-76.1 nM.  
Meanwhile, 6-indazole derivatives compound 211-216, table 3.8, also have 
the similar weak activity as 5-indazole derivatives. Compound 215 with 4-
fluorobenzyl at B region once again displayed potent activity than others compound 
in this series. 
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Table 3.7. IC50 values for inhibition of hQC by N-substituted urea compounds of 6-
amino-3-methylindazole derivative with benzimidazole at A region  
 
















a The values indicate the mean of at least three experiments. 
We also surveyed C-region with indole derivatives as in table 3.9, in which 
there was only one Nitrogen atom on heterocyclic ring. Unfortunately, although all 
of these compound 217-225 showed increased inhibitory activity 2-4 fold compare 
with leading compound 4, their activity much weaker compare with compound of 
indazole derivatives. This result could exhibited the important of hydrogen bonding 
between C-region and hQC active site.  
 
Table 3.8. IC50 values for inhibition of hQC by N-substituted urea compounds of 6-
amino-3-methylindazole derivatives with benzimidazole at A region 
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a The values indicate the mean of at least three experiments. 
 
Table 3.9. IC50 values for inhibition of hQC by N-substituted urea compounds of 5-
aminoindole derivatives 
 
Cpd. R1 R2 R3 IC50 (nM)a 
217 Me H 
 
49.5 (±5.9) 
218 Me H 
 
74.6 (±14.9) 
219 Me H 
 
61.2 (±4.2) 
220 Me Me 
 
48.1 (±7.2) 
221 Me Me 
 
41.9 (±10.0) 
222 Me Me 
 
41.7 (±7.7) 
223  H 
 
35.9 (±8.4) 
224  H 
 
60.3 (±5.8) 
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225  H 
 
60.0 (±6.5) 
a The values indicate the mean of at least three experiments. 
 
Finally we also considered C region with benzofuran, benzooxazole, 
benzothiazole derivatives 226-228 as showed in table 3.10 in order to continuously 
evaluate the important of biosteroisomer in this series. The in vitro result displayed 
the weak activity compared with those of indazole derivative. Even, compound with 
4-fluorobenzyl at B region also decreased activity significantly, especially compound 
228 of 6-aminobenzofuran derivative was the weakest inhibitory activity with IC50 of 
113 nM. 
 
Table 3.10. IC50 values for inhibition of hQC by N-substituted urea compounds of 
benzofuran, benzooxazole and benzothiazole derivatives  
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 X Y R IC50 (nM)a 
229 O N 
 
33.5 (±1.2) 
230 O N 
 
59.4 (±12.4) 
231 O N 
 
26.9 (±3.4) 
232 N O 
 
47.7 (±13.4) 
233 N O 
 
32.9 (±1.9) 
234 N O 
 
39.5 (±6.9) 
235 S N 
 
50.2 (±2.9) 
236 S N 
 
47.3 (±6.2) 
237 S N 
 
37.5 (±0.7) 
238 N S 
 
47.1 (±4.9) 
239 N S 
 
35.6 (±0.7) 
240 N S 
 
38.2 (±0.8) 
a The values indicate the mean of at least three experiments. 
 
3. Conclusion 
In this part, we continued to synthesize and evaluate the biological activity of C-
region with heterocyclic ring base on the binding complex of parent compound 1 and 
hQC active site of 72 compounds. In general, most of them were showed less activity 
compare with our previous study derivative. Compound with indazole at C region 
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had better activity than those of indole, benzooxazole, benzothiazole, benzofuran 
fragment. This suggested that the C region interact with hQC active site by H-bond 
play an important role. Furthermore, when we changed the A region from imidazole 
derivatives to benzimidazole derivates, hQC inhibitory activity reduced remarkably. 
We needed to evaluate in vivo and acute AD model test of 10 potent compound for 
further discovery.   
 
4. Experimental  
4.1. Chemistry 
4.1.1. General 
All chemical reagents were commercially available. Melting points were determined 
on a melting point Buchi B-540 apparatus and are uncorrected. Silica gel column 
chromatography was performed on silica gel 60, 230-400 mesh, Merck. 1H NMR 
spectra were recorded on a a JEOL JNM-LA 300 at 300 MHz, Bruker Analytik, 
DE/AVANCE Digital 400 at 400 MHz, a Bruker Analytik, DE/AVANCE Digital 500 
at 500 MHz, and a JEOL JNM-ECA-600 at 600 MHz. Mass spectra were recorded 
on a VG Trio-2 GC−MS instrument and a 6460 Triple Quad LC−MS instrument. All 
final compounds were assessed for purity by high performance liquid 
chromatography (HPLC) on Agilent 1120 Compact LC (G4288A) system via the 
following conditions. Column: Agilent TC-C18 column (4.6 mm × 250 mm, 5 μm). 
Mobile phase A: MeOH, Mobile phase B: 0.1% TFA in water (v/v) in 30 min. 
Wavelength: 254 nM. Flow: 0.7 mL/min. According to the HPLC analyses, all final 
compounds showed a purity of  ≥ 95%. 
 
4.1.2. General procedure 
4.1.2.1.  Produce 1- Nitration  
To a mechanically stirred slurry of conc. H2SO4 (93-98%, 360 mL) at -42 °C were 
added dropwise 2'-fluoro-acetophenone 45 (90.0 g, 652 mmol) and a solution of 
fuming nitric acid (53.1 mL) in conc. H2SO4 (129 mL). The slurry was stirred for 30 
min at -42 °C. The mixture was slowly poured onto 1.3 kg of ice. To the mixture was 
added water (1 L). The product precipitated out of solution. After all of the ice melted, 
the product was collected via filtration. The solid was dissolved with EtOAc. The 
organic layer was washed with 5% Na2CO3 (2 x 300 mL), water (300 mL), and brine 
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(300 mL), and dried over Na2SO4. It was filtered, the filtrate was concentrated to give 
compound  
 
4.1.2.2. Procedure 2- indazole cyclisation  
To a solution of 2-fluoroacetophenone derivatives (14.48 mmol, 1.0 equiv) in 
ethylene glycol (10 mL) was added hydrazine monohydrate (15.06 mmol, 1.04 equiv) 
at 25 °C. After 2 h at 25 °C, the reaction was heated to 165 °C and stirred until 
complete by TLC. After cooled to 25 °C, the mixture was extracted with CH2Cl2 (3 
x). The combined organic layers were washed with saturated aqueous NaHCO3 and 
dried over MgSO4. After filtration and concentration in vacuo, the residue was 
purified via flash column chromatography on silica gel to indazole analogs. 
 
4.1.2.3. Procedure 3 – Reductive amination  
To a solution of 10% AcOH in MeOH was added the SM (1 equiv) and 
dry acetone or aldehyde (0.90 equiv). The solution was stirred at RT 1 h, after which 
time it was cooled to 0 oC and treated with NaCNBH3 (1.5 equiv). The reaction was 
stirred at RT for 5 h. The mixture was concentrated and the residue brought to pH = 
10 using Na2CO3. The mixture was extracted with EtOAc and the organic layer was 
washed with H2O, brine, dried (MgSO4), and concentrated to dryness. The crude 
material was purified by silica gel column chromatography (2% MeOH/DCM) to 
provide the product as a yellow solid.  
 
4.1.2.4. Procedure 4 
Procedure 4.1. The primary amine in DMC was all nitrobenzensulfonyl chloride (1.3 
equiv) and TEA (2.0 equiv). Then the mixture was stirred at r.t until SM was 
consumed (by TCL). The mixture was pour into water and extracted by DCM (50 mL 
x 3 times). The combined organics were wash with brine, dried (MgSO4), and 
concentrated to dryness and purified by silia gel column chromatography to provide 
the product.  
 
Procedure 4.2. Solution of nitrobenzensulfonyl compound (1 equiv.) in DCM (10 mL) 
was add thiophenol (1.3 equiv.) and potassium carbonate (3 equiv.). The mixture was 
stirred at r.t. overnight then quenched with brine and extracted with DCM ( 3 time x 
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50 mL). The combined organics were dried (MgSO4) and concentrated and purified 
by silica gel column chromatography to get the desired product.  
 
4.1.2.5. Procedure 5 - Reduction 
Procedure 5.1. BH3 reduction: To a 0.24M THF suspension of the SM (1 equiv) at 0 
oC was added BH3-THF (3 equiv). The reaction mixture was stirred under Ar at r.t 
for 66 h then quenched by addition of EtOH (15 mL) at 0 oC and stirred an additional 
15 min. The mixture was poured into H2O and extracted with DCM. The combined 
organics were washed with brine, dried (Na2SO4), and concentrated to provide the 
crude product as a white solid.  
 
Procedure 5.2: Hydrogenation 
The nitro compound or alkene derivative was dissolved in MeOH (or mixture of 
MeOH and THF) and then 10% Pd/C was added. The mixture was stirred at room 
temperature under hydrogen gas until all starting material was consumed (confirmed 
by TCL). The crude mixture was filtered through celite filter, washed with MeOH (3 
x 50 mL) and then concentrated. The product was subjected to the next step without 
further purification. 
 
Procedure 5.3: Zinc powder reduction 
AcOH (5 equiv) and Zn dust (5 equiv) were added to a solution of a nitro compound 
in MeOH (10 mL) at room temperature. The reaction mixture was stirred at room 
temperature for 30 minutes and then filtered through a celite filter. The filtrate was 
portioned between H2O (10 mL) and DCM (30 mL). The organic layer was separated, 
dried over MgSO4, concentrated, and purified by column chromatography to provide 
the product. 
 
4.1.2.6. Procedure 6  
The entire two-step, one-pot reaction can be accomplished in less than 1 h. For each 
experiment, HBF4·OEt2 was added to the aldehyde (1 g) in CH2Cl2 (2 mL). A solution 
of ethyl diazoacetate in CH2Cl2 was introduced into the reaction mixture as the 
evolution of N2 gas permitted (ca. 3-6 min addition time) and the reaction was not 
allowed to go above 38 °C. Once gas evolution ceased, the reaction mixture was 
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concentrated by rotary evaporator and H2SO4 (0.3 to 0.5 mL) was added to the 
mixture while stirring. After 5 to 10 min, the mixture was diluted with CH2Cl2 (5 to 
10 mL) and the H2SO4 was quenched with solid NaHCO3. The mixture was then 
filtered through silica gel (1 g), and concentrated by rotary evaporator to give an oil, 
which slowly crystallized under high vacuum. 
 
4.1.2.7. Procedure 7 - Benzooxazole 
According to a procedure, the corresponding 2-aminophenol (5 mmol) and triethyl 
orthoformate (15 mL) was refluxed for 4 h. After cooling to room temperature, the 
remaining triethyl orthoformate was removed under reduced pressure and the residue 
was purified by column chromatography to yield the desired substituted benzoxazole  
 
4.1.2.8. Mitsunobu reaction (Procedure 8)  
Triphenylphosphine (1.3 equiv) was added to a solution of 4-nitroguanicol (1.0 equiv) 
in DCM under a nitrogen atmosphere, followed by the addition of a primary alcohol 
(1.2 equiv) and a solution of diethyl azodicarboxylate (1.3 equiv) in DCM. After the 
solution was stirred for 30 minutes at room temperature, the reaction was poured onto 
a column of silica and was eluted with EtOAc:n-hexane to yield the desired product. 
 
4.1.2.9. Boc protection and deprotection 
Procedure 9.1: Triethylamine (1.2 equiv) and di-tert-butyl dicarbonate (2.5 equiv) in 
DCM were added to a suspension of the starting amine material (1.0 equiv) in DCM 
in an ice bath. The mixture was stirred at room temperature until starting material was 
consumed (confirmed by TLC). Water was added to the mixture and subsequently 
extracted with DCM. The organic layer was washed with a 10% aqueous NaHCO3 
solution, water and brine, dried over MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography to obtain the desired product. 
 
Procedure 9.2: Trifluoroacetic acid (10 equiv) was added to the solution of the boc-
protected compound (1.0 equiv) in DCM (DCM:TFA = 1:1 (v/v)). Then, the mixture 
was stirred at room temperature until the starting material was consumed and 
evaporated. The residue was dissolved in MeOH and purified on an ion-exchange 
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column to obtain the desired product or subjected to the next step without further 
purification. 
 
4.1.2.10 Procedure 10-Azide coupling reaction 
Procedure 10: Amine derivative (1 equiv), triphenylphosphine (1.1 equiv), 1-(3-
azidopropyl)-5-methyl-1H-imidazole (1.1 equiv) were dissolve in toluene (5 mL). 
The solution was degas then refluxed under CO2 condition overnight. The mixture 
was cooled down and evaporated to remove toluene. The residue was purified by 
DCM/ MeOH to get the product 
 
4.1.2.11. Procedure 11 – N-alkylation 
A mixture of the alkyl halide, nitrogen-containing compound and excess base  in 
DMF was stirred at 60 °C for 30 min. The reaction was quenched with water and 
extracted with EA. The organic layer was washed with water and brine, concentrated 




4.2.1.1. 1-(2-Fluoro-5-nitrophenyl)ethan-1-one (02). Starting with compound 01 
following the general procedure 01, compound 02 was obtained as yellow solid, yield 
75%. 1H NMR (300 MHz, CDCl3) δ 8.80 (dd, J = 2.91, 6.03 Hz, 1H), 8.44-8.38 (m, 
1H), 7.37 (t, J = 9.33 Hz, 1H), 2.71 (d, J = 4.77 Hz, 3H). 
 
4.2.1.2. 3-Methyl-5-nitro-1H-indazole (03). Starting with compound 02 following the 
general procedure 02, compound 03 was obtained as yellow solid, yield 84%. 1H 
NMR (300 MHz, DMSO) δ 13.30 (s, NH), 8.76 (s, 1H), 8.18 (dd, J = 2.01, 9.15 Hz, 
1H), 7.63 (d, J = 9.15 Hz, 1H), 2.56 (s, 3H). 
 
4.2.1.3. tert-Butyl 3-methyl-5-nitro-1H-indazole-1-carboxylate (04). Starting with 
compound 03 following the general procedure 9.1, compound 04 was obtained as 
yellow solid, yield 85%.  1H NMR (300 MHz, CDCl3) δ 8.61 (d, J = 2.01 Hz, 1H), 
8.40 (dd, J = 9.36, 2.22 Hz, 1H), 8.24 (d, J = 9.36 Hz, 1H), 2.67 (s, 3H), 1.74 (s, 9H). 
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4.2.1.4. 1,3-Dimethyl-5-nitro-1H-indazole (05). Starting with compound 03 
following the general procedure 11, compound 05 was obtained as pale solid, yield 
77%. 1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 2.04 Hz, 1H), 8.28 (dd, J = 2.19, 
9.15 Hz, 1H), 7.38 (d, J = 9.15 Hz, 1H), 4.06 (s, 3H), 2.62 (s, 3H), 1.56 (s, 9H). 
 
4.2.1.5. 3-Methyl-1-(2-(4-methylpiperazin-1-yl)ethyl)-5-nitro-1H-indazole (06). 
Starting with compound 03 following the general procedure 11, compound 06 was 
obtained as yellow solid, yield 65%. 1H NMR (300 MHz, CDCl3) δ 8.65 (d, J = 2.01 
Hz, 1H), 8.24 (dd, J = 9.15, 2.19 Hz, 1H), 7.41 (d, J = 9.15 Hz, 1H), 4.45 (t, J = 6.87 




yl)carbamate (07). Starting with compound 03 following the general procedure 11, 
compound 07 was obtained as yellow solid, yield 88%. 1H NMR (300 MHz, CDCl3) 
δ 8.65 (d, J = 2.01 Hz, 1H), 8.24 (dd, J = 9.15, 1.32 Hz, 1H), 8.11 (d, J = 4.74 Hz, 
1H), 7.95 (s, 1H), 7.77 (s, 1H), 7.35 (d, J = 9.15 Hz, 1H), 6.72 (dd, J = 5.13, 1.47 Hz, 
1H), 4.35 (t, J = 6.93 Hz, 2H), 2.62 (s, 3H), 2,62 (t, J = 7.62 Hz, 2H), 1.96 (quintet, 
J = 7.86 Hz, 2H), 1.74-1.58 (m, 2H).1.53 (s, 9H). 
 
4.2.1.7. 2,3-Dimethyl-5-nitro-2H-indazole (08). Starting with compound 03 
following the general procedure 11, compound 08 was obtained as yellow solid, yield 
20%.  1H NMR (300 MHz, CDCl3) δ 8.67 (dd, J = 2.01, 0.57 Hz, 1H), 8.05 (dd, J = 
9.33, 2.19 Hz, 1H), 7.47 (dd, J = 9.15, 0.54 Hz, 1H), 4.13 (s, 3H), 2.64 (s, 3H). 
 
4.2.1.8. tert-Butyl 5-amino-3-methyl-1H-indazole-1-carboxylate (09). Starting with 
compound 04 following the general procedure 5.2, compound 09 was obtained as red 
solid, yield 96%.  1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.97 Hz, 1H), 6.92 (dd, 
J = 8.79, 2.19 Hz, 1H), 6.84 (d, J = 1.83 Hz, 1H), 3.73 (s, 2H), 2.51 (s, 3H), 1.70 (s, 
9H). 
 
4.2.1.9. 1,3-Dimethyl-1H-indazol-5-amine (10). Starting with compound 05 
following the general procedure 5.2, compound 10 was obtained as pink solid, yield 
99%.  1H NMR (300 MHz, CDCl3) δ 7.13 (d, J = 9.33 Hz, 1H), 6.87-6.83 (m, 2H), 
3.92 (s, 3H), 2.46 (s, 3H). 
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4.2.1.10. 3-Methyl-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indazol-5-amine 
(11). Starting with compound 06 following the general procedure 5.2, compound 11 
was obtained as red solid, yield 90%. 1H NMR (300 MHz, CDCl3) δ 7.19 (d, J = 9.33 
Hz, 1H), 6.86-6.84 (m, 2H), 4.37 (t, J = 7.35 Hz, 2H), 3.36 (br, 2H), 2.82 (t, J = 7.35 
Hz, 2H), 2.56 (br, 4H), 2.47 (s, 3H), 2.44 (br, 4H), 2.27 (s, 3H). 
 
4.2.1.11. tert-Butyl (4-(4-(5-amino-3-methyl-1H-indazol-1-yl)butyl)pyridin-
2-yl)carbamate (12). Starting with compound 07 following the general procedure 5.2, 
compound 12 was obtained as red solid, yield 94%. 1H NMR (300 MHz, CDCl3) δ 
8.33 (s, 1H), 8.11 (d, J = 4.74 Hz, 1H), 7.13 (d, J = 9.45 Hz, 1H), 6.98-6.95 (m, 2H), 
6.86-6.82 (m, 2H), 4.26 (t, J = 6.78 Hz, 2H), 3.86 (br, 2H), 2.59 (t, J = 7.86 Hz, 2H), 
2.48 (s, 3H), 1.93-1.86 (m, 2H), 1.42 (s, 9H). 
 
4.2.1.12. 2,3-Dimethyl-2H-indazol-5-amine (13). Starting with compound 08 
following the general procedure 5.2, compound 13 was obtained as red solid, yield 
99%. 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.97 Hz, 1H), 7.33 (s, 1H), 7.04 (d, 
J = 8.97 Hz, 1H), 3.98 (s, 3H), 2.49 (s, 3H). 
 
4.2.1.13. tert-Butyl 3-methyl-5-((2-nitrophenyl)sulfonamido)-1H-indazole-1-
carboxylate (14). Starting with compound 09 following the general procedure 4.1, 
compound 14 was obtained as pale solid, yield 76%. 1H NMR (300 MHz, CDCl3) δ 
8.00 (d, J = 7.89 Hz, 1H), 7.89-7.79 (m, 2H), 7.75-7.65 (m, 2H), 7.55-7.51 (m, 2H), 
7.26 (d, J = 8.61 Hz, 1H), 2.54 (s, 3H), 1.70 (s, 9H). 
 
4.2.1.14. N-(2,3-Dimethyl-2H-indazol-5-yl)-2-nitrobenzenesulfonamide (15). 
Starting with compound 10 following the general procedure 4.1, compound 15 was 
obtained as pale solid, yield 71%. 
 
4.2.1.15. tert-Butyl 5-((N-(cyclopentylmethyl)-2-nitrophenyl)sulfonamido)-3-
methyl-1H-indazole-1-carboxylate (16). Starting with compound 14 following the 
general procedure 8, compound 16 was obtained as red solid, yield 53%. 1H NMR 
(500 MHz, CDCl3) δ 8.00 (d, J = 8.80 Hz, 1H), 7.62-7.58 (m, 2H), 7.53 (s, 1H), 7.41-
7.36 (m, 2H), 7.28 (dd, J = 1.60, 8.85 Hz, 1H), 6.37 (s, 1H), 3.74 (d, J = 7.70 Hz, 2H), 
2.52 (s, 3H), 1.87-1.83 (m, 1H), 1.68 (s, 9H), 1.65-1.58 (m, 4H), 1.51-1.47 (m, 2H), 
1.33-1.23 (m, 4H). 
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4.2.1.16. N-(cyclopentylmethyl)-N-(2,3-dimethyl-2H-indazol-5-yl)-2-
nitrobenzenesulfonamide (17). Starting with compound 15 following the general 
procedure 08, compound 17 was obtained as pale red solid, yield 64%. 
 
4.2.1.17. tert-Butyl 5-(cyclohexylamino)-3-methyl-1H-indazole-1-carboxylate 
(18). Starting with compound 09 following the general procedure 03, compound 18 
was obtained as pale red solid, yield 65%. 1H NMR (300 MHz, CDCl3) δ 7.86 (d, J = 
8.40 Hz, 1H), 6.85 (dd, J = 2.40, 8.97 Hz, 1H), 6.65 (d, J = 2.19 Hz, 1H), 3.34-3.27 
(m, 1H), 2.51 (s, 3H), 2.10-2.07 (m, 2H), 1.80-1.76 (m, 2H0, 1.67 (s, 9H), 1.65-1.60 
(m, 2H), 1.48-1.30 (m, 3H), 1.26-1.16 (m, 3H). 
 
4.2.1.18. tert-Butyl 5-((cyclopentylmethyl)amino)-3-methyl-1H-indazole-1-
carboxylate (19). Starting with compound 16 following the general procedure 4.2, 
compound 19 was obtained as opaque solid, yield 77%. 1H NMR (300 MHz, CDCl3) 
δ 7.87 (d, J = 8.79 Hz, 1H), 6.87 (dd, J = 2.40, 8.97 Hz, 1H), 6.65 (d, J = 2.19 Hz, 
1H), 3.73 (br, NH), 3.08 (d, J = 7.32 Hz, 2H), 2.52 (s, 3H), 2.24-2.12 (m, 1H), 1.90-
1.80 (m, 2H), 1.70 (s, 9H), 1.67-1.60 (m, 4H), 1.33-1.23 (m, 2H) 
 
4.2.1.19. tert-Butyl 5-(4-fluorobenzylamino)-3-methyl-1H-indazole-1-
carboxylate (20). Starting with compound 09 following the general procedure 03, 
compound 20 was obtained as red crude solid. 1H NMR (300 MHz, CDCl3) δ 7.89 (d, 
J = 8.43 Hz, 1H), 7.39-7.32 (m, 2H), 7.08-7.02 (m, 2H), 6.91-6.87 (dd, J = 8.76, 2.19 
Hz, 1H), 6.68 (d, J = 2.04 Hz, 1H), 4.35 (s, 2H), 4.08 (s, 1H), 2.49 (s, 3H), 1.70 (s, 
9H). 
 
4.2.1.20. N-Cyclohexyl-1,3-dimethyl-1H-indazol-5-amine (21). Starting with 
compound 10 following the general procedure 03, compound 21 was obtained as red 
solid, yield 66%. 1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.79 Hz, 1H), 6.81 (dd, 
J = 2.19, 8.97 Hz, 1H), 6.69 (d, J = 1.83 Hz, 1H), 3.92 (s, 3H), 3.31-3.25 (m, 1H), 
2.49 (s, 3H), 2.11-2.08 (m, 2H), 1.80-1.76 (m, 2H), 1.65-1.56 (m, 3H), 1.46-1.34 (m, 
2H), 1.29-1.15 (m, 3H).  
 
4.2.1.21. N-(Cyclopentylmethyl)-2,3-dimethyl-2H-indazol-5-amine (22). 
Starting with compound 17 following the general procedure 4.2, compound 22 was 
obtained as opaque solid, yield 75%. 
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4.2.1.22. N-(4-Fluorobenzyl)-1,3-dimethyl-1H-indazol-5-amine (23). Starting 
with compound 10 following the general procedure 03, compound 23 was obtained 
as pink solid, yield 67%. 1H NMR (300 MHz, CDCl3) δ 7.36 (dd, J = 8.43, 5.49 Hz, 
2H), 7.14 (d, J = 8.79 Hz, 1H), 7.04-6.99 (m, 2H), 6.82 (dd, J = 8.97, 2.19 Hz, 1H), 
6.68 (d, J = 2.01 Hz, 1H), 4.31 (s, 2H), 3.92 (s, 3H), 2.45 (s, 3H). 
 
4.2.1.23. 1,3-Dimethyl-N-(pyridin-3-ylmethyl)-1H-indazol-5-amine (24). 
Starting with compound 10 following the general procedure 03, compound 24 was 
obtained as pink solid, yield 58%.  1H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 8.48 
(s, 1H), 7.68 (d, J = 7.89 Hz, 1H), 7.23-7.19 (m, 1H), 7.11 (d, J = 8.79 Hz, 1H), 6.78 
(d, J = 8.97 Hz, 1H), 6.62 (s, 1H), 4.34 (s, 2H), 3.87 (s, 3H), 2.39 (s, 3H). 
 
4.2.1.24. N-Cyclobutyl-1,3-dimethyl-1H-indazol-5-amine (25). Starting with 
compound 10 following the general procedure 03, compound 25 was obtained as 
opaque solid, yield 57%. 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.85 Hz, 1H), 
6.76 (d, J = 8.80 Hz, 1H), 6.59 (d, J = 1.55 Hz, 1H), 3.97-3.93 (m, 1H), 3.90 (s, 3H), 
2.47 (s, 3H), 2.45-2.39 (m, 2H), 1.85-1.76 (m, 4H). 
 
4.2.1.25. N-Cyclopentyl-1,3-dimethyl-1H-indazol-5-amine (26). Starting with 
compound 10 following the general procedure 03, compound 26 was obtained as pale 
red solid, yield 77%. 1H NMR (500 MHz, CDCl3) δ 7.12 (d, J = 8.80 Hz, 1H), 6.78 
(dd, J = 1.55, 8.85 Hz, 1H), 6.66 (s, 1H), 3.90 (s, 3H), 3.84-3.79 (m, 1H), 3.48 (s, 
3H), 2.07-2.01 (m, 2H), 1.73-1.58 (m, 4H), 1.52-1.47 (m, 2H). 
 
4.2.1.26. N-Cyclohexyl-2,3-dimethyl-2H-indazol-5-amine (27). Starting with 
compound 13 following the general procedure 03, compound 27 was obtained as red 
solid, yield 35%.  1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 9.10 Hz, 1H), 6.71 (d, J 
= 8.75 Hz, 1H), 6.44 (s, 1H), 4.00 (s, 3H), 3.28-3.22 (m, 1H), 2.49 (s, 3H), 2.10-2.07 
(m, 2H), 1.77-1.74 (m, 2H), 1.66-1.63 (m, 1H), 1.41-1.24 (m, 2H), 1.21-1.14 (m, 3H). 
 
4.2.1.27. N-(4-Fluorobenzyl)-2,3-dimethyl-2H-indazol-5-amine (28). Starting 
with compound 13 following the general procedure 03, compound 28 was obtained 
as red solid, yield 50%. 1H NMR (300 MHz, CDCl3) δ 8.39 (d, J = 8.97 Hz, 1H), 7.31 
(dd, J = 8.61, 5.67 Hz, 1H), 6.96-6.94 (m, 2H), 6.71 (dd, J = 9.15, 2.19 Hz, 1H), 6.35 
(d, J = 2.01 Hz, 1H), 4.24 (s, 2H), 3.96 (s, 3H), 2.42 (s, 3H). 
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4.2.1.28. 2,3-Dimethyl-N-(pyridin-3-ylmethyl)-2H-indazol-5-amine (29). 
Starting with compound 13 following the general procedure 03, compound 29 was 
obtained as dark solid, yield 29%. 1H NMR (300 MHz, CDCl3) δ 8.52 (s, 1H), 8.47 
(s, 1H), 8.01 (d, J = 8.43 Hz, 1H), 7.58-7.49 (m, 1H), 7.32 (d, J = 7.26 Hz, 1H), 6.74 
(d, J = 9.18, 2.40 Hz, 1H), 6.14 (d, J = 2.01 Hz, 1H), 4.41 (s, 2H), 3.88 (s, 3H), 2.35 
(s, 3H). 
 
4.2.1.29. 5-Nitro-1-propyl-1H-indazole (31). Starting with compound 30 
following the general procedure 11, compound 31 was obtained as yellow solid, yield 
77%. 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 1.96 Hz, 1H), 8.26 (dd, J = 2.08, 
9.20 Hz, 1H), 8.18 (s, 1H), 7.45 (d, J = 9.24 Hz, 1H), 4.39 (t, J = 7.00 Hz, 2H), 
2.01-.91 (p, m, 2H), 0.93 (t, J = 7.48 Hz, 3H).  
 
4.2.1.30. 1-Isobutyl-5-nitro-1H-indazole (32). Starting with compound 30 
following the general procedure 11, compound 32 was obtained as yellow solid, yield 
51%. 1H NMR (300 MHz, CDCl3) δ 8.71 (d, J = 2.01 Hz, 1H), 8.24 (dd, J = 8.52, 
2.01 Hz, 1H), 8.19 (d, J = 0.72 Hz, 1H), 7.43 (d, J = 9.15 Hz, 1H), 4.20 (d, J = 7.32 
Hz, 2H), 2.34 (hept, J = 6.78 Hz, 1H), 0.92 (d, J = 6.60 Hz, 6H). 
 
4.2.1.31. 1-Propyl-1H-indazol-5-amine (33). Starting with compound 31 
following the general procedure 5.2, compound 33 was obtained as red solid, yield 
88%. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 0.75 Hz, 1H), 7.22 (d, J = 8.79 Hz, 
1H), 6.91 (dd, J = 0.75, 2.01 Hz, 1H), 6.85 (dd, J = 2.19, 8.79 Hz, 1H), 4.27 (t, J = 
6.93 Hz, 2H), 1.96-.84 (m, 2H), 0.91 (t, J = 7.32 Hz, 3H). 
 
4.2.1.32. 1-Isobutyl-1H-indazol-5-amine (34). Starting with compound 32 
following the general procedure 5.2, compound 34 was obtained as red solid, yield 
92%. 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 0.72 Hz, 1H), 7.20 (d, J = 8.79 Hz, 
1H), 6.91 (d, J = 1.47 Hz, 1H), 6.83 (dd, J = 8.79, 2.19 Hz, 1H), 4.08 (d, J = 7.35 Hz, 
2H), 3.57 (br, 2H), 2.29 (hept, J = 6.96 Hz, 1H), 0.88 (d, J = 6.78 Hz, 6H). 
 
4.2.1.33. N-Cyclohexyl-1-propyl-1H-indazol-5-amine (35). Starting with 
compound 33 following the general procedure 3, compound 35 was obtained as red 
solid, yield 59%. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 0.72 Hz, 1H), 7.20 (d, J 
= 9.51 Hz, 1H), 6.78-6.75 (m, 2H), 4.26 (t, J = 7.14 Hz, 2H), 3.37 (br, NH), 3.27-
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3.20 (m, 1H), 2.10-2.02 (m, 2H), 1.95 (p, J = 7.32 Hz, 2H), 1.78-1.73 (m, 2H), 1.67-
1.62 (m, 1H), 1.43-1.31 (m, 2H), 1.27-1.09 (m, 3H), 0.91 (t, J = 7.32 Hz, 3H). 
 
4.2.1.34. N-(4-Fluorobenzyl)-1-propyl-1H-indazol-5-amine (36). Starting 
with compound 33 following the general procedure 3, compound 36 was obtained as 
red solid, yield: 84%. 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 0.93 Hz, 1H), 7.40-
7.35 (m, 2H), 7.23 (s, 1H), 7.07-7.00 (m, 2H), 6.84 (dd, J = 8.79, 2.19 Hz, 1H), 6.76 
(d, J = 1.65 Hz, 1H), 4.32 (s, 2H), 4.27 (t, J = 7.14 Hz, 2H), 1.92 (hex, J = 6.96 Hz, 
2H), 0.91 (t, J = 7.32 Hz, 3H). 
 
4.2.1.35. N-Cyclohexyl-1-isobutyl-1H-indazol-5-amine (37). Starting with 
compound 34 following the general procedure 3, compound 37 was obtained as red 
solid, yield 87%. 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 0.72 Hz, 1H), 7.13 (d, J 
= 8.61 Hz, 1H), 6.76 (s, 1H), 6.75 (d, J = 8.97 Hz, 1H), 4.01 (d, J = 7.32 Hz, 2H), 
3.21-3.14 (m, 1H), 2.23 (hept, J = 6.78 Hz, 1H), 2.02 (d, J = 12.45 Hz, 2H), 1.71-
1.56 (m, 3H), 1.36-1.06 (m, 5H), 0.83 (d, J = 6.60 Hz, 6H). 
 
4.2.1.36. N-(4-Fluorobenzyl)-1-isobutyl-1H-indazol-5-amine (38). Starting 
with compound 34 following the general procedure 3, compound 38 was obtained as 
red solid, yield 75%. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 0.93 Hz, 1H), 7.37-
7.33 (m, 2H), 7.21 (d, J = 8.97 Hz, 1H), 7.06-6.99 (m, 2H), 6.81 (dd, J = 8.79, 2.22 
Hz, 1H), 6.74 (d, J = 1.65 Hz, 1H), 4.30 (s, 2H), 4.08 (d, J = 7.32 Hz, 2H), 3.92 (br, 
1H), 2.29 (hept, J = 6.78 Hz, 1H), 0.69 (d, J = 6.78 Hz, 6H). 
 
4.2.1.37. tert-Butyl 3-methyl-6-nitro-1H-indazole-1-carboxylate (40). Starting 
with compound 39 following the general procedure 9.1, compound 40 was obtained 
as yellow solid, yield 94%. 1H NMR (300 MHz, CDCl3) δ 9.03 (d, J = 1.62 Hz, 1H), 
8.18 (dd, J = 8.61, 2.01 Hz, 1H), 7.78 (dd, J = 8.79, 0.72 Hz, 1H), 2.66 (s, 3H), 1.76 
(s, 9H). 
 
4.2.1.38. 1,3-Dimethyl-6-nitro-1H-indazole (41). Starting with compound 39 




(42). Starting with compound 39 following the general procedure 11, compound 42 
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was obtained as yellow solid, yield 54%. 1H NMR (300 MHz, CDCl3) δ 8.42 (d, J = 
1.47 Hz, 1H), 7.96 (dd, J = 8.79, 1.83 Hz, 1H), 7.72 (d, J = 8.79 Hz, 1H), 4.50 (t, J = 
6.57 Hz, 2H), 2.85 (t, J = 6.42 Hz, 2H), 2.61 (s, 3H), 2.56 (br, 4H), 2.41 (br, 4H), 
2.67 (s, 3H). 
 
4.2.1.40. tert-Butyl (4-(4-(3-methyl-6-nitro-1H-indazol-1-yl)butyl)pyridin-2-
yl)carbamate (43).  Starting with compound 39 following the general procedure 11, 
compound 42 was obtained as yellow solid, yield 76%. 
 
4.2.1.41. tert-Butyl (4-(4-(3-methyl-6-nitro-1H-indazol-1-yl)butyl)pyridin-2-
yl)carbamate (43). Starting with compound 39 following the general procedure 11, 
compound 43 was obtained as yellow solid, yield 57%. 1H NMR (500 MHz, CDCl3) 
δ 8.32 (s, 1H), 8.25 (d, J = 1.50 Hz, 1H), 8.11 (d, J = 5.10 Hz, 1H), 7.93 (dd, J = 8.80, 
1.80 Hz, 1H), 7.75 (s, 1H), 7.70 (d, J = 8.80 Hz, 1H), 6.71 (d, J = 5.10 Hz, 1H), 4.37 
(t, J = 7.05 Hz, 2H), 2.61 (t, J = 7.90 Hz, 2H), 2.58 (s, 3H), 1.95 (quintet, J = 7.50 
Hz, 2H), 1.65 (quintet, J = 7.50 hz, 2H), 1.50 (s, 9H). 
 
4.2.1.42. 2,3-Dimethyl-6-nitro-2H-indazole (44). Starting with compound 39 
following the general procedure 11, compound 43 was obtained as yellow solid, yield 
59%. 
 
4.2.1.43. tert-Butyl 6-amino-3-methyl-1H-indazole-1-carboxylate (45). 
Starting with compound 40 following the general procedure 5.2, compound 45 was 
obtained as red solid, yield 98%. 1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 8.43 Hz, 
1H), 7.37 (s, 1H), 6.65 (dd, J = 8.43, 2.01 Hz, 1H), 3.99 (s, 2H), 2.50 (s, 3H), 1.70 (s, 
9H). 
 
4.2.1.44. 1,3-Dimethyl-1H-indazol-6-amine (46). Starting with compound 41 




(47). Starting with compound 42 following the general procedure 5.2, compound 47 
was obtained as red solid, yield 83%. 1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 9.15 
Hz, 1H), 6.54-6.51 (m, 2H), 4.03 (t, J = 7.32 Hz, 2H), 3.84 (br, 2H), 2.81 (t, J = 7.68 
Hz, 2H), 2.58 (br, 4h), 2.47 (br, 7H), 2.82 (s, 3H). 
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4.2.1.46. tert-Butyl (4-(4-(6-amino-3-methyl-1H-indazol-1-yl)butyl)pyridin-
2-yl)carbamate (48). Starting with compound 43 following the general procedure 5.2, 
compound 48 was obtained as red solid, yield 78%. 1H NMR (300 MHz, CDCl3) δ 
8.32 (s, 1H), 8.11 (d, J = 4.95 Hz, 1H), 7.36 (d, J = 8.43 Hz, 1H), 7.76 (s, 1H), 6.72 
(d, J = 5.13 Hz, 1H), 6.51 (dd, J = 8.61, 1.83 Hz, 1H), 6.42 (d, J = 1.80 Hz, 1H), 4.17 
(t, J = 6.96 Hz, 2H), 3.85 (br, 2H), 2.64 (t, J = 7.50 Hz, 2H), 2.47 (s, 3H), 1.89 (quintet, 
J = 7.32 Hz, 2H), 1.70-1.60 (m, 4H), 1.43 (s, 9H). 
 
4.2.1.47. 2,3-Dimethyl-2H-indazol-6-amine (49). Starting with compound 44 
following the general procedure 5.2, compound 49 was obtained as red solid, yield 
89%. 1H NMR (300 MHz, CDCl3) δ 7.34 (dd, J = 8.79, 0.75 Hz, 1H), 6.72 (dd, J = 




carboxylate (50). Starting with compound 45 following the general procedure 4.1, 
compound 50 was obtained as pale semi solid, yield 62%. 1H NMR (300 MHz, CDCl3) 
δ 7.98 (d, J = 1.47 Hz, 1H), 7.88-7.85 (m, 2H), 7.71-7.51 (m, 3H), 7.46 (s, 1H), 7.20 
(dd, J = 1.83, 8.61 Hz, 1H), 2.53 (s, 3H), 1.69 (m, 9H). 
 
4.2.1.49. N-(1,3-Dimethyl-1H-indazol-6-yl)-2-nitrobenzenesulfonamide (51). 
Starting with compound 46 following the general procedure 4.1, compound 51 was 
obtained as pale red solid, yield 74%. 1H NMR (300 MHz, CDCl3) δ 7.88-7.79 (m, 
2H), 7.70-7.64 (m, 1H), 7.56-7.45 (m, 2H), 7.38-7.30 (m, 1H), 7.28 (d, J = 1.11 Hz, 
1H), 6.84 (d, J = 1.83 Hz, 1H), 8.43 Hz, 1H), 3.95 (s, 3H), 2.49 (s, 3H) 
 
4.2.1.50. tert-Butyl 6-((N-(cyclopentylmethyl)-2-nitrophenyl)sulfonamido)-3-
methyl-1H-indazole-1-carboxylate (52). Starting with compound 50 following the 
general procedure 08, compound 52 was obtained as yellow solid, yield 63%. 1H 
NMR (300 MHz, CDCl3) δ 7.95 (s,  1H), 7.62-7.55 (m, 3H), 7.48-7.37 (m, 2H), 7.22 
(dd, J = 1.83, 8.43 Hz, 1H), 3.80 (d, J = 7.68 Hz, 2H), 2.57 (s, 3H), 1.94-1.89 (m, 
1H), 1.75-1.70  (m, 2H), 1.66 (s, 9H), 1.59-1.49 (m, 4H), 1.36-1.30 (m, 2H). 
 
4.2.1.51. N-(Cyclopentylmethyl)-N-(1,3-dimethyl-1H-indazol-6-yl)-2-
nitrobenzenesulfonamide (53). Starting with compound 51 following the general 
procedure 08, compound 53 was obtained as yellow solid, yield 56%. 1H NMR (300 
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MHz, CDCl3) δ 7.61-7.59 (m, 2H), 7.51 (d, J = 8.43 Hz, 1H), 7.46-7.32 (m, 2H), 6.85 
(dd, J = 1.65, 8.58 Hz, 1H), 6.36 (br, 1H), 3.96 (s, 3H), 3.79 (d, J = 7.68 Hz, 2H), 
2.53 (s, 3H), 1.93-1.88 (m, 1H), 1.75-1.60 (m, 4H), 1.55 (s, 9H), 1.52-1.42 (m, 2H), 
1.40-1.30 (m, 2H). 
 
4.2.1.52. tert-Butyl 6-(cyclohexylamino)-3-methyl-1H-indazole-1-carboxylate 
(54). Starting with compound 45 following the general procedure 3, compound 54 
was obtained as red solid, yield 59%. 1H NMR (300 MHz, CDCl3) δ 7.34 (d, J = 8.43 
Hz, 1H), 7.18 (s, 1H), 6.55 (dd, J = 2.01, 8.58 Hz, 1H), 3.93 (br, NH), 3.37-3.30 (m, 
1H), 2.47 (s, 3H), 2.12-2.09 (m, 2H), 1.80-1.76 (m, 2H), 1.70 (s, 9H), 1.68-1.61 (m, 
1H), 1.42-1.30 (m, 2H), 1.25-1.18 (m, 3H). 
 
4.2.1.53. tert-Butyl 6-((cyclopentylmethyl)amino)-3-methyl-1H-indazole-1-
carboxylate (55). Starting with compound 52 following the general procedure 4.2, 
compound 55 was obtained as pale yellow solid, yield 68%. 1H NMR (300 MHz, 
CDCl3) δ 7.35 (d, J = 8.61 Hz, 1H), 7.22 (s, 1H), 6.59 (dd, J = 2.01, 8.61 Hz, 1H), 
4.05 (s, NH),  3.12 (d, J = 5.13 Hz, 2H), 2.48 (s, 3H), 2.25-2.15 (m, 1H), 1.99-1.83 
(m, 2H), 1.70 (s, 9H), 1.68-1.60 (m, 4H), 1.32-1.23 (m, 2H). 
 
4.2.1.54. tert-Butyl 6-(4-fluorobenzylamino)-3-methyl-1H-indazole-1-
carboxylate (56). Starting with compound 45 following the general procedure 3, 
compound 56 was obtained as red solid, yield 75%. 1H NMR (300MHz, CDCl3) δ 
7.38 (d, J = 8.43 Hz, 1H), 7.37-7.32 (m, 2H), 7.28 (s, 1H), 7.08-7.01 (m, 2H), 6.01 
(dd, J = 8.91, 2.31 Hz, 1H), 4.38 (s, 2H), 2.49 (s, 3H), 1.66 (s, 9H).   
 
4.2.1.55. tert-Butyl 3-methyl-6-(pyridin-3-ylmethylamino)-1H-indazole-1-
carboxylate (57). Starting with compound 45 following the general procedure 3, 
compound 57 was obtained as red solid, yield 61%. 1H NMR (300 MHz, CDCl3) δ 
8.66 (d, J = 2.01 Hz, 1H), 8.56 (dd, J = 4.74, 1.65 Hz, 1H), 7.71 (td, J = 8.07 Hz, 1H), 
7.39 (d, J = 8.43 Hz, 1H), 7.31-7.28 (m, 1H), 6.63 (dd, J = 8.43, 2.01 Hz, 1H), 4.46 
(s, 2H), 4.41 (br, 1H), 2.50 (s, 3H), 1.65 (s, 9H). 
 
4.2.1.56. tert-Butyl 3-methyl-6-((1-methylpiperidin-4-yl)amino)-1H-indazole-
1-carboxylate (58). Starting with compound 45 following the general procedure 3, 
compound 58 was obtained as red solid, yield 61%. 
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4.2.1.57. N-Cyclohexyl-1,3-dimethyl-1H-indazol-6-amine (59). Starting with 
compound 46 following the general procedure 3, compound 59 was obtained as red 
solid, yield 53%. 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.60 Hz, 1H), 6.41 (dd, 
J = 1.84, 8.60 Hz, 1H), 6.23 (d, J = 1.60 Hz, 1H), 3.84 (s, 3H), 3.35-3.28 (m, 1H), 
2.43 (s, 3H), 2.11-2.07 (m, 2H), 1.79-1.74 (m, 2H), 1.68-1.63 (m, 1H), 1.45-1.34 (m, 
2H), 1.28-1.13 (m, 3H). 
 
4.2.1.58. N-(Cyclopentylmethyl)-1,3-dimethyl-1H-indazol-6-amine (60). 
Starting with compound 53 following the general procedure 4.2, compound 60 was 
obtained as pale yellow solid, yield 86%. 1H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 
8.61 Hz, 1H), 6.47 (dd, J = 1.83, 8.61 Hz, 1H), 6.25 (d, J = 1.65 Hz, 1H), 3.87 (s, 
3H), 3.10 (d, J = 7.32 Hz, 2H), 2.46 (s, 3H), 2.26-2.16 (m, 1H), 1.89-1.81 (m, 2H), 
1.69-1.58 (m, 4H), 1.34-1.23 (m, 2H).  
 
4.2.1.59. N-(4-Fluorobenzyl)-1,3-dimethyl-1H-indazol-6-amine (61). Starting 
with compound 46 following the general procedure 3, compound 61 was obtained as 
red solid, yield 92%. 1H NMR (300 MHz, CDCl3) δ 7.40-7.34 (m, 3H), 7.08-7.01 (m, 
2H), 6.49 (dd, J = 8.61, 1.83 Hz, 1H), 6.27 (d, J = 1.65 Hz, 1H), 4.39 (s, 2H), 4.23 (s, 
1H), 3.84 (s, 3H), 2.47 (s, 3H). 
 
4.2.1.60. 1,3-Dimethyl-N-(pyridin-3-ylmethyl)-1H-indazol-6-amine (62). 
Starting with compound 46 following the general procedure 3, compound 62 was 
obtained as red solid, yield 88%.  1H NMR (300 MHz, CDCl3) δ 8.68 (d, J = 1.83 Hz, 
1H), 8.55 (dd, J = 4.95, 1.65 Hz, 1H), 7.73 (dt-like, J = 7.68 Hz, 1H), 7.40 (d, J = 
8.61 Hz, 1H), 7.29 (dd, J = 8.43, 4.77 Hz, 1H), 6.51 (dd, J = 8.41, 2.04 Hz, 1H), 6.27 
(d, J = 1.83 Hz, 1H), 4.44 (d, J = 4.59 Hz, 1H), 4.27 (s, 1H), 3.83 (s, 3H), 2.47 (s, 
3H). 
 
4.2.1.61. 1,3-Dimethyl-N-(1-methylpiperidin-4-yl)-1H-indazol-6-amine (63). 
Starting with compound 46 following the general procedure 3, compound 63 was 
obtained as red solid, yield 71%.   
 
4.2.1.62. N-Cyclobutyl-1,3-dimethyl-1H-indazol-6-amine (64). Starting with 
compound 46 following the general procedure 3, compound 64 was obtained as red 
solid, yield 76%. 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.61 Hz, 1H), 6.41 (dd, 
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J = 8.61, 1.65 Hz, 1H), 6.18 (d, J = 1.65 Hz, 1H), 4.02-3.95 (m, 1H), 3.87 (s, 3H), 
2.52-2.46 (m, 2H), 2.46 (s, 3H), 1.90-1.82 (m, 2H). 
 
4.2.1.63. N-Cyclopentyl-1,3-dimethyl-1H-indazol-6-amine (65). Starting with 
compound 46 following the general procedure 3, compound 65 was obtained as red 
solid, yield 81%. 1H NMR (300 MHz, CDCl3) δ 7.34 (d, J = 8.61 Hz, 1H), 6.42 (dd, 
J = 8.58, 1.83 Hz, 1H), 6.26 (d, J = 1.65 Hz, 1H), 3.92-3.81 (m, 1H), 3.87 (s, 3H), 
2.46 (s, 3H), 2.11-2.03 (m, 2H), 1.81-1.43 (m, 6H). 
 
4.2.1.64. N-(4-Fluorobenzyl)-2,3-dimethyl-2H-indazol-6-amine (66). Starting 
with compound 49 following the general procedure 3, compound 66 was obtained as 
red solid, yield: 94%. 1H NMR (300 MHz, CDCl3) δ 7.38-34 (m, 2H), 7.32 (dd, J = 
8.79, 0.54 Hz, 1H), 7.04-7.69 (m, 2H), 6.52 (s, 1H), 6.49 (dd, J = 8.61, 1.83 Hz, 1H), 
4.33 (s, 2H), 4.07 (s, 1H), 3.97 (s, 3H), 2.51 (s, 3H). 
 
4.2.1.65. 2,3-Dimethyl-N-(pyridin-3-ylmethyl)-2H-indazol-6-amine (67). 
Starting with compound 49 following the general procedure 3, compound 67 was 
obtained as white solid, yield 87%. 1H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.51 
(d, J = 4.77 Hz, 1H), 7.73 (d, J = 7.68 Hz, 1H), 7.33 (d, J = 8.61 Hz, 1H), 7.26-7.23 
(m, 1H), 6.53-6.50 (m, 2H), 4.40 (s, 2H), 4.12 (br, 1H), 3.97 (s, 3H), 2.51 (s, 3H). 
 
4.2.1.66. tert-Butyl 6-nitro-1H-indazole-1-carboxylate (69). Starting with 
compound 68 following the general procedure 9.1, compound 69 was obtained as 
white solid, yield 78%.  
 
4.2.1.67. 1-Methyl-6-nitro-1H-indazole (70). Starting with compound 68 
following the general procedure 11, compound 70 was obtained as white solid, yield 
61%. 
 
4.2.1.68. 6-Nitro-1-propyl-1H-indazole (71). Starting with compound 68 
following the general procedure 11, compound 71 was obtained as yellow solid, yield 
81%. 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 8.10 (d, J = 0.72 Hz, 1H), 8.00 (dd, 
J = 1.88, 8.96 Hz, 1H), 7.82 (d, J = 9.04 Hz, 1H), 4.43 (t, J = 7.08 Hz, 2H), 2.03-1.94 
(m, 2H), 0.95 (t, J = 7.44 Hz, 3H). 
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4.2.1.69. tert-Butyl 6-amino-1H-indazole-1-carboxylate (72). Starting with 
compound 69 following the general procedure 5.2, compound 72 was obtained as red 
solid, yield 88%. 
 
4.2.1.70. 1-Methyl-1H-indazol-6-amine (73). Starting with compound 70 
following the general procedure 5.2, compound 73 was obtained as red solid, yield 
85%. 
 
4.2.1.71. 1-Propyl-1H-indazol-6-amine (74). Starting with compound 71 
following the general procedure 5.2, compound 74 was obtained as red solid, yield 
83%. 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 0.75 Hz, 1H), 7.42 (d, J = 9.18 Hz, 
1H), 6.50-6.4 (m, 2H), 4.15 (t, J = 6.96 Hz, 2H), 1.90-1.78 (m, 2H), 0.87 (t, J = 7.32 
Hz, 3H). 
 
4.2.1.72. tert-Butyl 6-(4-fluorobenzylamino)-1H-indazole-1-carboxylate (75). 
Starting with compound 72 following the general procedure 3, compound 75 was 
obtained as red solid, yield 84%. 1H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 0.54 Hz, 
1H), 7.46 (d, J = 8.61 Hz, 1H), 7.37-7.33 (m, 3H), 7.07-7.02 (m, 2H), 6.63 (dd, J = 
8.58, 2.01 Hz, 1H), 4.39 (s, 2H), 1.67 (s, 9H). 
 
4.2.1.73. N-(4-Fluorobenzyl)-1-methyl-1H-indazol-6-amine (76). Starting 
with compound 73 following the general procedure 3, compound 76 was obtained as 
red solid, yield 57%. 
 
4.2.1.74. N-(4-Fluorobenzyl)-1-propyl-1H-indazol-6-amine (77). Starting 
with compound 74 following the general procedure 3, compound 77 was obtained as 
red solid, yield 51%. 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 0.72 Hz, 1H), 7.46 
(d, J = 8.61 Hz, 1H), 7.37 (dd, J = 5.49, 8.79 Hz, 2H), 7.05 (t, J = 8.61 Hz, 2H), 6.52 
(dd, J = 2.04, 8.61 Hz, 1H), 6.3 (s, 1H), 4.34 (s, 2H), 4.17 (t, J = 6.96 Hz, 2H), 1.88-
1.79 (m, 2H), 0.90 (t, J = 7.32 Hz, 3H). 
 
4.2.1.75. N-Allyl-2-chloro-4-nitroaniline (79). Starting with compound 78 
following the general procedure 3, compound 79 was obtained as yellow solid, yield 
55%. 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 2.58 Hz, 1H), 8.06 (dd, J = 2.55, 
9.15 Hz, 1H), 6.60 (d, J = 8.97 Hz, 1H), 5.96-5.84 (m, 1H), 5.30-5.23 (m, 2H), 3.96-
3.91 (m, 2H). 
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4.2.1.76. tert-Butyl allyl(2-chloro-4-nitrophenyl)carbamate (80). Starting 
with compound 79 following the general procedure 9.1, compound 80 was obtained 
as white solid, yield 69%. 1H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 2.35 Hz, 1H), 
8.10 (dd, J = 2.40, 8.65 Hz, 1H), 7.35 (s, 1H), 5.89-5.81 (m, 1H), 5.10-5.04 (m, 2H), 
4.36 (br, 1H), 4.02 (br, 1H), 1.34 (s, 9H). 
 
4.2.1.77. tert-Butyl 3-methyl-5-nitro-1H-indole-1-carboxylate (81). Starting 
with compound 80 following the general procedure 6, compound 81 was obtained as 
yellow solid, yield 24%. 1H NMR (300 MHz, CDCl3) δ 8.51 (s, Hz, 1H), 8.08 (dd, J 
= 2.04, 8.40 Hz, 1H), 7.31 (d, J = 8.97 Hz, 1H), 7.05 (s, 1H), 2.31 (d, J = 0.90 Hz, 
3H), 1.97 (s, 9H). 
 
4.2.1.78. 1-Methyl-5-nitro-1H-benzo[d]imidazole (83). Starting with 
compound 82 following the general procedure 3, compound 83 was obtained as 
yellow solid, yield 35%. 
 
4.2.1.79. 1,3-Dimethyl-5-nitro-1H-indole (84). Starting with compound 81 
following the general procedure 9.2 and 11, compound 84 was obtained as yellow 
solid, yield 76%. 1H NMR (300 MHz, CDCl3) δ 8.52 (d, J = 2.19 Hz, 1H), 8.11 (dd, 
J = 2.22 Hz, 1H), 7.26 (d, J = 8.40 Hz, 1H), 6.94 (s, 1H), 3.77 (s, 3H), 2.33 (d, J= 
1.08 Hz, 3H). 
 
4.2.1.80. 5-Nitro-1-propyl-1H-indole (85). Starting with compound 82 
following the general procedure 11, compound 85 was obtained as white solid, yield 
73%. 1H NMR (300 MHz, CDCl3) δ 8.59 (d, J = 2.19 Hz, 1H), 8.13 (dd, J = 2.19, 
8.97 Hz, 1H), 7.37 (d, J = 8.97 Hz, 1H), 7.25 (d, J = 3.30 Hz, 1H), 6.68 (dd, J = 0.90, 
3.30 Hz, 1H), 4.16 (t, J = 7.14 Hz, 2H), 1.95-1.83 (m, 2H), 0.96 (t, J = 7.32 Hz, 3H) 
 
4.2.1.81. 1-Methyl-1H-indol-5-amine (86). Starting with compound 83 
following the general procedure 5.2, compound 86 was obtained as red solid, yield 
93%. 1H NMR (300 MHz, CDCl3) δ 7.12 (d, J = 8.43 Hz, 1H), 6.95 (dd, J = 3.12 Hz, 
1H), 6.69 (dd, J = 2.19, 8.61 Hz, 1H), 6.27 (dd, J = 0.72, 2.91 Hz, 1H) 
 
4.2.1.82. 1,3-Dimethyl-1H-indol-5-amine (87). Starting with compound 84 
following the general procedure 5.2, compound 87 was obtained as red solid, yield 
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91%. 1H NMR (300 MHz, CDCl3) δ 7.07 (d, J = 8.43 Hz, 1H), 6.84 (d, J = 2.19 Hz, 
1H), 6.72 (s, 1H), 6.68 (dd, J = 2.01, 8.43 Hz, 1H), 3.64 (s, 3H), 2.22 (s, 3H). 
 
4.2.1.83. 1-Propyl-1H-indol-5-amine (88). Starting with compound 85 
following the general procedure 5.2, compound 88 was obtained as red semi solid, 
yield 95%. 1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.61 Hz, 1H), 7.01 (d, J = 3.12 
Hz, 1H), 6.93 (dd, J = 3.60, 1.83 Hz, 1H), 6.68 (dd, J = 2.19, 8.61 Hz, 1H), 6.29 (dd, 
J = 0.72, 3.12 Hz, 1H), 4.03 (t, J = 7.14 Hz, 2H), 1.89-1.77 (m, 2H), 0.93 (t, J = 7.32 
Hz, 3H). 
 
4.2.1.84. N-(1-Methyl-1H-indol-5-yl)-2-nitrobenzenesulfonamide (89). 
Starting with compound 86 following the general procedure 4.1, compound 89 was 
obtained as red solid, yield 81%. 1H NMR (300 MHz, CDCl3) δ 7.79 (dd, J = 1.08, 
8.04 Hz, 1H), 7.64 (dd, J = 1.29, 7.71 Hz, 1H), 7.60 (td, Jd = 1.47, Jt = 7.86 Hz, 1H), 
7.42 (td, Jd = 1.29, Jt = 7.68 Hz, 1H), 7.34 (d, J = 2.19 Hz, 1H), 7.15 (br, NH), 7.12 
(d, J = 8.61 Hz, 1H), 9.99-6.93 (m, 2H), 6.33 (d, J = 3.12 Hz, 1H), 3.76 (s, 3H). 
 
4.2.1.85. N-(1,3-Dimethyl-1H-indol-5-yl)-2-nitrobenzenesulfonamide (90). 
Starting with compound 87 following the general procedure 4.1, compound 90 was 
obtained as pale solid, yield 78%. 1H (300 MHz, CDCl3) δ 7.85 (dd, J = 1.29, 8.07 
Hz, 1H), 7.70 (td, Jd = 1.47 Hz, Jt = 7.89 Hz, 1H), 7.63 (dd, J = 1.47, 7.71 Hz, 1H), 
7.48 (td, Jd = 1.26 Hz, Jt = 7.68 Hz, 1H), 7.32 (d, J = 2.01 Hz, 1H), 7.20 (s, 1H), 7.10 
(d, J = 8.58 Hz, 1H), 6.96 (dd, J = 2.19, 8.61 Hz, 1H), 6.80 (s, 1H), 3.66 (s, 3H), 2.20 
(s, 3H). 
 
4.2.1.86. 2-Nitro-N-(1-propyl-1H-indol-5-yl)benzenesulfonamide (91). 
Starting with compound 88 following the general procedure 4.1, compound 91 was 
obtained as yellow solid, yield 75%. 1H NMR (300 MHz, CDCl3) δ 7.87 (dd, J = 1.29, 
7.86 Hz, 1H), 7.74 (dd, J = 1.44, 7.86 Hz, 1H), 7.67 (td, Jd = 1.47 Hz, Jt = 7.71 Hz, 
1H), 7.51 (td, Jd = 1.29 Hz, Jt = 7.71 Hz, 1H), 7.40 (d, J = 2.01 Hz, 1H), 7.21 (d, J = 
8.79 Hz, 1H), 7.10 (d, J = 3.12 Hz, 1H), 7.02 (dd, J = 2.01, 8.61 Hz, 1H), 6.40 (dd, J 




nitrobenzenesulfonamide (92). Starting with compound 89 following the general 
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procedure 08, compound 92 was obtained as yellow solid, yield 63%. 1H NMR (300 
MHz, CDCl3) δ 7.56-7.51 (m, 2H), 7.44 (d, J = 2.04 Hz, 1H), 7.39-7.29 (m, 2H), 7.20 
(d, J = 8.79 Hz, 1H), 7.06 (d, J = 3.12 Hz, 1H), 7.01 (dd, J = 2.01, 8.79 Hz, 1H), 6.4 
(d, J = 2.94 Hz, 1H), 3.76 (s, 3H), 3.72 (d, J = 7.68 Hz, 2H), 1.94-1.84 (m, 1H), 1.68-
1.57 (m, 4H), .47-1.42 (m, 2H), 1.36-1.26 (m, 2H).   
 
4.2.1.88. N-(Cyclopentylmethyl)-N-(1,3-dimethyl-1H-indol-5-yl)-2-
nitrobenzenesulfonamide (93). Starting with compound 90 following the general 
procedure 08, compound 93 was obtained asred solid, yield 67%. 1H NMR (300 MHz, 
CDCl3) δ 7.57-7.55 (m, 2H), 7.39-7.29 (m, 3H), 7.14 (d, J = 8.58 Hz, 1H), 6.97 (dd, 
J = 2.01, 8.79 Hz, 1H), 6.82 (s, 1H), 3.72 (d, J = 7.68 Hz, 2H), 3.69 (s, 3H), 2.20 (d, 




yl)benzenesulfonamide (94). Starting with compound 91 following the general 
procedure 08, compound 94 was obtained as white solid, yield 49%. 1H NMR (300 
MHz, CDCl3) δ 7.51-7.47 (m, 2H), 7.37-7.24 (m, 3H), 7.16 (d, J = 8.61 Hz, 1H), 7.06 
(d, J = 3.12 Hz, 1H), 6.93 (dd, J = 2.01, 8.61 Hz, 1H), 6.35 (d, J = 3.09 Hz, 1H), 4.00 
(t, J = 6.96 Hz, 2H), 3.66 (d, J = 7.68 Hz, 2H), 1.86-1.73 (m, 1H), 1.63-1.53 (m, 4H), 
1.43-1.39 (m, 2H), .29-1.26 (m, 2H), 1.21 (t, J = 7.14 Hz, 2H), 0.89 (t, J = 7.32 Hz, 
3H).   
 
4.2.1.90. N-Cyclohexyl-1-methyl-1H-indol-5-amine (95). Starting with 
compound 86 following the general procedure 3, compound 95 was obtained as red 
solid, yield 41%. 1H NMR (300 MHz, CDCl3) δ 7.06 (d, J = 8.61 Hz, 1H), 6.87 (d, J 
= 2.94 Hz, 1H), 6.77 (d, J = 2.19 Hz, 1H), 6.59 (dd, J = 2.22, 8.91 Hz, 1H), 6.22 (d, 
J = 2.37 Hz, 1H), 3.64 (s, 3H), 3.23-3.14 (m, 1H), 2.05-1.97 (m, 2H), .72-.67 (m, 2H0, 
1.60-1.56 (m, 1H), 1.37-1.24 (m, 2H), 1.20-1.01 (m, 3H). 
 
4.2.1.91. N-(Cyclopentylmethyl)-1-methyl-1H-indol-5-amine (96). Starting 
with compound 92following the general procedure 4.2, compound 96 was obtained 
as white solid, yield 89%. 1H NMR (400 MHz, CDCl3) δ 7.12 (d, J = 8.72 Hz, 1H), 
6.92 (d, J = 3.0 Hz, 1H), 6.82 (d, J = 2.12 Hz, 2H), 6.65 (dd, J = 2.12, 10.80 Hz, 1H), 
6.28 (d, J = 2.88 Hz, 1H), 3.70 (s, 3H), 3.06 (d, J = 7.16 Hz, 2H), 2.21-2.14 (m, 
1H), .86-.78 (m, 2H), 1.66-.49 (m, 4H), 1.31-1.22 (m, 2H). 
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4.2.1.92. N-(4-Fluorobenzyl)-1-methyl-1H-indol-5-amine (97). Starting with 
compound 86 following the general procedure 3, compound 97 was obtained as red 
solid, yield 45%. 1H NMR (300 MHz, CDCl3) δ 7.28 (dd, J = 5.52, 8.61 Hz, 2H), 6.97 
(t, J = 8.58 Hz, 2H), 6.67 (s, NH), 6.52-6.46 (m, 2H), 6.40-6.33 (m, 2H), 4.15 (s, 2H), 
3.66 (s, 3H). 
 
4.2.1.93. N-Cyclohexyl-1,3-dimethyl-1H-indol-5-amine (98). Starting with 
compound 87 following the general procedure 3, compound 98 was obtained as red 
solid, yield 58%. 1H NMR (300 MHz, CDCl3) δ 7.07 (d, J = 8.61 Hz, 1H), 6.74 (d, J 
= 2.04 Hz, 1H), 6.70 (s, 1H), 6.64 (dd, J = 2.22, 8.61 Hz, 1H), 3.64 (s, 3H), 3.31-3.23 
(m, 1H), 2.23 (d, J = 0.93 Hz, 3H), 2.10-2.07 (m, 2H), 1.76-1.72 (m, 2H), 1.65-1.60 
(m, 1H), 1.42-1.30 (m, 2H), 1.19-1.07 (m, 3H) 
 
4.2.1.94. N-(Cyclopentylmethyl)-1,3-dimethyl-1H-indol-5-amine (99). 
Starting with compound 93 following the general procedure 4.2, compound 99 was 
obtained as white solid, yield 80%. 1H NMR (300 MHz, CDCl3) δ 7.08 (d, J = 8.61 
Hz, 1H), 6.75 (d, J = 2.01 Hz, 1H), 6.70 (s, 1H), 6.67 (dd, J = 2.01, 8.61 Hz, 1H), 
3.64 (s, 3H), 3.09 (d, J = 7.14 Hz, 2H), 2.24 (s, 3H), 2.21-2.13 (m, 1H), 1.84-1.78 (m, 
2H), 1.66-1.52 (m, 4H), 1.31-1.23 (m, 2H). 
 
4.2.1.95. N-(4-Fluorobenzyl)-1,3-dimethyl-1H-indol-5-amine (100). Starting 
with compound 87 following the general procedure 3, compound 100 was obtained 
as red solid, yield 63%. 1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J = 5.49, 8.61 Hz, 
2H), 7.09 (d, J = 8.61 Hz, 1H), 6.99 (t, J = 8.64 Hz, 2H), 6.86 (s, 1H), 6.73 (s, 1H), 
4.33 (s, 2H), 3.65 (s, 3H), 2.20 (s, 3H). 
 
4.2.1.96. N-Cyclohexyl-1-propyl-1H-indol-5-amine (101). Starting with 
compound 88 following the general procedure 3, compound 101 was obtained as red 
solid, yield 54%. 1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.61 Hz, 1H), 6.99 (d, J 
= 3.09 Hz, 1H), 6.84 (d, J = 2.19 Hz, 1H), 6.63 (dd, J = 2.40, 8.79 Hz, 1H), 6.29 (d, 
J = 3.12 Hz, 1H), 4.03 (t, J = 7.14 Hz, 2H), 3.28-3.21 (m, 1H), 2.69 (t, J = 4.56 Hz, 
2H), 2.12-2.04 (m, 2H), 1.89-1.77 (m, 2H), 1.67-1.59 (m, 2H), 1.40-1.23 (m, 2H), 
1.19-1.09 (m, 3H), 0.96-0.86 (m, 5H). 
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4.2.1.97. N-(Cyclopentylmethyl)-1-propyl-1H-indol-5-amine (102). Starting 
with compound 94 following the general procedure 4.2, compound 102 was obtained 
as white solid, yield 76%. 1H NMR (300 MHz, CDCl3) δ 7.09 (d, J = 8.58 Hz, 1H), 
6.93 (d, J = 2.97 Hz, 1H), 6.76 (d, J = 2.01 Hz, 1H), 6.58 (dd, J = 2.19, 8.79 Hz, 1H), 
6.23 (dd, J = 0.75, 2.94 Hz, 1H), 3.95 (t, J = 6.96 Hz, 2H), 3.00 (d, J = 7.14 Hz, 2H), 
2.17-2.05 (m, 1H), 1.82-1.70 (m, 4H), 1.60-1.45 (m, 4H), 1.24-1.16 (m, 2H), 0.86 (t, 
J = 7.32 Hz, 3H). 
 
4.2.1.98. N-(4-Fluorobenzyl)-1-propyl-1H-indol-5-amine (103). Starting with 
compound 88 following the general procedure 3, compound 103 was obtained as red 
solid, yield 70%. 1H NMR (300 MHz, CDCl3) δ 7.33 (dd, J = 5.67, 8.61 Hz, 2H), 7.10 
(d, J = 8.79 Hz, 1H), 6.97-6.92 (m, 3H), 6.76 (d, J = 2.19 Hz, 1H), 6.60 (dd, J = 2.37, 
8.61 Hz, 1H), 6.22 (d, J = 2.37 Hz, 1H), 4.26 (s, 2H), 3.96 (t, J = 6.96 Hz, 2H), 1.80-
1.73 (m, 2H), 0.86 (t, J = 7.32 Hz, 3H). 
 
4.2.1.99. 2-(Hydroxymethyl)-5-nitrophenol (105). Starting with compound 
104 following the general procedure 5.1, compound 105 was obtained as yellow solid, 
yield 77%. 1H NMR (300MHz, CDCl3) δ 7.63 (dd, J = 8.43, 2.19 Hz, 1H), 7.55 (d, J 
= 2.40 Hz, 1H), 7.32 (d, J = 8.43 Hz, 1H), 4.69 (s, 2H). 
 
4.2.1.100. 2-Hydroxy-4-nitrobenzaldehyde (106). Starting with compound 105 
in DCM was added five times molar MnO2. The mixture reaction was stirred 
overnight at room temperature. Then, the solid was filtered off, the filtrate was 
concentrated and purified by silica gel column to get aldehyde derivative 106 was 
obtained as yellow solid, yield 84%. 1H NMR (300MHz, CDCl3) δ 11.13 (s, 1H), 
10.03 (s, 1H), 7.85-7.76 (m, 3H). 
 
4.2.1.101. Ethyl 5-nitrobenzofuran-3-carboxylate (108). Starting with 
compound 106 (1.0 equiv) in DCM was added solution HBF4·OEt2 (1.0 equiv) under 
nitrogen atmosphere at 0 oC, followed by adding dropwise solution of ethyl 
diazoacetate (1.3 equiv). Once gas evolution ceased, the reaction mixture was 
concentrated and added concentrated H2SO4 (about 0.5 mL). After 10 min stirring, 
the mixture was diluted with DCM, quenched with solution bicarbonate. The organic 
layer was collected, dried, concentrated and purified by silica gel column to afford 
ester benzofuran compound as borrow solid, yield: 60%. 1H NMR (500 MHz, CDCl3) 
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δ 8.95 (d, J = 2.50 Hz, 1H), 8.37 (s, 1H), 8.27 (dd, J = 9.10, 2.35 Hz, 1H), 7.62 (d, J 
= 9.10 Hz, 1H), 4.44 (q, J = 7.15 Hz, 2H), 1.44 (t, J = 7.10 Hz, 3H). 
 
4.2.1.102. Ethyl 6-nitrobenzofuran-3-carboxylate (109). Starting with 
compound 107 following the procedure as compound 108 to get product as yellow 
solid, yield 48%. 1H NMR (300 MHz, CDCl3) δ 8.46 (s, 1H), 8.44 (dd, J = 1.83, 0.36 
Hz, 1H), 8.27 (dd, J = 8.61, 2.01 Hz, 1H), 8.18 (d, J = 8.79 Hz, 1H), 4.42 (q, J = 6.96 
Hz, 2H), 1.42 (t, J = 7.14 Hz, 3H). 
4.2.1.103. 3-Methylbenzofuran-5-amine (110). Starting with compound 108 
(1.0 equiv) in toluene was added dropwise solution 1M DIBAL (1.05 equiv) in 
hexane under nitrogen atmosphere at 0 oC. After 2h of stirring at room temperature, 
the mixture was cooled again to 0 oC and taken play Fisher work-up. After work up, 
the solution was concentrated to have alcohol compound and used for next step 
without purification. 
A mixture of alcohol, Ph3P, imidazole and I2 in DCM was stirred for 1 h. Then the 
mixture was loaded directly in silica gel column to get designed iodine derivative.  
The iodine derivative in diethylene glycol was added slowly NaBH4 while stirring. 
Then the mixture was risen up to 40 oC for 2h. After that, the mixture was cooled to 
room temperature, quenched with water, extracted with DCM. The organic layer was 
washed with water and brine, dried and concentrated to get designed product. 
These nitro derivative (1.0 equiv) in ethanol was added 1-2 drops concentrated HCl 
and SnCl2.2H2O (5.0 equiv). The mixture reaction was refluxed for 2h, quenched with 
concentrated carbonate and extracted by EA. The organic layer was washed with 
water, dried with MgSO4, concentrated and used for next step without purification as 
yellow solid, yield 48%. 
 
4.2.1.104. 3-Methylbenzofuran-6-amine (111). Starting with compound 109 
following the procedure of compound 110 to get product as red solid, yield 42%. 1H 
NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.07 Hz, 1H), 7.20 (q, J = 1.29 Hz, 1H), 6.75 
(d, J = 1.83 Hz, 1H), 6.62 (dd, J = 8.04, 1.83 Hz, 1H), 3.69 (brs, 2H), 2.16 (d, J = 
1.29 Hz, 3H). 
 
4.2.1.105. N-Cyclohexyl-3-methylbenzofuran-5-amine (112). Starting with 
compound 110 following the general procedure 03, compound 112 was obtained to 
get product as red solid, yield 42%. 
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4.2.1.106. N-(4-Fluorobenzyl)-3-methylbenzofuran-5-amine (113). Starting 
with compound 110 following the general procedure 03, compound 113 was obtained 
as red solid, yield 53%. 
 
4.2.1.107. N-(4-Fluorobenzyl)-3-methylbenzofuran-6-amine (114). Starting 
with compound 111 following the general procedure 03, compound 114 was obtained 
as red solid, yield 40%. 1H NMR (300 MHz, CDCl3) δ 7.36-7.31 (m, 3H), 7.19 (q, J 
= 1.29 Hz, 1H), 7.04-6.98 (m, 2H), 6.64 (d, J = 2.04 Hz, 1H), 6.61-6.56 (m, 1H), 4.32 
(s, 2H), 4.09 (s, 1H), 2,15 (d, J = 1.29 Hz, 3H). 
 
4.2.1.108. 5-Nitrobenzo[d]oxazolem (117), Starting with compound 115 (5 
mmol) and triethyl orthoformate (15 mL) was refluxed for 4 h. After cooling to room 
temperature, the remaining triethyl orthoformate was removed under reduced 
pressure and the residue was purified by columnchromatography to yield the desired 
substituted benzoxazole as white solid, yield 61%. 1H (300 MHz, DMSO) δ 9.01 (s, 
1H), 8.68 (d, J = 2.19 Hz, 1H), 8.37 (dd, J = 2.19, 8.97 Hz, 1H), 8.04 (d, J = 8.97 Hz, 
1H). 
 
4.2.1.109. 6-Nitrobenzo[d]oxazole (118). Starting with compound 116 (5 mmol) 
and triethyl orthoformate (15 mL) was refluxed for 4 h. After cooling to room 
temperature, the remaining triethyl orthoformate was removed under reduced 
pressure and the residue was purified by columnchromatography to yield the desired 
substituted benzoxazole as white solid, yield 63%.  
 
4.2.1.110. Benzo[d]oxazol-5-amine (121).  Starting with compound 117 
following the general procedure 5.2, compound 121 was obtained to get product as 
red solid, yield 95%. 1H NMR (500 MHz, CDCl3) δ 7.97 (s, 1H), 1.04 (d, J = 8.55 
Hz, 1H), 7.03 (s, 1H), 6.73 (d, J = 8.50 Hz, 1H). 
 
4.2.1.111. Benzo[d]oxazol-6-amine (122). Starting with compound 118 
following the general procedure 5.2, compound 122 was obtained to get product as 
red semi solid, yield 95%. 1H NMR (500 MHz, CDCl3) δ 7.87 (s, 1H), 7.51 (d, J = 
8.50 Hz, 1H), 6.83 (d, J = 2.0 Hz, 1H), 6.70 (dd, J = 2.05, 8.40 Hz, 1H), 3.81 (br, 
2NH)  
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4.2.1.112. Benzo[d]oxazol-5-amine (123). Starting with compound 119 (1.0 
equiv) in ethanol was added 1-2 drops concentrated HCl and SnCl2.2H2O (5.0 equiv). 
The mixture reaction was refluxed for 2h, quenched with concentrated carbonate and 
extracted by EA. The organic layer was washed with water, dried with MgSO4, 
concentrated to obtanined compound 123 as red solid, yield 87%. 
 
4.2.1.113. Benzo[d]thiazol-6-amine (124). Starting with compound 120 (1.0 
equiv) in ethanol was added 1-2 drops concentrated HCl and SnCl2.2H2O (5.0 equiv). 
The mixture reaction was refluxed for 2h, quenched with concentrated carbonate and 
extracted by EA. The organic layer was washed with water, dried with MgSO4, 
concentrated to obtanined compound 124 as red solid, yield 91%. 1H NMR (300MHz, 
DMSO) δ 8.88 (s, 1H), 7.71 (d, J = 8.25 Hz, 1H), 7.12 (s, 1H), 6.81 (d, J = 8.61 Hz, 
1H), 5.40 (s, 2H). 
 
4.2.1.114. N-(Benzo[d]oxazol-5-yl)-2-nitrobenzenesulfonamide (125).  Starting 
with compound 121 following the general procedure 4.1, compound 125 was 
obtained as pale semi solid, yield 71%. 
 
4.2.1.115. N-(Benzo[d]oxazol-6-yl)-2-nitrobenzenesulfonamide (126). Starting 
with compound 122 following the general procedure 4.1, compound 126 was 
obtained as pale semi solid, yield 65%. 
 
4.2.1.116. N-(Benzo[d]thiazol-5-yl)-2-nitrobenzenesulfonamide (127). Starting 
with compound 123 following the general procedure 4.1, compound 127 was 
obtained as red solid, yield 43%. 1H NMR (300 MHz, CDCl3) δ 9.01 (s, 1H), 7.94-
7.82 (m, 4H), 7.68 (td, J = 7.68, 1.44 Hz, 1H), 7.57-7.51 (m, 2H), 7.42-7.38 (dd, J = 
8.61, 2.19 Hz, 1H),  
 
4.2.1.117. N-(Benzo[d]thiazol-6-yl)-2-nitrobenzenesulfonamide (128). Starting 
with compound 123 following the general procedure 4.1, compound 127 was 
obtained as red crude solid. 1H NMR (300 MHz, DMSO) δ 10.96 (br, 1H), 9.29 (s, 
1H), 8.30-8.26 (m, 1H), 8.14-7.76 (m, 5H), 7.29 (dd, J = 8.97. 2.19 Hz, 1H). 
 
4.2.1.118. N-(Benzo[d]oxazol-5-yl)-N-(cyclopentylmethyl)-2-
nitrobenzenesulfonamide (129). Starting with compound 125 following the general 
procedure 8, compound 129 was obtained as white solid, yield 75%. 
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4.2.1.119.  N-(Benzo[d]oxazol-6-yl)-N-(cyclopentylmethyl)-2-
nitrobenzenesulfonamide (130).  Starting with compound 126 following the general 
procedure 8, compound 130 was obtained as white solid, yield 65%. 
 
4.2.1.120. N-(Benzo[d]thiazol-5-yl)-N-(cyclopentylmethyl)-2-
nitrobenzenesulfonamide (131). Starting with compound 127 following the general 
procedure 8, compound 131 was obtained as red solid, yield 89%. 1H NMR (300 MHz, 
CDCl3) δ 9.03 (s, 1H), 7.94 (d, J = 2.37, 1H), 9.13 (d, J = 8.79 Hz, 1H), 7.65-7.58 (m, 
2H), 7.51-7.39 (m, 3H), 3.79 (d, J = 7.68 Hz, 2H), 1.90 (quintet, J = 7.35 Hz, 1H), 
1.66-1.58 (m, 4H), 1.52-1.49 (m, 2H), 1.34-1.23 (m, 2H). 
 
4.2.1.121. N-(Benzo[d]thiazol-6-yl)-N-(cyclopentylmethyl)-2-
nitrobenzenesulfonamide (132). Starting with compound 128 following the general 
procedure 8, compound 132 was obtained as red solid. 1H NMR (300 MHz, CDCl3) 
δ 9.05 (s, 1H), 8.04 (d, J = 8.64 Hz, 1H), 7.95 (d, J = 2.01 Hz, 1H), 7.66-7.59 (m, 
2H), 7.46-7.38 (m, 2H), 7.30 (dd, J = 8.49, 2.01 Hz, 1H), 3.79 (d, J = 7.68 Hz, 2H), 
1.96-1.86 (m, 1H), 1.76-1.65 (m, 4H), 1.52-1.47 (m, 2H), 1.38-1.25 (m, 2H). 
 
4.2.1.122. N-Cyclohexylbenzo[d]oxazol-5-amine (133). Starting with 
compound 121 following the general procedure 3, compound 133 was obtained as 
red solid, yield 43%. 1H (300 MHz, CDCl3) δ 7.90 (s, 1H), 7.27 (d, J = 8.79 Hz, 1H), 
6.87 (d, J = 2.37 Hz, 1H), 6.59 (dd, J = 2.19, 8.61 Hz, 1H), 3.50 (br, NH), 3.23-3.16 
(m, 1H), 2.04-2.00 (m, 2H), 1.73-1.58 (m, 3H), 1.38-1.26 (m, 2H), 1.18-1.02 (m, 3H). 
 
4.2.1.123.  N-(Fyclopentylmethyl)benzo[d]oxazol-5-amine (134). Starting with 
compound 129 following the general procedure 4.2, compound 134 was obtained as 
white solid, yield 43%.  
 
4.2.1.124. N-(4-Fluorobenzyl)benzo[d]oxazol-5-amine (135). Starting with 
compound 121 following the general procedure 3, compound 135 was obtained as 
red solid, yield 56%. 1H NMR (300 MHz, CDCl3) δ 7.96 (s, 1H), 7.36-7.31 (m, 3H), 
7.04 (tt, J = 2.01, 8.79 Hz, 2H), 6.92 (d, J = 2.40 Hz, 1H), 6.70 (dd, J = 2.40, 8.79 Hz, 
1H), 4.31 (s, 2H). 
 
4.2.1.125. N-Cyclohexylbenzo[d]oxazol-6-amine (136). Starting with 
compound 122 following the general procedure 3, compound 136 was obtained as 
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red solid, yield 56%. 1H (300 MHz, CDCl3) δ 7.83 (s, 1H), 7.48 (d, J = 8.61 Hz, 1H), 
6.70 (d, J = 2.19 Hz, 1H), 6.59 (dd, J = 2.19, 8.58 Hz, 1H), 3.28-3.17 (m, 1H), 2.08-
2.00 (m, 2H), 1.79-.63 (m, 3H), 1.43-1.31 (m, 2H), 1.27-1.09 (m, 3H). 
 
4.2.1.126. N-(Cyclopentylmethyl)benzo[d]oxazol-6-amine (137). Starting with 
compound 130 following the general procedure 4.2, compound 137 was obtained as 
white solid, yield 43%.  
 
4.2.1.127. N-(4-Fluorobenzyl)benzo[d]oxazol-6-amine (138), Starting with 
compound 122 following the general procedure 3, compound 138 was obtained as 
pale solid, yield 56%. 1H (300 MHz, CDCl3) δ 7.85 (s, 1H), 7.52 (d, J = 8.61 Hz, 1H), 
7.35 (dd, J = 5.49, 8.61 Hz, 2H), 7.05 (tt, J = 2.01, 8.61 Hz, 2H), 6.71-6.6 (m, 2H), 
4.23 (s, 2H). 
 
4.2.1.128. N-Cyclohexylbenzo[d]thiazol-5-amine (139). Starting with 
compound 123 following the general procedure 3, compound 139 was obtained as 
red solid, yield: 91%. 1H NMR (300MHz, CDCl3) δ 8.88 (s, 1H), 7.64 (d, J = 8.76 
Hz, 1H), 7.29 (d, J = 2.40 Hz, 1H), 6.76 (dd, J = 8.58, 2.19 Hz, 1H), 3.38-3.29 (m, 
1H), 2.15-2.10 (m, 2H), 1.81-1.62 (m, 4H), 1.48-1.12 (m, 4H). 
 
4.2.1.129. N-(Cyclopentylmethyl)benzo[d]thiazol-5-amine (140). Starting with 
compound 131 following the general procedure 4.2, compound 140 was obtained as 
red solid, yield 47%. 1H NMR (300 MHz, CDCl3) δ 8.89 (s, 1H), 7.66 (d, J = 8.58 
Hz, 1H), 7.29 (d, J = 2.37 Hz, 1H), 6.79 (dd, J = 8.61, 2.40 Hz, 1H), 3.87 (s, 1H), 
3.11 (d, J = 7.14 Hz, 2H), 2.28-2.15 (m, 1H), 1.89-1.80 (m, 2H), 1.69-1.54 (m, 4H), 
1.33-1.25 (m, 2H).  
 
4.2.1.130. N-(4-Fluorobenzyl)benzo[d]thiazol-5-amine (141). Starting with 
compound 123 following the general procedure 3, compound 141 was obtained as 
red solid, yield 91%. 1H NMR (300 MHz, CDCl3) δ 8.89 (s, 1H), 7.68 (d, J = 8.61 
Hz, 1H), 7.39-7.35 (m, 2H), 7.29 (d, J = 2.19 Hz, 1H), 7.07-7.00 (m, 2H), 6.82 (dd, 
J = 8.61, 2.37 Hz, 1H), 4.39 (s, 2H), 4.25 (s, 1H). 
 
4.2.1.131. N-Cyclohexylbenzo[d]thiazol-6-amine (142). Starting with 
compound 124 following the general procedure 3, compound 142 was obtained as 
red solid, yield 18%. 1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.85 (d, J = 8.97 
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Hz, 1H), 7.02 (d, J = 2.22 Hz, 1H), 6.76 (dd, J = 8.79, 2.4 Hz, 1H), 3.35-3.26 (m, 1H), 
2.11-2.07 (m, 2H), 1.80-1.13 (m, 8H). 
 
4.2.1.132. N-(Cyclopentylmethyl)benzo[d]thiazol-6-amine (143). Starting with 
compound 132 following the general procedure 4.2, compound 143 was obtained as 
red solid, yield 70%. 1H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.84 (d, J = 8.79 
Hz, 1H), 7.00 (d, J = 2.37 Hz, 1H), 6.77 (dd, J = 8.76, 2.37 Hz, 1H), 3.88 (s, 1H), 
3.06 (d, J = 7.14 Hz, 2H), 2.18 (hept, J = 7.50 Hz, 1H), 1.88-1.78 (m, 2H), 1.67-1.51 
(m, 4H), 1.30-1.22 (m, 2H). 
 
4.2.1.133. N-(4-Fluorobenzyl)benzo[d]thiazol-6-amine (144). Starting with 
compound 124 following the general procedure 3, compound 144 was obtained as 
red solid, yield 27%. 1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 7.89 (d, J = 8.79 
Hz, 1H), 7.38-7.32 (m, 2H), 7.08-7.02 (m, 3H), 6.84 (dd, J = 8.79, 2.40 Hz, 1H), 4.37 
(s, 2H), 4.28 (s, 1H). 
 
4.2.1.134. tert-Butyl 3-methyl-5-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-1H-indazole-1-carboxylate (145). Starting with compound 09 
following the general procedure 10, compound 145 was obtained as white solid, yield 
50%. 1H (300 MHz, CDCl3) δ 7.98-7.90 (m, 3H), 7.45 (s, 1H), 7.22 (dd, J = 1.83, 
8.97 Hz, 1H), 6.79 (s, 1H), 5.84 (t, J = 6.03 Hz, NH), 4.00 (t, J = 6.75 Hz, 2H), 3.26 




yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (146).  Starting with 
compound 18 following the general procedure 10, compound 146 was obtained as 
white semi solid, yield 56%. 1H (500 MHz, CDCl3) δ 8.14 (d, J = 8.65 Hz, 1H), 7.37 
(s, 1H), 7.30 (s, 1H), 7.23 (s, 1H), 6.68 (s, 1H), 4.48-4.43 (m, 1H), 3.83 (t, J = 5.55 
Hz, NH), 3.79 (t, J = 7.10 Hz, 2H), 3.14 (q, J = 6.40 Hz, 2H), 2.59 (s, 3H), 2.10 (s, 
3H), 1.89-1.87 (m, 2H), 1.87 (p, J = 6.80 Hz, 2H), 1.70 (s, 9H), 1.57-1.53 (m, 3H), 
1.42-1.34 (m, 2H), 1.00-0.93 (m, 2H), 0.85-0.82 (m, 1H). 
 
4.2.1.136. tert-Butyl 5-(1-(cyclopentylmethyl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (147). Starting with 
compound 19 following the general procedure 10, compound 147 was obtained as 
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white semid solid, yield 55%. 1H (500 MHz,  CDCl3) δ 8.16 (d, J = 8.65 Hz, 1H), 
7.46 (d, J = 1.45 Hz, 1H), 7.33-7.31 (m, 2H), 6.68 (s, 1H), 4.10 (t, J = 5.55 Hz, NH), 
3.80 (t, J = 7.15 Hz, 2H), 3.67 (d, J = 7.70 Hz, 2H), 3.17 (q, J = 6.50 Hz, 2H), 2.58 
(s, 3H), 2.11 (s, 3H), 1.97-1.94 (m, 1H), 1.85 (p, J = 6.90 Hz, 2H), 1.70 (s, 9H), 1.63-
1.59 (m, 4H), 1.48-1.46 (m, 2H), 1.27-1.22 (m, 4H). 
 
4.2.1.137. tert-Butyl 5-(1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (148). Starting with 
compound 20 following the general procedure 10, compound 148 was obtained as 
white solid. 1H NMR (300 MHz, CDCl3) δ 8.06 (d, J = 8.79 Hz, 1H), 7.35 (s, 1H), 
7.20-7.15 (m, 2H), 7.12 (dd, J = 8.79, 1.83 Hz, 1H), 6.95 (t, J = 8.61 Hz, 2H), 6.57 
(s, 1H), 4.85 (s, 2H), 4.34 (t, J = 5.85 Hz, 1H), 3.83 (t, J = 7.50 Hz, 2H), 3.22 (q, J = 
6.39 Hz, 2H), 2.50 (s, 3H), 2.13 (s, 3H), 1.83 (quintet, J = 7.14 Hz, 2H), 1.71 (s, 9H). 
 
4.2.1.138. tert-Butyl (4-(4-(3-methyl-5-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-1H-indazol-1-yl)butyl)pyridin-2-yl)carbamate (149). Starting with 
compound 12 following the general procedure 10, compound 149 was obtained as 
white solid, yield 56%. 1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 5.13 Hz, 1H), 7.72 
(s, 1H), 7.65 (s, 1H), 7.44 (s, 1H), 7.24-7.15 (m, 3H), 7.12 (s, 1H), 6.95 (d, J = 5.13 
Hz, 1H), 6.92 (s, 1H), 6.76 (s, 1H), 5.32 (t, J = 6.96 Hz, 1H), 4.29 (t, J = 6.96 Hz, 
2H), 3.93 (t, J = 6.96 Hz, 2H), 3.26 (q, J = 6.42 Hz, 2H), 2.60 (t, J = 7.50 Hz, 2H), 
2.52 (s, 3H), 2.19 (s, 3H), 1.99-1.89 (m, 4H), 1.66-1.61 (m, 2H), 1.40 (s, 1H). 
 
4.2.1.139. tert-Butyl 3-methyl-6-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-1H-indazole-1-carboxylate (150). Starting with compound 45 
following the general procedure 10, compound 150 was obtained as white solid, yield 
66%. 1H NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 8.08 (s, 1h), 7.48-7.45 (M, 2h), 
7.31-7.28 (m, 1H), 6.79 (s, 1H), 5.98 (t, J = 4.95 Hz, NH), 4.00 (t, J = 6.96 Hz, 2H), 




yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (151). Starting with 
compound 54 following the general procedure 10, compound 151 was obtained as 
white solid, yield 60%. 1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.70 (d, J = 8.61 
Hz, 1H), 7.31 (s, 1H), 7.08 (dd, J = 1.62, 8.22 Hz, 1H), 6.69 (s, 1H), 4.52-4.44 (m, 
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1H), 3.91 (t, J = 6.21 Hz, NH), 3.82 (t, J = 7.14 Hz, 2H), 3.18 (q, J = 6.78 Hz, 2H), 
2.61 (s, 3H), 2.11 (s, 3H), 1.92-1.88 (m, 2H), 1.83 (p, J = 6.96 Hz, 2H), 1.75-1.72 (m, 
2H), 1.71 (s, 9H), 1.68-1.60 (m, 1H), 1.48-1.34 (m, 2H), 1.11-1.00 (m, 2H), 0.90-
0.82 (m, 1H). 
 
4.2.1.141. tert-Butyl 6-(1-(cyclopentylmethyl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (152). Starting with 
compound 55 following the general procedure 10, compound 152 was obtained as 
white semi solid, yield 59%. 1H NMR (500 MHz,  CDCl3) δ 8.01 (s, 1H), 7.67 (d, J 
= 8.30 Hz, 1H), 7.31 (s, 1H), 7.14 (d, J = 8.25 Hz, 1H), 6.67 (s, 1H), 4.23 (t, J = 5.55 
Hz, 1H), 3.82 (t, J = 7.20 Hz, 2H), 3.71 (d, J = 7.65 Hz, 2H), 3.18 (q, J = 6.45 Hz, 
2H), 2.58 (s, 3H), 3.12 (s, 3H), 2.02-1.97 (m, 2H), 1.87 (p, J = 6.95 Hz, 2H), 1.68 (s, 
9H), 1.65-1.55 (m, 4H), 1.48-1.46 (m, 2H), 1.32-1.22 (m, 4H). 
 
4.2.1.142. tert-Butyl 6-(1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-3-methyl-1H-indazole-1-carboxylate (153). Starting with 
compound 56 following the general procedure 10, compound 153 was obtained as 
white semi solid, yield 51%. 
 
4.2.1.143. tert-Butyl 3-methyl-6-(3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-
(pyridin-3-ylmethyl)ureido)-1H-indazole-1-carboxylate (154). Starting with 
compound 57 following the general procedure 10, compound 154 was obtained as 
white semi solid, yield 53%. 
 
4.2.1.144. tert-Butyl 3-methyl-6-(3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-
(1-methylpiperidin-4-yl)ureido)-1H-indazole-1-carboxylate (155).  Starting with 
compound 58 following the general procedure 10, compound 155 was obtained as off 
white solid, yield 55%. 1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.67 (d, J = 8.40 
Hz, 1H), 7.30 (s, 1H), 7.04 (dd, J = 2.01, 8.40 Hz, 1H), 6.67 (s, 1H), 4.56-4.49 (m, 
1H), 4.07 (t, J = 4.95 Hz, NH), 3.80 (t, J = 7.14 Hz, 2H), 3.14 (q, J = 6.60 Hz, 2H), 
2.87-2.80 (m, 2H), 2.58 (s, 3H), 2.23 (s, 3H), 2.09 (s, 3H), 1.85-1.79 (m, 4H), 1.68 
(s, 9H), 1.50-1.43 (m, 2H).  
 
4.2.1.145. tert-Butyl (4-(4-(3-methyl-6-(3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-1H-indazol-1-yl)butyl)pyridin-2-yl)carbamate (156). Starting with 
compound 58 following the general procedure 10, compound 156 was obtained as 
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white solid, yield 44%. 1H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H), 8.05 (d, J = 8.85 
Hz, 1H), 7.86 (s, 1H), 7.71 (d, 1H), 7.49 (s, 1H), 7.43 (d, J = 8.58 Hz, 1H), 6.98-6.96 
(m, 2H), 6.80 (s, 1H), 6.76 dd, J = 8.61 Hz, 1H), 5.87 (t, 1H), 4.25 (t, J = 6.96 Hz, 
2H), 3.98 (t, J = 6.75 Hz, 2H), 3.26 (q, J = 5.31 Hz, 2H), 2.63 (t, J = 7.68 Hz, 2H), 
2.49 (s, 3H), 2.22 (s, 3H), 2.02-1.90 (m, 4H), 1.69-2.58 (m, 2H), 1.43 (s, 9H). 
 
4.2.1.146. tert-Butyl 6-(1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)ureido)-1H-indazole-1-carboxylate (157). Starting with compound 75 
following the general procedure 10, compound 157 was obtained as white solid, yield 
22%. 1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 0.75 Hz, 1H), 7.97 (s, 1H), 7.71 (d, 
J = 7.41 Hz, 1H), 7.33 (s, 1H), 7.22-7.18 (m, 2H), 6.98 (dd, J = 8.43, 1.86 Hz, 1H), 
6.97-6.92 (m, 2H), 6.69 (s, 1H), 4.90 (s, 2H), 4.35 (t, J = 5.67 Hz, 1H), 3.84 (t, J = 
7.32 Hz, 2H), 3.23 (q, J = 6.21 Hz, 2H), 2.31 (s, 3H), 1.89 (quintet, J = 6.96 Hz, 2H), 
1.67 (s, 9H). 
 
4.2.1.147. tert-Butyl 5(6)-((3-cyclobutyl-3-(1,3-dimethyl-1H-indazol-5-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (158). Starting with 
compound 25 following the general procedure 10, compound 158 was obtained as 
white solid, yield 52%. 1H NMR (500 MHz, CDCl3) δ 8.35, 7.84 (d, J = 6.90 Hz, 1H), 
8.32, 7.82 (s, 1H), 7.54-7.51 (m, 2H), 7.36, 7.34 (d, J = 2.25 Hz, 1H), 7.24-7.21 (m, 
1H), 7.17-7.10 (m, 1H), 5.13-5.05 (m, 1H), 4.45 (d, J = 6.05 Hz, 2H), 4.37 (t, J = 4.75 
Hz, NH), 3.98 (s, 3H), 2.54 (s, 3H), 2.15-2.09 (s, 2H0, 1.79-1.74 (m, 2H), 1.66 (s, 
9H), 1.59-1.51 (m, 2H), 1.44-1.34 (m, 2H). 
 
4.2.1.148. tert-Butyl 5(6)-((3-cyclopentyl-3-(1,3-dimethyl-1H-indazol-5-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (159). Starting with 
compound 26 following the general procedure 10, compound 159 was obtained as 
white solid, yield 55%.  1H NMR (500 MHz, CDCl3) δ 8.35, 7.82 (s, 1H), 8.32, 7.84 
(d, J = 8.55 Hz, 1H), 7.54-7.51 (m, 2H), 7.33, 7.31 (d, J = 2.22 Hz, 1H), 7.22 (d, J = 
5.07 Hz, 1H), 7.17-7.12 (m, H), 4.92-4.88 (m, 1H), 4.46 (d, J = 7.0 Hz, 2H), 4.35 (t, 
J = 5.70 Hz, NH), 3.96 (s, 3H), 2.52 (s, 3H0, 1.90-1.88 (m, 2H), 1.65 (s, 9H), 1.52-
1.43 (m, 4H), 1.28-1.22 (m, 2H) 
 
4.2.1.149. tert-Butyl 5(6)-((3-cyclohexyl-3-(1,3-dimethyl-1H-indazol-5-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (160). Starting with 
compound 21 following the general procedure 10, compound 160 was obtained as 
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white solid, yield 54%. 1H NMR (300 MHz, CDCl3) δ 8.35, 7.84 (s, 1H), 8.34, 7.87 
(d, J = 7.89 Hz, 1H), 7.54-7.50 (m, 2H), 7.35-7.31 (m, 1H), 7.26-7.24 (m, 1H), 7.19-
7.13 (m, 2H), 4.59-4.51 (m, 1H), 4.47 (d, J = 5.70 Hz, 2H), 4.33 (t, J = 4.95 Hz, NH), 
3.98 (s, 3H), 2.55, 2.52 (s, 3H), 1.95-1.91 (m, 2H), 1.75-1.71 (m, 2H), 1.68, 1.65 (s, 
9H), 1.53-1.34 (m, 3H), 1.09-1.00 (m, 2H), 0.93-0.81 (m, 1H). 
 
4.2.1.150. tert-Butyl 5-((3-(cyclopentylmethyl)-3-(1,3-dimethyl-1H-indazol-5-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (161). Starting with 
compound 22 following the general procedure 10, compound 161 was obtained as 
white solid, yield 54%.  
 
4.2.1.151. tert-Butyl 5-((3-(1,3-dimethyl-1H-indazol-5-yl)-3-(4-
fluorobenzyl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (162). Starting 
with compound 23 following the general procedure 10, compound 162 was obtained 
as white solid, yield 45%.  
 
4.2.1.152. tert-Butyl 5(6)-((3-cyclobutyl-3-(1,3-dimethyl-1H-indazol-6-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (163). Starting with 
compound 64 following the general procedure 10, compound 163 was obtained as 
white solid, yield 74%. 1H NMR (300 MHz, CDCl3) δ 8.38, 8.35 (s, 1H), 7.87-7.85 
(m, 1H), 7.71-7.64 (m, 2H), 7.55-7.43 (m, 1H), 7.17-7.13 (m, 1H), 6.93-6.87 (m, 1H), 
5.11-5.05 (m, 1H), 4.47-4.43 (m, 3H), 3.99, 3.99 (s, 3H), 2.56, 2.56 (s, 3H), 2.17-2.09 
(m, 2H), 1.83-1.74 (m, 2H), 1.69-1.68 (s, 9H), 1.49-1.42 (m, 2H). 
 
4.2.1.153. tert-Butyl 5(6)-((3-cyclopentyl-3-(1,3-dimethyl-1H-indazol-6-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (164). Starting with 
compound 65 following the general procedure 10, compound 164 was obtained as 
off-white solid, yield 52%. 1H NMR (300 MHz, CDCl3) δ 8.38, 8.34 (s, 1H), 7.85 (s, 
1H), 7.70-7.63 (m, 2H), 7.55-7.43 (m, 1H), 7.24-7.13 (m, 1H), 6.93-6.87 (m, 1H), 
5.11-5.05 (m, 1), 4.47-4.43 (m, 3H), 4.00, 3.99 (s, 3H), 2.56 (s, 3H), 2.17-2.09 (m, 
2H), 1.83-1.74 (m, 2H), 1.69, 1.68 (s, 9H), 1.61-1.54 (m, 2H), 1.49-1.42 (m, 2H). 
 
4.2.1.154. tert-Butyl 5(6)-((3-cyclohexyl-3-(1,3-dimethyl-1H-indazol-6-
yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (165). Starting with 
compound 59 following the general procedure 10, compound 165 was obtained as 
white solid, yield 42%. 1H NMR (300 MHz, CDCl3) δ 8.38, 7.70 (s, 1H), 8.34, 7.85 
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(d, J = 11.16 Hz, 1H), 7.57-7.51 (m, 1H), 7.45-7.39 (m, 1H), 7.30-7.26 (m, 1H), 7.17-
7.12 (m, 1H), 6.95-6.92 (m, 1H), 4.46, 4.44 (d, J = 5.31 Hz, 2H), 4.40-4.32 (m, 1H), 
3.99, 3.98 (s, 3H), 2.55 (s, 3H), 1.93-1.86 (m, 2H), 1.75-1.70 (m, 2H), 1.68 (s, 9H), 
1.65-1.59 (m, 1H), 1.47-1.35 (m, 2H), 1.14-1.06 (m, 2H), 0.97-0.88 (m, 1H). 
 
4.2.1.155. tert-Butyl 5 (6)-((3-(cyclopentylmethyl)-3-(1,3-dimethyl-1H-
indazol-6-yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (166). Starting 
with compound 60 following the general procedure 10, compound 166 was obtained 
as white solid, yield 55%. 1H NMR (300 MHz, CDCl3) δ 8.38, 8.35 (s, 1H), 7.88-7.86 
(m, 1H), 7.28-7.26 (m, 2H), 7.24-7.20 (m, 2H), 7.03-6.97 (m, 1H), 4.71-4.61 (m, NH), 
4.51 (d, J = 5.31 Hz, 2H), 3.97 (s, 3H), 3.77 (d, J = 7.86 Hz, 2H), 2.54 (s, 3H), 2.10-
2.04 (m, 1H), 1.0-1.68 (m, 4H), 1.61 (s, 9H), 1.49-1.45 (m, 2H), 1.35-1.25 (m, 4H). 
 
4.2.1.156. tert-Butyl 5(6)-((3-(1,3-dimethyl-1H-indazol-6-yl)-3-(4-
fluorobenzyl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (167). Starting 
with compound 61 following the general procedure 10, compound 167 was obtained 
as white crude solid. 1H NMR (300 MHz, CDCl3) δ 8.39, 8.35 (s, 1H), 7.91-7.87 (m, 
1H), 7.70-7.47 (m, 3H), 7.29-7.21 (m, 2H), 7.02-6.92 (m, 3H), 6.85-6.80 (m, 1H), 
4.92 (s, 2H), 4.72-4.66 (m, 1H), 4.54, 4.52 (d, J = 5.7 Hz, 2H), 3.88 (s, 3H), 2.51 (s, 
3H), 1.69 (s, 9H).  
 
4.2.1.157. tert-Butyl 5 (6)-((3-(1,3-dimethyl-1H-indazol-6-yl)-3-(1-
methylpiperidin-4-yl)ureido)methyl)-1H-benzo[d]imidazole-1-carboxylate (168). 
Starting with compound 63 following the general procedure 10, compound 168 was 
obtained as white solid, yield 48%. 1H NMR (300 MHz, CDCl3) δ 8.36 (7.83) (s, 1H), 
8.32 (7.85) (d, J = 8.40 Hz, 1H), 7.66-7.58 (m, 2H), 7.19-7.10 (m, 3H), 6.91 (6.84) 
(dd, J = 1.65, 8.43 Hz, 1H), 4.59-4.51 (m, 1H), 4.44 (4.42) (s, 2H), 3.95 (3.94) (s, 
3H), 2.82-2.79 (m, 2H), 2.51 (s, 3H), 2.19 (s, 3H), 2.11-2.02 (m, 2H), 1.88-1.80 (m, 
2H), 1.66 (s, 9H), 1.50-1.41 (m, 2H).   
 
4.2.2. Final  
4.2.2.1. 1-(3-(5-Methyl-1H-imidazol-1-yl)propyl)-3-(3-methyl-1H-indazol-5-yl)urea 
(169). Starting with compound 145 following the general procedure 9.2, compound 
169 was obtained as white solid, yield 70%, mp = 90-91 oC. 1H NMR (300 MHz, 
CD3OD) δ 7.72 (d, J = 1.11 Hz, 1H), 7.59 (s, 1H), 7.38 (dd, J = 0.75, 8.79 Hz, 1H), 
7.27 (dd, J = 1.83, 8.79 Hz, 1H), 6.67 (s, 1H), 4.03 (t, J = 7.14 Hz, 2H), 3.25 (t, J = 
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6.78 Hz, 2H), 2.50 (s, 3H), 2.23 (d, J = 0.93 Hz, 3H), 2.00 (p, J = 6.78 Hz, 2H). 
MS (ESI) m/z 313 [M+H]+. HRMS (ESI) calc. 




indazol-5-yl)urea (170). Starting with compound 146 following the general 
procedure 9.2, compound 170 was obtained as white solid, yield 71%, mp = 103-104 
oC. 1H NMR (300 MHz, MeOD) δ 7.54-7.49 (m, 3H), 7.14 (d, J = 10.44 Hz, 1H), 
6.61 (s, 1H), 4.44-4.35 (m, 1H), 3.86 (t, J = 7.32 Hz, 2H), 3.11 (t, J = 6.60 Hz, 2H), 
2.55 (s, 3H), 2.14 (d, J = 0.93 Hz, 3H), 1.96-1.86 (m, 2H), 1.82-1.72 (m, 4H), 1.58-
1.53 (m, 1H), 1.41-1.28 (m, 2H), 1.12-1.00 (m, 2H), 0.93-0.85 (m, 1H). 
MS (ESI) m/z 395 [M+H]+. HRMS (ESI) calc. 




methyl-1H-indazol-5-yl)urea (171). Starting with compound 147 following the 
general procedure 9.2, compound 171 was obtained as white solid, yield 75%, mp = 
80-81 oC. 1H (500 MHz,  MeOD) δ 7.61 (d, J = 1.25 Hz, 1H), 7.55 (d, J = 8.75 Hz, 
1H), 7.50 (s, 1H), 7.23 (dd, J = 1.75 Hz, 1H), 6.62 (s, 1H), 3.88 (t, J = 7.15 Hz, 2H), 
3.65 (d, J = 7.65 Hz, 2H), 3.12 (t, J = 6.70 Hz, 2H), 2.55 (s, 3H), 2.16 (s, 3H), 2.02 
(p, J = 7.50 Hz, 2H), 1.98 (p, J = 6.70 Hz, 2H), 1.71-1.60 (m, 4H), 1.53-1.50 (m, 2H), 
1.28-1.20 (m, 4H). MS (ESI) m/z 395 [M+H]+. HRMS (ESI) calc. 




1H-indazol-5-yl)urea (172). Starting with compound 147 following the general 
procedure 9.2, compound 172 was obtained as white solid, yield 45%. 1H NMR (300 
MHz, CDCl3) δ 7.39 (d, J = 8.79 Hz, 1H), 7.34 (s, 1H), 7.30 (d, J = 1.29 Hz, 1H), 
7.21-7.17 (m, 2H), 6.97-6.90 (m, 3H), 6.69 (s, 1H), 4.84 (s, 2H), 4.34 (t, J = 5.85 Hz, 
1H), 3.83 (t, J = 7.14 Hz, 2H), 3.21 (q, J = 6.60 Hz, 2H), 2.51 (s, 3H), 2.12 (d, J = 
0.90 Hz, 3H), 1.88 (quintet, J = 6.60 Hz, 2H). HRMS (ESI) calc. for C23H26FN6O [M 
+ H]+ 421.2147, found 421.2161. 
PART II1- SAR MODIFICATION OF HETEROCYCLICS IN C REGION WITH 
UREA TYPE  
160 
Ngo Thi Hong Van _ 2013.31349 
4.2.2.5. 1-(1,3-Dimethyl-1H-indazol-5-yl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)urea (173). Starting with compound 10 following the general procedure 10, 
compound 173 was obtained as white solid, yield 63%.  1H NMR (300 MHz, CDCl3) 
δ 7.69 (s, 1H), 7.47 (s, 1H), 7.40 (d, J = 0.90 Hz, 1H), 7.21 (d, J = 8.25 Hz, 1H), 7.15 
(dd, J = 8.79, 1.83 Hz, 1H), 6.76 (s, 1H), 5.59 (t-like, 1H), 3.95 (s, 3H), 3.92 (t, J = 
6.96 Hz, 2H), 3.23 (q, J = 6.39 Hz, 2H), 2.50 (s, 3H), 2.19 (d, J = 0.75 Hz, 3H), 1.95 




imidazol-1-yl)propyl)urea (174). Starting with compound 21 following the general 
procedure 10, compound 174 was obtained as white solid, yield 41%.  1H NMR (300 
MHz, CDCl3) δ 7.36 (d, J = 1.65 Hz, 1H), 7.34 (d, J = 8.79 Hz, 1H), 7.29 (s, 1H), 
7.07 (dd, J = 8.79, 1.83 Hz, 1H), 6.67 (s, 1H), 4.50 (tt, J = 12.09, 3.48 Hz, 1H), 4.01 
(s, 3H), 3.90 (t, J = 5.85 Hz, 1H), 3.77 (t, J = 7.32 Hz, 2H), 3.11 (q, J = 6.21 Hz, 2H), 
2.55 (s, 3H), 2.09 (s, 3H), 1.89-1.82 (m, 2H), 1.79 (quintet, J = 6.96 Hz, 2H), 1.69 (d, 
J = 12.99 Hz, 2H), 1.53 (d, J = 12.65 Hz, 1H), 1.45-1.32 (m, 2H), 1.04-0.97 (m, 2H), 




1H-imidazol-1-yl)propyl)urea (175). Starting with compound 22 following the 
general procedure 10, compound 175 was obtained as white solid, yield 68%. 1H 
NMR (300 MHz, CDCl3) δ 7.47 (d, J = 1.83 Hz, 1H), 7.38 (d, J = 8.79 Hz, 1H), 7.31 
(s, 1H), 7.18 (dd, J = 8.79, 1.83 Hz, 1H), 6.69 (s, 1H), 4.16 (t, J = 5.85 Hz, 1H), 4.03 
(s, 3H), 3.81 (t, J = 7.14 Hz, 2H), 3.67 (d, J = 7.71 Hz, 2H), 3.16 (q, J = 6.39 Hz, 2H), 
2.57 (s, 3H), 2.12 (s, 3H), 2.05-1.95 (m, 1H), 1.84 (quintet, J = 7.14 Hz, 2H), 1.70-
1.65 (m, 4H), 1.55-1.45 (m, 2H), 1.38-1.24 (m, 2H). HRMS (ESI) calc. for C23H33N6O 
[M + H]+ 410.2739, found 410.2755. 
 
4.2.2.8. 1-(1,3-Dimethyl-1H-indazol-5-yl)-1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (176). Starting with compound 23 following the general 
procedure 10, compound 176 was obtained as white solid, yield 85%. 1H NMR (300 
MHz, CDCl3) δ 7.37 (s, 1H), 7.27 (d, J = 6.03 Hz, 1H), 7.25 (s, 1H), 7.16 (dd, J = 
8.43, 5.49 Hz, 1H), 6.95-6.89 (m, 3H), 6.69 (s, 1H), 4.81 (s, 2H), 4.20 (t, J = 6.06 Hz, 
1H), 3.97 (s, 3H), 3.81 (t, J = 7.32 Hz, 2H), 3.18 (q, J = 6.42 Hz, 2H), 2.47 (s, 3H), 
PART II1- SAR MODIFICATION OF HETEROCYCLICS IN C REGION WITH 
UREA TYPE  
161 
Ngo Thi Hong Van _ 2013.31349 
2.11 (s, 3H), 1.88-1.82 (m, 2H). HRMS (ESI) calc. for C24H28FN6O [M + H]+ 
435.2303, found 435.2314. 
 
4.2.2.9. 1-(1,3-Dimethyl-1H-indazol-5-yl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-
1-(pyridin-3-ylmethyl)urea (177). Starting with compound 24 following the general 
procedure 10, compound 177 was obtained as white solid, yield 68%. 1H NMR (300 
MHz, CDCl3) δ 8.48 (d, J = 3.09 Hz, 1H), 8.37 (s, 1H), 7.64 (d, J = 7.68 Hz, 1H), 
7.35 (s, 1H), 7.29-7.26 (m, 2H), 7.21 (dd, J = 8.04, 4.92 Hz, 1H), 6.93 (dd, J = 8.79, 
1.83 Hz, 1H), 6.68 (s, 1H), 4.86 (s, 2H), 4.25 (t-like, 1H), 3.81(t, J = 7.14 Hz, 2H), 
3.17 (q, J = 6.39 Hz, 2H), 2.47 (s, 3H), 2.11 (s, 3H), 1.87-1.82 (m, 2H). HRMS (ESI) 
calc. for C23H28N7O [M + H]+ 418.2350, found 418.2344. 
 
4.2.2.10. 1-(3-Methyl-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indazol-5-yl)-
3-(3-(5-methyl-1H-imidazol-1-yl)propyl)urea (178). Starting with compound 11 
following the general procedure 10, compound 178 was obtained as white solid, yield 
59%. 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 1.47 Hz, 1H), 7.40 (s, 1H), 7.28 (d, 
J = 8.97 Hz, 1H), 7.17 (dd, J = 8.97, 2.04 Hz, 1H), 7.15 (s, 1H), 6.76 (s, 1H), 5.33 (t, 
1H), 4.40 (t, J = 6.96 Hz, 2H), 3.93 (t, J = 6.96 Hz, 2H), 3.24 (q, J = 6.03 Hz, 2H), 
2.83 (t, J = 7.32 Hz. 2H), 2.55 (br, 4H), 2.52 (s, 3H), 2.43 (br, 4H), 2.27 (s, 3H), 2.19 
(s, 3H), 1.96 (quintet, J = 6.60 Hz, 2H). ). HRMS (ESI) calc. for C23H35N8O [M + H]+ 
439.2928, found 439.2925. 
 
4.2.2.11. 1-(1-(4-(2-Aminopyridin-4-yl)butyl)-3-methyl-1H-indazol-5-yl)-3-
(3-(5-methyl-1H-imidazol-1-yl)propyl)urea (179). Starting with compound 149 
following the general procedure 9.2, compound 179 was obtained as white solid, yield 
91%. 1H NMR (300 MHz, CDCl3) δ 7.87 (d, J = 5.85 Hz, 1H), 7.67 (s, 1H), 7.44 (s, 
1H), 7.33 (s, 1H), 7.20-7.14 (m, 2H), 6.75 (s, 1H), 6.39 (dd, J = 5.31, 1.47 Hz, 1H), 
6.15 (s, 1H), 5.46 (brt, 1H), 4.27 (t, J = 6.75 Hz, 2H), 3.92 (t, J = 6.78 Hz, 2H), 3.24 
(q, J = 6.06 Hz, 2H), 2.51 (s, 3H), 2.44 (t, J = 7.50 Hz, 2H), 1.99-1.83 (m, 4H), 1.61-
1.51 (m, 2H). HRMS (ESI) calc. for C25H33N8O [M + H]+ 461.2772, found 461.2789. 
 
4.2.2.12. 1-Cyclohexyl-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(1-propyl-
1H-indazol-5-yl)urea (180). Starting with compound 35 following the general 
procedure 10, compound 180 was obtained as white solid, yield 51%, mp = 53-54 oC. 
1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 0.90 Hz, 1H), 7.47 (d, J = 1.29 Hz, 1H), 
7.43 (d, J = 8.79 Hz, 1H), 7.27 (s, 1H), 7.08 (dd, J = 1.83, 8.79 Hz, 1H), 6.66 (s, 1H), 
PART II1- SAR MODIFICATION OF HETEROCYCLICS IN C REGION WITH 
UREA TYPE  
162 
Ngo Thi Hong Van _ 2013.31349 
4.49-4.41 (m, 1H), 4.36 (t, J = 6.96 Hz, 2H), 3.90 (t, J = 5.94 Hz, NH), 3.79 (t, J = 
7.14 Hz, 2H), 3.15 (q, J = 6.45 Hz, 2H), 2.08 (d, J = 0.90 Hz, 3H), 2.00 (p, J = 7.14 
Hz, 2H), 1.88-1.84 (m, 2H), 1.82 (p, J = 7.14 Hz, 2H), 1.73-.65 (m, 2H), .54-1.50 (m, 
1H), 1.44-1.31 (m, 2H), 1.06-0.98 (m, 2H), 0.89-0.77(m, 1H). 
MS (ESI) m/z 423 [M+H]+. HRMS (ESI) calc. for C24H34N6O 
[M+H]+ 423.2867, found 423.2880. Anal. HPLC 95.4% (Rt = 7.379 min). 
 
4.2.2.13. 1-(4-Fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(1-
propyl-1H-indazol-5-yl)urea (181). Starting with compound 36 following the general 
procedure 10, compound 181 was obtained as white solid, yield 54%. 1H NMR (300 
MHz, CDCl3) δ 7.95 (d, J = 0.93 Hz, 1H), 7.38 (d, J = 8.79 Hz, 1H), 7.36 (d, J = 1.29 
Hz, 1H), 7.32 (s, 1H), 7.22-1.17 (m, 2H), 6.98 (dd, J = 8.79, 2.04 Hz, 1H), 6.97-6.92 
(m, 2H), 6.69 (s, 1H), 4.84 (s, 2H), 4.33 (t, J = 6.96 Hz, 2H), 4.23 (t, J = 5.88 Hz, 
1H), 3.82 (t, J = 7.14 Hz, 2H), 3.20 (q, J = 6.21 Hz, 2H), 2.12 (d, J = 0.90 Hz, 3H), 
1.98 (hex, J = 7.32 Hz, 2H), 1.87 (quintet, J = 6.96 Hz, 2H), 0.95 (t, J = 7.32 Hz, 3H). 
HRMS (ESI) calc. for C25H30FN6O [M + H]+ 449.2460, found 449.2471. 
 
4.2.2.14. 1-Cyclohexyl-1-(1-isobutyl-1H-indazol-5-yl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (182). Starting with compound 37 following the general 
procedure 10, compound 182 was obtained as white solid, yield 78%. 1H NMR (300 
MHz, CDCl3) δ 7.99 (d, J = 0.93 Hz, 1H), 7.47 (d, J = 1.29 Hz, 1H), 7.40 (d, J = 8.79 
Hz, 1H), 7.27 (s, 1H), 7.06 (dd, J = 8.61, 1.83 Hz, 1H), 6.66 (s, 1H), 4.44 (tt, J = 
12.09, 3.66 Hz, 1H), 4.16 (d, J = 5.34 Hz, 2H), 3.91 (t, J = 5.67 Hz, 2H), 3.76 (t, J = 
7.14 Hz, 2H), 3.11 (q, J = 6.78 Hz, 2H), 2.35 (hept, J = 6.60 Hz, 1H), 2.08 (d, J = 
0.72 Hz, 3H), 1.88-1.75 (m, 4H), 1.69 (d, J = 13.38 Hz, 2H), 1.52 (d, J = 12.84 Hz, 
1H), 1.44-1.31 (qt-like, 2H), 1.05-0.94 (m, 2H), 0.95 (d, J = 6.60 Hz, 6H), 0.90-0.77 
(dt-like, 1H). HRMS (ESI) calc. for C25H37N6O [M + H]+ 437.3023, found 437.3036. 
 
4.2.2.15. 1-(4-Fluorobenzyl)-1-(1-isobutyl-1H-indazol-5-yl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)urea (183). Starting with compound 38 following the 
general procedure 10, compound 183 was obtained as white solid, yield: 62%. 1H 
NMR (300 MHz, CDCl3) δ 7.88 (d, J = 0.72 Hz, 1H), 7.32-7.25 (m, 2H), 7.15-7.10 
(m, 2H), 6.93-6.85 (m, 3H), 6.62 (s, 1H), 4.76 (s, 2H), 4.18 (t, J = 6.33 Hz, 1H), 4.09 
(t, J = 7.32 Hz, 2H), 3.75 (t, J = 7.14 Hz, 2H), 3.13 (q, J = 6.42 Hz, 2H), 2.26 (hept, 
J = 6.60 Hz, 1H), 2.04 (d, J = 0.72 Hz, 3H), 1.80 (quintet, J = 6.96 Hz, 2H), 0.87 (d, 
PART II1- SAR MODIFICATION OF HETEROCYCLICS IN C REGION WITH 
UREA TYPE  
163 
Ngo Thi Hong Van _ 2013.31349 




1H-imidazol-1-yl)propyl)urea (184). Starting with compound 27 following the 
general procedure 10, compound 184 was obtained as white solid, yield 56%. 1H 
NMR (300 MHz, CDCl3) δ 7.64 (d, J = 8.97 Hz, 1H), 7.31 (s, 1H), 7.28 (d, J = 1.29 
Hz, 1H), 6.93 (dd, J = 8.97, 1.83 hz, 1H), 6.69 (s, 1H), 4.43 (tt, J = 12.06, 3.48 Hz, 
1H), 4.11 (s, 3H), 4.01 (t, J = 5.67 Hz, 1H), 3.77 (t, J = 7.32 Hz, 2H), 3.11 (q, J = 
6.21 Hz, 2H), 2.61 (s, 3H), 2.09 (s, 3H), 1.86-1.78 (m, 2H), 1.77 (quintet, J = 7.14 
Hz, 2H), 1.72-1.67 (m, 2H), 1.53 (d, J = 12.99 Hz, 1H), 1.44-1.31 (m, 2H), 1.06-1.03 




methyl-1H-imidazol-1-yl)propyl)urea (185). Starting with compound 28 following 
the general procedure 10, compound 185 was obtained as white solid, yield 55%.  1H 
NMR (300 MHz, CDCl3) δ 7.57 (d, J = 8.97 Hz, 1H), 7.29 (s, 1H), 7.18 (dd, J = 8.40, 
5.49 Hz, 2H), 7.13 (d, J = 1.47 Hz, 1H), 6.91 (t, J = 8.61 Hz, 2H), 6.84 (dd, J = 8.79, 
2.01 Hz, 1H), 6.67 (s, 1H), 4.80 (s, 2H), 4.29 (t, J = 6.06 Hz, 1H), 4.08 (s, 3H), 3.79 
(t, J = 7.14 Hz, 2H), 3.17 (q, J = 6.60 Hz, 2H), 2.52 (s, 3H), 2.10 (d, J = 0.72 Hz, 3H), 
1.83 (quintet, J = 7.32 Hz, 2H). HRMS (ESI) calc. for C24H28FN6O [M + H]+ 
425.2303, found 425.2304. 
 
4.2.2.18. 1-(2,3-Dimethyl-2H-indazol-5-yl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)-1-(pyridin-3-ylmethyl)urea (186). Starting with compound 29 following 
the general procedure 10, compound 186 was obtained as white solid, yield 28%. 1H 
NMR (300 MHz, CDCl3) δ 8.48 (d, J = 3.30 Hz, 1H), 8.44 (s, 1H), 7.91 (d, J = 1.26 
Hz, 1H), 7.64 (d, 1H), 7.61 (d, J = 8.97 Hz, 1H), 7.25-7.21 (m, 2H), 6.88 (dd, J = 
8.97, 2.04 Hz, 1H), 6.83 (s, 1H), 4.88 (s, 2H), 4.56 (t, J = 5.85 Hz, 1H), 4.09 (s, 3H), 
3.96 (t, J = 6.93 Hz, 2H), 3.24 (q, J = 6.21 Hz, 2H), 2.55 (s, 3H), 2.20 (d, J = 0.90 Hz, 
3H), 1.90 (quintet, J = 6.96 Hz, 2H). 
 
4.2.2.19. 1-(3-(5-Methyl-1H-imidazol-1-yl)propyl)-3-(3-methyl-1H-indazol-
6-yl)urea (187). Starting with compound 150 following the general procedure 9.2, 
compound 187 was obtained as white solid, yield 69%, mp = over 200 oC. 1H NMR 
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(300 MHz, MeOD) δ 7.76 (d, J = 1.08 Hz, 1H), 7.59 (s, 1H), 7.56 (d, J = 8.79 Hz, 
1H), 6.88 (dd, J = 1.83, 8.61 Hz, 1H), 6.67 (s, 1H), 4.03 (t, J = 7.14 Hz, 2H), 3.26 (t, 
J = 6.78 Hz, 2H), 2.48 (s, 3H), 2.23 (d, J = 0.93 Hz, 3H), 2.01 (p, J = 6.78 Hz, 2H). 
MS (ESI) m/z 313 [M+H]+. HRMS (ESI) calc. 




methyl-1H-indazol-6-yl)urea (188). Starting with compound 151 following the 
general procedure 9.2, compound 188 was obtained as white solid, yield 71%, mp = 
73-74 oC. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.43 Hz, 1H), 7.29 (s, 1H), 7.14 
(s, 1H), 6.88 (dd, J = 1.47, 8.22 Hz, 1H), 6.68 (s, 1H), 4.50-4.41 (m, 1H), 3.91 (t, J = 
6.42 Hz, NH), 3.82 (t, J = 6.96 Hz, 2H), 3.20 (q, J = 6.60 Hz, 2H), 2.61 (s, 3H), 2.11 
(d, J = 0.75 Hz, 3H), 1.90-1.81 (m, 4H), 1.72-1.64 (m, 2H), 1.57-1.53 (m, 1H), 1.44-
1.36 (m, 2H), 1.10-1.03 (m, 2H), 0.92-0.83 (m, 1H). MS (ESI) m/z 395 [M+H]+. 
HRMS (ESI) calc. for C22H30N6O [M+H]+ 395.2554, found 395.2577. Anal. HPLC 
96.6% (Rt = 4.163 min). 
 
4.2.2.21. 1-(Cyclopentylmethyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-
(3-methyl-1H-indazol-6-yl)urea (189). Starting with compound 152 following the 
general procedure 9.2, compound 189 was obtained as white solid, yield 77%, mp = 
80-81 oC. 1H NMR (500 MHz,  MeOD) δ 7.79 (d, J = 8.45 Hz, 1H), 7.50 (s, 1H), 7.34 
(s, 1H), 6.99 (d, J = 8.35 Hz, 1H), 6.62 (s, 1H), 3.88 (t, J = 7.15 Hz, 2H), 3.67 (d, J = 
7.65 Hz, 2H), 3.13 (t, J = 6.55 Hz, 2H), 2.55 (s, 3H), 2.16 (s, 3H), 2.04 (p, J = 5.70 
Hz, 2H), 1.86 (p, J = 6.70 Hz, 2H),, 1.86-1.60 (m, 4H), 1.51-1.49 (m, 2H), 1.31-1.23 
(m, 4H). MS (ESI) m/z 395 [M+H]+. HRMS (ESI) calc. 




methyl-1H-indazol-6-yl)urea (190). Starting with compound 153 following the 
general procedure 9.2, compound 190 was obtained as white solid, yield 93%. 1H 
NMR (300 MHz, CDCl3) δ 7.63 (d, J = 8.43 Hz, 1H), 7.33 (s, 1H), 7.16 (t, J = 8.25 
Hz, 2H), 6.94-6.88 (m, 3H), 6.78 (d, J = 8.61 Hz, 1H), 6.65 (s, 1H), 4.83 (s, 2H), 4.37 
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(br, 1H), 3.84 (t, J = 6.96 Hz, 2H), 3.25 (q, J = 5.88 Hz, 2H), 2.54 (s, 3H), 2.18 (s, 
3H), 2.02-1.92 (m, 2H). 
 
4.2.2.23. tert-Butyl 3-methyl-6-(pyridin-3-ylmethylamino)-1H-indazole-1-
carboxylate (191). Starting with compound 154 following the general procedure 9.2, 
compound 191 was obtained as white solid, yield: 91%. 1H NMR (300 MHz, CDCl3) 
δ 8.42 (br, 2H), 7.62-7.56 (m, 3H), 7.19 (br, 1H), 7.03 (s, 1H), 6.78 (d, J = 8.43 Hz, 
1H), 6.70 (br, 1H), 4.88 (s, 3H), 3.91 (t, J = 6.78 Hz, 2H), 3.29 (q, J = 6.03 Hz, 2H), 
2.46 (s, 3H), 2.15 (s, 3H), 1.95 (quintet, J = 6.78 Hz, 2H). HRMS (ESI) calc. for 
C22H26N7O [M + H]+ 404.2193, found 404.2210. 
 
4.2.2.24. 3-(3-(5-Methyl-1H-imidazol-1-yl)propyl)-1-(3-methyl-1H-indazol-
6-yl)-1-(1-methylpiperidin-4-yl)urea (192). Starting with compound 155 following 
the general procedure 9.2, compound 192 was obtained as white solid, yield 91%, mp 
= 182-183 oC. 1H NMR (300 MHz, MeOH) δ 7.80 (d, J = 8.43 Hz, 1H), 7.50 (d, J = 
1.11 Hz, 1H), 7.28 (d, J = 0.90 Hz, 1H), 6.91 (dd, J = 1.62, 8.58 Hz, 1H), 6.62 (s, 
1H), 4.43-4.35 (m, 1H), 3.87 (t, J = 6.96 Hz, 2H), 3.12 (t, J = 6.39 Hz, 2H), 2.86-2.82 
(m, 2H), 2.17 (s, 3H), 2.15 (d, J = 0.93 Hz, 3H), 2.12-2.08 (m, 2H), 1.86-1.75 (m, 
4H), 1.49-1.41 (m, 2H). MS (ESI) m/z 410 [M+H]+. HRMS (ESI) calc. 




yl)propyl)urea (193). Starting with compound 46 following the general procedure 10, 
compound 193 was obtained as white solid, yield 73%, mp = 77-78 oC. 1H NMR (300 
MHz, CDCl3) δ 8.13 (s, 1H), 7.84 (s, 1H), 7.46 (s, 1H), 7.44 (d, J = 8.61 Hz, 1H), 
6.80 (s, 1H), 6.66 (dd, J = 1.47, 8.40 Hz, 1H), 6.04 (t, J = 4.95 Hz, NH), 4.00 (t, J = 
6.57 Hz, 2H), 3.92 (s, 3H), 3.25 (q, J = 5.67 Hz, 2H), 2.49 (s, 3H), 2.22 (s, 3H), 2.02 
(p, J = 6.21 Hz, 2H). MS (ESI) m/z 327 [M+H]+. HRMS (ESI) calc. 




imidazol-1-yl)propyl)urea (194). Starting with compound 59 following the general 
procedure 10, compound 194 was obtained as white solid, yield 65%, mp = 91-92oC. 
1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.43 Hz, 1H), 7.39 (s, 1H), 7.08 (d, J = 
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1.11 Hz, 1H), 6.86 (dd, J = 1.65, 8.43 Hz, 1H), 6.68 (s, 1H), 4.51-4.43 (m, 1H), 4.01 
(s, 3H), 3.94 (t, J = 6.03 Hz, NH), 3.81 (t, J = 7.14 Hz, 2H), 3.18 (q, J = 6.78 Hz, 2H), 
2.58 (s, 3H), 2.11 (d, J = 0.90 Hz, 3H), 1.93-1.89 (m, 2H), 1.84 (p, J = 7.14 Hz, 2H), 
1.77-1.70 (m, 2H), 1.58-1.54 (m, 1H), 1.47-1.34 (m, 2H), 1.11-1.00 (m, 2H), 0.94-
0.85 (m, 1H). MS (ESI) m/z 409 [M+H]+. HRMS (ESI) calc. 




methyl-1H-imidazol-1-yl)propyl)urea (195). Starting with compound 60 following 
the general procedure 10, compound 195 was obtained as white solid, yield 75%, mp 
= 71-72 oC. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.22 Hz, 1H), 7.31 (s, 1H), 
7.16 (s, 1H), 6.95 (dd, J = 1.65, 8.43 Hz, 1H), 6.69 (s, 1H), 4.22 (t, J = 4.59 Hz, NH), 
4.00 (s, 3H), 3.83 (t, J = 7.14 Hz, 2H), 3.72 (d, J = 7.71 Hz, 2H), 3.21 (q, J = 6.78 Hz, 
2H), 2.57 (s, 3H), 2.12 (d, J = 0.72 Hz, 3H), 2.03-1.95 (m, 1H), 1.89 (p, J = 7.14 Hz, 
2H), 1.69-1.66 (m, 2H), 1.64-1.58 (m, 2H), 1.53-1.48 (m, 2H), 1.35-1.25 (m, 2H). 
MS (ESI) m/z 409 [M+H]+. HRMS (ESI) calc. 




methyl-1H-imidazol-1-yl)propyl)urea (196). Starting with compound 61 following 
the general procedure 10, compound 196 was obtained as white solid, yield 30%.  1H 
NMR (300 MHz, CDCl3) δ 7.61 (dd, J = 8.43, 0.54 Hz, 1H), 7.32 (s, 1H), 7.23-7.18 
(m, 2H), 6.98-6.92 (m, 3H), 6.75 (dd, J = 8.43, 1.83 Hz, 1H), 6.69 (s, 1H), 4.87 (s, 
2H), 4.28 (t, J = 5.85 Hz, 1H), 3.92 (s, 3H), 3.83 (t, J = 7.14 Hz, 2H), 3.21 (q, J = 
6.24 Hz, 2H), 2.55 (s, 3H), 2.12 (d, J = 0.90 Hz, 3H), 1.87 (quintet, J = 7.14 Hz, 2H). 
HRMS (ESI) calc. for C24H28FN6O [M + H]+ 435.2303, found 435.2313. 
 
4.2.2.29. 1-(1,3-Dimethyl-1H-indazol-6-yl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)-1-(pyridin-3-ylmethyl)urea (197). Starting with compound 62 following 
the general procedure 10, compound 197 was obtained as white solid, yield 24%. 1H 
NMR (300 MHz, CDCl3) δ 8.50 (d, J = 4.95 Hz, 1H), 8.41 (s, 1H), 7.67 (dt-like, 8.01 
Hz, 1H), 7.63 (d, J = 8.43 Hz, 1H), 7.32 (s, 1H), 7.23 (dd, J = 7.89, 2.76 Hz, 1H), 
6.97 (s, 1H), 6.76 (dd, J = 8.40, 1.44 Hz, 1H), 6.69 (s, 1H), 4.92 (s, 2H), 4.32 (t-like, 
1H), 3.92 (s, 3H), 3.83 (t, J = 6.96 Hz, 2H), 3.21 (q, J = 6.60 Hz, 2H), 2.55 (ds, 3H), 
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2.12 (s, 3H), 1.87 (quintet, J = 6.96 Hz, 2H). HRMS (ESI) calc. for C23H28N7O [M + 
H]+ 418.2350, found 418.2365. 
 
4.2.2.30. 1-(1,3-Dimethyl-1H-indazol-6-yl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)-1-(1-methylpiperidin-4-yl)urea (198). Starting with compound 63 
following the general procedure 10, compound 198 was obtained as white solid, yield 
35%, mp > 200 oC. 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.43 Hz, 1H), 7.23 (s, 
1H), 7.01 (s, 1H), 6.77 (d, J = 8.43 Hz, 1H), 6.62 (s, 1H), 4.48-4.40 (m, 1H), 3.92 (s, 
1H), 3.84 (t, J = 4.95 Hz, NH), 3.75 (t, J = 7.32 Hz, 2H), 3.09 (q, J = 6.60 Hz, 2H), 
2.77-2.73 (m, 2H), 2.50 (s, 3H), 2.13 (s, 3H), 2.04-1.97 (m, 5H), 1.78-1.73 (m, 4H), 
1.42-1.34 (m, 2H). HRMS (ESI) calc. for C23H33N7O [M + H]+ 423.2747. 
 
4.2.2.31. 1-(3-Methyl-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indazol-6-yl)-
3-(3-(5-methyl-1H-imidazol-1-yl)propyl)urea (199). Starting with compound 47 
following the general procedure 10, compound 199 was obtained as white solid, yield 
51%. 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 1H), 7.48-7.45 (m, 2H), 7.43 (s, 1H), 
6.79 (s, 1H), 6.72 (dd, J = 8.40, 2.13 Hz, 1H), 5.51 (t, 1H), 4.38 (t, J = 7.14 Hz, 2H), 
3.98 (t, J = 6.78 Hz, 2H), 3.26 (q, J = 5.85 Hz, 2H), 2.84 (t, J = 6.93 Hz, 2H), 2.57 
(br, 4H), 2.50 (s, 3H), 2.42 (br, 4H), 2.27 (s, 3H), 2.20 (s, 3H), 2.05-1.99 (m, 2H). ). 
HRMS (ESI) calc. for C23H35N8O [M + H]+ 439.2928, found 439.2949. 
 
4.2.2.32. 1-(1-(4-(2-Aminopyridin-4-yl)butyl)-3-methyl-1H-indazol-6-yl)-3-
(3-(5-methyl-1H-imidazol-1-yl)propyl)urea (200). Starting with compound 156 
following the general procedure 9.2, compound 200 was obtained as white solid, yield 
97%. 1H NMR (300 MHz, CDCl3) δ 8.27 (s, 1H), 7.88 (d, J = 5.31 Hz, 1H), 7.82 (s, 
1H), 7.42 (s, 1H), 7.41 (d, J = 8.43 Hz, 1H), 6.79 (s, 1H), 6.65 (dd, J = 8.43, 1.47 Hz, 
1H), 6.41 (d, J = 4.32 Hz, 1H), 6.27 (s, 1H), 6.06 (t, 1H), 4.50 (s, 2H), 4.23 (t, J = 
7.32 Hz, 2H), 3.94 (t, J = 6.60 Hz, 2H), 3.23 (q, J = 5.88 Hz, 2H), 2.49 (s, 3H), 2.46 
(t, J = 7.71 Hz, 2H), 2.19 (s, 3H), 1.97 (quintet, J = 6.21 Hz, 2H), 1.90-1.83 (m, 2H), 
1.59 (quintet, J = 6.96 Hz, 2H). ). HRMS (ESI) calc. for C25H33N8O [M + H]+ 
461.2772, found 461.2765. 
 
4.2.2.33. 1-(4-Fluorobenzyl)-1-(1H-indazol-6-yl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (201). Starting with compound 157 following the general 
procedure 9.2, compound 201 was obtained as white solid, yield 93%. 1H NMR (300 
MHz, CDCl3) δ 8.05 (s, 1H), 7.73 (d, J = 8.61 Hz, 1H), 7.35 (s, 1H), 7.20-7.15 (m, 
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2H), 6.98 (s, 1H), 6.96-6.89 (m, 2H), 6.82 (dd, J = 8.61, 1.83 Hz, 1H), 6.66 (s, 1H), 
4.84 (s, 2H), 4.33 (br, 1H), 3.86 (t, J = 6.78 Hz, 2H), 3.26 (q, J = 6.39 Hz, 2H), 2.13 
(s, 3H), 1.91 (quintet, J = 6.57 Hz, 2H). ). HRMS (ESI) calc. for C22H24FN6O [M + 
H]+ 407.1990, found 407.2004. 
 
4.2.2.34. 1-(4-Fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(1-
methyl-1H-indazol-6-yl)urea (202). Starting with compound 76 following the general 
procedure 10, compound 202 was obtained as white solid, yield 43%. 1H NMR (300 
MHz, CDCl3) δ 7.97 (d, J = 0.75 Hz, 1H), 7.70 (d, J = 8.43 Hz, 1H), 7.32 (s, 1H), 
7.23-7.18 (m, 2H), 7.02 (s, 1H), 6.98-6.92 (m, 2H), 6.80 (d, J = 8.40, 1.62 Hz, 1H), 
6.68 (s, 1H), 4.87 (s, 2H), 4.30 (t, J = 5.85 Hz, 1H), 3.99 (s, 3H), 3.83 (t, J = 7.14 Hz, 
2H), 3.22 (q, J = 6.78 Hz, 2H), 2.12 (s, 3H), 1.88 (quintet, J = 6.96 Hz, 2H). ). HRMS 
(ESI) calc. for C23H26FN6O [M + H]+ 421.2147, found 421.2159. 
 
4.2.2.35. 1-(4-Fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(1-
propyl-1H-indazol-6-yl)urea (203). Starting with compound 77 following the general 
procedure 10, compound 203 was obtained as white solid, yield 57%. 1H (300 MHz, 
CDCl3) δ 7.97 (d, J = 0.93 Hz, 1H), 7.71 (d, J = 8.43 Hz, 1H), 7.30 (s, 1H), 7.19 (dd, 
J = 5.49, 8.79 Hz, 2H), 9.94-6.88 (m, 3H), 6.81 (dd, J = 1.83, 8.61 Hz, 1H), 6.67 (s, 
1H), 4.83 (s, 1H), 4.25 (t, J = 5.16 Hz, NH), 4.20 (t, J = 6.78 Hz, 2H), 3.83 (t, J = 
7.14 Hz, 2H), 3.23 (q, J = 6.78 Hz, 2H)2.10 (d, J = 0.93 Hz, 3H), 1.87-1.78 (m, 4H0, 
0.84 (t, J = 7.32 Hz, 3H). MS (ESI) m/z 449 [M+H]+. HRMS (ESI) calc. 




methyl-1H-imidazol-1-yl)propyl)urea (204). Starting with compound 66 following 
the general procedure 10, compound 204 was obtained as white solid, yield 41%. 1H 
NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.61 Hz, 1H), 7.30 (s, 1H), 7.23-7.18 (m, 2H), 
6.94-6.88 (m, 2H), 6.69 (s, 1H), 6.67 (d, J = 8.79, 1.65 Hz, 1H), 4.86 (s, 2H), 4.45 (t, 
J = 5.49 Hz, 1H), 4.08 (s, 3H), 3.81 (t, J = 7.32 Hz, 2H), 3.19 (q, J = 6.24 Hz, 2H), 
2.60 (s, 3H), 1.86 (quintet, J = 7.14 Hz, 2H). HRMS (ESI) calc. for C24H28FN6O [M 
+ H]+ 435.2303, found 435.2314. 
 
4.2.2.37. 1-(2,3-Dimethyl-2H-indazol-6-yl)-3-(3-(5-methyl-1H-imidazol-1-
yl)propyl)-1-(pyridin-3-ylmethyl)urea (205). Starting with compound 67 following 
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the general procedure 10, compound 205 was obtained as white solid, yield 37%.  1H 
NMR (300 MHz, CDCl3) δ 8.46 (br, 1H), 8.40 (br, 1H), 7.67 (d, J = 7.68 Hz, 1H), 
7.56 (d, J = 8.61 Hz, 1H), 7.30 (s, 1H), 7.27 (s, 1H), 7.23-7.19 (m, 1H), 7.69 (s, 1H), 
6.67 (d, J = 8.79 Hz, 1H), 4.91 (s, 2H), 4.49 (t, J = 5.67 Hz, 1H), 4.09 (s, 3H), 3.83 




dimethyl-1H-indazol-5-yl)urea (206). Starting with compound 158 following the 
general procedure 9.2, compound 206 was obtained as white solid, yield 88%, mp = 
140-11 oC. 1H NMR (300 MHz, MeOD) δ 8.09 (s, 1H0, 7.57-7.53 (m, 2H), 7.50 (d, 
J = 7.89 Hz, 1H), 7.43 (s, 1H), 7.19 (dd, J = 2.01, 8.79 Hz, 1H), 7.13 (d, J = 8.43 Hz, 
1H), 4.95-4.92 (m, 1H), 4.37 (s, 2H), 3.99 (m, 3H), 2.52 (s, 3H0, 2.12-2.09 (m, 2H), 
1.82-1.75 (m, 2H), 1.59-1.42 (m, 2H). MS (ESI) m/z 389 [M+H]+. HRMS (ESI) calc. 
for C22H24N6O [M+H]+ 389.2084, found  
389.2099. Anal. HPLC 100.0% (Rt = 7.708 min).   
 
4.2.2.39. 3-((1H-Benzo[d]imidazol-5-yl)methyl)-1-cyclopentyl-1-(1,3-
dimethyl-1H-indazol-5-yl)urea (207). Starting with compound 159 following the 
general procedure 9.2, compound 207 was obtained as white solid, yield 71%, mp = 
137-138 oC. 1H NMR (300 MHz,  CDCl3) δ 7.95 (s, 1H), 7.45-7.42 (m, 3H), 7.35 (d, 
J = 8.58 Hz, 1H), 7.17 (dd, J = 1.83, 8.79 Hz, 1H), 7.06 (d, J = 8.25 Hz, 1H), 4.97-
4.86 (m, 1H), 4.44 (s, 2H), 3.99 (s, 3H), 2.54 (s, 3H), 1.99-1.89 (m, 2H), 1.50-1.46 
(m, 4H), 1.29-1.25 (m, 2H). MS (ESI) m/z 403 [M+H]+. HRMS (ESI) calc. 




dimethyl-1H-indazol-5-yl)urea (208). Starting with compound 160 following the 
general procedure 9.2, compound 208 was obtained as white solid, yield 72%, mp = 
150-151 oC. 1H NMR (300 MHz, MeOD) δ 8.09 (s, 1H), 7.54-7.51 (m, 2H), 7.48 (s, 
1H), 7.42 (s, 1H), 7.21 (dd, J = 1.65, 8.79 Hz, 1H), 7.12 (d, J = 8.43 Hz, 1H), 4.37 (s, 
2H), 4.35-4.31 (m, 1H), 3.98 (s, 3H), 2.51 (s, 3H), 1.93-1.89 (m, 2H), 1.76-1.72 (m, 
2H), 1.55-1.51 (m, 1H), 1.41-1.27 (m, 2H), 1.08-1.03 (m, 2H), 0.90-0.86 (m, 1H). 
MS (ESI) m/z 417 [M+H]+. HRMS (ESI) calc. 
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(1,3-dimethyl-1H-indazol-5-yl)urea (209). Starting with compound 161 following the 
general procedure 9.2, compound 209 was obtained as white solid. 1H NMR (600 
MHz, CDCl3) δ 7.94 (s, 1H), 7.49 (d, J = 1.38 Hz, 1H), 7.43 (br, 2H), 7.32 (d, J = 
8.70 Hz, 1H), 7.21 (dd, J = 8.70, 1.80 Hz, 1H), 7.05 (d, J = 8.22 Hz, 1H), 4.61 (t, J = 
6.0 Hz, 1H), 4.43 (d, J = 5.46 Hz, 2H), 3.96 (s, 3H), 3.70 (d, J = 7.80 Hz, 2H), 2.52 
(s, 3H), 2.03-1.98 (m, 1H), 1.67-1.62 (m, 2H), 1.59-1.55 (m, 2H), 1.46-1.44 (m, 2H), 




5-yl)-1-(4-fluorobenzyl)urea (210). Starting with compound 162 following the 
general procedure 9.2, compound 210 was obtained as white solid, yield 79%. 1H 
NMR (600 MHz, CDCl3) δ 7.94 (s, 1H), 7.45 (br, 2H), 7.30 (d, J = 1.32 Hz, 1H), 7.22 
(d, J = 8.70 Hz, 1H), 7.18 (dd, J = 8.22, 5.46 Hz, 2H), 7.08 (d, J = 8.28 Hz, 1H), 6.97 
(dd, J = 8.70, 1.86 Hz, 1H), 6.91 (t, J = 8.58 Hz, 2H), 4.86 (s, 2H), 4.66 (t, J = 6.00 
Hz, 1H), 4.47 (d, J = 5.94 Hz, 2H), 3.93 (s, 3H), 2.44 (s, 3H). HRMS (ESI) calc. for 
C25H24FN6O [M + H]+ 443.1990, found 443.1999. 
 
4.2.2.43. 3-((1H-Benzo[d]imidazol-5-yl)methyl)-1-cyclobutyl-1-(1,3-
dimethyl-1H-indazol-6-yl)urea (211). Starting with compound 163 following the 
general procedure 9.2, compound 211 was obtained as white solid, yield 89%. 1H 
NMR (300MHz, CDCl3) δ 7.90 (s, 1H), 7.66 (d, J = 8.25 Hz, 1H), 7.47-7.43 (m, 2H), 
7.14 (s, 1H), 7.02 (d, J = 8.22 Hz, 1H), 6.88 (dd, J = 8.43, 1.47 Hz, 1H), 5.10-4.98 
(m, 1H), 4.66 (t, J = 5.85 Hz, 1H), 4.43 (d, J = 5.67 Hz, 2H), 3.96 (s, 3H), 2.54 (s, 
3H), 2.17-2.09 (m, 2H), 1.87-1.73 (m, 2H), 1.63-1.38 (m, 2H). HRMS (ESI) calc. for 
C22H25N6O [M + H]+ 389.2084, found 389.2100. 
 
4.2.2.44. 3-((1H-Benzo[d]imidazol-5-yl)methyl)-1-cyclopentyl-1-(1,3-
dimethyl-1H-indazol-6-yl)urea (212). Starting with compound 164 following the 
general procedure 9.2, compound 212 was obtained as white solid, yield 98%. 1H 
NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.64 (d, J = 8.25 Hz, 1H), 7.45 (d, J = 9.15 
Hz, 1H), 7.44 (s, 1H), 7.15 (d, J = 0.93 Hz, 1H), 7.02 (dd, J = 8.22, 1.2 Hz, 1H), 6.91 
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(dd, J = 8.25, 1.47 Hz, 1H), 4.94-4.83 (m, 1H). 4.62 (t, J = 5.49 Hz, 1H), 4.44 (d, J = 
5.85 Hz, 2H), 3.95 (s, 3H), 2.53 (s, 3H), 1.92-1.88 (m, 2H), 1.49-1.46 (m, 4H), 1.40-
1.26 (m, 2H). HRMS (ESI) calc. for C23H27N6O [M + H]+ 403.2241, found 403.2259. 
 
4.2.2.45. 3-((1H-Benzo[d]imidazol-5-yl)methyl)-1-cyclohexyl-1-(1,3-
dimethyl-1H-indazol-6-yl)urea (213). Starting with compound 165 following the 
general procedure 9.2, compound 213 was obtained as white solid, yield 75%, mp = 
133-134 oC. 1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.65 (d, J = 8.25 Hz, 1H), 
7.51 (d, J = 8.61 Hz, 1H), 7.45 (s, 1H), 7.12 (s, 1H), 7.07 (d, J = 8.25 Hz, 1H), 6.91 
(dd, J = 1.65, 8.40 Hz, 1H), 4.56-4.48 (m, 1H), 4.43 (s, 2H), 3.97 (s, 3H), 2.55 (s, 
3H), 1.95-1.91 (m, 2H), 1.73-1.69 (m, 2H), 1.56-1.52 (m, 1H), 1.44-1.30 (m, 2H), 
1.13-1.02 (m, 2H), 0.89-0.84 (m, 1H). MS (ESI) m/z 417 [M+H]+. HRMS (ESI) calc. 




(1,3-dimethyl-1H-indazol-6-yl)urea (214). Starting with compound 166 following the 
general procedure 9.2, compound 214 was obtained as white solid, yield 70%, mp = 
122-123 oC. 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.66 (d, J = 8.43 Hz, 1H), 
7.55-7.48 (m, 2H), 7.19 (s, 1H), 7.12 (d, J = 8.25 Hz, 1H), 7.00 (d, J = 8.40 Hz, 1H), 
4.68 (t, J = 4.59 Hz, NH), 4.48 (d, J = 5.88 Hz, 2H), 3.96 (s, 3H), 3.77 (d, J = 7.50 
Hz, 2H), 2.54 (s, 3H), 2.10-2.01 (m, 1H), 1.75-1.62 (m, 4H), 1.52-1.48 (m, 2H), 1.30-
1.26 (m, 4H). MS (ESI) m/z 417 [M+H]+. HRMS (ESI) calc. 




6-yl)-1-(4-fluorobenzyl)urea (215). Starting with compound 167 following the 
general procedure 9.2, compound 215 was obtained as white solid. 1H NMR (300 
MHz, CDCl3) δ 7.96 (s, 1H), 7.58 (d, J = 8.97 Hz, 1H), 7.53-7.49 (m, 2H), 7.22 (dd, 
J = 8.25, 5.49 Hz, 1H), 7.11 (d, J = 8.25 Hz, 1H), 6.98 (s, 1H), 6.94 (t, J = 8.61 Hz, 
2H), 6.81 (d, J = 8.40 Hz, 1H), 4.92 (s, 2H), 4.79 (t, J = 5.67 Hz, 1H), 4.50 (d, J = 
5.67 Hz, 2H), 3.87 (s, 3H), 2.51 (s, 3H). 
 
4.2.2.48. 3-((1H-Benzo[d]imidazol-5-yl)methyl)-1-(1,3-dimethyl-1H-indazol-
6-yl)-1-(1-methylpiperidin-4-yl)urea (216). Starting with compound 168 following 
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the general procedure 9.2, compound 216 was obtained as white solid, yield 51%, mp 
= 74-75 oC. 1H NMR (300 MHz, MeOH) δ 8.10 (s, 1H), 7.77 (d, J = 8.43 Hz, 1H), 
7.50 (d, J = 8.25 Hz, 1H), 7.44 (s, 1H), 7.37 (d, J = 0.90 Hz, 1H), 7.14 (dd, J = 1.26, 
8.40 Hz, 1H), 6.95 (dd, J = 1.65, 8.40 Hz, 1H), 4.47-4.42 (m, 1H), 4.37 (s, 2H), 3.94 
(s, 3H), 2.88-2.84 (m, 2H), 2.50 (s, 3H), 2.19 (s, 3H), 2.15-2.12 (m, 2H), 1.92-1.87 
(m, 2H), 1.53-1.41 (m, 2H). MS (ESI) m/z 432 [M+H]+. HRMS (ESI) calc. 




methyl-1H-indol-5-yl)urea (217). Starting with compound 95 following the general 
procedure 10, compound 217 was obtained as white solid, yield 56%, mp = 51-52 oC. 
1H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 1.65 Hz, 1H), 7.33 (d, J = 8.61 Hz, 1H), 
7.12 (d, J = 3.12 Hz, 1H), 6.94 (dd, J = 2.01, 8.61 Hz, 1H), 6.66 (s, 1H), 6.49 (dd, J 
= 0.72, 3.12 Hz, 1H), .4.48-4.40 (m, 1H), 3.99 (t, J = 5.70 Hz, NH), 3.81 (s, 3H), 3.77 
(t, J = 7.32 Hz, 2H), 3.12 (q, J = 6.60 Hz, 2H), 2.08 (d, J = 0.93 Hz, 3H), 1.89-1.85 
(m, 2H), 1.82 (p, J = 6.78 Hz, 2H), 1.72-1.66 (m, 2H), 1.53-1.49 (m, 2H), 1.43-1.30 
(m, 2H0, 1.09-0.97 (m, 2H), 0.88-0.80 (m, 1H). MS (ESI) m/z 394 [M+H]+. 
HRMS (ESI) calc. for C23H31N5O [M+H]+ 394.2601, found 394.2613. Anal. HPLC 
99.5% (Rt = 5.339 min). 
 
4.2.2.50. 1-(Cyclopentylmethyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-
(1-methyl-1H-indol-5-yl)urea (218)). Starting with compound 96 following the 
general procedure 10, compound 218 was obtained as white solid, yield 56%, mp = 
66-67 oC. 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 1.65 Hz, 1H), 7.35 (d, J = 8.61 
Hz, 1H), 7.25 (s, 1H), 7.12 (d, J = 3.12 Hz, 1H), 7.03 (dd, J = 1.83, 8.40 Hz, 1H), 
6.67 (s, 1H), 6.49 (d, J = 3.09 Hz, 1H), 4.21 (t, J = 5.67 Hz, NH), 3.81 (s, 3H), 3.79 
(t, J = 7.35 Hz, 2h), 3.66 (d, J = 7.50 Hz, 2H), 3.15 (q, J = 6.60 Hz, 2H), 2.09 (d, J = 
0.72 Hz, 3H), 2.04-1.94 (m, 1H), 1.83 (p, J = 6.75 Hz, 2H0, 1.65-1.57 (m, 4H), 1.48-
1.42 (m, 2H), 1.30-1.20 (m, 2H). MS (ESI) m/z 394 [M+H]+. HRMS (ESI) calc. 




methyl-1H-indol-5-yl)urea (219). Starting with compound 97 following the general 
procedure 10, compound 219 was obtained as white solid, yield 51%, mp = 55-56 oC. 
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1H NMR (300 MHz, CDCl3) δ 7.27-7.24 (m, 2H), 7.20 (dd, J = 5.49, 8.58 Hz, 2H), 
7.10 (d, J = 3.12 Hz, 1H), 6.94 (t, J = 8.79 Hz, 2H), 6.81 (dd, J = 2.01 Hz, 1H), 6.67 
(s, 1H), 6.43 (d, J = 3.12 Hz, 1H), 4.82 (s, 2H), 4.27 (t, J = 5.94 Hz, NH), 3.78 (s, 
3H0, 3.75 (t, J = 7.32 Hz, 2H), 3.18 (q, J = 6.57 Hz, 2H), 2.09 (d, J = 0.90 Hz, 3H), 
1.86 (p, J = 7.50 Hz, 2H). MS (ESI) m/z 420 [M+H]+. HRMS (ESI) calc. 




imidazol-1-yl)propyl)urea (220). Starting with compound 98 following the general 
procedure 10, compound 220 was obtained as white solid, yield 55%, mp = 79-80 oC. 
1H NMR (300 MHz, CDCl3) δ 7.41 (s, 1H), 7.28-7.25 (m, 2H), 6.92-6.89 (m, 2H), 
6.71 (s, 1H), 4.48-4.40 (m, 1H), 4.00 (t, J = 5.04 Hz, NH), 3.81 (t, J = 7.32 Hz, 2H), 
3.75 (s, 3H), 3.11 (q, J = 6.96 Hz, 2H), 2.29 (s, 3H), 2.10 (s, 3H), 1.90-1.86 (m, 2H), 
1.80 (p, J = 6.96 Hz, 2H), 1.71-1.67 (m, 2H), 1.55-1.49 (m, 1H), 1.40-1.36 (m, 2H), 
1.16-1.07 (m, 2H), 0.85-0.81 (m, 1H). MS (ESI) m/z 408 [M+H]+. HRMS (ESI) calc. 




methyl-1H-imidazol-1-yl)propyl)urea (221). Starting with compound 99 following 
the general procedure 10, compound 221 was obtained as white solid, yield 51%, mp 
= 53-53 oC. 1H NMR (500 MHz, CDCl3) δ 7.36-7.35 (m, 2H), 7.29 (d, J = 8.55 Hz, 
1H), 7.00 (dd, J = 1.70, 8.45 Hz, 1H), 6.89 (s, 1H), 6.70 (s, 1H), 4.24 (t, J = 5.65 Hz, 
NH), 3.80 (t, J = 7.25 Hz, 2H), 3.74 (s, 3H), 3.67 (d, J = 7.70 Hz, 2H), 3.14 (q, J = 
6.35 Hz, 2H), 2.29 (s, 3H), 2.10 (s, 3H), 2.03-1.99 (m, 1H), 1.82 (p, J = 6.75 Hz, 2H), 
1.65-1.59 (m, 4H), 1.47-1.45 (m, 2H), 1.30-1.23 (m, 2H). MS (ESI) m/z 408 [M+H]+. 
HRMS (ESI) calc. for C24H33N5O [M+H]+ 408.2758, found 408.2765. Anal. HPLC 
98.6% (Rt = 6.982 min). 
 
4.2.2.54. 1-(1,3-Dimethyl-1H-indol-5-yl)-1-(4-fluorobenzyl)-3-(3-(5-methyl-
1H-imidazol-1-yl)propyl)urea (222). Starting with compound 100 following the 
general procedure 10, compound 222 was obtained as white solid, yield 51%, mp = 
71-72 oC. 1H NMR (300 MHz, CDCl3) δ 7.36 (s, 1H), 7.16-7.12 (m, 4H), 6.89 (t, J = 
8.79 Hz, 2H), 6.81 (s, 1H), 6.72 (dd, J = 1.83, 8.40 Hz, 1H), 6.66 (s, 1H), 4.77 (s, 
2H), 4.25 (t, J = 5.67 Hz, NH), 3.79 (t, J = 7.14 Hz, 2H), 3.66 (s, 3H), 3.14 (q, J = 
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6.39 Hz, 2H), 2.17 (s, 3H), 2.06 (s, 3H), 1.81 (p, J = 6.60 Hz, 2H). 
MS (ESI) m/z 434 [M+H]+. HRMS (ESI) calc. 




1H-indol-5-yl)urea (223). Starting with compound 101 following the general 
procedure 10, compound 223 was obtained as white solid, yield 51%, mp = 44-45 oC. 
1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 1.76 Hz, 1H), 7.33 (d, J = 8.60 Hz, 1H), 
7.25 (s, 1H), 7.16 (d, J = 3.08 Hz, 1H), 6.90 (dd, J = 1.88, 8.56 Hz, 1H), 6.66 (s, 1H), 
6.49 (d, J = 3.08 Hz, 1H), 4.48-4.40 (m, 1H), 4.10 (t, J = 7.12 Hz, 2H), 4.01 (t, J = 
5.76 Hz, NH), 3.77 (t, J = 7.36 Hz, 2H), 3.12 (q, J = 6.52 Hz, 2H), 2.07 (s, 3H), 1.92-
1.85 (m, 4H), 1.81 (p, J = 6.76 Hz, 2H), 1.69-1.66 (m, 2H), 1.52-1.49 (m, 1H), 1.43-
1.32 (m, 2H), 1.10-1.00 (m, 2H), 0.98 (t, J = 7.44 Hz, 3H), 0.87-0.81 (m, 1H). 
MS (ESI) m/z 422 [M+H]+. HRMS (ESI) calc. 




(1-propyl-1H-indol-5-yl)urea (224). Starting with compound 102 following the 
general procedure 10, compound 224 was obtained as white solid, yield 56%, mp = 
52-53 oC. 1H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 1.83 Hz, 1H), 7.36 (d, J = 8.61 
Hz, 1H), 7.27 (s, 1H), 7.17 (d, J = 3.09 Hz, 1H), 7.00 (dd, J = 2.01, 8.61 Hz, 1H), 
6.67 (s, 1H), 6.48 (d, J = 3.12 Hz, 1H), 4.26 (t, J = 5.67 Hz, NH), 4.10 (t, J = 6.96 Hz, 
2H), 3.79 (t, J = 7.14 Hz, 2H), 3.66 (d, J = 7.68 Hz, 2H), 3.16 (q, J = 6.60 Hz, 2H), 
2.09 (d, J = 1.11 Hz, 3H), 1.88-1.75 (m, 4H), 1.68-1.58 (m, 4H), 1.60-1.42 (m, 2H), 
1.27 (t, J = 7.14 Hz, 2H), 0.97 (t, J = 7.32 Hz, 3H). MS (ESI) m/z 422 [M+H]+. 
HRMS (ESI) calc. for C25H35N5O [M+H]+ 422.2914, found 422.2930. Anal. HPLC 
100.0% (Rt = 7.708 min). 
 
4.2.2.57. 1-(4-Fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(1-
propyl-1H-indol-5-yl)urea (225). Starting with compound 103 following the general 
procedure 10, compound 225 was obtained as white solid, yield 58%, mp = 73-74 oC. 
1H NMR (300 MHz, CDCl3) δ 7.28 (s, 1H), 7.24 (s, 1H), 7.22-7.17 (m, 2H), 7.14 (d, 
J = 3.12 Hz, 1H), 6.94 (t, J = 8.76 Hz, 2H), 6.76 (dd, J = 2.01, 8.58 Hz, 1H), 6.67 (s, 
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1H), 6.42 (d, J = 2.37 Hz, 1H), 4.81 (s, 2H), 4.31 (t, J = 4.59 Hz, NH), 4.07 (t, J = 
7.14 Hz, 2H), 3.80 (t, J = 7.14 Hz, 2H), 3.19 (q, J = 6.57 Hz, 2H), 2.08 (d, J = 0.90 
hz, 3H0, 1.88-1.77 (m, 4H), 0.95 (t, J = 7.35 Hz, 3H). MS (ESI) m/z 448 [M+H]+. 
HRMS (ESI) calc. for C26H30FN5O [M+H]+ 448.2507, found 448.2520. Anal. HPLC 
100.0% (Rt = 4.851 min). 
 
4.2.2.58. 1-Cyclohexyl-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(3-
methylbenzofuran-5-yl)urea (226). Starting with compound 112 following the 
general procedure 10, compound 226 was obtained as white solid, yield 42%. 1H 
NMR (300 MHz, CDCl3) δ 7.47-7.45 (m, 2H), 7.27 (m, 1H), 7.00 (dd, J = 8.61, 2.19 
Hz, 1H), 6.67 (s, 1H), 4.49-4.41 (tt-like, 1H), 3.89 (t-like, 1H), 3.77 (t, J = 7.32 Hz, 
2H), 3.12 (q, J = 6.42 Hz, 2H), 2.23 (d, J = 1.11 Hz, 3H), 2.09 (d, J = 0.72 Hz, 3H), 
1.89-1.78 (m, 4H), 1.70 (d, J = 12.27 Hz, 2H), 1.54 (d-like, 1H), 1.45-1.32 (m, 2H), 
1.07-0.99 (m, 2H), 0.92-0.78 (m, 1H). HRMS (ESI) calc. for C23H31N4O2 [M + H]+ 
395.2442, found 395.2448. 
 
4.2.2.59. 1-(4-Fluorobenzyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1-(3-
methylbenzofuran-5-yl)urea (227). Starting with compound 113 following the 
general procedure 10, compound 227 was obtained as white solid, yield 51%. 1H 
NMR (300 MHz, CDCl3) δ 7.44 (d, J = 1.08 Hz, 1H), 7.38 (d, J = 8.58 Hz, 1H), 7.29 
(s, 1H), 7.20-7.13 (m, 3H), 6.92 (t, J = 8.61 Hz, 2H), 6.85 (dd, J = 8.61, 2.19 Hz, 1H), 
6.68 (s, 1H), 4.81 (s, 2H), 4.19 (t, J = 5.70 Hz, 1H), 3.79 (t, J = 7.14 Hz, 2H), 3.17 (q, 
J = 6.21 Hz, 2H), 2.16 (d, J = 1.29 Hz, 3H), 2.10 (d, J = 0.90 Hz, 3H), 1.84 (quintet, 




methylbenzofuran-6-yl)urea (228). Starting with compound 114 following the 
general procedure 10, compound 228 was obtained as white solid, yield 22%. 1H 
NMR (300 MHz, CDCl3) δ 7.41 (d, J = 8.22 Hz, 1H), 7.38 (q, J = 1.11 Hz, 1H), 7.15-
7.10 (m, 3H), 7.05 (d, J = 1.47 Hz, 1H), 6.90-6.79 (m, 4H), 4.76 (s, 2H), 4.23 (t-like, 
1H), 3.77 (t-like, 2H), 3.13 (q, J = 5.88 Hz, 2H), 2.16 (d, J = 1.29 Hz, 3H), 2.06 (s, 
3H), 1.81-1.74 (m, 2H). HRMS (ESI) calc. for C24H26FN4O2 [M + H]+ 421.2034, 
found 421.2043. 
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4.2.2.61. 1-(Benzo[d]oxazol-5-yl)-1-cyclohexyl-3-(3-(5-methyl-1H-imidazol-
1-yl)propyl)urea (229). Starting with compound 133 following the general procedure 
10, compound 229 was obtained as white solid, yield 55%, mp = 84-85 oC. 1H NMR 
(300 MHz, CDCl3) δ 8.14 (s, 1H), 7.61 (d, J = 8.61 Hz, 1H), 7.55 (d, J = 1.83 Hz, 
1H),  (s, 1H), 7.14 (dd, J = 2.01, 8.58 Hz, 1H), 6.64 (s, 1H), 4.47-4.396 (m, 1H), 3.80 
(t, J = 4.95 Hz, NH), 3.77 (t, J = 7.14 Hz, 2H), 3.13 (q, J = 6.57 Hz, 2H), 2.07 (d, J = 
0.93 Hz, 3H), 1.86-1.83 (m, 2H), 1.81 (p, J = 7.14 Hz, 2H), 1.70-1.65 (m, 2H), 1.53-
1.49 (m, 1H), 1.42-1.29 (m, 2H), 1.01-0.93 (m, 2H), 0.88-0.78 (m, 1H). 
MS (ESI) m/z 382 [M+H]+. HRMS (ESI) calc. 




imidazol-1-yl)propyl)urea (230). Starting with compound 134 following the general 
procedure 10, compound 230 was obtained as white solid, yield 57%, mp = 60-61 oC. 
1H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H), 7.65-7.62 (m, 2H), 7.28 (s, 1H), 7.25 (dd, 
J = 2.01, 8.40 Hz, 1H), 6.67 (s, 1H), 4.14 (t, J = 5.04 Hz, NH), 3.81 (t, J = 7.14 Hz, 
2H), 3.67 (d, J = 7.68 Hz, 2H), 3.18 (q, J = 6.78 Hz, 2H), 2.10 (s, 3H), 1.98-1.93 (m, 
1H), .87 (p, J = 7.14 Hz, 2H), 1.65-1.57 (m, 4H), 1.50-1.43 (m, 2H), 1.30-1.19 (m, 
2H). MS (ESI) m/z 382 [M+H]+. HRMS (ESI) calc. 




imidazol-1-yl)propyl)urea (231). Starting with compound 135 following the general 
procedure 10, compound 231 was obtained as white solid, yield 51%, mp = 74-75 oC. 
1H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 7.56 (d, J = 8.61 Hz, 1H), 7.45 (d, J = 
2.01 Hz, 1H), 7.28 (s, 1H), 7.17 (dd, J = 5.31, 8.61 Hz, 1H), 7.04 (dd, J = 2.01, 8.40 
Hz, 1H), 6.94 (tt, J = 2.19, 8.61 Hz, 1H), 6.67 (s, 1H), 4.83 (s, 2H), 4.16 (t, J = 4.95 
Hz, NH), 3.82 (t, J = 7.14 Hz, 2H), 3.22 (q, J = 6.78 Hz, 2H), 2.10 (d, J = 0.90 Hz, 
3H), 1.90 (p, J = 6.96 Hz, 2H). MS (ESI) m/z 408 [M+H]+. HRMS (ESI) calc. 




1-yl)propyl)urea (232). Starting with compound 136 following the general procedure 
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10, compound 232 was obtained as white solid, yield 45%, mp = 96-97 oC. 1H NMR 
(300 MHz, CDCl3) δ 8.12 (s, 1H), 7.78 (d, J = 8.43 Hz, 1H), 7.33 (d, J = 1.65 Hz, 
1H), 7.23 (s, 1H), 7.10 (dd, J = 1.83, 8.25 Hz, 1H), 6.62 (s, 1H), 4.46-4.35 (m, 1H), 
3.81 (t, J = 6.03 Hz, NH), 3.75 (t, J = 7.14 Hz, 2H), 3.12 (q, J = 6.57 Hz, 2H), 2.05 
(s, 3H), 1.84-1.81 (m, 2H), 1.78 (p, J = 7.14 Hz, 2H), 1.68-1.63 (m, 2H), 1.51-1.47 
(m, 1H), 1.39-.26 (m, 2H), 1.01-0.92 (m, 2H), 0.89-0.73 (m, 1H). 
MS (ESI) m/z 382 [M+H]+. HRMS (ESI) calc. 




imidazol-1-yl)propyl)urea (233). Starting with compound 137 following the general 
procedure 10, compound 233 was obtained as white solid, yield 55%, mp = 130-131 
oC. 1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.78 (d, J = 8.40 Hz, 1H), 7.41 (d, J 
= 1.83 Hz, 1H), 7.25 (s, 1H), 7.18 (dd, J = 2.01, 8.43 Hz, 1H), 6.62 (s, 1H), 4.12 (t, j 
= 5.85 Hz, NH), 3.77 (t, j = 7.14 Hz, 2H), 3.63 (d, j = 7.68 Hz, 2H), 3.15 (q, J = 6.78 
Hz, 2H), 2.06 (s, 3H), 1.97-1.86 (m, 1H), 1.83 (p, J = 6.75 Hz, 2H), 1.61-1.53 (m, 
4H), 1.48-1.42 (m, 2H), 1.21-1.16 (m, 2H). MS (ESI) m/z 382 [M+H]+. HRMS (ESI) 




imidazol-1-yl)propyl)urea (234). Starting with compound 138 following the general 
procedure 10, compound 234 was obtained as white solid, yield 55%, mp = 48-49 oC. 
1H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 7.76 (d, J = 8.43 Hz, 1H), 7.30 (s, 1H), 
7.18 (dd, J = 5.49, 8.43 Hz, 2H), 7.06 (dd, J = 1.83, 8.22 Hz, 1H), 6.67 (s, 1H), 4.83 
(s, 2H0, 4.18 (t, J = 6.03 Hz, NH), 3.83 (t, J = 7.14 Hz, 2H), 3.12 (q, J = 6.42 Hz, 
2H), 2.11 (d, J = 0.72 Hz, 3H), 1.88 (p, J = 6.57 Hz, 2H). MS (ESI) m/z 408 [M+H]+. 
HRMS (ESI) calc. for C22H22FN5O2 [M+H]+ 408.1830, found 408.1837. 
 
4.2.2.67. 1-(Benzo[d]thiazol-5-yl)-1-cyclohexyl-3-(3-(5-methyl-1H-imidazol-
1-yl)propyl)urea (235). Starting with compound 139 following the general procedure 
10, compound 235 was obtained as white solid, yield 67%. 1H NMR (300 MHz, 
CDCl3) δ 9.10 (s, 1H), 8.02 (d, J = 8.43 Hz, 1H), 7.93 (d, J = 1.83 Hz, 1H), 7.29 (s, 
1H), 7.22 (dd, J = 8.43, 2.01 Hz, 1H), 6.68 (s, 1H), 4.50 (tt, J = 12.06, 3.69 Hz, 1H), 
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3.92 (t, J = 5.49 Hz, 1H), 3.80 (t, J = 7.32 Hz, 2H), 3.15 (q, J = 6.21 Hz, 2H), 2.11 (s, 
3H), 1.92 (d, J = 12.99 Hz, 2H), 1.88-1.79 (m, 2H), 1.73 (d, J = 13.17 Hz, 2H), 1.56 
(d, J = 12.45 Hz, 1H), 1.47-1.34 (m, 2H), 1.04 (qd, J = 12.27, 3.66 Hz, 2H), 0.90-
0.80 (m, 1H). 
 
4.2.2.68. 1-(Benzo[d]thiazol-5-yl)-1-(cyclopentylmethyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (236). Starting with compound 140 following the general 
procedure 10, compound 236 was obtained as white solid, yield 71%. 1H NMR (300 
MHz, CDCl3) δ 9.07 (s, 1H), 8.01 (d, J = 8.58 Hz, 1H), 7.98 (d, J = 1.83 Hz, 1H), 
7.31-7.28 (m, 2H), 6.66 (s, 1H), 4.19 (t-like, 1H), 3.79 (t, J = 7.14 Hz, 2H), 3.70 (d, 
J = 7.68 Hz, 2H), 3.16 (q, J = 6.06 Hz, 2H), 2.10 (d, J = 0.57 Hz, 3H), 2.01-1.94 (m, 
1H), 1.83 (quintet, J = 7.14 Hz, 2H), 1.70-1.55 (m, 4H), 1.50-1.45 (m, 2H), 1.27-1.23 
(m, 2H). HRMS (ESI) calc. for C21H28N5OS [M + H]+ 398.2009, found 398.2020. 
 
4.2.2.69. 1-(Benzo[d]thiazol-5-yl)-1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (237). Starting with compound 141 following the general 
procedure 10, compound 237 was obtained as white solid, yield 58%. 1H NMR (300 
MHz, CDCl3) δ 9.06 (s, 1H), 7.94 (d, J = 8.40 Hz, 1H), 7.84 (d, J = 2.01 Hz, 1H), 
7.31 (s, 1H), 7.22-7.18 (dd, J = 8.43, 7.29 Hz, 2H), 7.10 (dd, J = 8.40, 2.04 Hz, 2H), 
6.68 (s, 1H), 4.89 (s, 2H), 4.29 (t, J = 5.88 Hz, 1H), 3.83 (t, J = 7.14 Hz, 2H), 3.22 (q, 
J = 6.60 Hz, 2H), 2.12 (s, 3H), 1.88 (quintet, J = 7.14 Hz, 2H). HRMS (ESI) calc. for 
C22H23FN5OS [M + H]+ 424.1602, found 424.1609. 
 
4.2.2.70. 1-(Benzo[d]thiazol-6-yl)-1-cyclohexyl-3-(3-(5-methyl-1H-imidazol-
1-yl)propyl)urea (238). Starting with compound 142 following the general procedure 
10, compound 238 was obtained as white solid, yield 64%. 1H NMR (300 MHz, 
CDCl3) δ 9.09 9s, 1H), 8.18 (d, J = 8.40 Hz, 1H), 7.75 (d, J = 1.83 Hz, 1H), 7.33 (s, 
1H), 7.30-7.27 (m, 1H), 6.69 (s, 1H), 4.49 (tt, J = 8.22, 3.27 Hz, 1H), 3.91 (t, J = 6.60 
Hz, 1H), 3.80 (t, J = 7.14 Hz, 2H), 3.16 (q, J = 6.57 Hz, 2H), 2.11 (s, 3H), 1.92-1.71 
(m, 6H), 1.56 (d, J = 13.2 Hz, 1H), 1.47-1.34 (m, 2H), 1.10-0.97 (m, 2H), 0.89-0.80 
(m, 1H). HRMS (ESI) calc. for C21H28N5OS [M + H]+ 398.2009, found 398.2023. 
 
4.2.2.71. 1-(Benzo[d]thiazol-6-yl)-1-(cyclopentylmethyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (239). Starting with compound 143 following the general 
procedure 10, compound 239 was obtained as off-white solid, yield 73%. 1H NMR 
(300 MHz, CDCl3) δ 9.04 (s, 1H), 8.15 (d, J = 8.61 Hz, 1H), 7.79 (d, J = 2.01 Hz, 
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1H), 7.34 (dd, J = 8.61, 2.19 Hz, 1H), 7.29 (s, 1H), 6.66 (s, 1H), 4.17 (t, J = 5.85 Hz, 
1H), 3.79 (t, J = 7.32 Hz, 2H), 3.68 (d, J = 7.77 Hz, 2H), 3.16 (q, J = 6.24 Hz, 2H), 
2.10 (s, 3H), 1.99-1.92 (m, 2H), 1.83 (quintet, J = 6.96 Hz, 2H), 1.62-1.54 (m, 4H), 
1.50-1.47 (m, 2H), 1.27-1.24 (m, 2H). HRMS (ESI) calc. for C21H28N5OS [M + H]+ 
398.2009, found 398.2020. 
 
4.2.2.72. 1-(Benzo[d]thiazol-6-yl)-1-(4-fluorobenzyl)-3-(3-(5-methyl-1H-
imidazol-1-yl)propyl)urea (240). Starting with compound 144 following the general 
procedure 10, compound 240 was obtained as white solid, yield 49%. 1H NMR (300 
MHz, CDCl3) δ 9.04 (s, 1H), 8.09 (d, J = 8.58 Hz, 1H), 7.62 (d, J = 2.01 Hz, 1H), 
7.32 (s, 1H), 7.22-7.17 (m, 3H), 6.99-6.92 (m, 2H), 6.67 (s, 1H), 4.87 (s, 2H), 4.34 (t, 
J = 5.67 Hz, 2H), 3.83 (t, J = 7.20 Hz, 2H), 3.23 (q, J = 6.78 Hz, 2H), 2.12 (s, 3H), 
1.88 (quintet, J = 6.96 Hz, 2H). HRMS (ESI) calc. for C22H23FN5OS [M + H]+ 
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ann, Hans- Ulrich Demuth, and Ulrich Heiser, 
Structure−Activity Relationships of Benzimidazole-Based Glutaminyl Cyclase 
Inhibitors Featuring,  J. Med. Chem, 2013, 56, 6613−6625 
71.   Li, M.; Dong, Y.; Yu, X.; Li, Y.; Zou, Y.; Zheng, Y.; He, Z.; Liu, Z.; Quan, J.; 
Bu, X.; Wu, H. J. Med. Chem. 2017, 60, 6664 
72.   Ngo, V.T.H.; Hoang, V-H.; Tran, P-T.; Ann, J.; Cui, M.; Park, G.; Choi, S.;  
Lee, J.; Kim, H.; Ha, H-J.; Choi, K.; Kim, Y-H.; Lee, J. Bioorg. Med. Chem.  
2018, 26, 1035 
73.   Hielscher-Michael, S.; Griehl, C.; Buchholz, M.; Demuth, H-U.; Arnold, N.;  
Wessjohann, L. A. Mar, Drugs 2016, 14, 203 
74.   Li, M.; Dong, Y.; Yu, X.; Zou, Y.; Zheng, Y.; Bu, X.; Quan, J.; He, Z.; Wu, H.
 Bioorg. Med. Chem. 2016, 24, 2280 
 
186 
Ngo Thi Hong Van _ 2013.31349 
75.   Szaszkó, M.; Hajdú, I.; Flachner, B.; Dobi, K.; Magyar, C.; Simon, I.; Lörincz,
 Z.; Kapui, Z.; Pázmány, T.; Cseh, S.; Dormán, G. Mol. Divers 2017, 21, 175 
76.   Safety and tolerability of PQ912 in subjects with early alzheimer's disease (sap
hir), https://clinicaltrials.gov/ct2/show/NCT02389413 
77.   New alzheimer’s drug shows safety, hints of efficacy in phase 2, https://www.a
lzforum.org/news/research-news/new-alzheimers-drug-shows-safety-hints-
efficacy-phase-2 
78.   The Metablism of 4-methoxy-β-chloro styrene by Liver Microsomal Mono- 
oxygenase, B.Mansour and V. Ullrich, Biochemical Pharmacology. Vol. 28, pp. 
2321-2326 
79.   Torsten Hoffmann, Antje Meyer, Ulrich Heiser, Stephan Kurat, Livia Böhme, 
Martin Kleinschmidt, Karl-Ulrich Bühring, Birgit Hutter-Paier, Martina  
Farcher, Hans-Ulrich Demuth, Inge Lues, Stephan Schilling, Glutaminyl 
Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s 
Disease Studies on Relation to Effective Target Occupancy, J Pharmacol Exp  
Ther, 2017, 362: 119–130 
80.   PCT Int. Appl., 2013028670, 28 Feb 2013 
81.   PCT Int. Appl., 2010046780, 29 Apr 2010 
82.   Patent Reference: WO2007084786, page 112 
83.   Toshiyuki K., Tohru Fukuyama, https://doi.org/10.1002/047084289X.rn00466 
84.   M. E. Dudley, M. M. Morshed, M. M. Hossain, A Convenient Method of Synt
hesizing 3-Ethoxycarbonylbenzofurans from Salicylaldehydes and Ethyl  
Diazoacetate, Synthesis, 2006, 1711-1714.,  
85.   S. H. Cho, J. Y. Kim, S. Y. Lee, S. Chang, Angew. Chem. Int. Ed., 2009, 48, 91
27-9130 
86.   Diego Carnaroglio1 , Katia Martina1 , Giovanni Palmisano , Andrea Penoni , 
Claudia Domini, and Giancarlo Cravotto, One-pot sequential synthesis of  
isocyanates and urea derivatives via a microwave-assisted Staudinger–aza-






Ngo Thi Hong Van _ 2013.31349 
알츠하이머 병 (Alzheimer 's disease, AD)은 기억력 상실과 인지력을 심각하게 
저하시키는 지속적이고, 끊임 없는 신경 퇴행성의 장애로 간주된다. 지금까지 
뇌에서 신경 독성 Aβ 종의 형성 수준을 낮추는 것이 AD 치료의 우선적인 
병리학으로 간주되고 있다. 최근 연구사례들에 따르면 AD 환자의 뇌에서 
과도하게 발현되어 농도가 높아진 pyroglutamate (pE-Aβ)는 Aβ 보다 빠르게 
응집되고 더 큰 독성을 갖고 있다고 한다. pE-Aβ 는 Glutaminyl Cyclase(QC) 라는 
효소에 의해  Amino-terminally 절단된 Aβ 의 glutamate 3 또는 11 을 기질로 하여 
cyclization 이 촉매작용이 일어나서 만들어진 생성물이다. 
최근 임상 연구에 따르면 QC 는 AD 치료에 대한 대체적 치료표적이 될 수 
있음을 보여주고 있다. 우리 연구 그룹에서는 일련의 QC 저해제의 연구 개발, 
특히 기존의 저해제를 기준으로 B-region 과 C-region 에서의 구조적 변형을 
통해 좀더 확장된 구조에 초점을 맞추고 있다. 이 연구에는 저희는 우선 Arg 
region 을 모방한 유사체의 구조 활성 관계 (SAR)에 대해 연구했다. Arg region 
시리즈에서 대부분의 화합물들은 in-vitro 실험에서 우수한 활성을 보여주었다. 
그중 IC50 < 10 nM 의 우수한 활성을 화합물들을 선별하여 in-vivo 실험을 
진행하였다. 그 결과 2-aminopyridi 에  aminoethyl 을 도입한 경우 in-vitro 
실험에서 약 2.5 배의 활성이 증가됨을 보였다. 그리고 분자 도킹 모델 연구를 
통해 화합물 202 가 hQC 의 active site 에 추가적인 hydrophobic interation 을 
보여줌으로써 QC 저해제로서 유력한 후보로 기대된다. 
앞서 언급된 결과들을 바탕으로 part2 에서는 위에서 설계한 약리활성 구조를 
대체하기 위해 3-alinoalaklyloxy-4-methoxyphele 및 4-aminoalkoxheyphel 을 
포함한 새로운 QC 저해제를 계속해서 개발하였다. IC50 값을 기반으로 활성이 
우수한 화합물들을 식별하였다. 그렇게 선별된 화합물들은 in vitro 독성과 in 
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vivo 활성을 추가로 진행하였다. 그 결과 QC 저해제 51 과 53 은 BBB 투과가 
가능한 in vivo 급성 모델에서 우수한 AβN3pE-40-Lowering Effect 를 나타냈고, 
cytotoxicity 와 hERG 저해를 나타내지 않았다. 두 화합물 중 모델 분석의 
대상으로 화합물 53 을 선택했다. 모델 결과 53 의 우수한 효과는 
활성부위에서의 염다리효과와 수소결합이라고 설명할 수 있다. BBB 의 투과가 
더 양호한 이 화합물은 Anti-Alzheimer 에이전트의 잠재적 후보가 될 수 있을 
것이다 
마지막으로 중요한 것은 C지역의 dimethoxy이 안정적이지 않고 간 신진대사에 
독성을 일으키며 B-region 의 변형은 in-vitro 활성을 증가시킨다는 것을 
발견했다. 따라서, 새로운 heterocyclic 을 C-region 과 B-region 과 C-region 의 
연결 고리에 계속 도입했다. 그러나, 모 화합물과 비교하여, C 영역의 헤테로 
고리, 특히 인돌, 벤조 퓨란, 벤조 옥사졸, 벤조 티아졸의 고리들은 활성을 2.0 ~ 
6.0 배 감소시킨 다는 것을 보였다. 흥미롭게도 일부의 고리 구조들은 B 영역에 
도입되었을 때  in vitro 활성이 약간 증가함을 보였다.  이러한 결과들은 
잠재적인 독성이 없고 우수한 투과력과 활성을 갖는 QC 저해제의 개발에 있어 
선도물질 최적화에 귀중한 정보를 줄것이라고 생각한다. 
키워드: Alzheimer Disease, Glutaminyl Cyclase, Aβ, hQC, pyroglutamate;  
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